Reduced size self-delivering rnai compounds

ABSTRACT

The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. The RNAi constructs may be, for instance, miRNA constructs that are miRNA modulators.

RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 13/069,780, entitled “Reduced Size Self-delivering RNAi Compounds ”, filed Mar. 23, 2011, which claims the benefit under 35 U.S.C. § 120, as a Continuation in Part, of U.S. application Ser. No. 13/120,342 entitled “Reduced Size Self-delivering RNAi Compounds,” filed on Mar. 22, 2011, which is a national stage filing under 35 U.S.C. § 371 of international application PCT/US2009/005247, filed Sep. 22, 2009, which was published under PCT Article 21(20) in English, and claims the benefit under 35 U.S.C. § 119(e) of U.S. provisional application serial number US 61/192,954, entitled “Chemically Modified Polyucleotides and Methods of Using the Same,” filed on Sep. 22, 2008, U.S. 61/149,946, entitled “Minimum Length Triggers of RNA Interference,” filed on Feb. 4, 2009, and US 61/224,031, entitled “Minimum Length Triggers of RNA Interference,” filed on Jul. 8, 2009, the disclosure of each of which is incorporated by reference herein in its entirety.

FIELD OF INVENTION

The invention pertains to the field of RNA interference (RNAi). The invention more specifically relates to nucleic acid molecules with improved in vivo delivery properties without the use of a delivering agent and their use in efficient gene silencing.

BACKGROUND OF INVENTION

Complementary oligonucleotide sequences are promising therapeutic agents and useful research tools in elucidating gene functions. However, prior art oligonucleotide molecules suffer from several problems that may impede their clinical development, and frequently make it difficult to achieve intended efficient inhibition of gene expression (including protein synthesis) using such compositions in vivo.

A major problem has been the delivery of these compounds to cells and tissues. Conventional double-stranded RNAi compounds, 19-29 bases long, form a highly negatively-charged rigid helix of approximately 1.5 by 10-15 nm in size. This rod type molecule cannot get through the cell-membrane and as a result has very limited efficacy both in vitro and in vivo. As a result, all conventional RNAi compounds require some kind of a delivery vehicle to promote their tissue distribution and cellular uptake. This is considered to be a major limitation of the RNAi technology.

There have been previous attempts to apply chemical modifications to oligonucleotides to improve their cellular uptake properties. One such modification was the attachment of a cholesterol molecule to the oligonucleotide. A first report on this approach was by Letsinger et al., in 1989. Subsequently, ISIS Pharmaceuticals, Inc. (Carlsbad, CA) reported on more advanced techniques in attaching the cholesterol molecule to the oligonucleotide (Manoharan, 1992).

With the discovery of siRNAs in the late nineties, similar types of modifications were attempted on these molecules to enhance their delivery profiles. Cholesterol molecules conjugated to slightly modified (Soutschek, 2004) and heavily modified (Wolfrum, 2007) siRNAs appeared in the literature. Yamada et al., 2008 also reported on the use of advanced linker chemistries which further improved cholesterol mediated uptake of siRNAs. In spite of all this effort, the uptake of these types of compounds appears to be inhibited in the presence of biological fluids resulting in highly limited efficacy in gene silencing in vivo, limiting the applicability of these compounds in a clinical setting.

Therefore, it would be of great benefit to improve upon the prior art oligonucleotides by designing oligonucleotides that have improved delivery properties in vivo and are clinically meaningful.

SUMMARY OF INVENTION

Described herein are asymmetric chemically modified nucleic acid molecules with minimal double stranded regions, and the use of such molecules in gene expression modulation. RNAi molecules associated with the invention contain single stranded regions and double stranded regions, and can contain a variety of chemical modifications within both the single stranded and double stranded regions of the molecule. Additionally, the RNAi molecules can be attached to a hydrophobic conjugate such as a conventional and advanced sterol-type molecule. This new class of RNAi molecules has superior efficacy both in vitro and in vivo than previously described RNAi molecules.

Aspects of the invention relate to an isolated nucleic acid molecule having a guide strand of 18-23 nucleotides in length that has complementarity to a miRNA sequence and a passenger strand of 8-16 nucleotides in length. The guide strand and the passenger strand form the nucleic acid molecule such that the nucleic acid has a double stranded region and a single stranded region, wherein the single stranded region is the 3′ end of the guide strand and is 2-13 nucleotides in length and comprises at least two phosphorothioate modifications. At least 50% of the pyrimidines in the nucleic acid molecule are modified.

In some embodiments the nucleotide in position one of the guide strand has a 2′-O-methyl modification. For example, the nucleotide in position one of the guide strand may be a 5P-2′O-methyl U. In other embodiments, at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% of the pyrimidines in the nucleic acid molecule are modified. 100% of the pyrimidines in the nucleic acid molecule are modified in other embodiments. The modified pyrimidines may be, for instance, 2′fluoro or 2′O methyl modified.

In some embodiments at least one U or C includes a hydrophobic modification. In other embodiments a plurality of U's and/or C's include a hydrophobic modification. The hydrophobic modification may be, for instance, a methyl or ethyl hydrophobic base modification.

The guide strand may include a number of phosphate backbone modifications, such as phosphorothioate modifications. The guide strand contains 6-8 phosphorothioate modifications in some embodiments. In other embodiments the 3′ terminal 10 nucleotides of the guide strand include at least eight phosphorothioate modifications. In yet other embodiments the guide strand includes 4-14 phosphate modifications. These modifications may be on the single stranded region, the double stranded region or both.

The nucleic acid molecule includes a single stranded and a double stranded region. The single stranded region of the guide strand, in some embodiments, is 6 nucleotides long. In other embodiments the single stranded region of the guide strand is 8 nucleotides long. The double stranded region may be 12-14 or 13 nucleotides long in other embodiments.

Optionally, the double stranded nucleic acid molecule has one end that is blunt or includes a one nucleotide overhang.

The passenger strand is linked at the 3′ end to a lipophilic group according to some embodiments. The lipophilic group may be a sterol, such as cholesterol.

The isolated double stranded nucleic acid molecule in some embodiments is an miRNA mimic. The miRNA sequence to which the guide strand is complementary in the miRNA mimic is a miRNA recognition element. In some embodiments the miRNA mimic is a mimic of an miRNA selected from the group consisting of miR21, miR 139, miR 7, miR29, miR 122, miR 302-367 cluster, miR 221, miR-96, miR 126, miR 225 and miR 206.

In other embodiments the isolated double stranded nucleic acid molecule is an miRNA inhibitor. The miRNA sequence to which the guide strand is complementary in the miRNA inhibitor is an antisense strand of a mature miRNA. In some embodiments the guide strand is at least 50% chemically modified. In other embodiments the mature miRNA is miR 17-92.

According to aspects of the invention, a method for modulating miRNA-mediated gene expression in a mammalian cell is provided. The method involves contacting the mammalian cell with an isolated double stranded nucleic acid molecule described herein in an effective amount to modulate miRNA-mediated gene expression. In some embodiments miRNA-mediated gene expression in the mammalian cell is reduced. In other embodiments miRNA-mediated gene expression in the mammalian cell is increased. The mammalian cell may contacted with the isolated nucleic acid in vivo, ex vivo, or in vitro.

The invention also involves in other aspects a method for modulating miRNA-mediated gene expression in a stem cell. The method involves contacting the stem cell with an isolated double stranded nucleic acid molecule described herein in an effective amount to modulate miRNA-mediated gene expression in the stem cell. The methods are useful for example in promoting or inhibiting stem cell differentiation, tissue remodeling, organ preservation etc.

Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention. This invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways.

BRIEF DESCRIPTION OF DRAWINGS

The accompanying drawings are not intended to be drawn to scale. In the drawings, each identical or nearly identical component that is illustrated in various figures is represented by a like numeral. For purposes of clarity, not every component may be labeled in every drawing. In the drawings:

FIGS. 1A-1D are a schematic depicting proposed structures of asymmetric double stranded RNA molecules (adsRNA). Bold lines represent sequences carrying modification patterns compatible with RISC loading. Striped lines represent polynucleotides carrying modifications compatible with passenger strands. Plain lines represent a single stranded polynucleotide with modification patterns optimized for cell interaction and uptake. FIG. 1A depicts adsRNA with extended guide or passenger strands; FIG. 1B depicts adsRNA with length variations of a cell penetrating polynucleotide; FIG. 1C depicts adsRNA with 3′ and 5′ conjugates; FIG. 1D depicts adsRNAs with mismatches.

FIG. 2 is a schematic depicting asymmetric dsRNA molecules with different chemical modification patterns. Several examples of chemical modifications that might be used to increase hydrophobicity are shown including 4-pyridyl, 2-pyridyl, isobutyl and indolyl based position 5 uridine modifications.

FIG. 3 is a schematic depicting the use of dsRNA binding domains, protamine (or other Arg rich peptides), spermidine or similar chemical structures to block duplex charge to facilitate cellular entry.

FIG. 4 is a schematic depicting positively charged chemicals that might be used for polynucleotide charge blockage.

FIG. 5 is a schematic depicting examples of structural and chemical compositions of single stranded RISC entering polynucleotides. The combination of one or more modifications including 2′d, 2′Ome, 2′F, hydrophobic and phosphorothioate modifications can be used to optimize single strand entry into the RISC.

FIG. 6 is a schematic depicting examples of structural and chemical composition of RISC substrate inhibitors. Combinations of one or more chemical modifications can be used to mediate efficient uptake and efficient binding to preloaded RISC complex.

FIGS. 7A-7D are a schematic depicting structures of polynucleotides with sterol type molecules attached, where R represent a polycarbonic tail of 9 carbons or longer. FIG. 7A depicts an adsRNA molecule; FIG. 7B depicts an siRNA molecule of approximately 17-30 bp long; FIG. 7C depicts a RISC entering strand; FIG. 7D depicts a substrate analog strand. Chemical modification patterns, as depicted in FIGS. 7A-7D, can be optimized to promote desired function.

FIG. 8 is a schematic depicting examples of naturally occurring phytosterols with a polycarbon chain that is longer than 8, attached at position 17. More than 250 different types of phytosterols are known.

FIG. 9 is a schematic depicting examples of sterol-like structures, with variations in the size of the polycarbon chains attached at position 17.

FIG. 10 presents schematics and graphs demonstrating that the percentage of liver uptake and plasma clearance of lipid emulsions containing sterol type molecules is directly affected by the size of the polycarbon chain attached at position 17. This figure is adapted from Martins et al, Journal of Lipid Research (1998).

FIGS. 11A-11C are a schematic depicting micelle formation. FIG. 11A depicts a polynucleotide with a hydrophobic conjugate; FIG. 11B depicts linoleic acid; FIG. 11C depicts a micelle formed from a mixture of polynucleotides containing hydrophobic conjugates combined with fatty acids.

FIG. 12 is a schematic depicting how alteration in lipid composition can affect pharmacokinetic behavior and tissue distribution of hydrophobically modified and/or hydrophobically conjugated polynucleotides. In particular, use of lipid mixtures enriched in linoleic acid and cardiolipin results in preferential uptake by cardiomyocites.

FIG. 13 is a schematic showing examples of RNAi constructs and controls used to target MAP4K4 expression. RNAi construct 12083 corresponds to SEQ ID NOs:597 and 598. RNAi construct 12089 corresponds to SEQ ID NO:599.

FIG. 14 is a graph showing MAP4K4 expression following transfection with RNAi constructs associated with the invention. RNAi constructs tested were: 12083 (Nicked), 12085 (13nt Duplex), 12089 (No Stem Pairing) and 12134 (13nt miniRNA). Results of transfection were compared to an untransfected control sample. RNAi construct 12083 corresponds to SEQ ID NOs:597 and 598. RNAi construct 12085 corresponds to SEQ ID NOs:600 and 601. RNAi construct 12089 corresponds to SEQ ID NO:599. RNAi construct 12134 corresponds to SEQ ID NOs:602 and 603.

FIG. 15 is a graph showing expression of MAP4K4 24 hours post-transfection with RNAi constructs associated with the invention. RNAi constructs tested were: 11546 (MAP4K4 rxRNA), 12083 (MAP4K4 Nicked Construct), 12134 (12bp soloRNA) and 12241 (14/3/14 soloRNA). Results of transfection were compared to a filler control sample. RNAi construct 11546 corresponds to SEQ ID NOs:604 and 605. RNAi construct 12083 corresponds to SEQ ID NOs:597 and 598. RNAi construct 12134 corresponds to SEQ ID NOs:602 and 603. RNAi construct 12241 corresponds to SEQ ID NOs:606 and 607.

FIG. 16 presents a graph and several tables comparing parameters associated with silencing of MAP4K4 expression following transfection with RNAi constructs associated with the invention. The rxRNA construct corresponds to SEQ ID NOs:604 and 605. The 14-3-14 soloRNA construct corresponds to SEQ ID NOs:606 and 607. The 13/19 duplex (nicked construct) corresponds to SEQ ID NOs:597 and 598. The 12-bp soloRNA construct corresponds to SEQ ID NOs:602 and 603.

FIG. 17 is a schematic showing examples of RNAi constructs and controls used to target SOD1 expression. The 12084 RNAi construct corresponds to SEQ ID NOs:612 and 613.

FIG. 18 is a graph showing SOD1 expression following transfection with RNAi constructs associated with the invention. RNAi constructs tested were: 12084 (Nicked), 12086 (13nt Duplex), 12090 (No Stem Pairing) and 12035 (13nt MiniRNA). Results of transfection were compared to an untransfected control sample. The 12084 RNAi construct corresponds to SEQ ID NOs:612 and 613. The 12086 RNAi construct corresponds to SEQ ID NOs:608 and 609. The 12035 RNAi construct corresponds to

SEQ ID NOs:610 and 611.

FIG. 19 is a graph showing expression of SOD1 24 hours post-transfection with RNAi constructs associated with the invention. RNAi constructs tested were: 10015 (SOD1 rxRNA) and 12084 (SOD1 Nicked Construct). Results of transfection were compared to a filler control sample. The 10015 RNAi construct corresponds to SEQ ID NOs:614 and 615. The 12084 RNAi construct corresponds to SEQ ID NOs:612 and 613.

FIG. 20 is a schematic indicating that RNA molecules with double stranded regions that are less than 10 nucleotides are not cleaved by Dicer.

FIG. 21 is a schematic revealing a hypothetical RNAi model for RNA induced gene silencing.

FIG. 22 is a graph showing chemical optimization of asymmetric RNAi compounds. The presence of chemical modifications, in particular 2′F UC, phosphorothioate modifications on the guide strand, and complete CU 2′OMe modification of the passenger strands results in development of functional compounds. Silencing of MAP4K4 following lipid-mediated transfection is shown using RNAi molecules with specific modifications. RNAi molecules tested had sense strands that were 13 nucleotides long and contained the following modifications: unmodified; C and U 2′OMe; C and U 2′OMe and 3′ Chl; rxRNA 2′OMe pattern; or full 2′OMe, except base 1. Additionally, the guide (anti-sense) strands of the RNAi molecules tested contained the following modifications: unmodified; unmodified with 5′P; C and U 2′F; C and U 2′F with 8 PS 3′ end; and unmodified (17 nt length). Results for rxRNA 12/10 Duplex and negative controls are also shown.

FIG. 23 demonstrates that the chemical modifications described herein significantly increase in vitro efficacy in un-assisted delivery of RNAi molecules in HeLa cells. The structure and sequence of the compounds were not altered; only the chemical modification patterns of the molecules were modified. Compounds lacking 2′F, 2′O-me, phosphorothioate modification, or cholesterol conjugates were completely inactive in passive uptake. A combination of all 4 of these types of modifications produced the highest levels of activity (compound 12386).

FIG. 24 is a graph showing MAP4K4 expression in Hela cells following passive uptake transfection of: NT Accell modified siRNA, MAP4K4 Accell siRNA, Non-Chl nanoRNA (12379) and sd-nanoRNA (12386).

FIG. 25 is a graph showing expression of MAP4K4 in HeLa cells following passive uptake transfection of various concentrations of RNA molecules containing the following parameters: Nano Lead with no 3′Chl; Nano Lead; Accell MAP4K4; 21mer GS with 8 PS tail; 21mer GS with 12 PS tail; and 25mer GS with 12 PS tail.

FIG. 26 is a graph demonstrating that reduction in oligonucleotide content increases the efficacy of unassisted uptake. Similar chemical modifications were applied to asymmetric compounds, traditional siRNA compounds and 25 mer RNAi compounds. The asymmetric small compounds demonstrated the most significant efficacy.

FIGS. 27A and 27B are graphs demonstrating the importance of phosphorothioate content for un-assisted delivery. FIG. 27A demonstrates the results of a systematic screen that revealed that the presence of at least 2-12 phosphorothioates in the guide strand significantly improves uptake; in some embodiments, 4-8 phosphorothioate modifications were found to be preferred. FIG. 27B reveals that the presence or absence of phosphorothioate modifications in the sense strand did not alter efficacy.

FIG. 28 is a graph showing expression of MAP4K4 in primary mouse hepatocytes following passive uptake transfection of: Accell Media-Ctrl-UTC; MM APOB Alnylam; Active APOB Alnylam; nanoRNA without chl; nanoRNA MAP4K4; Mouse MAP4K4 Accell Smartpool; DY547 Accell Control; Luc Ctrl rxRNA with Dy547; MAP4K4 rxRNA with DY547; and AS Strand Alone (nano).

FIG. 29 is a graph showing expression of ApoB in mouse primary hepatocytes following passive uptake transfection of: Accell Media-Ctrl-UTC; MM APOB Alnylam; Active APOB Alnylam; nanoRNA without chl; nanoRNA MAP4K4; Mouse MAP4K4 Accell Smartpool; DY547 Accell Control; Luc Ctrl rxRNA with Dy547; MAP4K4 rxRNA with DY547; and AS Strand Alone (nano).

FIG. 30 is a graph showing expression of MAP4K4 in primary human hepatocytes following passive uptake transfection of: 11550 MAP4K4 rxRNA; 12544 MM MAP4K4 nanoRNA; 12539 Active MAP4K4 nanoRNA; Accell Media; and UTC.

FIG. 31 is a graph showing ApoB expression in primary human hepatoctyes following passive uptake transfection of: 12505 Active ApoB chol-siRNA; 12506 MM ApoB chol-siRNA; Accell Media; and UTC.

FIG. 32 is an image depicting localization of sd-rxRNA^(nano) localization. FIG. 33 is an image depicting localization of Chol-siRNA (Alnylam).

FIG. 34 is a schematic of 1^(st) generation (G1) sd-rxRNA^(nano) molecules associated with the invention indicating regions that are targeted for modification, and functions associated with different regions of the molecules.

FIG. 35 depicts modification patterns that were screened for optimization of sd-rxRNA^(nano) (G1). The modifications that were screened included, on the guide strand, lengths of 19, 21 and 25 nucleotides, phosphorothioate modifications of 0-18 nucleotides, and replacement of 2′F modifications with 2′OMe, 5 Methyl C and/or ribo Thymidine modifications. Modifications on the sense strand that were screened included nucleotide lengths of 11, 13 and 19 nucleotides, phosphorothiote modifications of 0-4 nucleotides and 2′OMe modifications.

FIG. 36 is a schematic depicting modifications of sd-rxRNA^(nano) that were screened for optimization.

FIG. 37 is a graph showing percent MAP4K4 expression in Hek293 cells following transfection of: Risc Free siRNA; rxRNA; Nano (unmodified); GS alone; Nano Lead (no Chl); Nano (GS: (3) 2′OMe at positions 1, 18, and 19, 8 PS, 19 nt); Nano (GS: (3) 2′OMe at positions 1, 18, and 19, 8 PS, 21 nt); Nano (GS: (3) 2′OMe at positions 1, 18, and 19, 12 PS, 21 nt); and Nano (GS: (3) 2′OMe at positions 1, 18, and 19, 12 PS, 25 nt);

FIG. 38 is a graph showing percent MAP4K4 expression in HeLa cells following passive uptake transfection of: GS alone; Nano Lead; Nano (GS: (3) 2′OMe at positions 1, 18, and 19, 8 PS, 19 nt); Nano (GS: (3) 2′OMe at positions 1, 18, and 19, 8 PS, 21 nt); Nano (GS: (3) 2′OMe at positions 1, 18, and 19, 12 PS, 21 nt); Nano (GS: (3) 2′OMe at positions 1, 18, and 19, 12 PS, 25 nt).

FIG. 39 is a graph showing percent MAP4K4 expression in Hek293 cells following lipid mediated transfection of: Guide Strand alone (GS: 8PS, 19 nt); Guide Strand alone (GS: 18PS, 19 nt); Nano (GS: no PS, 19 nt); Nano (GS: 2 PS, 19 nt); Nano (GS: 4 PS, 19 nt); Nano (GS: 6 PS, 19 nt); Nano Lead (GS: 8 PS, 19 nt); Nano (GS: 10 PS, 19 nt); Nano (GS: 12 PS, 19 nt); and Nano (GS: 18 PS, 19 nt).

FIG. 40 is a graph showing percent MAP4K4 expression in Hek293 cells following lipid mediated transfection of: Guide Strand alone (GS: 8PS, 19 nt); Guide Strand alone (GS: 18PS, 19 nt); Nano (GS: no PS, 19 nt); Nano (GS: 2 PS, 19 nt); Nano (GS: 4 PS, 19 nt); Nano (GS: 6 PS, 19 nt); Nano Lead (GS: 8 PS, 19 nt); Nano (GS: 10 PS, 19 nt); Nano (GS: 12 PS, 19 nt); and Nano (GS: 18 PS, 19 nt).

FIG. 41 is a graph showing percent MAP4K4 expression in HeLa cells following passive uptake transfection of: Nano Lead (no Chl); Guide Strand alone (18 PS); Nano (GS: 0 PS, 19 nt); Nano (GS: 2 PS, 19 nt); Nano (GS: 4 PS, 19 nt); Nano (GS: 6 PS, 19 nt); Nano Lead (GS: 8 PS, 19 nt); Nano (GS: 10 PS, 19 nt); Nano (GS: 12 PS, 19 nt); and

Nano (GS: 18 PS, 19 nt).

FIG. 42 is a graph showing percent MAP4K4 expression in HeLa cells following passive uptake transfection of: Nano Lead (no Chl); Guide Strand alone (18 PS); Nano (GS: 0 PS, 19 nt); Nano (GS: 2 PS, 19 nt); Nano (GS: 4 PS, 19 nt); Nano (GS: 6 PS, 19 nt); Nano Lead (GS: 8 PS, 19 nt); Nano (GS: 10 PS, 19 nt); Nano (GS: 12 PS, 19 nt); and Nano (GS: 18 PS, 19 nt).

FIG. 43 is a schematic depicting guide strand chemical modifications that were screened for optimization.

FIG. 44 is a graph showing percent MAP4K4 expression in Hek293 cells following reverse transfection of: RISC free siRNA; GS only (2′F C and Us); GS only (2′OMe C and Us); Nano Lead (2′F C and Us); nano (GS: (3) 2′OMe, positions 16-18); nano (GS: (3) 2′OMe, positions 16, 17 and 19); nano (GS: (4) 2′OMe, positions 11, 16-18); nano (GS: (10) 2′OMe,C and Us); nano (GS: (6) 2′OMe, positions 1 and 5-9); nano (GS: (3) 2′OMe, positions 1, 18 and 19); and nano (GS: (5) 2′OMe Cs).

FIG. 45 is a graph demonstrating efficacy of various chemical modification patterns. In particular, 2-OMe modification in positions 1 and 11-18 was well tolerated. 2′OMe modifications in the seed area resulted in a slight reduction of efficacy (but were still highly efficient). Ribo-modifications in the seed were well tolerated. This data enabled the generation of self delivering compounds with reduced or no 2′F modifications. This is significant because 2′F modifications may be associated with toxicity in vivo.

FIG. 46 is a schematic depicting sense strand modifications.

FIG. 47 is a graph demonstrating sense strand length optimization. A sense strand length between 10-15 bases was found to be optimal in this assay. Increasing sense strand length resulted in a reduction of passive uptake of these compounds but may be tolerated for other compounds. Sense strands containing LNA modification demonstrated similar efficacy to non-LNA containing compounds. In some embodiments, the addition of LNA or other thermodynamically stabilizing compounds can be beneficial, resulting in converting non-functional sequences into functional sequences.

FIG. 48 is a graph showing percent MAP4K4 expression in HeLa cells following passive uptake transfection of: Guide Strand Alone (2′F C and U); Nano Lead; Nano Lead (No Chl); Nano (SS: 11 nt 2′OMe C and Us, Chl); Nano (SS: lint, complete 2′OMe, Chl); Nano (SS: 19 nt, 2′OMe C and Us, Chl); Nano (SS: 19 nt, 2′OMe C and Us, no Chl).

FIG. 49 is a graph showing percent MAP4K4 expression in HeLa cells following passive uptake transfection of: Nano Lead (No Chl); Nano (SS no PS); Nano Lead (SS:2 PS); Nano (SS:4 PS).

FIG. 50 is a schematic depicting a sd-rxRNA^(nano) second generation (GII) lead molecule.

FIG. 51 presents a graph indicating EC50 values for MAP4K4 silencing in the presence of sd-rxRNA, and images depicting localization of DY547-labeled rxRNA^(ori) and DY547-labeled sd-rxRNA.

FIG. 52 is a graph showing percent MAP4K4 expression in HeLa cells in the presence of optimized sd-rxRNA molecules.

FIG. 53 is a graph depicting the relevance of chemistry content in optimization of sd-rxRNA efficacy.

FIG. 54 presents schematics of sterol-type molecules and a graph revealing that sd-rxRNA compounds are fully functional with a variety of linker chemistries. GII asymmetric compounds were synthesized with sterol type molecules attached through TEG and amino caproic acid linkers. Both linkers showed identical potency. This functionality independent of linker chemistry indicates a significant difference between the molecules described herein and previously described molecules, and offers significant advantages for the molecules described herein in terms of scale up and synthesis.

FIG. 55 demonstrates the stability of chemically modified sd-rxRNA compounds in human serum in comparison to non modified RNA. The oligonucleotides were incubated in 75% serum at 37 ° C. for the number of hours indicated. The level of degradation was determined by running the samples on non-denaturing gels and staining with SYBGR.

FIG. 56 is a graph depicting optimization of cellular uptake of sd-rxRNA through minimizing oligonucleotide content.

FIG. 57 is a graph showing percent MAP4K4 expression after spontaneous cellular uptake of sd-rxRNA in mouse PEC-derived macrophages, and phase and fluorescent images showing localization of sd-rxRNA.

FIG. 58 is a graph showing percent MAP4K4 expression after spontaneous cellular uptake of sd-rxRNA (targeting) and sd-rxRNA (mismatch) in mouse primary hepatocytes, and phase and fluorescent images showing localization of sd-rxRNA.

FIG. 59 presents images depicting localization of DY547-labeled sd-rxRNA delivered to RPE cells with no formulation.

FIG. 60 is a graph showing silencing of MAP4K4 expression in RPE cells treated with sd-rxRNA^(nano) without formulation.

FIG. 61 presents a graph and schematics of RNAi compounds showing the chemical/ structural composition of highly effective sd-rxRNA compounds. Highly effective compounds were found to have the following characteristics: anti sense strands of 17-21 nucleotides, sense strands of 10-15 nucleotides, single-stranded regions that contained 2-12 phosphorothioate modifications, preferentially 6-8 phosphorothioate modifications, and sense strands in which the majority of nucleotides were 2′OMe modified, with or without phosphorothioate modification. Any linker chemistry can be used to attach these molecules to hydrophobic moieties such as cholesterol at the 3′ end of the sense strand. Version GIIa-b of these RNA compounds demonstrate that elimination of 2′F content has no impact on efficacy.

FIG. 62 presents a graph and schematics of RNAi compounds demonstrating the superior performance of sd-rxRNA compounds compared to compounds published by Wolfrum et. al. Nature Biotech, 2007. Both generation I and II compounds (GI and GIIa) developed herein show great efficacy. By contrast, when the chemistry described in Wolfrum et al. (all oligos contain cholesterol conjugated to the 3′ end of the sense strand) was applied to the same sequence in a context of conventional siRNA (19 bp duplex with two overhang) the compound was practically inactive. These data emphasize the significance of the combination of chemical modifications and asymmetrical molecules described herein, producing highly effective RNA compounds.

FIG. 63 presents images showing that sd-rxRNA accumulates inside cells while other less effective conjugate RNAs accumulate on the surface of cells.

FIG. 64 presents images showing that sd-rxRNA molecules, but not other molecules, are internalized into cells within minutes.

FIGS. 65A-65F present images demonstrating that sd-rxRNA compounds have drastically better cellular and tissue uptake characteristics when compared to conventional cholesterol conjugated siRNAs (such as those published by Soucheck et al). FIG. 65A-65B compare uptake in RPE cells, FIG. 65C-65D compare uptake upon local administration to skin and FIG. 65E-65F compare uptake by the liver upon systemic administration. The level of uptake is at least an order of magnitude higher for the sd-rxRNA compounds relative to the regular siRNA-cholesterol compounds.

FIG. 66 presents images depicting localization of rxRNA^(ori) and sd-rxRNA following local delivery.

FIG. 67 presents images depicting localization of sd-rxRNA and other conjugate RNAs following local delivery.

FIG. 68 presents a graph revealing the results of a screen performed with sd-rxRNAGII chemistry to identify functional compounds targeting the SPP1 gene. Multiple effective compounds were identified, with 14131 being the most effective. The compounds were added to A-549 cells and the level of the ratio of SPP 1/PPM was determined by B-DNA after 48 hours.

FIG. 69 presents a graph and several images demonstrating efficient cellular uptake of sd-rxRNA within minutes of exposure. This is a unique characteristics of the sd-rxRNA compounds described herein, not observed with any other RNAi compounds. The Soutschek et al. compound was used as a negative control.

FIG. 70 presents a graph and several images demonstrating efficient uptake and silencing of sd-rxRNA compounds in multiple cell types with multiple sequences. In each case silencing was confirmed by looking at target gene expression using a Branched DNA assay.

FIG. 71 presents a graph revealing that sd-rxRNA is active in the presence and absence of serum. A slight reduction in efficacy (2-5 fold) was observed in the presence of serum. This minimal reduction in efficacy in the presence of serum differentiates the sd-rxRNA compounds described herein from previously described RNAi compounds, which had a greater reduction in efficacy, and thus creates a foundation for in vivo efficacy of the sd-rxRNA molecules described herein.

FIG. 72 presents images demonstrating efficient tissue penetration and cellular uptake upon single intradermal injection of sd-rxRNA compounds described herein. This represents a model for local delivery of sd-rxRNA compounds as well as an effective demonstration of delivery of sd-rxRNA compounds and silencing of genes in dermatological applications.

FIG. 73 presents images and a graph demonstrating efficient cellular uptake and in vivo silencing with sd-rxRNA following intradermal injection.

FIG. 74 presents graphs demonstrating that sd-rxRNA compounds have improved blood clearance and induce effective gene silencing in vivo in the liver upon systemic administration.

FIG. 75 presents a graph demonstrating that the presence of 5-Methyl C in an RNAi compound resulted in an increase in potency of lipid mediated transfection, demonstrating that hydrophobic modification of Cs and Us in the content of RNAi compounds can be beneficial. In some embodiments, these types of modifications can be used in the context of 2′ ribose modified bases to insure optimal stability and efficacy.

FIG. 76 presents a graph showing percent MAP4K4 expression in HeLa cells following passive uptake transfection of: Guide strand alone; Nano Lead; Nano Lead (No cholesterol); Guide Strand w/5MeC and 2′F Us Alone; Nano Lead w/GS 5MeC and 2′F Us; Nano Lead w/GS riboT and 5 Methyl Cs; and Nano Lead w/Guide dT and 5 Methyl Cs.

FIG. 77 presents images comparing localization of sd-rxRNA and other RNA conjugates following systemic delivery to the liver.

FIG. 78A presents schematics demonstrating 5-uridyl modifications with improved hydrophobicity characteristics. Incorporation of such modifications into sd-rxRNA compounds can increase cellular and tissue uptake properties. FIG. 78B presents a new type of RNAi compound modification which can be applied to compounds to improve cellular uptake and pharmacokinetic behavior. This type of modification, when applied to sd-rxRNA compounds, may contribute to making such compounds orally available.

FIG. 79 presents schematics revealing the structures of synthesized modified sterol type molecules, where the length and structure of the C17 attached tail is modified. Without wishing to be bound by any theory, the length of the C17 attached tail may contribute to improving in vitro and in vivo efficacy of sd-rxRNA compounds.

FIG. 80 presents a schematic demonstrating the lithocholic acid route to long side chain cholesterols.

FIG. 81 presents a schematic demonstrating a route to 5-uridyl phosphoramidite synthesis.

FIG. 82 presents a schematic demonstrating synthesis of tri-functional hydroxyprolinol linker for 3′-cholesterol attachment.

FIG. 83 presents a schematic demonstrating synthesis of solid support for the manufacture of a shorter asymmetric RNAi compound strand.

FIG. 84 demonstrates SPPI sd-rxRNA compound selection. Sd-rxRNA compounds targeting SPP1 were added to A549 cells (using passive transfection) and the level of SPP1 expression was evaluated after 48 hours. Several novel compounds effective in SPP1 silencing were identified, the most potent of which was compound 14131.

FIG. 85 demonstrates independent validation of sd-rxRNA compounds 14116, 14121, 14131, 14134, 14139, 14149, and 14152 efficacy in SPP1 silencing.

FIG. 86 demonstrates results of sd-rxRNA compound screens to identify sd-rxRNA compounds functional in CTGF knockdown.

FIG. 87 demonstrates results of sd-rxRNA compound screens to identify sd-rxRNA functional in CTGF knockdown.

FIG. 88 demonstrates a systematic screen identifying the minimal length of the asymmetric compounds. The passenger strand of 10-19 bases was hybridized to a guide strand of 17-25 bases. In this assay, compounds with duplex regions as short as 10 bases were found to be effective in inducing.

FIG. 89 demonstrates that positioning of the sense strand relative to the guide strand is critical for RNAi Activity. In this assay, a blunt end was found to be optimal, a 3′ overhang was tolerated, and a 5′ overhang resulted in complete loss of functionality.

FIG. 90 demonstrates that the guide strand, which has homology to the target only at nucleotides 2-17, resulted in effective RNAi when hybridized with sense strands of different lengths. The compounds were introduced into HeLa cells via lipid mediated transfection.

FIG. 91 is a schematic depicting a panel of sterol-type molecules which can be used as a hydrophobic entity in place of cholesterol. In some instances, the use of sterol-type molecules comprising longer chains results in generation of sd-rxRNA compounds with significantly better cellular uptake and tissue distribution properties.

FIG. 92 presents schematics depicting a panel of hydrophobic molecules which might be used as a hydrophobic entity in place of cholesterol. These list just provides representative examples; any small molecule with substantial hydrophobicity can be used.

DETAILED DESCRIPTION

Aspects of the invention relate to methods and compositions involved in gene silencing. The invention is based at least in part on the surprising discovery that asymmetric nucleic acid molecules with a double stranded region of a minimal length such as 8-14 nucleotides, are effective in silencing gene expression. Molecules with such a short double stranded region have not previously been demonstrated to be effective in mediating RNA interference. It had previously been assumed that that there must be a double stranded region of 19 nucleotides or greater. The molecules described herein are optimized through chemical modification, and in some instances through attachment of hydrophobic conjugates.

The invention is based at least in part on another surprising discovery that asymmetric nucleic acid molecules with reduced double stranded regions are much more effectively taken up by cells compared to conventional siRNAs. These molecules are highly efficient in silencing of target gene expression and offer significant advantages over previously described RNAi molecules including high activity in the presence of serum, efficient self delivery, compatibility with a wide variety of linkers, and reduced presence or complete absence of chemical modifications that are associated with toxicity.

In contrast to single-stranded polynucleotides, duplex polynucleotides have been difficult to deliver to a cell as they have rigid structures and a large number of negative charges which makes membrane transfer difficult. Unexpectedly, it was found that the polynucleotides of the present invention, although partially double-stranded, are recognized in vivo as single-stranded and, as such, are capable of efficiently being delivered across cell membranes. As a result the polynucleotides of the invention are capable in many instances of self delivery. Thus, the polynucleotides of the invention may be formulated in a manner similar to conventional RNAi agents or they may be delivered to the cell or subject alone (or with non-delivery type carriers) and allowed to self deliver. In one embodiment of the present invention, self delivering asymmetric double-stranded RNA molecules are provided in which one portion of the molecule resembles a conventional RNA duplex and a second portion of the molecule is single stranded.

The polynucleotides of the invention are referred to herein as isolated double stranded or duplex nucleic acids, oligonucleotides or polynucleotides, nano molecules, nano RNA, sd-rxRNA^(nano), sd-rxRNA or RNA molecules of the invention.

The oligonucleotides of the invention in some aspects have a combination of asymmetric structures including a double stranded region and a single stranded region of 5 nucleotides or longer, specific chemical modification patterns and are conjugated to lipophilic or hydrophobic molecules. This new class of RNAi like compounds have superior efficacy in vitro and in vivo. Based on the data described herein it is believed that the reduction in the size of the rigid duplex region in combination with phosphorothioate modifications applied to a single stranded region are new and important for achieving the observed superior efficacy. Thus, the RNA molecules described herein are different in both structure and composition as well as in vitro and in vivo activity.

In a preferred embodiment the RNAi compounds of the invention comprise an asymmetric compound comprising a duplex region (required for efficient RISC entry of 10-15 bases long) and single stranded region of 4-12 nucleotides long; with a 13 nucleotide duplex. A 6 nucleotide single stranded region is preferred in some embodiments. The single stranded region of the new RNAi compounds also comprises 2-12 phosphorothioate internucleotide linkages (referred to as phosphorothioate modifications). 6-8 phosphorothioate internucleotide linkages are preferred in some embodiments. Additionally, the RNAi compounds of the invention also include a unique chemical modification pattern, which provides stability and is compatible with RISC entry. The combination of these elements has resulted in unexpected properties which are highly useful for delivery of RNAi reagents in vitro and in vivo.

The chemically modification pattern, which provides stability and is compatible with RISC entry includes modifications to the sense, or passenger, strand as well as the antisense, or guide, strand. For instance the passenger strand can be modified with any chemical entities which confirm stability and do not interfere with activity. Such modifications include 2′ ribo modifications (O-methyl, 2′ F, 2 deoxy and others) and backbone modification like phosphorothioate modifications. A preferred chemical modification pattern in the passenger strand includes O-methyl modification of C and U nucleotides within the passenger strand or alternatively the passenger strand may be completely O-methyl modified.

The guide strand, for example, may also be modified by any chemical modification which confirms stability without interfering with RISC entry. A preferred chemical modification pattern in the guide strand includes the majority of C and U nucleotides being 2′F modified and the 5′end being phosphorylated. Another preferred chemical modification pattern in the guide strand includes 2′Omethyl modification of position 1 and C/U in positions 11-18 and 5′end chemical phosphorylation. Yet another preferred chemical modification pattern in the guide strand includes 2′Omethyl modification of position 1 and C/U in positions 11-18 and 5′ end chemical phosphorylation and 2′F modification of C/U in positions 2-10.

It was surprisingly discovered according to the invention that the above-described chemical modification patterns of the oligonucleotides of the invention are well tolerated and actually improved efficacy of asymmetric RNAi compounds. See, for instance, FIG. 22.

It was also demonstrated experimentally herein that the combination of modifications to RNAi when used together in a polynucleotide results in the achievement of optimal efficacy in passive uptake of the RNAi. Elimination of any of the described components (Guide strand stabilization, phosphorothioate stretch, sense strand stabilization and hydrophobic conjugate) or increase in size results in sub-optimal efficacy and in some instances complete lost of efficacy. The combination of elements results in development of compound, which is fully active following passive delivery to cells such as HeLa cells. (FIG. 23). The degree to which the combination of elements results in efficient self delivery of RNAi molecules was completely unexpected.

The data shown in FIGS. 26, 27 and 43 demonstrated the importance of the various modifications to the RNAi in achieving stabilization and activity. For instance, FIG. 26 demonstrates that use off asymmetric configuration is important in getting efficacy in passive uptake. When the same chemical composition is applied to compounds of traditional configurations (19-21 bases duplex and 25 mer duplex) the efficacy was drastically decreased in a length dependent manner. FIG. 27 demonstrated a systematic screen of the impact of phosphorothioate chemical modifications on activity. The sequence, structure, stabilization chemical modifications, hydrophobic conjugate were kept constant and compound phosphorothioate content was varied (from 0 to 18 PS bond). Both compounds having no phosphorothioate linkages and having 18 phosphorothioate linkages were completely inactive in passive uptake. Compounds having 2-16 phosphorothioate linkages were active, with compounds having 4-10 phosphorothioate being the most active compounds.

The data in the Examples presented below demonstrates high efficacy of the oligonucleotides of the invention both in vitro in variety of cell types (supporting data) and in vivo upon local and systemic administration. For instance, the data compares the ability of several competitive RNAi molecules having different chemistries to silence a gene. Comparison of sd-rxRNA (oligonucleotides of the invention) with RNAs described in Soucheck et al. and Wolfrum at al., as applied to the same targeting region, demonstrated that only sd-rxRNA chemistry showed a significant functionality in passive uptake. The composition of the invention achieved EC50 values of 10-50 pM. This level of efficacy is un-attainable with conventional chemistries like those described in Sauthceck at al and Accell. Similar comparisons were made in other systems, such as in vitro (RPE cell line), in vivo upon local administration (wounded skin) and systemic (50 mg/kg) as well as other genes (FIGS. 65 and 68). In each case the oligonucleotides of the invention achieved better results. FIG. 64 includes data demonstrating efficient cellular uptake and resulting silencing by sd-rxRNA compounds only after 1 minute of exposure. Such an efficacy is unique to this composition and have not been seen with other types of molecules in this class. FIG. 70 demonstrates efficient uptake and silencing of sd-rxRNA compounds in multiple cell types with multiple sequences. The sd-rxRNA compounds are also active in cells in presence and absence of serum and other biological liquids. FIG. 71 demonstrates only a slight reduction in activity in the presence of serum. This ability to function in biologically aggressive environment effectively further differentiates sd-rxRNA compounds from other compounds described previously in this group, like Accell and Soucheck et al, in which uptake is drastically inhibited in a presence of serum.

Significant amounts of data also demonstrate the in vivo efficacy of the compounds of the invention. For instance FIGS. 72-74 involve multiple routes of in vivo delivery of the compounds of the invention resulting in significant activity. FIG. 72, for example, demonstrates efficient tissue penetration and cellular uptake upon single intradermal injection. This is a model for local delivery of sd-rxRNA compounds as well as an effective delivery mode for sd-rxRNA compounds and silencing genes in any dermatology applications. FIG. 73 demonstrated efficient tissue penetration, cellular uptake and silencing upon local in vivo intradermal injection of sd-rxRNA compounds. The data of FIG. 74 demonstrate that sd-rxRNA compounds result in highly effective liver uptake upon IV administration. Comparison to Souicheck at al molecule showed that the level of liver uptake at identical dose level was quite surprisingly, at least 50 fold higher with the sd-rxRNA compound than the Souicheck at al molecule.

The sd-rxRNA can be further improved in some instances by improving the hydrophobicity of compounds using of novel types of chemistries. For example one chemistry is related to use of hydrophobic base modifications. Any base in any position might be modified, as long as modification results in an increase of the partition coefficient of the base. The preferred locations for modification chemistries are positions 4 and 5 of the pyrimidines. Preferably the base modification is a methyl or ethyl modification. The major advantage of these positions is (a) ease of synthesis and (b) lack of interference with base-pairing and A form helix formation, which are essential for RISC complex loading and target recognition. Examples of these chemistries is shown in FIGS. 75-83. A version of sd-rxRNA compounds where multiple deoxy Uridines are present without interfering with overall compound efficacy was used. In addition major improvement in tissue distribution and cellular uptake might be obtained by optimizing the structure of the hydrophobic conjugate. In some of the preferred embodiment the structure of sterol is modified to alter (increase/ decrease) C17 attached chain. This type of modification results in significant increase in cellular uptake and improvement of tissue uptake prosperities in vivo.

This invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of “including,” “comprising,” or “having,” “containing,” “involving,” and variations thereof herein, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.

Thus, aspects of the invention relate to isolated double stranded nucleic acid molecules comprising a guide (antisense) strand and a passenger (sense) strand. As used herein, the term “double-stranded” refers to one or more nucleic acid molecules in which at least a portion of the nucleomonomers are complementary and hydrogen bond to form a double-stranded region. In some embodiments, the length of the guide strand ranges from 16-29 nucleotides long. In certain embodiments, the guide strand is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29 nucleotides long. The guide strand has complementarity to a target gene. Complementarity between the guide strand and the target gene may exist over any portion of the guide strand. Complementarity as used herein may be perfect complementarity or less than perfect complementarity as long as the guide strand is sufficiently complementary to the target that it mediates RNAi. In some embodiments complementarity refers to less than 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, or 1% mismatch between the guide strand and the target. Perfect complementarity refers to 100% complementarity. Thus the invention has the advantage of being able to tolerate sequence variations that might be expected due to genetic mutation, strain polymorphism, or evolutionary divergence. For example, siRNA sequences with insertions, deletions, and single point mutations relative to the target sequence have also been found to be effective for inhibition. Moreover, not all positions of a siRNA contribute equally to target recognition. Mismatches in the center of the siRNA are most critical and essentially abolish target RNA cleavage. Mismatches upstream of the center or upstream of the cleavage site referencing the antisense strand are tolerated but significantly reduce target RNA cleavage. Mismatches downstream of the center or cleavage site referencing the antisense strand, preferably located near the 3′ end of the antisense strand, e.g. 1, 2, 3, 4, 5 or 6 nucleotides from the 3′ end of the antisense strand, are tolerated and reduce target RNA cleavage only slightly.

While not wishing to be bound by any particular theory, in some embodiments, the guide strand is at least 16 nucleotides in length and anchors the Argonaute protein in RISC. In some embodiments, when the guide strand loads into RISC it has a defined seed region and target mRNA cleavage takes place across from position 10-11 of the guide strand. In some embodiments, the 5′ end of the guide strand is or is able to be phosphorylated. The nucleic acid molecules described herein may be referred to as minimum trigger RNA.

In some embodiments, the length of the passenger strand ranges from 8-14 nucleotides long. In certain embodiments, the passenger strand is 8, 9, 10, 11, 12, 13 or 14 nucleotides long. The passenger strand has complementarity to the guide strand. Complementarity between the passenger strand and the guide strand can exist over any portion of the passenger or guide strand. In some embodiments, there is 100% complementarity between the guide and passenger strands within the double stranded region of the molecule.

Aspects of the invention relate to double stranded nucleic acid molecules with minimal double stranded regions. In some embodiments the region of the molecule that is double stranded ranges from 8-14 nucleotides long. In certain embodiments, the region of the molecule that is double stranded is 8, 9, 10, 11, 12, 13 or 14 nucleotides long. In certain embodiments the double stranded region is 13 nucleotides long. There can be 100% complementarity between the guide and passenger strands, or there may be one or more mismatches between the guide and passenger strands. In some embodiments, on one end of the double stranded molecule, the molecule is either blunt-ended or has a one-nucleotide overhang. The single stranded region of the molecule is in some embodiments between 4-12 nucleotides long. For example the single stranded region can be 4, 5, 6, 7, 8, 9, 10, 11 or 12 nucleotides long. However, in certain embodiments, the single stranded region can also be less than 4 or greater than 12 nucleotides long. In certain embodiments, the single stranded region is 6 nucleotides long.

RNAi constructs associated with the invention can have a thermodynamic stability (ΔG) of less than -13 kkal/mol. In some embodiments, the thermodynamic stability (ΔG) is less than -20 kkal/mol. In some embodiments there is a loss of efficacy when (ΔG) goes below −21 kkal/mol. In some embodiments a (ΔG) value higher than −13 kkal/mol is compatible with aspects of the invention. Without wishing to be bound by any theory, in some embodiments a molecule with a relatively higher (ΔG) value may become active at a relatively higher concentration, while a molecule with a relatively lower (ΔG) value may become active at a relatively lower concentration. In some embodiments, the (ΔG) value may be higher than −9 kkcal/mol. The gene silencing effects mediated by the RNAi constructs associated with the invention, containing minimal double stranded regions, are unexpected because molecules of almost identical design but lower thermodynamic stability have been demonstrated to be inactive (Rana et al 2004).

Without wishing to be bound by any theory, results described herein suggest that a stretch of 8-10 bp of dsRNA or dsDNA will be structurally recognized by protein components of RISC or co-factors of RISC. Additionally, there is a free energy requirement for the triggering compound that it may be either sensed by the protein components and/or stable enough to interact with such components so that it may be loaded into the Argonaute protein. If optimal thermodynamics are present and there is a double stranded portion that is preferably at least 8 nucleotides then the duplex will be recognized and loaded into the RNAi machinery.

In some embodiments, thermodynamic stability is increased through the use of

LNA bases. In some embodiments, additional chemical modifications are introduced . Several non-limiting examples of chemical modifications include: 5′ Phosphate, 2′-O-methyl, 2′-O-ethyl, 2′-fluoro, ribothymidine, C-5 propynyl-dC (pdC) and C-5 propynyl-dU (pdU); C-5 propynyl-C (pC) and C-5 propynyl-U (pU); 5-methyl C, 5-methyl U, 5-methyl dC, 5-methyl dU methoxy, (2,6-diaminopurine), 5′-Dimethoxytrityl-N4-ethyl-2′-deoxyCytidine and MGB (minor groove binder). It should be appreciated that more than one chemical modification can be combined within the same molecule.

Molecules associated with the invention are optimized for increased potency and/or reduced toxicity. For example, nucleotide length of the guide and/or passenger strand, and/or the number of phosphorothioate modifications in the guide and/or passenger strand, can in some aspects influence potency of the RNA molecule, while replacing 2′-fluoro (2′F) modifications with 2′-O-methyl (2′OMe) modifications can in some aspects influence toxicity of the molecule. Specifically, reduction in 2′F content of a molecule is predicted to reduce toxicity of the molecule. The Examples section presents molecules in which 2′F modifications have been eliminated, offering an advantage over previously described RNAi compounds due to a predicted reduction in toxicity. Furthermore, the number of phosphorothioate modifications in an RNA molecule can influence the uptake of the molecule into a cell, for example the efficiency of passive uptake of the molecule into a cell. Preferred embodiments of molecules described herein have no 2′F modification and yet are characterized by equal efficacy in cellular uptake and tissue penetration. Such molecules represent a significant improvement over prior art, such as molecules described by Accell and Wolfrum, which are heavily modified with extensive use of 2′F.

In some embodiments, a guide strand is approximately 18-19 nucleotides in length and has approximately 2-14 phosphate modifications. For example, a guide strand can contain 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or more than 14 nucleotides that are phosphate-modified. The guide strand may contain one or more modifications that confer increased stability without interfering with RISC entry. The phosphate modified nucleotides, such as phosphorothioate modified nucleotides, can be at the 3′ end, 5′ end or spread throughout the guide strand. In some embodiments, the 3′ terminal 10 nucleotides of the guide strand contains 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 phosphorothioate modified nucleotides. The guide strand can also contain 2′F and/or 2′OMe modifications, which can be located throughout the molecule. In some embodiments, the nucleotide in position one of the guide strand (the nucleotide in the most 5′ position of the guide strand) is 2′OMe modified and/or phosphorylated. C and U nucleotides within the guide strand can be 2′F modified. For example, C and U nucleotides in positions 2-10 of a 19 nt guide strand (or corresponding positions in a guide strand of a different length) can be 2′F modified. C and U nucleotides within the guide strand can also be 2′OMe modified. For example, C and U nucleotides in positions 11-18 of a 19 nt guide strand (or corresponding positions in a guide strand of a different length) can be 2′OMe modified. In some embodiments, the nucleotide at the most 3′ end of the guide strand is unmodified. In certain embodiments, the majority of Cs and Us within the guide strand are 2′F modified and the 5′ end of the guide strand is phosphorylated. In other embodiments, position 1 and the Cs or Us in positions 11-18 are 2′OMe modified and the 5′ end of the guide strand is phosphorylated. In other embodiments, position 1 and the Cs or Us in positions 11-18 are 2′OMe modified, the 5′ end of the guide strand is phosphorylated, and the Cs or Us in position 2-10 are 2′F modified.

In some aspects, an optimal passenger strand is approximately 11-14 nucleotides in length. The passenger strand may contain modifications that confer increased stability. One or more nucleotides in the passenger strand can be 2′OMe modified. In some embodiments, one or more of the C and/or U nucleotides in the passenger strand is 2′OMe modified, or all of the C and U nucleotides in the passenger strand are 2′OMe modified. In certain embodiments, all of the nucleotides in the passenger strand are 2′OMe modified. One or more of the nucleotides on the passenger strand can also be phosphate-modified such as phosphorothioate modified. The passenger strand can also contain 2′ ribo, 2′F and 2 deoxy modifications or any combination of the above. As demonstrated in the Examples, chemical modification patterns on both the guide and passenger strand are well tolerated and a combination of chemical modifications is shown herein to lead to increased efficacy and self-delivery of RNA molecules.

Aspects of the invention relate to RNAi constructs that have extended single-stranded regions relative to double stranded regions, as compared to molecules that have been used previously for RNAi. The single stranded region of the molecules may be modified to promote cellular uptake or gene silencing. In some embodiments, phosphorothioate modification of the single stranded region influences cellular uptake and/or gene silencing. The region of the guide strand that is phosphorothioate modified can include nucleotides within both the single stranded and double stranded regions of the molecule. In some embodiments, the single stranded region includes 2-12 phosphorothioate modifications. For example, the single stranded region can include 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 phosphorothioate modifications. In some instances, the single stranded region contains 6-8 phosphorothioate modifications.

Molecules associated with the invention are also optimized for cellular uptake. In RNA molecules described herein, the guide and/or passenger strands can be attached to a conjugate. In certain embodiments the conjugate is hydrophobic. The hydrophobic conjugate can be a small molecule with a partition coefficient that is higher than 10. The conjugate can be a sterol-type molecule such as cholesterol, or a molecule with an increased length polycarbon chain attached to C17, and the presence of a conjugate can influence the ability of an RNA molecule to be taken into a cell with or without a lipid transfection reagent. The conjugate can be attached to the passenger or guide strand through a hydrophobic linker. In some embodiments, a hydrophobic linker is 5-12C in length, and/or is hydroxypyrrolidine-based. In some embodiments, a hydrophobic conjugate is attached to the passenger strand and the CU residues of either the passenger and/or guide strand are modified. In some embodiments, at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% of the CU residues on the passenger strand and/or the guide strand are modified. In some aspects, molecules associated with the invention are self-delivering (sd). As used herein, “self-delivery” refers to the ability of a molecule to be delivered into a cell without the need for an additional delivery vehicle such as a transfection reagent.

Aspects of the invention relate to selecting molecules for use in RNAi. Based on the data described herein, molecules that have a double stranded region of 8-14 nucleotides can be selected for use in RNAi. In some embodiments, molecules are selected based on their thermodynamic stability (ΔG). In some embodiments, molecules will be selected that have a (ΔG) of less than −13 kkal/mol. For example, the (ΔG) value may be −13, −14, −15, −16, −17, −18, −19, −21, −22 or less than −22 kkal/mol. In other embodiments, the (ΔG) value may be higher than −13 kkal/mol. For example, the (ΔG) value may be −12, ×11, ×10, ×9, ×8, ×7 or more than −7 kkal/mol. It should be appreciated that ΔG can be calculated using any method known in the art. In some embodiments ΔG is calculated using Mfold, available through the Mfold internet site (mfold.bioinfo.rpi.edu/cgi-bin/rna-forml.cgi). Methods for calculating ΔG are described in, and are incorporated by reference from, the following references: Zuker, M. (2003) Nucleic Acids Res., 31(13):3406-15; Mathews, D. H., Sabina, J., Zuker, M. and Turner, D. H. (1999) J. Mol. Biol. 288:911-940; Mathews, D. H., Disney, M. D., Childs, J. L., Schroeder, S. J., Zuker, M., and Turner, D. H. (2004) Proc. Natl. Acad. Sci. 101:7287-7292; Duan, S., Mathews, D. H., and Turner, D. H. (2006) Biochemistry 45:9819-9832; Wuchty, S., Fontana, W., Hofacker, I. L., and Schuster, P. (1999) Biopolymers 49:145-165.

Aspects of the invention relate to using nucleic acid molecules described herein, with minimal double stranded regions and/or with a (4G) of less than −13 kkal/mol, for gene silencing. RNAi molecules can be administered in vivo or in vitro, and gene silencing effects can be achieved in vivo or in vitro.

In certain embodiments, the polynucleotide contains 5′- and/or 3′-end overhangs. The number and/or sequence of nucleotides overhang on one end of the polynucleotide may be the same or different from the other end of the polynucleotide. In certain embodiments, one or more of the overhang nucleotides may contain chemical modification(s), such as phosphorothioate or 2′-OMe modification.

In certain embodiments, the polynucleotide is unmodified. In other embodiments, at least one nucleotide is modified. In further embodiments, the modification includes a 2′-H or 2′-modified ribose sugar at the 2nd nucleotide from the 5′-end of the guide sequence. The “2nd nucleotide” is defined as the second nucleotide from the 5′-end of the polynucleotide.

As used herein, “2′-modified ribose sugar” includes those ribose sugars that do not have a 2′-OH group. “2′-modified ribose sugar” does not include 2′-deoxyribose (found in unmodified canonical DNA nucleotides). For example, the 2′-modified ribose sugar may be 2′-0-alkyl nucleotides, 2′-deoxy-2′-fluoro nucleotides, 2′-deoxy nucleotides, or combination thereof.

In certain embodiments, the 2′-modified nucleotides are pyrimidine nucleotides (e.g., C/U). Examples of 2′-O-alkyl nucleotides include 2′-O-methyl nucleotides, or 2′-O-allyl nucleotides.

In certain embodiments, the miniRNA polynucleotide of the invention with the above-referenced 5′-end modification exhibits significantly (e.g., at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or more) less “off-target” gene silencing when compared to similar constructs without the specified 5′-end modification, thus greatly improving the overall specificity of the RNAi reagent or therapeutics.

As used herein, “off-target” gene silencing refers to unintended gene silencing due to, for example, spurious sequence homology between the antisense (guide) sequence and the unintended target mRNA sequence.

According to this aspect of the invention, certain guide strand modifications further increase nuclease stability, and/or lower interferon induction, without significantly decreasing RNAi activity (or no decrease in RNAi activity at all).

In some embodiments, the 5′-stem sequence may comprise a 2′-modified ribose sugar, such as 2′-O-methyl modified nucleotide, at the 2^(nd) nucleotide on the 5′-end of the polynucleotide and, in some embodiments, no other modified nucleotides. The hairpin structure having such modification may have enhanced target specificity or reduced off-target silencing compared to a similar construct without the 2′-O-methyl modification at said position.

Certain combinations of specific 5′-stem sequence and 3′-stem sequence modifications may result in further unexpected advantages, as partly manifested by enhanced ability to inhibit target gene expression, enhanced serum stability, and/or increased target specificity, etc.

In certain embodiments, the guide strand comprises a 2′-O-methyl modified nucleotide at the 2^(nd) nucleotide on the 5′-end of the guide strand and no other modified nucleotides.

In other aspects, the miniRNA structures of the present invention mediates sequence-dependent gene silencing by a microRNA mechanism. As used herein, the term “microRNA” (“miRNA”), also referred to in the art as “small temporal RNAs” (“stRNAs”), refers to a small (10-50 nucleotide) RNA which are genetically encoded (e.g., by viral, mammalian, or plant genomes) and are capable of directing or mediating RNA silencing. An “miRNA disorder” shall refer to a disease or disorder characterized by an aberrant expression or activity of an miRNA.

miRNAs are important modulators of cellular homeostasis and differention. Reduced levels of miRNA expreression or excessive expression of miRNA have been shown to be involved in many diseases. microRNAs are involved in down-regulating target genes in critical pathways, such as development and cancer, in mice, worms and mammals. In particular significant reduction of different miRNA expression is related to tumor development and progression. Gene silencing through a microRNA mechanism is achieved by specific yet, in some cases, imperfect base-pairing of the miRNA and its target messenger RNA (mRNA). Various mechanisms may be used in microRNA-mediated down-regulation of target mRNA expression.

miRNAs are noncoding RNAs of approximately 22 nucleotides which can regulate gene expression at the post transcriptional or translational level during plant and animal development. One common feature of miRNAs is that they are all excised from an approximately 70 nucleotide precursor RNA stem-loop termed pre-miRNA, probably by Dicer, an RNase III-type enzyme, or a homolog thereof. Naturally-occurring miRNAs are expressed by endogenous genes in vivo and are processed from a hairpin or stem-loop precursor (pre-miRNA or pri-miRNAs) by Dicer or other RNAses. miRNAs can exist transiently in vivo as a double-stranded duplex but only one strand is taken up by the RISC complex to direct gene silencing.

In some embodiments a version of sd-rxRNA compounds, which are effective in cellular uptake and modulating miRNA activity are described. Essentially the compounds are similar to RISC entering version but large strand chemical modification patterns are optimized in the way to block cleavage and act as an effective inhibitor of the RISC action. For example, the compound might be completely or mostly O-methyl modified with the PS content described previously. For these types of compounds the 5′ phosphorylation is not necessary. The presence of double stranded region is preferred as it is promotes cellular uptake and efficient RISC loading.

Finding a way to modulate miRNA expression is an important unresolved problem in miRNA based drug development. The invention describes novel miRNA modulating compounds (miRNA mimics and miRNA inhibitors). The miRNA modulating compounds of the invention have the same basic structural properties described herein for self delivering RNA. Exemplary, non-limiting, sequences of the miRNA modulating compounds of the invention are shown in Tables 4-5.

In general, the miRNA modulating compounds have two strands, a guide (or antisense) strand that is 18 -23 bases long and a passenger (or sense) strand that is 8-16 bases long. The size difference of the two strands results in a double stranded and a single strand region of the molecule. In some embodiments the single stranded region is substantially modified, for example, with phosphorothioates. The presence of this phosphorothioated region is believed to be important for improved PK/PD, tissue distribution and cellular uptake properties of these molecules.

In some instances it is preferred that the first position of the guide strand has a 2′O-methyl modification such as a 5P- 2 o-methyl U. The presence of this modification in the guide strand further promotes the association with and loading into RISC complex.

Preferably both strands of the miRNA modulators are extensively modified, as described herein. For instance many of the pyrimidines are preferably 2′ modified. These modifications contribute to the stability of the molecule.

Additionally the overall hydrophobicity of the miRNA modulating compounds of the invention is increased to enhance cellular entry. This may be accomplished through the presence of some hydrophobic modification in the bases. For instance, position 5 or 4 of uridines and cytidine may include hydrophobic base modifications. These modifications increase and promote RISC association, stability, specificity and cellular entry. An example of a preferred hydrophobic base modification is methyl or ethyl. The presence of these type of modifications appear to not interfere with RISC entry of the miRNA modulating compounds and actually seem to promotes RISC entry.

In addition to hydrophobic base modification, other hydrophobic moieties may be linked to the molecule. A preferred location for linkage of hydrophobic moieties is the 3′ end position of the passenger strand.

The compounds of the invention having these structural properties are excellent modulators of miRNA expression in vivo. Administration of these compounds is expected to mimic natural miRNA expression in a targeted cells or inhibit undesirable miRNA, depending on the specificity of the guide strand. These compounds are useful in modulating miRNA level and activity in many tissues, such as brain, spinal cord, tumors, liver, lung, kidney skin, heart, vasculature, and spleen. Additionally these compounds may be used ex vivo and in primary, dentritic or stem cells to modulate cellular properties prior to introduction or reintroduction of the cells into a subject. For instance they may be used in dendritic cells or primary tumors to help with a cancer vaccine development. The compounds may be used in stem cells or tissues or organs ex vivo or in vitro to promote or stop stem cells differentiation, tissue remodeling, organ preservation and many other applications.

The miRNA modulating compounds of the invention are miRNA mimics or miRNA inhibitors. An miRNA mimic as used herein refers to a double stranded nucleic acid having a guide strand that has a nucleic acid sequence that is similar, or in some cases identical, to a guide strand of a naturally occurring mature miRNA. Naturally occurring miRNA are processed from long nucleic acids having secondary structural properties (referred to as pri-miRNA and pre-miRNA) to produce naturally occurring mature miRNA. The mature miRNA is a double stranded molecule of about 22 nucleotides in length having a guide strand that binds to an miRNA recognition element (MRE) in the 3′ untranslated region (UTR) of a target mRNA (in a RISC complex) and suppresses its translation or initiates degradation of the mRNA.

The miRNA mimic of the invention includes a guide strand that is identical to or similar to the sequence of a guide strand of a naturally occurring mature miRNA. Identical to the sequence, as used herein refers to the same nucleic acid bases in the nucleotide as are found in the mature miRNA. Similar to the sequence, in this context, refers to a nucleic acid molecule having a sequence which is less than identical but at least 75% homologous to the mature miRNA. In some instances “similar to the sequence” refers to a sequence which is less than identical but at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homologous to the mature miRNA. In some cases the sequence of the miRNA mimic may include the same bases, but the base of the mimic may be modified, i.e. hydrophobically modified. In other cases the mimic may include one or more different bases or nucleotides than the naturally occurring mature miRNA.

The guide strand of the miRNA mimic is complementary to a miRNA recognition element (MRE). “Complementary to a miRNA recognition element” as used herein refers to base complementarity between at least 6 or 7 nucleotides of the miRNA mimic guide strand (preferably the 5′ end of the guide strand) and the MRE. The region of complementarity is referred to as the seed region. In some embodiments the seed region or region of complementarity is 6, 7, 8, 9, 10, 11, 12 or 13 nucleotides in length. The complementarity of the seed region may be perfect (100%) or may be less i.e. greater than 90%, 95%, 96%, 97%, 98%, or 99%, but preferably is 100%. The complementarity between the entire miRNA and the MRE may be greater than 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

The miRNA mimics of the invention are useful for mimicking the activity of any naturally occurring miRNA. Non-limiting examples include: miR21, miR 139, miR 7, miR29, miR 122, miR 302-367 cluster, miR 221, miR-96, miR 126, miR 225 and miR 206.

An miRNA inhibitor as used herein refers to a double stranded nucleic acid having a guide strand that has a nucleic acid sequence that is complementary to a guide strand or antisense strand of a naturally occurring mature miRNA. “Complementary to an antisense strand of a naturally occurring mature miRNA” as used herein refers to base complementarity between the guide strand of the inhibitor and the antisense strand of the naturally occurring mature miRNA. In some embodiments the complementarity may be perfect (100%) or may be less than perfect i.e. greater than 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% complementarity. The guide strand of the miRNA inhibitor is extensively chemically modified (i.e. with O-methyls or other modification), to prevent its entry into RISC. The association of the miRNA inhibitor guide strand with the naturally occurring (or miRNA mimic guide strand) miRNA loaded RISC is enhanced by the chemical modifications and sequence complementarily, such that it competes for binding with the naturally occurring mRNA.

The structure and function of miRNAs has been the subject of extensive research and several miRNAs have been sequenced and investigated regarding their function in human disease. Some non-limiting examples of known human miRNAs, the expression of which can be modulated with agents and methods provided herein are let-7, let-7a-1, let-7a-2, let-7a-3, let-7b, let-7c, let-7d, let-7e, let-7f-1, let-7f-2, let-7g, let-7i, mir-1, mir-10, mir-100, mir-101, mir-101-1, mir-101-2, mir-103, mir-103-1, mir-103-2, mir-105, mir-105-1, mir-105-2, mir-106a, mir-106b, mir-107, mir-10a, mir-10b, mir-1-1, mir-1-2, mir-124, mir-124-1, mir-124-2, mir-124-3, mir-125, mir-125a, mir-125b-1, mir-125b-2, mir-128, mir-128a, mir-128b, mir-129, mir-129-1, mir-129-2, mir-130, mir-130a, mir-130b, mir-132, mir-132, mir-133, mir-133a-1, mir-133a-2, mir-133b, mir-135, mir-135a-1, mir-135a-2, mir-135b, mir-138, mir-138-1, mir-138-2, mir-141, mir-146, mir-146a, mir-146b, mir-147, mir-147a, mir-147b, mir-148, mir-148a, mir-148b, mir-15, mir-151, mir-152, mir-153, mir-153-1, mir-153-2, mir-154, mir-154, mir-15a, mir-15b, mir-16-1, mir-16-2, mir-17, mir-181, mir-181a-1, mir-181a-2, mir-181b-1, mir-181b-2, mir-181c, mir-181d, mir-188, mir-188, mir-18a, mir-18b, mir-19, mir-190, mir-190, mir-190b, mir-192, mir-192, mir-193, mir-193a, mir-193b, mir-194, mir-194-1, mir-194-2, mir-195, mir-196, mir-196a-1, mir-196a-2, mir-196b, mir-199, mir-199a-1, mir-199a-2, mir-199b, mir-19a, mir-19b-1, mir-19b-2, mir-200a, mir-200b, mir-200c, mir-204, mir-204, mir-206, mir-208, mir-208, mir-208b, mir-20a, mir-20b, mir-211, mir-212, mir-215, mir-216, mir-216a, mir-216b, mir-218, mir-218-1, mir-218-2, mir-219, mir-219-1, mir-219-2, mir-220, mir-220, mir-220b, mir-221, mir-221, mir-222, mir-23, mir-23a, mir-23b, mir-24, mir-24-1, mir-24-2, mir-25, mir-25, mir-26, mir-26a-1, mir-26a-2, mir-26b, mir-27, mir-27a, mir-27b, mir-28, mir-28, mir-29, mir-290, mir-29a, mir-29b-1, mir-29b-2, mir-29c, mir-30, mir-300, mir-301a, mir-301b, mir-302, mir-302a, mir-302b, mir-302c, mir-302d, mir-30a, mir-30b, mir-30c-1, mir-30c-2, mir-30d, mir-30e, mir-323, mir-329, mir-329-1, mir-329-2, mir-33, mir-33a, mir-33b, mir-34, mir-34a, mir-34b, mir-34c, mir-365, mir-365-1, mir-365-2, mir-368, mir-369, mir-371, mir-372, mir-374, mir-374a, mir-374b, mir-376a-1, mir-376a-2, mir-376b, mir-376c, mir-377, mir-379, mir-379, mir-380, mir-381, mir-3 82, mir-409, mir-410, mir-411, mir-421, mir-429, mir-449, mir-449a, mir-449b, mir-450, mir-450a-1, mir-450a-2, mir-450b, mir-453, mir-487a, mir-487b, mir-494, mir-495, mir-496, mir-500, mir-500, mir-501, mir-502, mir-506, mir-506, mir-507, mir-508, mir-509, mir-509-1, mir-509-2, mir-509-3, mir-510, mir-511, mir-511-1, mir-511-2, mir-512, mir-512-1, mir-512-2, mir-513, mir-513-1, mir-513-2, mir-514-1, mir-514-2, mir-514-3, mir-515, mir-515-1, mir-515-2, mir-516a-1, mir-516a-2, mir-516b-1, mir-516b-2, mir-517a, mir-517b, mir-517c, mir-518a-1, mir-518a-2, mir-518b, mir-518c, mir-518d, mir-518e, mir-518f, mir-519a-1, mir-519a-2, mir-519b, mir-519c, mir-519d, mir-519e, mir-520a, mir-520b, mir-520c, mir-520d, mir-520e, mir-520f, mir-520g, mir-520h, mir-521-1, mir-521-2, mir-522, mir-523, mir-524, mir-525, mir-526a-1, mir-526a-2, mir-526b, mir-527, mir-532, mir-539, mir-543, mir-545, mir-548, mir-548a-1, mir-548a-2, mir-548a-3, mir-548b, mir-548c, mir-548d-1, mir-548d-2, mir-550, mir-550-1, mir-550-2, mir-551, mir-551a, mir-551b, mir-570, mir-579, mir-603, mir-655, mir-656, mir-660, mir-7, mir-7-1, mir-7-2, mir-7-3, mir-758, mir-8, mir-891, mir-891a, mir-891b, mir-892, mir-892a, mir-892b, mir-9, mir-9-1, mir-9-2, mir-92a-1, mir-92a-2, mir-92b, mir-93, mir-9-3, mir-941, mir-941-1, mir-941-2, mir-941-3, mir-941-4, mir-95, mir-95, mir-98, mir-99, mir-99a, mir-99b. Sequence, structural information, and functions of these and other miRNAs are well known to those of skill in the art and are described, for example, in the miRBase database, Release 16, September 2010, accessible at www.mirbase.org, and described in more detail in “miRBase: tools for microRNA genomics” by Griffiths-Jones S, Saini H K, van Dongen S, Enright A J, Nucleic Acids Res. 2008 36:D154-D158; “miRBase: microRNA sequences, targets and gene nomenclature” by Griffiths-Jones S, Grocock R J, van Dongen S, Bateman A, Enright A J, Nucleic Acids Res. 2006 34:D140-D144; and “The miRNA Registry” by Griffiths-Jones S, Nucleic Acids Res. 2004 32:D109-D111. The entire contents of miRBase, Release 16, Sep. 2010, and the three references provided immediately above are incorporated herein in their entirety by reference for disclosure of miRNA sequences, structure, and function.

In some embodiments, the miRNA that is modulated using an agent or method provided herein is an miRNA that is implicated or known to be involved in the pathogenesis or the progression of a human disease, for example, in a cancer or neoplastic disease. MiRNAs implicated or known to be involved in the pathogenesis or the progression of a human disease are well known to those of skill in the art and include, but are not limited to the miRNAs described in the Human MiRNA & Disease Database (HMDD), Release January 2011, accessible at 202.38.126.151/hmdd/mirna/md/, and described in more detail in Lu M, Zhang Q, Deng M, Miao J, Guo Y, et al. (2008) An Analysis of Human MicroRNA and Disease Associations. PLoS ONE 3(10): e3420; the mir2disease base, Release March 2011, accessible at www.mir2disease.org, and described in more detail in Jiang Q., Wang Y., Hao Y., Juan L., Teng M., Zhang X., Li M., Wang G., Liu Y., (2009) miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res 37:D98-104; the entire contents of each database and reference are incorporated herein by reference.

In some embodiments, an miRNA modulating agent or method is provided that targets a particular miRNA or a particular miRNA cluster. For example, in some embodiments, the target miRNA is mir139 (e.g., miRBase accession: MI0000261). Mir139 has been described to act as a tumor suppressor and aberrant expression of mir139 has been reported to be associated with leukemia, for example, chronic lymphocytic leukemia, and with certain carcinomas, for example, adenocarcinoma, epithelial ovarian carcinoma, gastric carcinoma, and non-small cell lung carcinoma. In some embodiments, a miRNA modulating agent or method provided herein is useful for the alleviation of a disease or condition associated with aberrant mir139.

In some embodiments, the target miRNA is let-7 (e.g., miRBase accession: MI0000060-MI0000068). Let-7 has been reported to act as a tumor suppressor and aberrant expression of let-7 has been reported to be associated with tumorigenesis and tumor progression. In some embodiments, a let-7 mimic as provided herein is introduced into a neoplastic cell or tissue, for example, into a tumor cell or tumor tissue to alleviate tumor growth and/or any associated disease or condition. In some embodiments, introduction of a let-7 mimic into a tumor results in tumor regression.

In some embodiments, the target miRNA is mir-29 (e.g., miRBase accession: MI0000087, MI0000105, MI0000107). Aberrant expression of mir-29 has been reported to be associated with abnormal cell or tissue proliferation. For example, lack of miR-29a and/or miR-29b is implicated in progression of HCV infection, fibrosis or neuron remodeling and degeneration during Alzeheimer's disease. In some embodiments, introduction of a mir-29 mimic into an affected cell or tissue of a diseased subject is of therapeutic benefit in neurological disorders, liver and pulmonary fibrosis, HCV or other liver infection, cardiac hypertension and other indications with a reported involvement of mir-29. In some embodiments, introduction of a mir-29 mimic, as provided herein, for example, of a mir-29b mimic, can result in PDPN downregulation, which is involved in glioblastoma progression. In some embodiments, introduction of a mir-29 mimic as provided herein into a glioblastoma cell or tissue, for example, brain tissue of a glioblastoma patient, results in arrest or delay of tumor progression, tumor regression, or an alleviation of the disease state.

In some embodiments, the target miRNA is mir-133 (e.g., miRBase accession: MI0000450, MI0000451, MI0000822). Aberrant expression of miR-133 has been reported to be associated with CTGF downregulation as well as downregulation of molecular signaling pathways implicated in fibrosis. In some embodiments, a mir-133 mimic provided herein is used as an anti-fibrotic agent.

In some embodiments, the target miRNA is a miRNA of the mir-302-367 cluster, comprising mir-302a-mir302d and mir-367 (e.g., miRBase accession: MI0000738, MI0000772, MI0000773, MI0000775). Aberrant expression of the miRNA 302- 367 cluster has been reported to be associated with inhibition of HDac2-regulated reprogramming of somatic cells into pluripotent stem cells. In some embodiments, introduction of a mimic of a miRNA in the miRNA 302- 367 cluster into somatic stem cells supports or enhances the reprogramming of the somatic cells into pluripotent stem cells, which can be used for regenerative medicine approaches, and organ and tissue development.

In some embodiments, the target miRNA is mir-221 (e.g., miRBase accession: MI0000298). Mir-221 has been reported to act as a tumor suppressor, and aberrant expression of mir-221 has been reported to be associated with glioblastoma progression. In some embodiments, introduction, e.g., by direct ingection or intrabrain infusion of a mir-221 mimic provided herein is used to treat or alleviate a symptom observed in glioblastoma patients.

In some embodiments, the target miRNA is mir-96 (e.g., miRBase accession: MI0000098). Mir-96 has been reported to be involved in hair growth regulation and aberrant expression of mir-96 has been reported to be associated with alopecia, for example, or chemotherapy-induced alopecia. In some embodiments, a mir-96 mimic as provided herein is used to treat alopecia.

In some embodiments, the target miRNA is mir-126, mir-335, or mir-206 (e.g., miRBase accession: MI0000471, MI0000816, MI0000490). These miRNAs are potent suppressors of tumor metastasis formation or maturation. For example, mir-126 has been reported to suppress endothelium cellular recruitment and, thus, metastasis maturation. In some embodiment, introduction of a mir-126, mir-335, or mir-206 mimic as provided herein into a primary tumor, or systemic administration to a subject having a tumor results in a partial or complete inhibition of metastasis formation.

In some embodiments, the target miRNA is a miRNA of the mir-17-92 cluster, comprising mir-17, mir-18a, mir-19a, mir-20a, mir-19b-1, and mir-92a-1 (e.g., miRBase accession: MI0000071, MI0000072, MI0000073, MI0000076, MI0000074, MI0000093). The mir-17-92 cluster has been reported to act as an oncogene and overexpression of the cluster, or of any member of the cluster has been reported to be associated with tumorigenesis. In some embodiments, a miRNA inhibitory agent targeting the mir-17-92 cluster as provided herein is administered to a tumor cell or tissue, or systemically, to a patient diagnosed with or suspected to have a tumor. Another pathway that uses small RNAs as sequence-specific regulators is the RNA interference (RNAi) pathway, which is an evolutionarily conserved response to the presence of double-stranded RNA (dsRNA) in the cell. The dsRNAs are cleaved into −20-base pair (bp) duplexes of small-interfering RNAs (siRNAs) by Dicer. These small RNAs get assembled into multiprotein effector complexes called RNA-induced silencing complexes (RISCs). The siRNAs then guide the cleavage of target mRNAs with perfect complementarity.

Some aspects of biogenesis, protein complexes, and function are shared between the siRNA pathway and the miRNA pathway. The subject single-stranded polynucleotides may mimic the dsRNA in the siRNA mechanism, or the microRNA in the miRNA mechanism.

In certain embodiments, the modified RNAi constructs may have improved stability in serum and/or cerebral spinal fluid compared to an unmodified RNAi constructs having the same sequence.

In certain embodiments, the structure of the RNAi construct does not induce interferon response in primary cells, such as mammalian primary cells, including primary cells from human, mouse and other rodents, and other non-human mammals. In certain embodiments, the RNAi construct may also be used to inhibit expression of a target gene in an invertebrate organism.

To further increase the stability of the subject constructs in vivo, the 3′-end of the hairpin structure may be blocked by protective group(s). For example, protective groups such as inverted nucleotides, inverted abasic moieties, or amino-end modified nucleotides may be used. Inverted nucleotides may comprise an inverted deoxynucleotide. Inverted abasic moieties may comprise an inverted deoxyabasic moiety, such as a 3′, 3′-linked or 5′, 5′-linked deoxyabasic moiety.

The RNAi constructs of the invention are capable of inhibiting the synthesis of any target protein encoded by target gene(s). The invention includes methods to inhibit expression of a target gene either in a cell in vitro, or in vivo. As such, the RNAi constructs of the invention are useful for treating a patient with a disease characterized by the overexpression of a target gene.

The target gene can be endogenous or exogenous (e.g., introduced into a cell by a virus or using recombinant DNA technology) to a cell. Such methods may include introduction of RNA into a cell in an amount sufficient to inhibit expression of the target gene. By way of example, such an RNA molecule may have a guide strand that is complementary to the nucleotide sequence of the target gene, such that the composition inhibits expression of the target gene.

The invention also relates to vectors expressing the nucleic acids of the invention, and cells comprising such vectors or the nucleic acids. The cell may be a mammalian cell in vivo or in culture, such as a human cell.

The invention further relates to compositions comprising the subject RNAi constructs, and a pharmaceutically acceptable carrier or diluent.

Another aspect of the invention provides a method for inhibiting the expression of a target gene in a mammalian cell, comprising contacting the mammalian cell with any of the subject RNAi constructs.

The method may be carried out in vitro, ex vivo, or in vivo, in, for example, mammalian cells in culture, such as a human cell in culture.

The target cells (e.g., mammalian cell) may be contacted in the presence of a delivery reagent, such as a lipid (e.g., a cationic lipid) or a liposome.

Another aspect of the invention provides a method for inhibiting the expression of a target gene in a mammalian cell, comprising contacting the mammalian cell with a vector expressing the subject RNAi constructs.

In one aspect of the invention, a longer duplex polynucleotide is provided, including a first polynucleotide that ranges in size from about 16 to about 30 nucleotides; a second polynucleotide that ranges in size from about 26 to about 46 nucleotides, wherein the first polynucleotide (the antisense strand) is complementary to both the second polynucleotide (the sense strand) and a target gene, and wherein both polynucleotides form a duplex and wherein the first polynucleotide contains a single stranded region longer than 6 bases in length and is modified with alternative chemical modification pattern, and/or includes a conjugate moiety that facilitates cellular delivery. In this embodiment, between about 40% to about 90% of the nucleotides of the passenger strand between about 40% to about 90% of the nucleotides of the guide strand, and between about 40% to about 90% of the nucleotides of the single stranded region of the first polynucleotide are chemically modified nucleotides.

In an embodiment, the chemically modified nucleotide in the polynucleotide duplex may be any chemically modified nucleotide known in the art, such as those discussed in detail above. In a particular embodiment, the chemically modified nucleotide is selected from the group consisting of 2′ F modified nucleotides ,2′-O-methyl modified and 2′deoxy nucleotides. In another particular embodiment, the chemically modified nucleotides results from “hydrophobic modifications” of the nucleotide base. In another particular embodiment, the chemically modified nucleotides are phosphorothioates. In an additional particular embodiment, chemically modified nucleotides are combination of phosphorothioates, 2′-O-methyl, 2′deoxy, hydrophobic modifications and phosphorothioates. As these groups of modifications refer to modification of the ribose ring, back bone and nucleotide, it is feasible that some modified nucleotides will carry a combination of all three modification types.

In another embodiment, the chemical modification is not the same across the various regions of the duplex. In a particular embodiment, the first polynucleotide (the passenger strand), has a large number of diverse chemical modifications in various positions. For this polynucleotide up to 90% of nucleotides might be chemically modified and/or have mismatches introduced.

In another embodiment, chemical modifications of the first or second polynucleotide include, but not limited to, 5′ position modification of Uridine and Cytosine (4-pyridyl, 2-pyridyl, indolyl, phenyl (C₆H₅OH); tryptophanyl (C8H6N)CH2CH(NH2)CO), isobutyl, butyl, aminobenzyl; phenyl; naphthyl, etc), where the chemical modification might alter base pairing capabilities of a nucleotide. For the guide strand an important feature of this aspect of the invention is the position of the chemical modification relative to the 5′ end of the antisense and sequence. For example, chemical phosphorylation of the 5′ end of the guide strand is usually beneficial for efficacy. 0-methyl modifications in the seed region of the sense strand (position 2-7 relative to the 5′ end) are not generally well tolerated, whereas 2′F and deoxy are well tolerated. The mid part of the guide strand and the 3′ end of the guide strand are more permissive in a type of chemical modifications applied. Deoxy modifications are not tolerated at the 3′ end of the guide strand.

A unique feature of this aspect of the invention involves the use of hydrophobic modification on the bases. In one embodiment, the hydrophobic modifications are preferably positioned near the 5′ end of the guide strand, in other embodiments, they localized in the middle of the guides strand, in other embodiment they localized at the 3′ end of the guide strand and yet in another embodiment they are distributed thought the whole length of the polynucleotide. The same type of patterns is applicable to the passenger strand of the duplex.

The other part of the molecule is a single stranded region. The single stranded region is expected to range from 7 to 40 nucleotides.

In one embodiment, the single stranded region of the first polynucleotide contains modifications selected from the group consisting of between 40% and 90% hydrophobic base modifications, between 40%-90% phosphorothioates, between 40% -90% modification of the ribose moiety, and any combination of the preceding.

Efficiency of guide strand (first polynucleotide) loading into the RISC complex might be altered for heavily modified polynucleotides, so in one embodiment, the duplex polynucleotide includes a mismatch between nucleotide 9, 11, 12, 13, or 14 on the guide strand (first polynucleotide) and the opposite nucleotide on the sense strand (second polynucleotide) to promote efficient guide strand loading.

More detailed aspects of the invention are described in the sections below.

Duplex Characteristics

Double-stranded oligonucleotides of the invention may be formed by two separate complementary nucleic acid strands. Duplex formation can occur either inside or outside the cell containing the target gene.

As used herein, the term “duplex” includes the region of the double-stranded nucleic acid molecule(s) that is (are) hydrogen bonded to a complementary sequence. Double-stranded oligonucleotides of the invention may comprise a nucleotide sequence that is sense to a target gene and a complementary sequence that is antisense to the target gene. The sense and antisense nucleotide sequences correspond to the target gene sequence, e.g., are identical or are sufficiently identical to effect target gene inhibition (e.g., are about at least about 98% identical, 96% identical, 94%, 90% identical, 85% identical, or 80% identical) to the target gene sequence.

In certain embodiments, the double-stranded oligonucleotide of the invention is double-stranded over its entire length, i.e., with no overhanging single-stranded sequence at either end of the molecule, i.e., is blunt-ended. In other embodiments, the individual nucleic acid molecules can be of different lengths. In other words, a double-stranded oligonucleotide of the invention is not double-stranded over its entire length. For instance, when two separate nucleic acid molecules are used, one of the molecules, e.g., the first molecule comprising an antisense sequence, can be longer than the second molecule hybridizing thereto (leaving a portion of the molecule single-stranded). Likewise, when a single nucleic acid molecule is used a portion of the molecule at either end can remain single-stranded.

In one embodiment, a double-stranded oligonucleotide of the invention contains mismatches and/or loops or bulges, but is double-stranded over at least about 70% of the length of the oligonucleotide. In another embodiment, a double-stranded oligonucleotide of the invention is double-stranded over at least about 80% of the length of the oligonucleotide. In another embodiment, a double-stranded oligonucleotide of the invention is double-stranded over at least about 90%-95% of the length of the oligonucleotide. In another embodiment, a double-stranded oligonucleotide of the invention is double-stranded over at least about 96%-98% of the length of the oligonucleotide. In certain embodiments, the double-stranded oligonucleotide of the invention contains at least or up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mismatches.

Modifications

The nucleotides of the invention may be modified at various locations, including the sugar moiety, the phosphodiester linkage, and/or the base.

Sugar moieties include natural, unmodified sugars, e.g., monosaccharide (such as pentose, e.g., ribose, deoxyribose), modified sugars and sugar analogs. In general, possible modifications of nucleomonomers, particularly of a sugar moiety, include, for example, replacement of one or more of the hydroxyl groups with a halogen, a heteroatom, an aliphatic group, or the functionalization of the hydroxyl group as an ether, an amine, a thiol, or the like.

One particularly useful group of modified nucleomonomers are 2′-O-methyl nucleotides. Such 2′-O-methyl nucleotides may be referred to as “methylated,” and the corresponding nucleotides may be made from unmethylated nucleotides followed by alkylation or directly from methylated nucleotide reagents. Modified nucleomonomers may be used in combination with unmodified nucleomonomers. For example, an oligonucleotide of the invention may contain both methylated and unmethylated nucleomonomers.

Some exemplary modified nucleomonomers include sugar- or backbone-modified ribonucleotides. Modified ribonucleotides may contain a non-naturally occurring base (instead of a naturally occurring base), such as uridines or cytidines modified at the 5′-position, e.g., 5′-(2-amino)propyl uridine and 5′-bromo uridine; adenosines and guanosines modified at the 8-position, e.g., 8-bromo guanosine; deaza nucleotides, e.g., 7-deaza-adenosine; and N-alkylated nucleotides, e.g., N6-methyl adenosine. Also, sugar-modified ribonucleotides may have the 2′-OH group replaced by a H, alxoxy (or OR), R or alkyl, halogen, SH, SR, amino (such as NH₂, NHR, NR₂,), or CN group, wherein R is lower alkyl, alkenyl, or alkynyl.

Modified ribonucleotides may also have the phosphodiester group connecting to adjacent ribonucleotides replaced by a modified group, e.g., of phosphorothioate group. More generally, the various nucleotide modifications may be combined.

Although the antisense (guide) strand may be substantially identical to at least a portion of the target gene (or genes), at least with respect to the base pairing properties, the sequence need not be perfectly identical to be useful, e.g., to inhibit expression of a target gene's phenotype. Generally, higher homology can be used to compensate for the use of a shorter antisense gene. In some cases, the antisense strand generally will be substantially identical (although in antisense orientation) to the target gene.

The use of 2′-O-methyl modified RNA may also be beneficial in circumstances in which it is desirable to minimize cellular stress responses. RNA having 2′-O-methyl nucleomonomers may not be recognized by cellular machinery that is thought to recognize unmodified RNA. The use of 2′-O-methylated or partially 2′-O-methylated RNA may avoid the interferon response to double-stranded nucleic acids, while maintaining target RNA inhibition. This may be useful, for example, for avoiding the interferon or other cellular stress responses, both in short RNAi (e.g., siRNA) sequences that induce the interferon response, and in longer RNAi sequences that may induce the interferon response.

Overall, modified sugars may include D-ribose, 2′-O-alkyl (including 2′-O-methyl and 2′-O-ethyl), i.e., 2′-alkoxy, 2′-amino, 2′-S-alkyl, 2′-halo (including 2′-fluoro), 2′- methoxyethoxy, 2′-allyloxy (—OCH₂CH═CH₂), 2′-propargyl, 2′-propyl, ethynyl, ethenyl, propenyl, and cyano and the like. In one embodiment, the sugar moiety can be a hexose and incorporated into an oligonucleotide as described (Augustyns, K., et al., Nucl. Acids. Res. 18:4711 (1992)). Exemplary nucleomonomers can be found, e.g., in U.S. Pat. No. 5,849,902, incorporated by reference herein.

The term “alkyl” includes saturated aliphatic groups, including straight-chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc.), branched-chain alkyl groups (isopropyl, tert-butyl, isobutyl, etc.), cycloalkyl (alicyclic) groups (cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In certain embodiments, a straight chain or branched chain alkyl has 6 or fewer carbon atoms in its backbone (e.g., C₁-C₆ for straight chain, C₃-C₆ for branched chain), and more preferably 4 or fewer. Likewise, preferred cycloalkyls have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure. The term C₁-C₆ includes alkyl groups containing 1 to 6 carbon atoms.

Moreover, unless otherwise specified, the term alkyl includes both “unsubstituted alkyls” and “substituted alkyls,” the latter of which refers to alkyl moieties having independently selected substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkyl carbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Cycloalkyls can be further substituted, e.g., with the substituents described above. An “alkylaryl” or an “arylalkyl” moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (benzyl)). The term “alkyl” also includes the side chains of natural and unnatural amino acids. The term “n-alkyl” means a straight chain (i.e., unbranched) unsubstituted alkyl group.

The term “alkenyl” includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double bond. For example, the term “alkenyl” includes straight-chain alkenyl groups (e.g., ethylenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, etc.), branched-chain alkenyl groups, cycloalkenyl (alicyclic) groups (cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, and cycloalkyl or cycloalkenyl substituted alkenyl groups. In certain embodiments, a straight chain or branched chain alkenyl group has 6 or fewer carbon atoms in its backbone (e.g., C₂-C₆ for straight chain, C₃-C₆ for branched chain). Likewise, cycloalkenyl groups may have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure. The term C₂-C₆ includes alkenyl groups containing 2 to 6 carbon atoms.

Moreover, unless otherwise specified, the term alkenyl includes both “unsubstituted alkenyls” and “substituted alkenyls,” the latter of which refers to alkenyl moieties having independently selected substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.

The term “alkynyl” includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond. For example, the term “alkynyl” includes straight-chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, etc.), branched-chain alkynyl groups, and cycloalkyl or cycloalkenyl substituted alkynyl groups. In certain embodiments, a straight chain or branched chain alkynyl group has 6 or fewer carbon atoms in its backbone (e.g., C₂-C₆ for straight chain, C₃-C₆ for branched chain). The term C₂-C₆ includes alkynyl groups containing 2 to 6 carbon atoms.

Moreover, unless otherwise specified, the term alkynyl includes both “unsubstituted alkynyls” and “substituted alkynyls,” the latter of which refers to alkynyl moieties having independently selected substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.

Unless the number of carbons is otherwise specified, “lower alkyl” as used herein means an alkyl group, as defined above, but having from one to five carbon atoms in its backbone structure. “Lower alkenyl” and “lower alkynyl” have chain lengths of, for example, 2-5 carbon atoms.

The term “alkoxy” includes substituted and unsubstituted alkyl, alkenyl, and alkynyl groups covalently linked to an oxygen atom. Examples of alkoxy groups include methoxy, ethoxy, isopropyloxy, propoxy, butoxy, and pentoxy groups. Examples of substituted alkoxy groups include halogenated alkoxy groups. The alkoxy groups can be substituted with independently selected groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulffiydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfmyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moieties. Examples of halogen substituted alkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, etc.

The term “heteroatom” includes atoms of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorus.

The term “hydroxy” or “hydroxyl” includes groups with an —OH or —O⁻ (with an appropriate counterion).

The term “halogen” includes fluorine, bromine, chlorine, iodine, etc. The term “perhalogenated” generally refers to a moiety wherein all hydrogens are replaced by halogen atoms.

The term “substituted” includes independently selected substituents which can be placed on the moiety and which allow the molecule to perform its intended function. Examples of sub stituents include alkyl, alkenyl, alkynyl, aryl, (CR′R″)₀₋₃NR′R″, (CR′R″)₀₋₃CN, NO₂, halogen, (CR′R″)₀₋₃C(halogen)₃, (CR′R″)₀₋₃CH(halogen)₂, (CR′R″)₀₋₃CH₂(halogen), (CR′R″)₀₋₃CONR′R″, (CR′R″)₀₋₃S(O)₁₋₂NR′R″, (CR′R″)₀₋₃CHO, (CR′R″)₀₋₃O(CR′R″)₀₋₃H, (CR′R″)₀₋₃S(O)₀₋₂R′, (CR′R″)₀₋₃O(CR′R″)₀₋₃H, (CR′R″)₀₋₃COR′, (CR′R″)₀₋₃CO₂R′, or (CR′R″)₀₋₃OR′ groups; wherein each R′ and R″ are each independently hydrogen, a C₁-C₅ alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl, or aryl group, or R′ and R″ taken together are a benzylidene group or a —(CH₂)₂O(CH₂)₂- group.

The term “amine” or “amino” includes compounds or moieties in which a nitrogen atom is covalently bonded to at least one carbon or heteroatom. The term “alkyl amino” includes groups and compounds wherein the nitrogen is bound to at least one additional alkyl group. The term “dialkyl amino” includes groups wherein the nitrogen atom is bound to at least two additional alkyl groups.

The term “ether” includes compounds or moieties which contain an oxygen bonded to two different carbon atoms or heteroatoms. For example, the term includes “alkoxyalkyl,” which refers to an alkyl, alkenyl, or alkynyl group covalently bonded to an oxygen atom which is covalently bonded to another alkyl group.

The term “base” includes the known purine and pyrimidine heterocyclic bases, deazapurines, and analogs (including heterocyclic substituted analogs, e.g., aminoethyoxy phenoxazine), derivatives (e.g., 1-alkyl-, 1-alkenyl-, heteroaromatic- and 1-alkynyl derivatives) and tautomers thereof. Examples of purines include adenine, guanine, inosine, diaminopurine, and xanthine and analogs (e.g., 8-oxo-N⁶-methyladenine or 7-diazaxanthine) and derivatives thereof. Pyrimidines include, for example, thymine, uracil, and cytosine, and their analogs (e.g., 5-methylcytosine, 5-methyluracil, 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine and 4,4-ethanocytosine). Other examples of suitable bases include non-purinyl and non-pyrimidinyl bases such as 2-aminopyridine and triazines.

In a preferred embodiment, the nucleomonomers of an oligonucleotide of the invention are RNA nucleotides. In another preferred embodiment, the nucleomonomers of an oligonucleotide of the invention are modified RNA nucleotides. Thus, the oligunucleotides contain modified RNA nucleotides.

The term “nucleoside” includes bases which are covalently attached to a sugar moiety, preferably ribose or deoxyribose. Examples of preferred nucleosides include ribonucleosides and deoxyribonucleosides. Nucleosides also include bases linked to amino acids or amino acid analogs which may comprise free carboxyl groups, free amino groups, or protecting groups. Suitable protecting groups are well known in the art (see P. G. M. Wuts and T. W. Greene, “Protective Groups in Organic Synthesis”, 2^(nd) Ed., Wiley-Interscience, New York, 1999).

The term “nucleotide” includes nucleosides which further comprise a phosphate group or a phosphate analog.

As used herein, the term “linkage” includes a naturally occurring, unmodified phosphodiester moiety (—O—(PO²⁻)—O—) that covalently couples adjacent nucleomonomers. As used herein, the term “substitute linkage” includes any analog or derivative of the native phosphodiester group that covalently couples adjacent nucleomonomers. Substitute linkages include phosphodiester analogs, e.g., phosphorothioate, phosphorodithioate, and P-ethyoxyphosphodiester, P-ethoxyphosphodiester, P-alkyloxyphosphotriester, methylphosphonate, and nonphosphorus containing linkages, e.g., acetals and amides. Such substitute linkages are known in the art (e.g., Bjergarde et al. 1991. Nucleic Acids Res. 19:5843; Caruthers et al. 1991. Nucleosides Nucleotides. 10:47). In certain embodiments, non-hydrolizable linkages are preferred, such as phosphorothiate linkages.

In certain embodiments, oligonucleotides of the invention comprise hydrophobically modified nucleotides or “hydrophobic modifications.” As used herein “hydrophobic modifications” refers to bases that are modified such that (1) overall hydrophobicity of the base is significantly increased, and/or (2) the base is still capable of forming close to regular Watson-Crick interaction. Several non-limiting examples of base modifications include 5-position uridine and cytidine modifications such as methyl, ethyl, phenyl, 4-pyridyl, 2-pyridyl, indolyl, and isobutyl, phenyl (C6H5OH); tryptophanyl (C8H6N)CH2CH(NH2)CO), butyl, aminobenzyl; and naphthyl.

In certain embodiments, oligonucleotides of the invention comprise 3′ and 5′ termini (except for circular oligonucleotides). In one embodiment, the 3′ and 5′ termini of an oligonucleotide can be substantially protected from nucleases e.g., by modifying the 3′ or 5′ linkages (e.g., U .S. Pat. No. 5,849,902 and WO 98/13526). For example, oligonucleotides can be made resistant by the inclusion of a “blocking group.” The term “blocking group” as used herein refers to substituents (e.g., other than OH groups) that can be attached to oligonucleotides or nucleomonomers, either as protecting groups or coupling groups for synthesis (e.g., FITC, propyl (CH₂—CH₂—CH₃), glycol (—O—CH₂—CH₂—O—) phosphate (PO₃ ²⁻), hydrogen phosphonate, or phosphoramidite). “Blocking groups” also include “end blocking groups” or “exonuclease blocking groups” which protect the 5′ and 3′ termini of the oligonucleotide, including modified nucleotides and non-nucleotide exonuclease resistant structures.

Exemplary end-blocking groups include cap structures (e.g., a 7-methylguanosine cap), inverted nucleomonomers, e.g., with 3′-3′ or 5′-5′ end inversions (see, e.g., Ortiagao et al. 1992. Antisense Res. Dev. 2:129), methylphosphonate, phosphoramidite, non-nucleotide groups (e.g., non-nucleotide linkers, amino linkers, conjugates) and the like. The 3′ terminal nucleomonomer can comprise a modified sugar moiety. The 3′ terminal nucleomonomer comprises a 3′-O that can optionally be substituted by a blocking group that prevents 3′-exonuclease degradation of the oligonucleotide. For example, the 3′-hydroxyl can be esterified to a nucleotide through a 3′→3′ internucleotide linkage. For example, the alkyloxy radical can be methoxy, ethoxy, or isopropoxy, and preferably, ethoxy. Optionally, the 3′→3′ linked nucleotide at the 3′ terminus can be linked by a substitute linkage. To reduce nuclease degradation, the 5′ most 3′→5′ linkage can be a modified linkage, e.g., a phosphorothioate or a P-alkyloxyphosphotriester linkage. Preferably, the two 5′ most 3′→5′ linkages are modified linkages. Optionally, the 5′ terminal hydroxy moiety can be esterified with a phosphorus containing moiety, e.g., phosphate, phosphorothioate, or P-ethoxyphosphate.

Another type of conjugates that can be attached to the end (3′ or 5′ end), the loop region, or any other parts of the miniRNA might include a sterol, sterol type molecule, peptide, small molecule, protein, etc. In some embodiments, a miniRNA may contain more than one conjugates (same or different chemical nature). In some embodiments, the conjugate is cholesterol.

Another way to increase target gene specificity, or to reduce off-target silencing effect, is to introduce a 2′-modification (such as the 2′-O methyl modification) at a position corresponding to the second 5′-end nucleotide of the guide sequence. This allows the positioning of this 2′-modification in the Dicer-resistant hairpin structure, thus enabling one to design better RNAi constructs with less or no off-target silencing.

In one embodiment, a hairpin polynucleotide of the invention can comprise one nucleic acid portion which is DNA and one nucleic acid portion which is RNA. Antisense (guide) sequences of the invention can be “chimeric oligonucleotides” which comprise an RNA-like and a DNA-like region.

The language “RNase H activating region” includes a region of an oligonucleotide, e.g., a chimeric oligonucleotide, that is capable of recruiting RNase H to cleave the target RNA strand to which the oligonucleotide binds. Typically, the RNase activating region contains a minimal core (of at least about 3-5, typically between about 3-12, more typically, between about 5-12, and more preferably between about 5-10 contiguous nucleomonomers) of DNA or DNA-like nucleomonomers. (See, e.g., U .S. Pat. No. 5,849,902). Preferably, the RNase H activating region comprises about nine contiguous deoxyribose containing nucleomonomers.

The language “non-activating region” includes a region of an antisense sequence, e.g., a chimeric oligonucleotide, that does not recruit or activate RNase H. Preferably, a non-activating region does not comprise phosphorothioate DNA. The oligonucleotides of the invention comprise at least one non-activating region. In one embodiment, the non-activating region can be stabilized against nucleases or can provide specificity for the target by being complementary to the target and forming hydrogen bonds with the target nucleic acid molecule, which is to be bound by the oligonucleotide.

In one embodiment, at least a portion of the contiguous polynucleotides are linked by a substitute linkage, e.g., a phosphorothioate linkage.

In certain embodiments, most or all of the nucleotides beyond the guide sequence (2′-modified or not) are linked by phosphorothioate linkages. Such constructs tend to have improved pharmacokinetics due to their higher affinity for serum proteins. The phosphorothioate linkages in the non-guide sequence portion of the polynucleotide generally do not interfere with guide strand activity, once the latter is loaded into RISC.

Antisense (guide) sequences of the present invention may include “morpholino oligonucleotides.” Morpholino oligonucleotides are non-ionic and function by an RNase H-independent mechanism. Each of the 4 genetic bases (Adenine, Cytosine, Guanine, and Thymine/Uracil) of the morpholino oligonucleotides is linked to a 6-membered morpholine ring. Morpholino oligonucleotides are made by joining the 4 different subunit types by, e.g., non-ionic phosphorodiamidate inter-subunit linkages. Morpholino oligonucleotides have many advantages including: complete resistance to nucleases (Antisense & Nucl. Acid Drug Dev. 1996. 6:267); predictable targeting (Biochemica Biophysica Acta. 1999. 1489:141); reliable activity in cells (Antisense & Nucl. Acid Drug Dev. 1997. 7:63); excellent sequence specificity (Antisense & Nucl. Acid Drug Dev. 1997. 7:151); minimal non-antisense activity (Biochemica Biophysica Acta. 1999. 1489:141); and simple osmotic or scrape delivery (Antisense & Nucl. Acid Drug Dev. 1997. 7:291). Morpholino oligonucleotides are also preferred because of their non-toxicity at high doses. A discussion of the preparation of morpholino oligonucleotides can be found in Antisense & Nucl. Acid Drug Dev. 1997. 7:187.

The chemical modifications described herein are believed, based on the data described herein, to promote single stranded polynucleotide loading into the RISC. Single stranded polynucleotides have been shown to be active in loading into RISC and inducing gene silencing. However, the level of activity for single stranded polynucleotides appears to be 2 to 4 orders of magnitude lower when compared to a duplex polynucleotide.

The present invention provides a description of the chemical modification patterns, which may (a) significantly increase stability of the single stranded polynucleotide (b) promote efficient loading of the polynucleotide into the RISC complex and (c) improve uptake of the single stranded nucleotide by the cell. FIG. 5 provides some non-limiting examples of the chemical modification patterns which may be beneficial for achieving single stranded polynucleotide efficacy inside the cell. The chemical modification patterns may include combination of ribose, backbone, hydrophobic nucleoside and conjugate type of modifications. In addition, in some of the embodiments, the 5′ end of the single polynucleotide may be chemically phosphorylated.

In yet another embodiment, the present invention provides a description of the chemical modifications patterns, which improve functionality of RISC inhibiting polynucleotides. Single stranded polynucleotides have been shown to inhibit activity of a preloaded RISC complex through the substrate competition mechanism. For these types of molecules, conventionally called antagomers, the activity usually requires high concentration and in vivo delivery is not very effective. The present invention provides a description of the chemical modification patterns, which may (a) significantly increase stability of the single stranded polynucleotide (b) promote efficient recognition of the polynucleotide by the RISC as a substrate and/or (c) improve uptake of the single stranded nucleotide by the cell. FIG. 6 provides some non-limiting examples of the chemical modification patterns that may be beneficial for achieving single stranded polynucleotide efficacy inside the cell. The chemical modification patterns may include combination of ribose, backbone, hydrophobic nucleoside and conjugate type of modifications.

The modifications provided by the present invention are applicable to all polynucleotides. This includes single stranded RISC entering polynucleotides, single stranded RISC inhibiting polynucleotides, conventional duplexed polynucleotides of variable length (15- 40 bp),asymmetric duplexed polynucleotides, and the like. Polynucleotides may be modified with wide variety of chemical modification patterns, including 5′ end, ribose, backbone and hydrophobic nucleoside modifications.

Synthesis

Oligonucleotides of the invention can be synthesized by any method known in the art, e.g., using enzymatic synthesis and/or chemical synthesis. The oligonucleotides can be synthesized in vitro (e.g., using enzymatic synthesis and chemical synthesis) or in vivo (using recombinant DNA technology well known in the art).

In a preferred embodiment, chemical synthesis is used for modified polynucleotides. Chemical synthesis of linear oligonucleotides is well known in the art and can be achieved by solution or solid phase techniques. Preferably, synthesis is by solid phase methods. Oligonucleotides can be made by any of several different synthetic procedures including the phosphoramidite, phosphite triester, H-phosphonate, and phosphotriester methods, typically by automated synthesis methods.

Oligonucleotide synthesis protocols are well known in the art and can be found, e.g., in U.S. Pat. No. 5,830,653; WO 98/13526; Stec et al. 1984. J. Am. Chem. Soc. 106:6077; Stec et al. 1985. J. Org. Chem. 50:3908; Stec et al. J. Chromatog. 1985. 326:263; LaPlanche et al. 1986. Nucl. Acid. Res. 1986. 14:9081; Fasman G. D., 1989. Practical Handbook of Biochemistry and Molecular Biology. 1989. CRC Press, Boca Raton, Fla.; Lamone. 1993. Biochem. Soc. Trans. 21:1; U.S. Pat. No. 5,013,830; U.S. Pat. No. 5,214,135; U.S. Pat. No. 5,525,719; Kawasaki et al. 1993. J. Med. Chem. 36:831; WO 92/03568; U.S. Pat. No. 5,276,019; and U.S. Pat. No. 5,264,423.

The synthesis method selected can depend on the length of the desired oligonucleotide and such choice is within the skill of the ordinary artisan. For example, the phosphoramidite and phosphite triester method can produce oligonucleotides having 175 or more nucleotides, while the H-phosphonate method works well for oligonucleotides of less than 100 nucleotides. If modified bases are incorporated into the oligonucleotide, and particularly if modified phosphodiester linkages are used, then the synthetic procedures are altered as needed according to known procedures. In this regard, Uhlmann et al. (1990, Chemical Reviews 90:543-584) provide references and outline procedures for making oligonucleotides with modified bases and modified phosphodiester linkages. Other exemplary methods for making oligonucleotides are taught in Sonveaux. 1994. “Protecting Groups in Oligonucleotide Synthesis”; Agrawal. Methods in Molecular Biology 26:1. Exemplary synthesis methods are also taught in “Oligonucleotide Synthesis—A Practical Approach” (Gait, M. J. IRL Press at Oxford University Press. 1984). Moreover, linear oligonucleotides of defined sequence, including some sequences with modified nucleotides, are readily available from several commercial sources.

The oligonucleotides may be purified by polyacrylamide gel electrophoresis, or by any of a number of chromatographic methods, including gel chromatography and high pressure liquid chromatography. To confirm a nucleotide sequence, especially unmodified nucleotide sequences, oligonucleotides may be subjected to DNA sequencing by any of the known procedures, including Maxam and Gilbert sequencing, Sanger sequencing, capillary electrophoresis sequencing, the wandering spot sequencing procedure or by using selective chemical degradation of oligonucleotides bound to Hybond paper. Sequences of short oligonucleotides can also be analyzed by laser desorption mass spectroscopy or by fast atom bombardment (McNeal, et al., 1982, J. Am. Chem. Soc. 104:976; Viari, et al., 1987, Biomed. Environ. Mass Spectrom. 14:83; Grotjahn et al., 1982, Nuc. Acid Res. 10:4671). Sequencing methods are also available for RNA oligonucleotides.

The quality of oligonucleotides synthesized can be verified by testing the oligonucleotide by capillary electrophoresis and denaturing strong anion HPLC (SAX-HPLC) using, e.g., the method of Bergot and Egan. 1992. J. Chrom. 599:35.

Other exemplary synthesis techniques are well known in the art (see, e.g., Sambrook et al., Molecular Cloning: a Laboratory Manual, Second Edition (1989); DNA Cloning, Volumes I and II (DN Glover Ed. 1985); Oligonucleotide Synthesis (M J Gait Ed, 1984; Nucleic Acid Hybridisation (B D Hames and S J Higgins eds. 1984); A Practical Guide to Molecular Cloning (1984); or the series, Methods in Enzymology (Academic Press, Inc.)).

In certain embodiments, the subject RNAi constructs or at least portions thereof are transcribed from expression vectors encoding the subject constructs. Any art recognized vectors may be use for this purpose. The transcribed RNAi constructs may be isolated and purified, before desired modifications (such as replacing an unmodified sense strand with a modified one, etc.) are carried out.

Delivery/Carrier

-   Uptake of Oligonucleotides by Cells

Oligonucleotides and oligonucleotide compositions are contacted with (i.e., brought into contact with, also referred to herein as administered or delivered to) and taken up by one or more cells or a cell lysate. The term “cells” includes prokaryotic and eukaryotic cells, preferably vertebrate cells, and, more preferably, mammalian cells. In a preferred embodiment, the oligonucleotide compositions of the invention are contacted with human cells.

Oligonucleotide compositions of the invention can be contacted with cells in vitro, e.g., in a test tube or culture dish, (and may or may not be introduced into a subject) or in vivo, e.g., in a subject such as a mammalian subject. Oligonucleotides are taken up by cells at a slow rate by endocytosis, but endocytosed oligonucleotides are generally sequestered and not available, e.g., for hybridization to a target nucleic acid molecule. In one embodiment, cellular uptake can be facilitated by electroporation or calcium phosphate precipitation. However, these procedures are only useful for in vitro or ex vivo embodiments, are not convenient and, in some cases, are associated with cell toxicity.

In another embodiment, delivery of oligonucleotides into cells can be enhanced by suitable art recognized methods including calcium phosphate, DMSO, glycerol or dextran, electroporation, or by transfection, e.g., using cationic, anionic, or neutral lipid compositions or liposomes using methods known in the art (see e.g., WO 90/14074; WO 91/16024; WO 91/17424; U.S. Pat. No. 4,897,355; Bergan et al. 1993. Nucleic Acids Research. 21:3567). Enhanced delivery of oligonucleotides can also be mediated by the use of vectors (See e.g., Shi, Y. 2003. Trends Genet 2003 Jan. 19:9; Reichhart J M et al. Genesis. 2002. 34(1-2):1604, Yu et al. 2002. Proc. Natl. Acad Sci. USA 99:6047; Sui et al. 2002. Proc. Natl. Acad Sci. USA 99:5515) viruses, polyamine or polycation conjugates using compounds such as polylysine, protamine, or Ni, N12-bis (ethyl) spermine (see, e.g., Bartzatt, R. et a/.1989. Biotechnol. Appl. Biochem. 11:133; Wagner E. et al. 1992. Proc. Natl. Acad. Sci. 88:4255).

In certain embodiments, the miniRNA of the invention may be delivered by using various beta-glucan containing particles, such as those described in US 2005/0281781 A1, WO 2006/007372, and WO 2007/050643 (all incorporated herein by reference). In certain embodiments, the beta-glucan particle is derived from yeast. In certain embodiments, the payload trapping molecule is a polymer, such as those with a molecular weight of at least about 1000 Da, 10,000 Da, 50,000 Da, 100 kDa, 500 kDa, etc. Preferred polymers include (without limitation) cationic polymers, chitosans, or PEI (polyethylenimine), etc.

Such beta-glucan based delivery system may be formulated for oral delivery, where the orally delivered beta-glucan / miniRNA constructs may be engulfed by macrophages or other related phagocytic cells, which may in turn release the miniRNA constructs in selected in vivo sites. Alternatively or in addition, the miniRNA may changes the expression of certain macrophage target genes.

The optimal protocol for uptake of oligonucleotides will depend upon a number of factors, the most crucial being the type of cells that are being used. Other factors that are important in uptake include, but are not limited to, the nature and concentration of the oligonucleotide, the confluence of the cells, the type of culture the cells are in (e.g., a suspension culture or plated) and the type of media in which the cells are grown.

Encapsulating Agents

Encapsulating agents entrap oligonucleotides within vesicles. In another embodiment of the invention, an oligonucleotide may be associated with a carrier or vehicle, e.g., liposomes or micelles, although other carriers could be used, as would be appreciated by one skilled in the art. Liposomes are vesicles made of a lipid bilayer having a structure similar to biological membranes. Such carriers are used to facilitate the cellular uptake or targeting of the oligonucleotide, or improve the oligonucleotide's pharmacokinetic or toxicologic properties.

For example, the oligonucleotides of the present invention may also be administered encapsulated in liposomes, pharmaceutical compositions wherein the active ingredient is contained either dispersed or variously present in corpuscles consisting of aqueous concentric layers adherent to lipidic layers. The oligonucleotides, depending upon solubility, may be present both in the aqueous layer and in the lipidic layer, or in what is generally termed a liposomic suspension. The hydrophobic layer, generally but not exclusively, comprises phopholipids such as lecithin and sphingomyelin, steroids such as cholesterol, more or less ionic surfactants such as diacetylphosphate, stearylamine, or phosphatidic acid, or other materials of a hydrophobic nature. The diameters of the liposomes generally range from about 15 nm to about 5 microns.

A “hydrophobic modified polynucleotide” as used herein is a polynucleotide of the invention(i.e. sd-rxRNA) that has at least one modification that renders the polynucleotide more hydrophobic than the polynucleotide was prior to modification. The modification may be achieved by attaching (covalently or non-covalently) a hydrophobic molecule to the polynucleotide. In some instances the hydrophobic molecule is or includes a lipophilic group.

The term “lipophilic group” means a group that has a higher affinity for lipids than its affinity for water. Examples of lipophilic groups include, but are not limited to, cholesterol, a cholesteryl or modified cholesteryl residue, adamantine, dihydrotesterone, long chain alkyl, long chain alkenyl, long chain alkynyl, olely-lithocholic, cholenic, oleoyl-cholenic, palmityl, heptadecyl, myrisityl, bile acids, cholic acid or taurocholic acid, deoxycholate, oleyl litocholic acid, oleoyl cholenic acid, glycolipids, phospholipids, sphingolipids, isoprenoids, such as steroids, vitamins, such as vitamin E, fatty acids either saturated or unsaturated, fatty acid esters, such as triglycerides, pyrenes, porphyrines, Texaphyrine, adamantane, acridines, biotin, coumarin, fluorescein, rhodamine, Texas-Red, digoxygenin, dimethoxytrityl, t-butyldimethylsilyl, t-butyldiphenylsilyl, cyanine dyes (e.g. Cy3 or Cy5), Hoechst 33258 dye, psoralen, or ibuprofen. The cholesterol moiety may be reduced (e.g. as in cholestan) or may be substituted (e.g. by halogen). A combination of different lipophilic groups in one molecule is also possible.

The hydrophobic molecule may be attached at various positions of the polynucleotide. As described above, the hydrophobic molecule may be linked to the terminal residue of the polynucleotide such as the 3′ of 5′-end of the polynucleotide. Alternatively, it may be linked to an internal nucleotide or a nucleotide on a branch of the polynucleotide. The hydrophobic molecule may be attached, for instance to a 2′-position of the nucleotide. The hydrophobic molecule may also be linked to the heterocyclic base, the sugar or the backbone of a nucleotide of the polynucleotide.

The hydrophobic molecule may be connected to the polynucleotide by a linker moiety. Optionally the linker moiety is a non-nucleotidic linker moiety. Non-nucleotidic linkers are e.g. abasic residues (dSpacer), oligoethyleneglycol, such as triethyleneglycol (spacer 9) or hexaethylenegylcol (spacer 18), or alkane-diol, such as butanediol. The spacer units are preferably linked by phosphodiester or phosphorothioate bonds. The linker units may appear just once in the molecule or may be incorporated several times, e.g. via phosphodiester, phosphorothioate, methylphosphonate, or amide linkages.

Typical conjugation protocols involve the synthesis of polynucleotides bearing an aminolinker at one or more positions of the sequence, however, a linker is not required. The amino group is then reacted with the molecule being conjugated using appropriate coupling or activating reagents. The conjugation reaction may be performed either with the polynucleotide still bound to a solid support or following cleavage of the polynucleotide in solution phase. Purification of the modified polynucleotide by HPLC typically results in a pure material.

In some embodiments the hydrophobic molecule is a sterol type conjugate, a PhytoSterol conjugate, cholesterol conjugate, sterol type conjugate with altered side chain length, fatty acid conjugate, any other hydrophobic group conjugate, and/or hydrophobic modifications of the internal nucleoside, which provide sufficient hydrophobicity to be incorporated into micelles.

For purposes of the present invention, the term “sterols”, refers or steroid alcohols are a subgroup of steroids with a hydroxyl group at the 3-position of the A-ring. They are amphipathic lipids synthesized from acetyl-coenzyme A via the HMG-CoA reductase pathway. The overall molecule is quite flat. The hydroxyl group on the A ring is polar. The rest of the aliphatic chain is non-polar. Usually sterols are considered to have an 8 carbon chain at position 17.

For purposes of the present invention, the term “sterol type molecules”, refers to steroid alcohols, which are similar in structure to sterols. The main difference is the structure of the ring and number of carbons in a position 21 attached side chain.

For purposes of the present invention, the term “PhytoSterols” (also called plant sterols) are a group of steroid alcohols, phytochemicals naturally occurring in plants. There are more then 200 different known PhytoSterols

For purposes of the present invention, the term “Sterol side chain” refers to a chemical composition of a side chain attached at the position 17 of sterol-type molecule. In a standard definition sterols are limited to a 4 ring structure carrying a 8 carbon chain at position 17. In this invention, the sterol type molecules with side chain longer and shorter than conventional are described. The side chain may branched or contain double back bones.

Thus, sterols useful in the invention, for example, include cholesterols, as well as unique sterols in which position 17 has attached side chain of 2-7 or longer then 9 carbons. In a particular embodiment, the length of the polycarbon tail is varied between 5 and 9 carbons. FIG. 9 demonstrates that there is a correlation between plasma clearance, liver uptake and the length of the polycarbon chain. Such conjugates may have significantly better in vivo efficacy, in particular delivery to liver. These types of molecules are expected to work at concentrations 5 to 9 fold lower then oligonucleotides conjugated to conventional cholesterols.

Alternatively the polynucleotide may be bound to a protein, peptide or positively charged chemical that functions as the hydrophobic molecule. The proteins may be selected from the group consisting of protamine, dsRNA binding domain, and arginine rich peptides. Exemplary positively charged chemicals include spermine, spermidine, cadaverine, and putrescine.

In another embodiment hydrophobic molecule conjugates may demonstrate even higher efficacy when it is combined with optimal chemical modification patterns of the polynucleotide (as described herein in detail), containing but not limited to hydrophobic modifications, phosphorothioate modifications, and 2′ ribo modifications.

In another embodiment the sterol type molecule may be a naturally occurring PhytoSterols such as those shown in FIG. 8. The polycarbon chain may be longer than 9 and may be linear, branched and/or contain double bonds. Some PhytoSterol containing polynucleotide conjugates may be significantly more potent and active in delivery of polynucleotides to various tissues. Some PhytoSterols may demonstrate tissue preference and thus be used as a way to delivery RNAi specifically to particular tissues.

Targeting Agents

The delivery of oligonucleotides can also be improved by targeting the oligonucleotides to a cellular receptor. The targeting moieties can be conjugated to the oligonucleotides or attached to a carrier group (i.e., poly(L-lysine) or liposomes) linked to the oligonucleotides. This method is well suited to cells that display specific receptor-mediated endocytosis.

For instance, oligonucleotide conjugates to 6-phosphomannosylated proteins are internalized 20-fold more efficiently by cells expressing mannose 6-phosphate specific receptors than free oligonucleotides. The oligonucleotides may also be coupled to a ligand for a cellular receptor using a biodegradable linker. In another example, the delivery construct is mannosylated streptavidin which forms a tight complex with biotinylated oligonucleotides. Mannosylated streptavidin was found to increase 20-fold the internalization of biotinylated oligonucleotides. (Vlassov et al. 1994. Biochimica et Biophysica Acta 1197:95-108).

In addition specific ligands can be conjugated to the polylysine component of polylysine-based delivery systems. For example, transferrin-polylysine, adenovirus-polylysine, and influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides-polylysine conjugates greatly enhance receptor-mediated DNA delivery in eucaryotic cells. Mannosylated glycoprotein conjugated to poly(L-lysine) in aveolar macrophages has been employed to enhance the cellular uptake of oligonucleotides. Liang et al. 1999. Pharmazie 54:559-566.

Because malignant cells have an increased need for essential nutrients such as folic acid and transferrin, these nutrients can be used to target oligonucleotides to cancerous cells. For example, when folic acid is linked to poly(L-lysine) enhanced oligonucleotide uptake is seen in promyelocytic leukaemia (HL-60) cells and human melanoma (M-14) cells. Ginobbi et al. 1997. Anticancer Res. 17:29. In another example, liposomes coated with maleylated bovine serum albumin, folic acid, or ferric protoporphyrin IX, show enhanced cellular uptake of oligonucleotides in murine macrophages, KB cells, and 2.2.15 human hepatoma cells. Liang et al. 1999. Pharmazie 54:559-566.

Liposomes naturally accumulate in the liver, spleen, and reticuloendothelial system (so-called, passive targeting). By coupling liposomes to various ligands such as antibodies are protein A, they can be actively targeted to specific cell populations. For example, protein A-bearing liposomes may be pretreated with H-2K specific antibodies which are targeted to the mouse major histocompatibility complex-encoded H-2K protein expressed on L cells. (Vlassov et al. 1994. Biochimica et Biophysica Acta 1197:95-108).

Other in vitro and/or in vivo delivery of RNAi reagents are known in the art, and can be used to deliver the subject RNAi constructs. See, for example, U.S. patent application publications 20080152661, 20080112916, 20080107694, 20080038296, 20070231392, 20060240093, 20060178327, 20060008910, 20050265957, 20050064595, 20050042227, 20050037496, 20050026286, 20040162235, 20040072785, 20040063654, 20030157030, WO 2008/036825, WO04/065601, and AU2004206255B2, just to name a few (all incorporated by reference).

Administration

The optimal course of administration or delivery of the oligonucleotides may vary depending upon the desired result and/or on the subject to be treated. As used herein “administration” refers to contacting cells with oligonucleotides and can be performed in vitro or in vivo. The dosage of oligonucleotides may be adjusted to optimally reduce expression of a protein translated from a target nucleic acid molecule, e.g., as measured by a readout of RNA stability or by a therapeutic response, without undue experimentation.

For example, expression of the protein encoded by the nucleic acid target can be measured to determine whether or not the dosage regimen needs to be adjusted accordingly. In addition, an increase or decrease in RNA or protein levels in a cell or produced by a cell can be measured using any art recognized technique. By determining whether transcription has been decreased, the effectiveness of the oligonucleotide in inducing the cleavage of a target RNA can be determined.

Any of the above-described oligonucleotide compositions can be used alone or in conjunction with a pharmaceutically acceptable carrier. As used herein, “pharmaceutically acceptable carrier” includes appropriate solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, it can be used in the therapeutic compositions. Supplementary active ingredients can also be incorporated into the compositions.

Oligonucleotides may be incorporated into liposomes or liposomes modified with polyethylene glycol or admixed with cationic lipids for parenteral administration. Incorporation of additional substances into the liposome, for example, antibodies reactive against membrane proteins found on specific target cells, can help target the oligonucleotides to specific cell types.

Moreover, the present invention provides for administering the subject oligonucleotides with an osmotic pump providing continuous infusion of such oligonucleotides, for example, as described in Rataiczak et al. (1992 Proc. Natl. Acad. Sci. USA 89:11823-11827). Such osmotic pumps are commercially available, e.g., from Alzet Inc. (Palo Alto, Calif.). Topical administration and parenteral administration in a cationic lipid carrier are preferred.

With respect to in vivo applications, the formulations of the present invention can be administered to a patient in a variety of forms adapted to the chosen route of administration, e.g., parenterally, orally, or intraperitoneally. Parenteral administration, which is preferred, includes administration by the following routes: intravenous; intramuscular; interstitially; intraarterially; subcutaneous; intra ocular; intrasynovial; trans epithelial, including transdermal; pulmonary via inhalation; ophthalmic; sublingual and buccal; topically, including ophthalmic; dermal; ocular; rectal; and nasal inhalation via insufflation.

Pharmaceutical preparations for parenteral administration include aqueous solutions of the active compounds in water-soluble or water-dispersible form. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, or dextran, optionally, the suspension may also contain stabilizers. The oligonucleotides of the invention can be formulated in liquid solutions, preferably in physiologically compatible buffers such as Hank's solution or Ringer's solution. In addition, the oligonucleotides may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms are also included in the invention.

Pharmaceutical preparations for topical administration include transdermal patches, ointments, lotions, creams, gels, drops, sprays, suppositories, liquids and powders. In addition, conventional pharmaceutical carriers, aqueous, powder or oily bases, or thickeners may be used in pharmaceutical preparations for topical administration.

Pharmaceutical preparations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. In addition, thickeners, flavoring agents, diluents, emulsifiers, dispersing aids, or binders may be used in pharmaceutical preparations for oral administration.

For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are known in the art, and include, for example, for transmucosal administration bile salts and fusidic acid derivatives, and detergents. Transmucosal administration may be through nasal sprays or using suppositories. For oral administration, the oligonucleotides are formulated into conventional oral administration forms such as capsules, tablets, and tonics. For topical administration, the oligonucleotides of the invention are formulated into ointments, salves, gels, or creams as known in the art.

Drug delivery vehicles can be chosen e.g., for in vitro, for systemic, or for topical administration. These vehicles can be designed to serve as a slow release reservoir or to deliver their contents directly to the target cell. An advantage of using some direct delivery drug vehicles is that multiple molecules are delivered per uptake. Such vehicles have been shown to increase the circulation half-life of drugs that would otherwise be rapidly cleared from the blood stream. Some examples of such specialized drug delivery vehicles which fall into this category are liposomes, hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres.

The described oligonucleotides may be administered systemically to a subject. Systemic absorption refers to the entry of drugs into the blood stream followed by distribution throughout the entire body. Administration routes which lead to systemic absorption include: intravenous, subcutaneous, intraperitoneal, and intranasal. Each of these administration routes delivers the oligonucleotide to accessible diseased cells. Following subcutaneous administration, the therapeutic agent drains into local lymph nodes and proceeds through the lymphatic network into the circulation. The rate of entry into the circulation has been shown to be a function of molecular weight or size. The use of a liposome or other drug carrier localizes the oligonucleotide at the lymph node. The oligonucleotide can be modified to diffuse into the cell, or the liposome can directly participate in the delivery of either the unmodified or modified oligonucleotide into the cell.

The chosen method of delivery will result in entry into cells. Preferred delivery methods include liposomes (10-400 nm), hydrogels, controlled-release polymers, and other pharmaceutically applicable vehicles, and microinjection or electroporation (for ex vivo treatments).

The pharmaceutical preparations of the present invention may be prepared and formulated as emulsions. Emulsions are usually heterogeneous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter. The emulsions of the present invention may contain excipients such as emulsifiers, stabilizers, dyes, fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives, and anti-oxidants may also be present in emulsions as needed. These excipients may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase.

Examples of naturally occurring emulsifiers that may be used in emulsion formulations of the present invention include lanolin, beeswax, phosphatides, lecithin and acacia. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. Examples of finely divided solids that may be used as emulsifiers include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montrnorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

Examples of preservatives that may be included in the emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Examples of antioxidants that may be included in the emulsion formulations include free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

In one embodiment, the compositions of oligonucleotides are formulated as microemulsions. A microemulsion is a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution. Typically microemulsions are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a 4th component, generally an intermediate chain-length alcohol to form a transparent system.

Surfactants that may be used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DA0750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules.

Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C₈-C₁₂) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C₈-C₁₀ glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both oil/water and water/oil) have been proposed to enhance the oral bioavailability of drugs.

Microemulsions offer improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., Pharmaceutical Research, 1994, 11:1385; Ho et al., J. Pharm. Sci., 1996, 85:138-143). Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

In an embodiment, the present invention employs various penetration enhancers to affect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to increasing the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also act to enhance the permeability of lipophilic drugs.

Five categories of penetration enhancers that may be used in the present invention include: surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants. Other agents may be utilized to enhance the penetration of the administered oligonucleotides include: glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-15 pyrrol, azones, and terpenes such as limonene, and menthone.

The oligonucleotides, especially in lipid formulations, can also be administered by coating a medical device, for example, a catheter, such as an angioplasty balloon catheter, with a cationic lipid formulation. Coating may be achieved, for example, by dipping the medical device into a lipid formulation or a mixture of a lipid formulation and a suitable solvent, for example, an aqueous-based buffer, an aqueous solvent, ethanol, methylene chloride, chloroform and the like. An amount of the formulation will naturally adhere to the surface of the device which is subsequently administered to a patient, as appropriate. Alternatively, a lyophilized mixture of a lipid formulation may be specifically bound to the surface of the device. Such binding techniques are described, for example, in K. Ishihara et al., Journal of Biomedical Materials Research, Vol. 27, pp. 1309-1314 (1993), the disclosures of which are incorporated herein by reference in their entirety.

The useful dosage to be administered and the particular mode of administration will vary depending upon such factors as the cell type, or for in vivo use, the age, weight and the particular animal and region thereof to be treated, the particular oligonucleotide and delivery method used, the therapeutic or diagnostic use contemplated, and the form of the formulation, for example, suspension, emulsion, micelle or liposome, as will be readily apparent to those skilled in the art. Typically, dosage is administered at lower levels and increased until the desired effect is achieved. When lipids are used to deliver the oligonucleotides, the amount of lipid compound that is administered can vary and generally depends upon the amount of oligonucleotide agent being administered. For example, the weight ratio of lipid compound to oligonucleotide agent is preferably from about 1:1 to about 15:1, with a weight ratio of about 5:1 to about 10:1 being more preferred. Generally, the amount of cationic lipid compound which is administered will vary from between about 0.1 milligram (mg) to about 1 gram (g). By way of general guidance, typically between about 0.1 mg and about 10 mg of the particular oligonucleotide agent, and about 1 mg to about 100 mg of the lipid compositions, each per kilogram of patient body weight, is administered, although higher and lower amounts can be used.

The agents of the invention are administered to subjects or contacted with cells in a biologically compatible form suitable for pharmaceutical administration. By “biologically compatible form suitable for administration” is meant that the oligonucleotide is administered in a form in which any toxic effects are outweighed by the therapeutic effects of the oligonucleotide. In one embodiment, oligonucleotides can be administered to subjects. Examples of subjects include mammals, e.g., humans and other primates; cows, pigs, horses, and farming (agricultural) animals; dogs, cats, and other domesticated pets; mice, rats, and transgenic non-human animals.

Administration of an active amount of an oligonucleotide of the present invention is defined as an amount effective, at dosages and for periods of time necessary to achieve the desired result. For example, an active amount of an oligonucleotide may vary according to factors such as the type of cell, the oligonucleotide used, and for in vivo uses the disease state, age, sex, and weight of the individual, and the ability of the oligonucleotide to elicit a desired response in the individual. Establishment of therapeutic levels of oligonucleotides within the cell is dependent upon the rates of uptake and efflux or degradation. Decreasing the degree of degradation prolongs the intracellular half-life of the oligonucleotide. Thus, chemically-modified oligonucleotides, e.g., with modification of the phosphate backbone, may require different dosing.

The exact dosage of an oligonucleotide and number of doses administered will depend upon the data generated experimentally and in clinical trials. Several factors such as the desired effect, the delivery vehicle, disease indication, and the route of administration, will affect the dosage. Dosages can be readily determined by one of ordinary skill in the art and formulated into the subject pharmaceutical compositions. Preferably, the duration of treatment will extend at least through the course of the disease symptoms.

Dosage regim may be adjusted to provide the optimum therapeutic response. For example, the oligonucleotide may be repeatedly administered, e.g., several doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. One of ordinary skill in the art will readily be able to determine appropriate doses and schedules of administration of the subject oligonucleotides, whether the oligonucleotides are to be administered to cells or to subjects.

Physical methods of introducing nucleic acids include injection of a solution containing the nucleic acid, bombardment by particles covered by the nucleic acid, soaking the cell or organism in a solution of the nucleic acid, or electroporation of cell membranes in the presence of the nucleic acid. A viral construct packaged into a viral particle would accomplish both efficient introduction of an expression construct into the cell and transcription of nucleic acid encoded by the expression construct. Other methods known in the art for introducing nucleic acids to cells may be used, such as lipid-mediated carrier transport, chemical-mediated transport, such as calcium phosphate, and the like. Thus the nucleic acid may be introduced along with components that perform one or more of the following activities: enhance nucleic acid uptake by the cell, inhibit annealing of single strands, stabilize the single strands, or other-wise increase inhibition of the target gene.

Nucleic acid may be directly introduced into the cell (i.e., intracellularly); or introduced extracellularly into a cavity, interstitial space, into the circulation of an organism, introduced orally or by inhalation, or may be introduced by bathing a cell or organism in a solution containing the nucleic acid. Vascular or extravascular circulation, the blood or lymph system, and the cerebrospinal fluid are sites where the nucleic acid may be introduced.

The cell with the target gene may be derived from or contained in any organism. The organism may a plant, animal, protozoan, bacterium, virus, or fungus. The plant may be a monocot, dicot or gymnosperm; the animal may be a vertebrate or invertebrate. Preferred microbes are those used in agriculture or by industry, and those that are pathogenic for plants or animals.

Alternatively, vectors, e.g., transgenes encoding a siRNA of the invention can be engineered into a host cell or transgenic animal using art recognized techniques.

Another use for the nucleic acids of the present invention (or vectors or transgenes encoding same) is a functional analysis to be carried out in eukaryotic cells, or eukaryotic non-human organisms, preferably mammalian cells or organisms and most preferably human cells, e.g. cell lines such as HeLa or 293 or rodents, e.g. rats and mice. By administering a suitable nucleic acid of the invention which is sufficiently complementary to a target mRNA sequence to direct target-specific RNA interference, a specific knockout or knockdown phenotype can be obtained in a target cell, e.g. in cell culture or in a target organism.

Thus, a further subject matter of the invention is a eukaryotic cell or a eukaryotic non-human organism exhibiting a target gene-specific knockout or knockdown phenotype comprising a fully or at least partially deficient expression of at least one endogenous target gene wherein said cell or organism is transfected with at least one vector comprising DNA encoding an RNAi agent capable of inhibiting the expression of the target gene. It should be noted that the present invention allows a target-specific knockout or knockdown of several different endogenous genes due to the specificity of the RNAi agent.

Gene-specific knockout or knockdown phenotypes of cells or non-human organisms, particularly of human cells or non-human mammals may be used in analytic to procedures, e.g. in the functional and/or phenotypical analysis of complex physiological processes such as analysis of gene expression profiles and/or proteomes. Preferably the analysis is carried out by high throughput methods using oligonucleotide based chips.

Therapeutic use

By inhibiting the expression of a gene, the oligonucleotide compositions of the present invention can be used to treat any disease involving the expression of a protein. Examples of diseases that can be treated by oligonucleotide compositions, just to illustrate, include: cancer, retinopathies, autoimmune diseases, inflammatory diseases (i.e., ICAM-1 related disorders, Psoriasis, Ulcerative Colitus, Crohn's disease), viral diseases (i.e., HIV, Hepatitis C), miRNA disorders, and cardiovascular diseases.

In one embodiment, in vitro treatment of cells with oligonucleotides can be used for ex vivo therapy of cells removed from a subject (e.g., for treatment of leukemia or viral infection) or for treatment of cells which did not originate in the subject, but are to be administered to the subject (e.g., to eliminate transplantation antigen expression on cells to be transplanted into a subject). In addition, in vitro treatment of cells can be used in non-therapeutic settings, e.g., to evaluate gene function, to study gene regulation and protein synthesis or to evaluate improvements made to oligonucleotides designed to modulate gene expression or protein synthesis. In vivo treatment of cells can be useful in certain clinical settings where it is desirable to inhibit the expression of a protein. There are numerous medical conditions for which antisense therapy is reported to be suitable (see, e.g., U .S. Pat. No. 5,830,653) as well as respiratory syncytial virus infection (WO 95/22,553) influenza virus (WO 94/23,028), and malignancies (WO 94/08,003). Other examples of clinical uses of antisense sequences are reviewed, e.g., in Glaser. 1996. Genetic Engineering News 16:1. Exemplary targets for cleavage by oligonucleotides include, e.g., protein kinase Ca, ICAM-1, c-raf kinase, p53, c-myb, and the bcr/abl fusion gene found in chronic myelogenous leukemia.

The subject nucleic acids can be used in RNAi-based therapy in any animal having RNAi pathway, such as human, non-human primate, non-human mammal, non-human vertebrates, rodents (mice, rats, hamsters, rabbits, etc.), domestic livestock animals, pets (cats, dogs, etc.), Xenopus, fish, insects (Drosophila, etc.), and worms (C. elegans), etc.

The invention provides methods for inhibiting or preventing in a subject, a disease or condition associated with an aberrant or unwanted target gene expression or activity, by administering to the subject a nucleic acid of the invention. If appropriate, subjects are first treated with a priming agent so as to be more responsive to the subsequent RNAi therapy. Subjects at risk for a disease which is caused or contributed to by aberrant or unwanted target gene expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays known in the art. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the target gene aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending on the type of target gene aberrancy, for example, a target gene, target gene agonist or target gene antagonist agent can be used for treating the subject.

In another aspect, the invention pertains to methods of modulating target gene expression, protein expression or activity for therapeutic purposes. Accordingly, in an exemplary embodiment, the methods of the invention involve contacting a cell capable of expressing target gene with a nucleic acid of the invention that is specific for the target gene or protein (e.g., is specific for the mRNA encoded by said gene or specifying the amino acid sequence of said protein) such that expression or one or more of the activities of target protein is modulated. These methods can be performed in vitro (e.g., by culturing the cell with the agent), in vivo (e.g., by administering the agent to a subject), or ex vivo. The subjects may be first treated with a priming agent so as to be more responsive to the subsequent RNAi therapy if desired. As such, the present invention provides methods of treating a subject afflicted with a disease or disorder characterized by aberrant or unwanted expression or activity of a target gene polypeptide or nucleic acid molecule. Inhibition of target gene activity is desirable in situations in which target gene is abnormally unregulated and/or in which decreased target gene activity is likely to have a beneficial effect.

Thus the therapeutic agents of the invention can be administered to subjects to treat (prophylactically or therapeutically) disorders associated with aberrant or unwanted target gene activity. In conjunction with such treatment, pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, a physician or clinician may consider applying knowledge obtained in relevant pharmacogenomics studies in determining whether to administer a therapeutic agent as well as tailoring the dosage and/or therapeutic regimen of treatment with a therapeutic agent. Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons.

For the purposes of the invention, ranges may be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.

Moreover, for the purposes of the present invention, the term “a” or “an” entity refers to one or more of that entity; for example, “a protein” or “a nucleic acid molecule” refers to one or more of those compounds or at least one compound. As such, the terms “a” (or “an”), “one or more” and “at least one” can be used interchangeably herein. It is also to be noted that the terms “comprising”, “including”, and “having” can be used interchangeably. Furthermore, a compound “selected from the group consisting of” refers to one or more of the compounds in the list that follows, including mixtures (i.e., combinations) of two or more of the compounds. According to the present invention, an isolated, or biologically pure, protein or nucleic acid molecule is a compound that has been removed from its natural milieu. As such, “isolated” and “biologically pure” do not necessarily reflect the extent to which the compound has been purified. An isolated compound of the present invention can be obtained from its natural source, can be produced using molecular biology techniques or can be produced by chemical synthesis.

The present invention is further illustrated by the following Examples, which in no way should be construed as further limiting. The entire contents of all of the references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference.

EXAMPLES Example 1 Inhibition of Gene Expression using Minimum Length Trigger RNAs

Transfection of Minimum Length Trigger (mlt) RNA

mltRNA constructs were chemically synthesized (Integrated DNA Technologies, Coralville, Iowa) and transfected into HEK293 cells (ATCC, Manassas, Va.) using the Lipofectamine RNAiMAX (Invitrogen, Carlsbad, Calif.) reagent according to manufacturer's instructions. In brief, RNA was diluted to a 12× concentration and then combined with a 12× concentration of Lipofectamine RNAiMAX to complex. The RNA and transfection reagent were allowed to complex at room temperature for 20 minutes and make a 6× concentration. While complexing, HEK293 cells were washed, trypsinized and counted. The cells were diluted to a concentration recommended by the manufacturer and previously described conditions which was at 1×10⁵cells/ml. When RNA had completed complexing with the RNAiMAX transfection reagent, 20 ul of the complexes were added to the appropriate well of the 96-well plate in triplicate. Cells were added to each well (100 ul volume) to make the final cell count per well at 1×10⁴ cells/well. The volume of cells diluted the 6× concentration of complex to lx which was equal to a concentration noted (between 10-0.05 nM). Cells were incubated for 24 or 48 hours under normal growth conditions.

After 24 or 48 hour incubation cells were lysed and gene silencing activity was measured using the QuantiGene assay (Panomics, Freemont, Calif.) which employs bDNA hybridization technology. The assay was carried out according to manufacturer's instructions.

ΔG calculation

ΔG was calculated using Mfold, available through the Mfold internet site (mfold.bioinfarpi.edu/cgi-bin/rna-forml.cgi). Methods for calculating ΔG are described in, and are incorporated by reference from, the following references: Zuker, M. (2003) Nucleic Acids Res., 31(13):3406-15; Mathews, D. H., Sabina, J., Zuker, M. and Turner, D. H. (1999) J. Mol. Biol. 288:911-940; Mathews, D. H., Disney, M. D., Childs, J. L., Schroeder, S. J., Zuker, M., and Turner, D. H. (2004) Proc. Natl. Acad. Sci. 101:7287-7292; Duan, S., Mathews, D. H., and Turner, D. H. (2006) Biochemistry 45:9819-9832; Wuchty, S., Fontana, W., Hofacker, I. L., and Schuster, P. (1999) Biopolymers 49:145-165.

Example 2 Optimization of sd-rxRNA^(nano) Molecules for Gene Silencing

Asymmetric double stranded RNAi molecules, with minimal double stranded regions, were developed herein and are highly effective at gene silencing. These molecules can contain a variety of chemical modifications on the sense and/or anti-sense strands, and can be conjugated to sterol-like compounds such as cholesterol.

FIGS. 1-3 present schematics of RNAi molecules associated with the invention. In the asymmetric molecules, which contain a sense and anti-sense strand, either of the strands can be the longer strand. Either strand can also contain a single-stranded region. There can also be mismatches between the sense and anti-sense strand, as indicated in FIG. 1D. Preferably, one end of the double-stranded molecule is either blunt-ended or contains a short overhang such as an overhang of one nucleotide. FIG. 2 indicates types of chemical modifications applied to the sense and anti-sense strands including 2′F, 2′OMe, hydrophobic modifications and phosphorothioate modifications. Preferably, the single stranded region of the molecule contains multiple phosphorothioate modifications. Hydrophobicity of molecules can be increased using such compounds as 4-pyridyl at 5-U, 2-pyridyl at 5-U, isobutyl at 5-U and indolyl at 5-U (FIG. 2). Proteins or peptides such as protamine (or other Arg rich peptides), spermidine or other similar chemical structures can also be used to block duplex charge and facilitate cellular entry (FIG. 3). Increased hydrophobicity can be achieved through either covalent or non-covalent modifications. Several positively charged chemicals, which might be used for polynucleotide charge blockage are depicted in FIG. 4.

Chemical modifications of polynucleotides, such as the guide strand in a duplex molecule, can facilitate RISC entry. FIG. 5 depicts single stranded polynucleotides, representing a guide strand in a duplex molecule, with a variety of chemical modifications including 2′d, 2′OMe, 2′F, hydrophobic modifications, phosphorothioate modifications, and attachment of conjugates such as “X” in FIG. 5, where X can be a small molecule with high affinity to a PAZ domain, or sterol-type entity. Similarly, FIG. 6 depicts single stranded polynucleotides, representing a passenger strand in a duplex molecule, with proposed structural and chemical compositions of RISC substrate inhibitors. Combinations of chemical modifications can ensure efficient uptake and efficient binding to preloaded RISC complexes.

FIG. 7 depicts structures of polynucleotides with sterol-type molecules attached, where R represents a polycarbonic tail of 9 carbons or longer. FIG. 8 presents examples of naturally occurring phytosterols with a polycarbon chain longer than 8 attached at position 17. More than 250 different types of phytosterols are known. FIG. 9 presents examples of sterol-like structures with variations in the sizes of the polycarbon chains attached at position 17. FIG. 91 presents further examples of sterol-type molecules that can be used as a hydrophobic entity in place of cholesterol. FIG. 92 presents further examples of hydrophobic molecules that might be used as hydrophobic entities in place of cholestesterol. Optimization of such characteristics can improve uptake properties of the RNAi molecules. FIG. 10 presents data adapted from Martins et al. (J Lipid Research), showing that the percentage of liver uptake and plasma clearance of lipid emulsions containing sterol-type molecules is directly affected by the size of the attached polycarbon chain at position 17. FIG. 11 depicts a micelle formed from a mixture of polynucleotides attached to hydrophobic conjugates and fatty acids. FIG. 12 describes how alteration in lipid composition can affect pharmacokinetic behavior and tissue distribution of hydrophobically modified and/or hydrophobically conjugated polynucleotides. In particular, the use of lipid mixtures that are enriched in linoleic acid and cardiolipin results in preferential uptake by cardiomyocites.

FIG. 13 depicts examples of RNAi constructs and controls designed to target MAP4K4 expression. FIGS. 14 and 15 reveal that RNAi constructs with minimal duplex regions (such as duplex regions of approximately 13 nucleotides) are effective in mediating RNA silencing in cell culture. Parameters associated with these RNA molecules are shown in FIG. 16. FIG. 17 depicts examples of RNAi constructs and controls designed to target SOD1 expression. FIGS. 18 and 19 reveal the results of gene silencing experiments using these RNAi molecules to target SOD1 in cells. FIG. 20 presents a schematic indicating that RNA molecules with double stranded regions that are less than 10 nucleotides are not cleaved by Dicer, and FIG. 21 presents a schematic of a hypothetical RNAi model for RNA induced gene silencing.

The RNA molecules described herein were subject to a variety of chemical modifications on the sense and antisense strands, and the effects of such modifications were observed. RNAi molecules were synthesized and optimized through testing of a variety of modifications. In first generation optimization, the sense (passenger) and anti-sense (guide) strands of the sd-rxRNA^(nano) molecules were modified for example through incorporation of C and U 2′OMe modifications, 2′F modifications, phosphorothioate modifications, phosphorylation, and conjugation of cholesterol. Molecules were tested for inhibition of MAP4K4 expression in cells including HeLa, primary mouse hepatocytes and primary human hepatocytes through both lipid-mediated and passive uptake transfection.

FIG. 22 reveals that chemical modifications can enhance gene silencing. In particular, modifying the guide strand with 2′F UC modifications, and with a stretch of phosphorothioate modifications, combined with complete CU O′Me modification of the passenger strands, resulted in molecules that were highly effective in gene silencing. The effect of chemical modification on in vitro efficacy in un-assisted delivery in HeLa cells was also examined. FIG. 23 reveals that compounds lacking any of 2′F, 2′OMe, a stretch of phosphorothioate modifications, or cholesterol conjugates, were completely inactive in passive uptake. A combination of all 4 types of chemical modifications, for example in compound 12386, was found to be highly effective in gene silencing. FIG. 24 also shows the effectiveness of compound 12386 in gene silencing.

Optimization of the length of the oligonucleotide was also investigated. FIGS. 25 and 26 reveal that oligonucleotides with a length of 21 nucleotides were more effective than oligonucletides with a length of 25 nucleotides, indicating that reduction in the size of an RNA molecule can improve efficiency, potentially by assisting in its uptake. Screening was also conducted to optimize the size of the duplex region of double stranded RNA molecules. FIG. 88 reveals that compounds with duplexes of 10 nucleotides were effective in inducing gene silencing. Positioning of the sense strand relative to the guide strand can also be critical for silencing gene expression (FIG. 89). In this assay, a blunt end was found to be most effective. 3′ overhangs were tolerated, but 5′ overhangs resulted in a complete loss of functionality. The guide strand can be effective in gene silencing when hybiridized to a sense strand of varying lengths (FIG. 90). In this assay presented in FIG. 90, the compounds were introduced into HeLa cells via lipid mediated transfection.

The importance of phosphorothioate content of the RNA molecule for unassisted delivery was also investigated. FIG. 27 presents the results of a systematic screen that identified that the presence of at least 2-12 phosphorothioates in the guide strand as being highly advantageous for achieving uptake, with 4-8 being the preferred number. FIG. 27 also shows that presence or absence of phosphorothioate modifications in the sense strand did not alter efficacy.

FIGS. 28-29 reveal the effects of passive uptake of RNA compounds on gene silencing in primary mouse hepatocytes. nanoRNA molecules were found to be highly effective, especially at a concentration of 1 μM (FIG. 28). FIGS. 30 and 31 reveal that the RNA compounds associated with the invention were also effective in gene silencing following passive uptake in primary human hepatocytes. The cellular localization of the RNA molecules associated with the invention was examined and compared to the localization of Chol-siRNA (Alnylam) molecules, as shown in FIGS. 32 and 33.

A summary of 1^(st) generation sd-rxRNA molecules is presented in FIG. 21. Chemical modifications were introduced into the RNA molecules, at least in part, to increase potency, such as through optimization of nucleotide length and phosphorothioate content, to reduce toxicity, such as through replacing 2′F modifications on the guide strand with other modifications, to improve delivery such as by adding or conjugating the RNA molecules to linker and sterol modalities, and to improve the ease of manufacturing the RNA molecules. FIG. 35 presents schematic depictions of some of the chemical modifications that were screened in 1s^(t) generation molecules. Parameters that were optimized for the guide strand included nucleotide length (e.g., 19, 21 and 25 nucleotides), phosphorothioate content (e.g., 0-18 phosphorothioate linkages) and replacement of 2′F groups with 2′OMe and 5 Me C or riboThymidine. Parameters that were optimized for the sense strand included nucleotide length (e.g., 11, 13 and 19 nucleotides), phosphorothioate content (e.g., 0-4 phosphorothioate linkages), and 2′OMe modifications. FIG. 36 summarizes parameters that were screened. For example, the nucleotide length and the phosphorothioate tail length were modified and screened for optimization, as were the additions of 2′OMe C and U modifications. Guide strand length and the length of the phosphorothioate modified stretch of nucleotides were found to influence efficacy (FIGS. 37-38). Phosphorothioate modifications were tolerated in the guide strand and were found to influence passive uptake (FIGS. 39-42).

FIG. 43 presents a schematic revealing guide strand chemical modifications that were screened. FIGS. 44 and 45 reveal that 2′OMe modifications were tolerated in the 3′ end of the guide strand. In particular, 2′OMe modifications in positions 1 and 11-18 were well tolerated. The 2′OMe modifications in the seed area were tolerated but resulted in slight reduction of efficacy. Ribo- modifications in the seed were also well tolerated. These data indicate that the molecules associated with the invention offer the significant advantage of having reduced or no 2′F modification content. This is advantageous because 2′F modifications are thought to generate toxicity in vivo. In some instances, a complete substitution of 2′F modifications with 2′OMe was found to lead to some reduction in potency. However, the 2′OMe substituted molecules were still very active. A molecule with 50% reduction in 2′F content (including at positions 11, 16-18 which were changed to 2′OMe modifications), was found to have comparable efficacy to a compound with complete 2′F C and U modification. 2′OMe modification in position was found in some instances to reduce efficacy, although this can be at least partially compensated by 2′OMe modification in position 1 (with chemical phosphate). In some instances, 5 Me C and/or ribothymidine substitution for 2′F modifications led to a reduction in passive uptake efficacy, but increased potency in lipid mediated transfections compared to 2′F modifications. Optimization results for lipid mediated transfection were not necessarily the same as for passive uptake.

Modifications to the sense strand were also developed and tested, as depicted in FIG. 46. FIG. 47 reveals that in some instances, a sense strand length between 10-15 bases was found to be optimal. For the molecules tested in FIG. 47, an increase in the sense strand length resulted in reduction of passive uptake, however an increase in sense strand length may be tolerated for some compounds. FIG. 47 also reveals that LNA modification of the sense strand demonstrated similar efficacy to non-LNA containing compounds. In general, the addition of LNA or other thermodynamically stabilizing compounds has been found to be beneficial, in some instances resulting in converting non-functional sequences to functional sequences. FIG. 48 also presents data on sense strand length optimization, while FIG. 49 shows that phosphorothioate modification of the sense strand is not required for passive uptake.

Based on the above-described optimization experiments, 2^(nd) generation RNA molecules were developed. As shown in FIG. 50, these molecules contained reduced phosphorothioate modification content and reduced 2′F modification content, relative to 1^(st) generation RNA molecules. Significantly, these RNA molecules exhibit spontaneous cellular uptake and efficacy without a delivery vehicle (FIG. 51). These molecules can achieve self-delivery (i.e., with no transfection reagent) and following self-delivery can exhibit nanomolar activity in cell culture. These molecules can also be delivered using lipid-mediated transfection, and exhibit picomolar activity levels following transfection. Significantly, these molecules exhibit highly efficient uptake, 95% by most cells in cell culture, and are stable for more than three days in the presence of 100% human serum. These molecules are also highly specific and exhibit little or no immune induction. FIGS. 52 and 53 reveal the significance of chemical modifications and the configurations of such modifications in influencing the properties of the RNA molecules associated with the invention.

Linker chemistry was also tested in conjunction with the RNA molecules associated with the invention. As depicted in FIG. 54, 2^(nd) generation RNA molecules were synthesized with sterol-type molecules attached through TEG and amino caproic acid linkers. Both linkers showed identical potency. This functionality of the RNA molecules, independent of linker chemistry offers additional advantages in terms of scale up and synthesis and demonstrates that the mechanism of function of these RNA molecules is very different from other previously described RNA molecules.

Stability of the chemically modified sd-rxRNA molecules described herein in human serum is shown in FIG. 55 in comparison to unmodified RNA. The duplex molecules were incubated in 75% serum at 37 ° C. for the indicated periods of time. The level of degradation was determined by running the samples on non-denaturing gels and staining with SYBGR.

FIGS. 56 and 57 present data on cellular uptake of the sd-rxRNA molecules. FIG. 56 shows that minimizing the length of the RNA molecule is importance for cellular uptake, while FIG. 57 presents data showing target gene silencing after spontaneous cellular uptake in mouse PEC-derived macrophages. FIG. 58 demonstrates spontaneous uptake and target gene silencing in primary cells. FIG. 59 shows the results of delivery of sd-rxRNA molecules associated with the invention to RPE cells with no formulation. Imaging with Hoechst and DY547 reveals the clear presence of a signal representing the RNA molecule in the sd-rxRNA sample, while no signal is detectable in the other samples including the samples competing a competing conjugate, an rxRNA, and an untransfected control. FIG. 60 reveals silencing of target gene expression in RPE cells treated with sd-rxRNA molecules associated with the invention following 24-48 hours without any transfection formulation.

FIG. 61 shows further optimization of the chemical/structural composition of sd-rxRNA compounds. In some instances, preferred properties included an antisense strand that was 17-21 nucleotides long, a sense strand that was 10-15 nucleotides long, phosphorothioate modification of 2-12 nucleotides within the single stranded region of the molecule, preferentially phosphorothioate modification of 6-8 nucleotides within the single stranded region, and 2′OMe modification at the majority of positions within the sense strand, with or without phosphorothioate modification. Any linker chemistry can be used to attach the hydrophobic moiety, such as cholesterol, to the 3′ end of the sense strand. Version GIIb molecules, as shown in FIG. 61, have no 2′F modifications. Significantly, there is was no impact on efficacy in these molecules.

FIG. 62 demonstrates the superior performance of sd-rxRNA compounds compared to compounds published by Wolfrum et. al. Nature Biotech, 2007. Both generation I and II compounds (GI and GIIa) developed herein show great efficacy in reducing target gene expression. By contrast, when the chemistry described in Wolfrum et al. (all oligos contain cholesterol conjugated to the 3′ end of the sense strand) was applied to the same sequence in a context of conventional siRNA (19 bp duplex with two overhang) the compound was practically inactive. These data emphasize the significance of the combination of chemical modifications and assymetrical molecules described herein, producing highly effective RNA compounds.

FIG. 63 shows localization of sd-rxRNA molecules developed herein compared to localization of other RNA molecules such as those described in Soutschek et al. (2004) Nature, 432:173. sd-rxRNA molecules accumulate inside the cells whereas competing conjugate RNAs accumulate on the surface of cells. Significantly, FIG. 64 shows that sd-rxRNA molecules, but not competitor molecules such as those described in Soutschek et al. are internalized within minutes. FIG. 65 compares localization of sd-rxRNA molecules compared to regular siRNA-cholesterol, as described in Soutschek et al. A signal representing the RNA molecule is clearly detected for the sd-rxRNA molecule in tissue culture RPE cells, following local delivery to compromised skin, and following systemic delivery where uptake to the liver is seen. In each case, no signal is detected for the regular siRNA-cholesterol molecule. The sd-rxRNA molecule thus has drastically better cellular and tissue uptake characteristics when compared to conventional cholesterol conjugated siRNAs such as those described in Soutschek et al. The level of uptake is at least order of magnitude higher and is due at least in part to the unique combination of chemistries and conjugated structure. Superior delivery of sd-rxRNA relative to previously described RNA molecules is also demonstrated in FIGS. 66 and 67.

Based on the analysis of 2^(nd) generation RNA molecules associated with the invention, a screen was performed to identify functional molecules for targeting the SPP1/PPIB gene. As revealed in FIG. 68, several effective molecules were identified, with 14131 being the most effective. The compounds were added to A-549 cells and then the level of SPP1/ PPM ratio was determined by B-DNA after 48 hours.

FIG. 69 reveals efficient cellular uptake of sd-rxRNA within minutes of exposure. This is a unique characteristics of these molecules, not observed with any other RNAi compounds. Compounds described in Soutschek et al. were used as negative controls. FIG. 70 reveals that the uptake and gene silencing of the sd-rxRNA is effective in multiple different cell types including SH-SY5Y neuroblastoma derived cells, ARPE-19 (retinal pigment epithelium) cells, primary hepatocytes, and primary macrophages. In each case silencing was confirmed by looking at target gene expression by a Branched DNA assay.

FIG. 70 reveals that sd-rxRNA is active in the presence or absence of serum. While a slight reduction in efficacy (2-5 fold) was observed in the presence of serum, this small reduction in efficacy in the presence of serum differentiate the sd-rxRNA molecules from previously described molecules which exhibited a larger reduction in efficacy in the presence of serum. This demonstrated level of efficacy in the presence of serum creates a foundation for in vivo efficacy.

FIG. 72 reveals efficient tissue penetration and cellular uptake upon single intradermal injection. This data indicates the potential of the sd-rxRNA compounds described herein for silencing genes in any dermatology applications, and also represents a model for local delivery of sd-rxRNA compounds. FIG. 73 also demonstrates efficient cellular uptake and in vivo silencing with sd-rxRNA following intradermal injection. Silencing is determined as the level of MAP4K4 knockdown in several individual biopsies taken from the site of injection as compared to biopsies taken from a site injected with a negative control. FIG. 74 reveals that sd-rxRNA compounds has improved blood clearance and induced effective gene silencing in vivo in the liver upon systemic administration. In comparison to the RNA molecules described by Soutschek et al., the level of liver uptake at identical dose level is at least 50 fold higher with the sd-rxRNA molecules. The uptake results in productive silencing. sd-rxRNA compounds are also characterized by improved blood clearance kinetics.

The effect of 5-Methly C modifications was also examined. FIG. 75 demonstrates that the presence of 5-Methyl C in an RNAi molecule resulted in increased potency in lipid mediated transfection. This suggests that hydrophobic modification of Cs and Us in an RNAi molecule can be beneficial. These types of modifications can also be used in the context 2′ ribose modified bases to ensure optimal stability and efficacy. FIG. 76 presents data showing that incorporation of 5-Methyl C and/or ribothymidine in the guide strand can in some instances reduce efficacy.

FIG. 77 reveals that sd-rxRNA molecules are more effective than competitor molecules such as molecules described in Soutschek et al., in systemic delivery to the liver. A signal representing the RNA molecule is clearly visible in the sample containing sd-rxRNA, while no signal representing the RNA molecule is visible in the sample containing the competitor RNA molecule.

The addition of hydrophobic conjugates to the sd-rxRNA molecules was also explored (FIGS. 78-83). FIG. 78 presents schematics demonstrating 5-uridyl modifications with improved hydrophobicity characteristics. Incorporation of such modifications into sd-rxRNA compounds can increase cellular and tissue uptake properties. FIG. 78B presents a new type of RNAi compound modification which can be applied to compounds to improve cellular uptake and pharmacokinetic behavior. Significantly, this type of modification, when applied to sd-rxRNA compounds, may contribute to making such compounds orally available. FIG. 79 presents schematics revealing the structures of synthesized modified sterol-type molecules, where the length and structure of the C17 attached tail is modified. Without wishing to be bound by any theory, the length of the C17 attached tail may contribute to improving in vitro and in vivo efficacy of sd-rxRNA compounds.

FIG. 80 presents a schematic demonstrating the lithocholic acid route to long side chain cholesterols. FIG. 81 presents a schematic demonstrating a route to 5-uridyl phosphoramidite synthesis. FIG. 82 presents a schematic demonstrating synthesis of tri-functional hydroxyprolinol linker for 3′-cholesterol attachment. FIG. 83 presents a schematic demonstrating synthesis of solid support for the manufacture of a shorter asymmetric RNAi compound strand.

A screen was conducted to identify compounds that could effectively silence expression of SPP1 (Osteopontin). Compounds targeting SPP1 were added to A549 cells (using passive transfection), and the level of SPP1 expression was evaluated at 48 hours. Several novel compounds effective in SPP1 silencing were identified. Compounds that were effective in silencing of SPP1 included 14116, 14121, 14131, 14134, 14139, 14149, and 14152 (FIGS. 84-86). The most potent compound in this assay was 14131 (FIG. 84). The efficacy of these sd-rxRNA compounds in silencing SPP1 expression was independently validated (FIG. 85).

A similar screen was conducted to identify compounds that could effectively silence expression of CTGF (FIGS. 86-87). Compounds that were effective in silencing of CTGF included 14017, 14013, 14016, 14022, 14025, 14027.

Methods

-   Transfection of sd-rxRNA^(nano) -   Lipid Mediated Transfection

sd-rxRNA^(nano) constructs were chemically synthesized (Dharmacon, Lafayette, CO) and transfected into HEK293 cells (ATCC, Manassas, Va.) using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, Calif.) according to the manufacturer's instructions. In brief, RNA was diluted to a 12× concentration in Opti-MEM®1 Reduced Serum Media (Invitrogen, Carlsbad, Calif.) and then combined with a 12× concentration of Lipofectamine RNAiMAX. The RNA and transfection reagent were allowed to complex at room temperature for 20 minutes and make a 6× concentration. While complexing, HEK293 cells were washed, trypsinized and counted. The cells were diluted to a concentration recommended by the manufacturer and previously described of 1×10⁵ cells/ml. When RNA had completed complexing with the RNAiMAX transfection reagent, 20 ul of the complexes were added to the appropriate well of the 96-well plate in triplicate. Cells were added to each well (100 ul volume) to make the final cell count per well 1×10⁴ cells/well. The volume of cells diluted the 6× concentration of complex to 1× (between 10-0.05 nM). Cells were incubated for 24 or 48 hours under normal growth conditions. After 24 or 48 hour incubation, cells were lysed and gene silencing activity was measured using the QuantiGene assay (Panomics, Freemont, Calif.) which employs bDNA hybridization technology. The assay was carried out according to manufacturer's instructions.

Passive Uptake Transfection

Sd-rXRNA^(nano) constructs were chemically synthesized (Dharmacon, Lafayette, Colo.). 24 hours prior to transfection, HeLa cells (ATCC, Manassas, Va.) were plated at 1×10⁴ cells/well in a 96 well plate under normal growth conditions (DMEM, 10% FBS and 1% Penicillin and Streptomycin). Prior to transfection of HeLa cells, Sd-rXRNA^(nano) were diluted to a final concentration of 0.01 uM to 1 uM in Accell siRNA Delivery Media (Dharmacon, Lafayette, Colo.). Normal growth media was aspirated off cells and 100 uL of Accell Delivery media containing the appropriate concentration of sd-rxRNAnano was applied to the cells. 48 hours post transfection, delivery media was aspirated off the cells and normal growth media was applied to cells for an additional 24 hours.

After 48 or 72 hour incubation, cells were lysed and gene silencing activity was measured using the QuantiGene assay (Panomics, Freemont, Calif.) according to manufacturer's instructions.

TABLE 1 Oligo Accession Gene ID Number Number number Gene Name Symbol APOB-10167-20-12138 12138 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB-10167-20-12139 12139 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) MAP4K4-2931-13-12266 12266 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4-2931-16-12293 12293 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4-2931-16-12383 12383 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4-2931-16-12384 12384 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4-2931-16-12385 12385 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4-2931-16-12386 12386 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4-2931-16-12387 12387 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4-2931-15-12388 12388 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4-2931-13-12432 12432 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4-2931-13-12266.2 12266.2 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 APOB--21-12434 12434 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB--21-12435 12435 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) MAP4K4-2931-16-12451 12451 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4-2931-16-12452 12452 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4-2931-16-12453 12453 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4-2931-17-12454 12454 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4-2931-17-12455 12455 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4-2931-19-12456 12456 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 --27-12480 12480 --27-12481 12481 APOB-10167-21-12505 12505 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB-10167-21-12506 12506 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) MAP4K4-2931-16-12539 12539 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 APOB-10167-21-12505.2 12505.2 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB-10167-21-12506.2 12506.2 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) MAP4K4--13-12565 12565 MAP4K4 MAP4K4-2931-16-12386.2 12386.2 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4-2931-13-12815 12815 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 APOB--13-12957 12957 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) MAP4K4--16-12983 12983 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4--16-12984 12984 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4--16-12985 12985 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4--16-12986 12986 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4--16-12987 12987 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4--16-12988 12988 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4--16-12989 12989 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4--16-12990 12990 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4--16-12991 12991 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4--16-12992 12992 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4--16-12993 12993 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4--16-12994 12994 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4--16-12995 12995 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4-2931-19-13012 13012 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4-2931-19-13016 13016 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 PPIB--13-13021 13021 NM_000942 Peptidylprolyl Isomerase B PPIB (cyclophilin B) pGL3-1172-13-13038 13038 U47296 Cloning vector pGL3-Control pGL3 pGL3-1172-13-13040 13040 U47296 Cloning vector pGL3-Control pGL3 --16-13047 13047 SOD1-530-13-13090 13090 NM_000454 Superoxide Dismutase 1, soluble SOD1 (amyotrophic lateral sclerosis 1 (adult)) SOD1-523-13-13091 13091 NM_000454 Superoxide Dismutase 1, soluble SOD1 (amyotrophic lateral sclerosis 1 (adult)) SOD1-535-13-13092 13092 NM_000454 Superoxide Dismutase 1, soluble SOD1 (amyotrophic lateral sclerosis 1 (adult)) SOD1-536-13-13093 13093 NM_000454 Superoxide Dismutase 1, soluble SOD1 (amyotrophic lateral sclerosis 1 (adult)) SOD1-396-13-13094 13094 NM_000454 Superoxide Dismutase 1, soluble SOD1 (amyotrophic lateral sclerosis 1 (adult)) SOD1-385-13-13095 13095 NM_000454 Superoxide Dismutase 1, soluble SOD1 (amyotrophic lateral sclerosis 1 (adult)) SOD1-195-13-13096 13096 NM_000454 Superoxide Dismutase 1, soluble SOD1 (amyotrophic lateral sclerosis 1 (adult)) APOB-4314-13-13115 13115 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB-3384-13-13116 13116 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB-3547-13-13117 13117 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB-4318-13-13118 13118 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB-3741-13-13119 13119 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) PPIB--16-13136 13136 NM_000942 Peptidylprolyl Isomerase B PPIB (cyclophilin B) APOB-4314-15-13154 13154 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB-3547-15-13155 13155 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB-4318-15-13157 13157 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB-3741-15-13158 13158 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB--13-13159 13159 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB--15-13160 13160 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) SOD1-530-16-13163 13163 NM_000454 Superoxide Dismutase 1, soluble SOD1 (amyotrophic lateral sclerosis 1 (adult)) SOD1-523-16-13164 13164 NM_000454 Superoxide Dismutase 1, soluble SOD1 (amyotrophic lateral sclerosis 1 (adult)) SOD1-535-16-13165 13165 NM_000454 Superoxide Dismutase 1, soluble SOD1 (amyotrophic lateral sclerosis 1 (adult)) SOD1-536-16-13166 13166 NM_000454 Superoxide Dismutase 1, soluble SOD1 (amyotrophic lateral sclerosis 1 (adult)) SOD1-396-16-13167 13167 NM_000454 Superoxide Dismutase 1, soluble SOD1 (amyotrophic lateral sclerosis 1 (adult)) SOD1-385-16-13168 13168 NM_000454 Superoxide Dismutase 1, soluble SOD1 (amyotrophic lateral sclerosis 1 (adult)) SOD1-195-16-13169 13169 NM_000454 Superoxide Dismutase 1, soluble SOD1 (amyotrophic lateral sclerosis 1 (adult)) pGL3-1172-16-13170 13170 U47296 Cloning vector pGL3-Control pGL3 pGL3-1172-16-13171 13171 U47296 Cloning vector pGL3-Control pGL3 MAP4k4-2931-19-13189 13189 NM_004834 Mitogen-Activated Protein Kinase MAP4k4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 CTGF-1222-13-13190 13190 NM_001901.2 connective tissue growth factor CTGF CTGF-813-13-13192 13192 NM_001901.2 connective tissue growth factor CTGF CTGF-747-13-13194 13194 NM_001901.2 connective tissue growth factor CTGF CTGF-817-13-13196 13196 NM_001901.2 connective tissue growth factor CTGF CTGF-1174-13-13198 13198 NM_001901.2 connective tissue growth factor CTGF CTGF-1005-13-13200 13200 NM_001901.2 connective tissue growth factor CTGF CTGF-814-13-13202 13202 NM_001901.2 connective tissue growth factor CTGF CTGF-816-13-13204 13204 NM_001901.2 connective tissue growth factor CTGF CTGF-1001-13-13206 13206 NM_001901.2 connective tissue growth factor CTGF CTGF-1173-13-13208 13208 NM_001901.2 connective tissue growth factor CTGF CTGF-749-13-13210 13210 NM_001901.2 connective tissue growth factor CTGF CTGF-792-13-13212 13212 NM_001901.2 connective tissue growth factor CTGF CTGF-1162-13-13214 13214 NM_001901.2 connective tissue growth factor CTGF CTGF-811-13-13216 13216 NM_001901.2 connective tissue growth factor CTGF CTGF-797-13-13218 13218 NM_001901.2 connective tissue growth factor CTGF CTGF-1175-13-13220 13220 NM_001901.2 connective tissue growth factor CTGF CTGF-1172-13-13222 13222 NM_001901.2 connective tissue growth factor CTGF CTGF-1177-13-13224 13224 NM_001901.2 connective tissue growth factor CTGF CTGF-1176-13-13226 13226 NM_001901.2 connective tissue growth factor CTGF CTGF-812-13-13228 13228 NM_001901.2 connective tissue growth factor CTGF CTGF-745-13-13230 13230 NM_001901.2 connective tissue growth factor CTGF CTGF-1230-13-13232 13232 NM_001901.2 connective tissue growth factor CTGF CTGF-920-13-13234 13234 NM_001901.2 connective tissue growth factor CTGF CTGF-679-13-13236 13236 NM_001901.2 connective tissue growth factor CTGF CTGF-992-13-13238 13238 NM_001901.2 connective tissue growth factor CTGF CTGF-1045-13-13240 13240 NM_001901.2 connective tissue growth factor CTGF CTGF-1231-13-13242 13242 NM_001901.2 connective tissue growth factor CTGF CTGF-991-13-13244 13244 NM_001901.2 connective tissue growth factor CTGF CTGF-998-13-13246 13246 NM_001901.2 connective tissue growth factor CTGF CTGF-1049-13-13248 13248 NM_001901.2 connective tissue growth factor CTGF CTGF-1044-13-13250 13250 NM_001901.2 connective tissue growth factor CTGF CTGF-1327-13-13252 13252 NM_001901.2 connective tissue growth factor CTGF CTGF-1196-13-13254 13254 NM_001901.2 connective tissue growth factor CTGF CTGF-562-13-13256 13256 NM_001901.2 connective tissue growth factor CTGF CTGF-752-13-13258 13258 NM_001901.2 connective tissue growth factor CTGF CTGF-994-13-13260 13260 NM_001901.2 connective tissue growth factor CTGF CTGF-1040-13-13262 13262 NM_001901.2 connective tissue growth factor CTGF CTGF-1984-13-13264 13264 NM_001901.2 connective tissue growth factor CTGF CTGF-2195-13-13266 13266 NM_001901.2 connective tissue growth factor CTGF CTGF-2043-13-13268 13268 NM_001901.2 connective tissue growth factor CTGF CTGF-1892-13-13270 13270 NM_001901.2 connective tissue growth factor CTGF CTGF-1567-13-13272 13272 NM_001901.2 connective tissue growth factor CTGF CTGF-1780-13-13274 13274 NM_001901.2 connective tissue growth factor CTGF CTGF-2162-13-13276 13276 NM_001901.2 connective tissue growth factor CTGF CTGF-1034-13-13278 13278 NM_001901.2 connective tissue growth factor CTGF CTGF-2264-13-13280 13280 NM_001901.2 connective tissue growth factor CTGF CTGF-1032-13-13282 13282 NM_001901.2 connective tissue growth factor CTGF CTGF-1535-13-13284 13284 NM_001901.2 connective tissue growth factor CTGF CTGF-1694-13-13286 13286 NM_001901.2 connective tissue growth factor CTGF CTGF-1588-13-13288 13288 NM_001901.2 connective tissue growth factor CTGF CTGF-928-13-13290 13290 NM_001901.2 connective tissue growth factor CTGF CTGF-1133-13-13292 13292 NM_001901.2 connective tissue growth factor CTGF CTGF-912-13-13294 13294 NM_001901.2 connective tissue growth factor CTGF CTGF-753-13-13296 13296 NM_001901.2 connective tissue growth factor CTGF CTGF-918-13-13298 13298 NM_001901.2 connective tissue growth factor CTGF CTGF-744-13-13300 13300 NM_001901.2 connective tissue growth factor CTGF CTGF-466-13-13302 13302 NM_001901.2 connective tissue growth factor CTGF CTGF-917-13-13304 13304 NM_001901.2 connective tissue growth factor CTGF CTGF-1038-13-13306 13306 NM_001901.2 connective tissue growth factor CTGF CTGF-1048-13-13308 13308 NM_001901.2 connective tissue growth factor CTGF CTGF-1235-13-13310 13310 NM_001901.2 connective tissue growth factor CTGF CTGF-868-13-13312 13312 NM_001901.2 connective tissue growth factor CTGF CTGF-1131-13-13314 13314 NM_001901.2 connective tissue growth factor CTGF CTGF-1043-13-13316 13316 NM_001901.2 connective tissue growth factor CTGF CTGF-751-13-13318 13318 NM_001901.2 connective tissue growth factor CTGF CTGF-1227-13-13320 13320 NM_001901.2 connective tissue growth factor CTGF CTGF-867-13-13322 13322 NM_001901.2 connective tissue growth factor CTGF CTGF-1128-13-13324 13324 NM_001901.2 connective tissue growth factor CTGF CTGF-756-13-13326 13326 NM_001901.2 connective tissue growth factor CTGF CTGF-1234-13-13328 13328 NM_001901.2 connective tissue growth factor CTGF CTGF-916-13-13330 13330 NM_001901.2 connective tissue growth factor CTGF CTGF-925-13-13332 13332 NM_001901.2 connective tissue growth factor CTGF CTGF-1225-13-13334 13334 NM_001901.2 connective tissue growth factor CTGF CTGF-445-13-13336 13336 NM_001901.2 connective tissue growth factor CTGF CTGF-446-13-13338 13338 NM_001901.2 connective tissue growth factor CTGF CTGF-913-13-13340 13340 NM_001901.2 connective tissue growth factor CTGF CTGF-997-13-13342 13342 NM_001901.2 connective tissue growth factor CTGF CTGF-277-13-13344 13344 NM_001901.2 connective tissue growth factor CTGF CTGF-1052-13-13346 13346 NM_001901.2 connective tissue growth factor CTGF CTGF-887-13-13348 13348 NM_001901.2 connective tissue growth factor CTGF CTGF-914-13-13350 13350 NM_001901.2 connective tissue growth factor CTGF CTGF-1039-13-13352 13352 NM_001901.2 connective tissue growth factor CTGF CTGF-754-13-13354 13354 NM_001901.2 connective tissue growth factor CTGF CTGF-1130-13-13356 13356 NM_001901.2 connective tissue growth factor CTGF CTGF-919-13-13358 13358 NM_001901.2 connective tissue growth factor CTGF CTGF-922-13-13360 13360 NM_001901.2 connective tissue growth factor CTGF CTGF-746-13-13362 13362 NM_001901.2 connective tissue growth factor CTGF CTGF-993-13-13364 13364 NM_001901.2 connective tissue growth factor CTGF CTGF-825-13-13366 13366 NM_001901.2 connective tissue growth factor CTGF CTGF-926-13-13368 13368 NM_001901.2 connective tissue growth factor CTGF CTGF-923-13-13370 13370 NM_001901.2 connective tissue growth factor CTGF CTGF-866-13-13372 13372 NM_001901.2 connective tissue growth factor CTGF CTGF-563-13-13374 13374 NM_001901.2 connective tissue growth factor CTGF CTGF-823-13-13376 13376 NM_001901.2 connective tissue growth factor CTGF CTGF-1233-13-13378 13378 NM_001901.2 connective tissue growth factor CTGF CTGF-924-13-13380 13380 NM_001901.2 connective tissue growth factor CTGF CTGF-921-13-13382 13382 NM_001901.2 connective tissue growth factor CTGF CTGF-443-13-13384 13384 NM_001901.2 connective tissue growth factor CTGF CTGF-1041-13-13386 13386 NM_001901.2 connective tissue growth factor CTGF CTGF-1042-13-13388 13388 NM_001901.2 connective tissue growth factor CTGF CTGF-755-13-13390 13390 NM_001901.2 connective tissue growth factor CTGF CTGF-467-13-13392 13392 NM_001901.2 connective tissue growth factor CTGF CTGF-995-13-13394 13394 NM_001901.2 connective tissue growth factor CTGF CTGF-927-13-13396 13396 NM_001901.2 connective tissue growth factor CTGF SPP1-1025-13-13398 13398 NM_000582.2 Osteopontin SPP1 SPP1-1049-13-13400 13400 NM_000582.2 Osteopontin SPP1 SPP1-1051-13-13402 13402 NM_000582.2 Osteopontin SPP1 SPP1-1048-13-13404 13404 NM_000582.2 Osteopontin SPP1 SPP1-1050-13-13406 13406 NM_000582.2 Osteopontin SPP1 SPP1-1047-13-13408 13408 NM_000582.2 Osteopontin SPP1 SPP1-800-13-13410 13410 NM_000582.2 Osteopontin SPP1 SPP1-492-13-13412 13412 NM_000582.2 Osteopontin SPP1 SPP1-612-13-13414 13414 NM_000582.2 Osteopontin SPP1 SPP1-481-13-13416 13416 NM_000582.2 Osteopontin SPP1 SPP1-614-13-13418 13418 NM_000582.2 Osteopontin SPP1 SPP1-951-13-13420 13420 NM_000582.2 Osteopontin SPP1 SPP1-482-13-13422 13422 NM_000582.2 Osteopontin SPP1 SPP1-856-13-13424 13424 NM_000582.2 Osteopontin SPP1 SPP1-857-13-13426 13426 NM_000582.2 Osteopontin SPP1 SPP1-365-13-13428 13428 NM_000582.2 Osteopontin SPP1 SPP1-359-13-13430 13430 NM_000582.2 Osteopontin SPP1 SPP1-357-13-13432 13432 NM_000582.2 Osteopontin SPP1 SPP1-858-13-13434 13434 NM_000582.2 Osteopontin SPP1 SPP1-1012-13-13436 13436 NM_000582.2 Osteopontin SPP1 SPP1-1014-13-13438 13438 NM_000582.2 Osteopontin SPP1 SPP1-356-13-13440 13440 NM_000582.2 Osteopontin SPP1 SPP1-368-13-13442 13442 NM_000582.2 Osteopontin SPP1 SPP1-1011-13-13444 13444 NM_000582.2 Osteopontin SPP1 SPP1-754-13-13446 13446 NM_000582.2 Osteopontin SPP1 SPP1-1021-13-13448 13448 NM_000582.2 Osteopontin SPP1 SPP1-1330-13-13450 13450 NM_000582.2 Osteopontin SPP1 SPP1-346-13-13452 13452 NM_000582.2 Osteopontin SPP1 SPP1-869-13-13454 13454 NM_000582.2 Osteopontin SPP1 SPP1-701-13-13456 13456 NM_000582.2 Osteopontin SPP1 SPP1-896-13-13458 13458 NM_000582.2 Osteopontin SPP1 SPP1-1035-13-13460 13460 NM_000582.2 Osteopontin SPP1 SPP1-1170-13-13462 13462 NM_000582.2 Osteopontin SPP1 SPP1-1282-13-13464 13464 NM_000582.2 Osteopontin SPP1 SPP1-1537-13-13466 13466 NM_000582.2 Osteopontin SPP1 SPP1-692-13-13468 13468 NM_000582.2 Osteopontin SPP1 SPP1-840-13-13470 13470 NM_000582.2 Osteopontin SPP1 SPP1-1163-13-13472 13472 NM_000582.2 Osteopontin SPP1 SPP1-789-13-13474 13474 NM_000582.2 Osteopontin SPP1 SPP1-841-13-13476 13476 NM_000582.2 Osteopontin SPP1 SPP1-852-13-13478 13478 NM_000582.2 Osteopontin SPP1 SPP1-209-13-13480 13480 NM_000582.2 Osteopontin SPP1 SPP1-1276-13-13482 13482 NM_000582.2 Osteopontin SPP1 SPP1-137-13-13484 13484 NM_000582.2 Osteopontin SPP1 SPP1-711-13-13486 13486 NM_000582.2 Osteopontin SPP1 SPP1-582-13-13488 13488 NM_000582.2 Osteopontin SPP1 SPP1-839-13-13490 13490 NM_000582.2 Osteopontin SPP1 SPP1-1091-13-13492 13492 NM_000582.2 Osteopontin SPP1 SPP1-884-13-13494 13494 NM_000582.2 Osteopontin SPP1 SPP1-903-13-13496 13496 NM_000582.2 Osteopontin SPP1 SPP1-1090-13-13498 13498 NM_000582.2 Osteopontin SPP1 SPP1-474-13-13500 13500 NM_000582.2 Osteopontin SPP1 SPP1-575-13-13502 13502 NM_000582.2 Osteopontin SPP1 SPP1-671-13-13504 13504 NM_000582.2 Osteopontin SPP1 SPP1-924-13-13506 13506 NM_000582.2 Osteopontin SPP1 SPP1-1185-13-13508 13508 NM_000582.2 Osteopontin SPP1 SPP1-1221-13-13510 13510 NM_000582.2 Osteopontin SPP1 SPP1-347-13-13512 13512 NM_000582.2 Osteopontin SPP1 SPP1-634-13-13514 13514 NM_000582.2 Osteopontin SPP1 SPP1-877-13-13516 13516 NM_000582.2 Osteopontin SPP1 SPP1-1033-13-13518 13518 NM_000582.2 Osteopontin SPP1 SPP1-714-13-13520 13520 NM_000582.2 Osteopontin SPP1 SPP1-791-13-13522 13522 NM_000582.2 Osteopontin SPP1 SPP1-813-13-13524 13524 NM_000582.2 Osteopontin SPP1 SPP1-939-13-13526 13526 NM_000582.2 Osteopontin SPP1 SPP1-1161-13-13528 13528 NM_000582.2 Osteopontin SPP1 SPP1-1164-13-13530 13530 NM_000582.2 Osteopontin SPP1 SPP1-1190-13-13532 13532 NM_000582.2 Osteopontin SPP1 SPP1-1333-13-13534 13534 NM_000582.2 Osteopontin SPP1 SPP1-537-13-13536 13536 NM_000582.2 Osteopontin SPP1 SPP1-684-13-13538 13538 NM_000582.2 Osteopontin SPP1 SPP1-707-13-13540 13540 NM_000582.2 Osteopontin SPP1 SPP1-799-13-13542 13542 NM_000582.2 Osteopontin SPP1 SPP1-853-13-13544 13544 NM_000582.2 Osteopontin SPP1 SPP1-888-13-13546 13546 NM_000582.2 Osteopontin SPP1 SPP1-1194-13-13548 13548 NM_000582.2 Osteopontin SPP1 SPP1-1279-13-13550 13550 NM_000582.2 Osteopontin SPP1 SPP1-1300-13-13552 13552 NM_000582.2 Osteopontin SPP1 SPP1-1510-13-13554 13554 NM_000582.2 Osteopontin SPP1 SPP1-1543-13-13556 13556 NM_000582.2 Osteopontin SPP1 SPP1-434-13-13558 13558 NM_000582.2 Osteopontin SPP1 SPP1-600-13-13560 13560 NM_000582.2 Osteopontin SPP1 SPP1-863-13-13562 13562 NM_000582.2 Osteopontin SPP1 SPP1-902-13-13564 13564 NM_000582.2 Osteopontin SPP1 SPP1-921-13-13566 13566 NM_000582.2 Osteopontin SPP1 SPP1-154-13-13568 13568 NM_000582.2 Osteopontin SPP1 SPP1-217-13-13570 13570 NM_000582.2 Osteopontin SPP1 SPP1-816-13-13572 13572 NM_000582.2 Osteopontin SPP1 SPP1-882-13-13574 13574 NM_000582.2 Osteopontin SPP1 SPP1-932-13-13576 13576 NM_000582.2 Osteopontin SPP1 SPP1-1509-13-13578 13578 NM_000582.2 Osteopontin SPP1 SPP1-157-13-13580 13580 NM_000582.2 Osteopontin SPP1 SPP1-350-13-13582 13582 NM_000582.2 Osteopontin SPP1 SPP1-511-13-13584 13584 NM_000582.2 Osteopontin SPP1 SPP1-605-13-13586 13586 NM_000582.2 Osteopontin SPP1 SPP1-811-13-13588 13588 NM_000582.2 Osteopontin SPP1 SPP1-892-13-13590 13590 NM_000582.2 Osteopontin SPP1 SPP1-922-13-13592 13592 NM_000582.2 Osteopontin SPP1 SPP1-1169-13-13594 13594 NM_000582.2 Osteopontin SPP1 SPP1-1182-13-13596 13596 NM_000582.2 Osteopontin SPP1 SPP1-1539-13-13598 13598 NM_000582.2 Osteopontin SPP1 SPP1-1541-13-13600 13600 NM_000582.2 Osteopontin SPP1 SPP1-427-13-13602 13602 NM_000582.2 Osteopontin SPP1 SPP1-533-13-13604 13604 NM_000582.2 Osteopontin SPP1 APOB--13-13763 13763 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB--13-13764 13764 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) MAP4K4--16-13766 13766 MAP4K4 PPIB--13-13767 13767 NM_000942 peptidylprolyl isomerase B PPIB (cyclophilin B) PPIB--15-13768 13768 NM_000942 peptidylprolyl isomerase B PPIB (cyclophilin B) PPIB--17-13769 13769 NM_000942 peptidylprolyl isomerase B PPIB (cyclophilin B) MAP4K4--16-13939 13939 MAP4K4 APOB-4314-16-13940 13940 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB-4314-17-13941 13941 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB--16-13942 13942 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB--18-13943 13943 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB--17-13944 13944 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB--19-13945 13945 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB-4314-16-13946 13946 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB-4314-17-13947 13947 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB--16-13948 13948 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB--17-13949 13949 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB--16-13950 13950 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB--18-13951 13951 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB--17-13952 13952 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB--19-13953 13953 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) MAP4K4--16-13766.2 13766.2 MAP4K4 CTGF-1222-16-13980 13980 NM_001901.2 connective tissue growth factor CTGF CTGF-813-16-13981 13981 NM_001901.2 connective tissue growth factor CTGF CTGF-747-16-13982 13982 NM_001901.2 connective tissue growth factor CTGF CTGF-817-16-13983 13983 NM_001901.2 connective tissue growth factor CTGF CTGF-1174-16-13984 13984 NM_001901.2 connective tissue growth factor CTGF CTGF-1005-16-13985 13985 NM_001901.2 connective tissue growth factor CTGF CTGF-814-16-13986 13986 NM_001901.2 connective tissue growth factor CTGF CTGF-816-16-13987 13987 NM_001901.2 connective tissue growth factor CTGF CTGF-1001-16-13988 13988 NM_001901.2 connective tissue growth factor CTGF CTGF-1173-16-13989 13989 NM_001901.2 connective tissue growth factor CTGF CTGF-749-16-13990 13990 NM_001901.2 connective tissue growth factor CTGF CTGF-792-16-13991 13991 NM_001901.2 connective tissue growth factor CTGF CTGF-1162-16-13992 13992 NM_001901.2 connective tissue growth factor CTGF CTGF-811-16-13993 13993 NM_001901.2 connective tissue growth factor CTGF CTGF-797-16-13994 13994 NM_001901.2 connective tissue growth factor CTGF CTGF-1175-16-13995 13995 NM_001901.2 connective tissue growth factor CTGF CTGF-1172-16-13996 13996 NM_001901.2 connective tissue growth factor CTGF CTGF-1177-16-13997 13997 NM_001901.2 connective tissue growth factor CTGF CTGF-1176-16-13998 13998 NM_001901.2 connective tissue growth factor CTGF CTGF-812-16-13999 13999 NM_001901.2 connective tissue growth factor CTGF CTGF-745-16-14000 14000 NM_001901.2 connective tissue growth factor CTGF CTGF-1230-16-14001 14001 NM_001901.2 connective tissue growth factor CTGF CTGF-920-16-14002 14002 NM_001901.2 connective tissue growth factor CTGF CTGF-679-16-14003 14003 NM_001901.2 connective tissue growth factor CTGF CTGF-992-16-14004 14004 NM_001901.2 connective tissue growth factor CTGF CTGF-1045-16-14005 14005 NM_001901.2 connective tissue growth factor CTGF CTGF-1231-16-14006 14006 NM_001901.2 connective tissue growth factor CTGF CTGF-991-16-14007 14007 NM_001901.2 connective tissue growth factor CTGF CTGF-998-16-14008 14008 NM_001901.2 connective tissue growth factor CTGF CTGF-1049-16-14009 14009 NM_001901.2 connective tissue growth factor CTGF CTGF-1044-16-14010 14010 NM_001901.2 connective tissue growth factor CTGF CTGF-1327-16-14011 14011 NM_001901.2 connective tissue growth factor CTGF CTGF-1196-16-14012 14012 NM_001901.2 connective tissue growth factor CTGF CTGF-562-16-14013 14013 NM_001901.2 connective tissue growth factor CTGF CTGF-752-16-14014 14014 NM_001901.2 connective tissue growth factor CTGF CTGF-994-16-14015 14015 NM_001901.2 connective tissue growth factor CTGF CTGF-1040-16-14016 14016 NM_001901.2 connective tissue growth factor CTGF CTGF-1984-16-14017 14017 NM_001901.2 connective tissue growth factor CTGF CTGF-2195-16-14018 14018 NM_001901.2 connective tissue growth factor CTGF CTGF-2043-16-14019 14019 NM_001901.2 connective tissue growth factor CTGF CTGF-1892-16-14020 14020 NM_001901.2 connective tissue growth factor CTGF CTGF-1567-16-14021 14021 NM_001901.2 connective tissue growth factor CTGF CTGF-1780-16-14022 14022 NM_001901.2 connective tissue growth factor CTGF CTGF-2162-16-14023 14023 NM_001901.2 connective tissue growth factor CTGF CTGF-1034-16-14024 14024 NM_001901.2 connective tissue growth factor CTGF CTGF-2264-16-14025 14025 NM_001901.2 connective tissue growth factor CTGF CTGF-1032-16-14026 14026 NM_001901.2 connective tissue growth factor CTGF CTGF-1535-16-14027 14027 NM_001901.2 connective tissue growth factor CTGF CTGF-1694-16-14028 14028 NM_001901.2 connective tissue growth factor CTGF CTGF-1588-16-14029 14029 NM_001901.2 connective tissue growth factor CTGF CTGF-928-16-14030 14030 NM_001901.2 connective tissue growth factor CTGF CTGF-1133-16-14031 14031 NM_001901.2 connective tissue growth factor CTGF CTGF-912-16-14032 14032 NM_001901.2 connective tissue growth factor CTGF CTGF-753-16-14033 14033 NM_001901.2 connective tissue growth factor CTGF CTGF-918-16-14034 14034 NM_001901.2 connective tissue growth factor CTGF CTGF-744-16-14035 14035 NM_001901.2 connective tissue growth factor CTGF CTGF-466-16-14036 14036 NM_001901.2 connective tissue growth factor CTGF CTGF-917-16-14037 14037 NM_001901.2 connective tissue growth factor CTGF CTGF-1038-16-14038 14038 NM_001901.2 connective tissue growth factor CTGF CTGF-1048-16-14039 14039 NM_001901.2 connective tissue growth factor CTGF CTGF-1235-16-14040 14040 NM_001901.2 connective tissue growth factor CTGF CTGF-868-16-14041 14041 NM_001901.2 connective tissue growth factor CTGF CTGF-1131-16-14042 14042 NM_001901.2 connective tissue growth factor CTGF CTGF-1043-16-14043 14043 NM_001901.2 connective tissue growth factor CTGF CTGF-751-16-14044 14044 NM_001901.2 connective tissue growth factor CTGF CTGF-1227-16-14045 14045 NM_001901.2 connective tissue growth factor CTGF CTGF-867-16-14046 14046 NM_001901.2 connective tissue growth factor CTGF CTGF-1128-16-14047 14047 NM_001901.2 connective tissue growth factor CTGF CTGF-756-16-14048 14048 NM_001901.2 connective tissue growth factor CTGF CTGF-1234-16-14049 14049 NM_001901.2 connective tissue growth factor CTGF CTGF-916-16-14050 14050 NM_001901.2 connective tissue growth factor CTGF CTGF-925-16-14051 14051 NM_001901.2 connective tissue growth factor CTGF CTGF-1225-16-14052 14052 NM_001901.2 connective tissue growth factor CTGF CTGF-445-16-14053 14053 NM_001901.2 connective tissue growth factor CTGF CTGF-446-16-14054 14054 NM_001901.2 connective tissue growth factor CTGF CTGF-913-16-14055 14055 NM_001901.2 connective tissue growth factor CTGF CTGF-997-16-14056 14056 NM_001901.2 connective tissue growth factor CTGF CTGF-277-16-14057 14057 NM_001901.2 connective tissue growth factor CTGF CTGF-1052-16-14058 14058 NM_001901.2 connective tissue growth factor CTGF CTGF-887-16-14059 14059 NM_001901.2 connective tissue growth factor CTGF CTGF-914-16-14060 14060 NM_001901.2 connective tissue growth factor CTGF CTGF-1039-16-14061 14061 NM_001901.2 connective tissue growth factor CTGF CTGF-754-16-14062 14062 NM_001901.2 connective tissue growth factor CTGF CTGF-1130-16-14063 14063 NM_001901.2 connective tissue growth factor CTGF CTGF-919-16-14064 14064 NM_001901.2 connective tissue growth factor CTGF CTGF-922-16-14065 14065 NM_001901.2 connective tissue growth factor CTGF CTGF-746-16-14066 14066 NM_001901.2 connective tissue growth factor CTGF CTGF-993-16-14067 14067 NM_001901.2 connective tissue growth factor CTGF CTGF-825-16-14068 14068 NM_001901.2 connective tissue growth factor CTGF CTGF-926-16-14069 14069 NM_001901.2 connective tissue growth factor CTGF CTGF-923-16-14070 14070 NM_001901.2 connective tissue growth factor CTGF CTGF-866-16-14071 14071 NM_001901.2 connective tissue growth factor CTGF CTGF-563-16-14072 14072 NM_001901.2 connective tissue growth factor CTGF CTGF-823-16-14073 14073 NM_001901.2 connective tissue growth factor CTGF CTGF-1233-16-14074 14074 NM_001901.2 connective tissue growth factor CTGF CTGF-924-16-14075 14075 NM_001901.2 connective tissue growth factor CTGF CTGF-921-16-14076 14076 NM_001901.2 connective tissue growth factor CTGF CTGF-443-16-14077 14077 NM_001901.2 connective tissue growth factor CTGF CTGF-1041-16-14078 14078 NM_001901.2 connective tissue growth factor CTGF CTGF-1042-16-14079 14079 NM_001901.2 connective tissue growth factor CTGF CTGF-755-16-14080 14080 NM_001901.2 connective tissue growth factor CTGF CTGF-467-16-14081 14081 NM_001901.2 connective tissue growth factor CTGF CTGF-995-16-14082 14082 NM_001901.2 connective tissue growth factor CTGF CTGF-927-16-14083 14083 NM_001901.2 connective tissue growth factor CTGF SPP1-1091-16-14131 14131 NM_000582.2 Osteopontin SPP1 PPIB--16-14188 14188 NM_000942 peptidylprolyl isomerase B PPIB (cyclophilin B) PPIB--17-14189 14189 NM_000942 peptidylprolyl isomerase B PPIB (cyclophilin B) PPIB--18-14190 14190 NM_000942 peptidylprolyl isomerase B PPIB (cyclophilin B) pGL3-1172-16-14386 14386 U47296 Cloning vector pGL3-Control pGL3 pGL3-1172-16-14387 14387 U47296 Cloning vector pGL3-Control pGL3 MAP4K4-2931-25-14390 14390 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 miR-122--23-14391 14391 miR-122 14084 NM_000582.2 Osteopontin SPP1 14085 NM_000582.2 Osteopontin SPP1 14086 NM_000582.2 Osteopontin SPP1 14087 NM_000582.2 Osteopontin SPP1 14088 NM_000582.2 Osteopontin SPP1 14089 NM_000582.2 Osteopontin SPP1 14090 NM_000582.2 Osteopontin SPP1 14091 NM_000582.2 Osteopontin SPP1 14092 NM_000582.2 Osteopontin SPP1 14093 NM_000582.2 Osteopontin SPP1 14094 NM_000582.2 Osteopontin SPP1 14095 NM_000582.2 Osteopontin SPP1 14096 NM_000582.2 Osteopontin SPP1 14097 NM_000582.2 Osteopontin SPP1 14098 NM_000582.2 Osteopontin SPP1 14099 NM_000582.2 Osteopontin SPP1 14100 NM_000582.2 Osteopontin SPP1 14101 NM_000582.2 Osteopontin SPP1 14102 NM_000582.2 Osteopontin SPP1 14103 NM_000582.2 Osteopontin SPP1 14104 NM_000582.2 Osteopontin SPP1 14105 NM_000582.2 Osteopontin SPP1 14106 NM_000582.2 Osteopontin SPP1 14107 NM_000582.2 Osteopontin SPP1 14108 NM_000582.2 Osteopontin SPP1 14109 NM_000582.2 Osteopontin SPP1 14110 NM_000582.2 Osteopontin SPP1 14111 NM_000582.2 Osteopontin SPP1 14112 NM_000582.2 Osteopontin SPP1 14113 NM_000582.2 Osteopontin SPP1 14114 NM_000582.2 Osteopontin SPP1 14115 NM_000582.2 Osteopontin SPP1 14116 NM_000582.2 Osteopontin SPP1 14117 NM_000582.2 Osteopontin SPP1 14118 NM_000582.2 Osteopontin SPP1 14119 NM_000582.2 Osteopontin SPP1 14120 NM_000582.2 Osteopontin SPP1 14121 NM_000582.2 Osteopontin SPP1 14122 NM_000582.2 Osteopontin SPP1 14123 NM_000582.2 Osteopontin SPP1 14124 NM_000582.2 Osteopontin SPP1 14125 NM_000582.2 Osteopontin SPP1 14126 NM_000582.2 Osteopontin SPP1 14127 NM_000582.2 Osteopontin SPP1 14128 NM_000582.2 Osteopontin SPP1 14129 NM_000582.2 Osteopontin SPP1 14130 NM_000582.2 Osteopontin SPP1 14132 NM_000582.2 Osteopontin SPP1 14133 NM_000582.2 Osteopontin SPP1 14134 NM_000582.2 Osteopontin SPP1 14135 NM_000582.2 Osteopontin SPP1 14136 NM_000582.2 Osteopontin SPP1 14137 NM_000582.2 Osteopontin SPP1 14138 NM_000582.2 Osteopontin SPP1 14139 NM_000582.2 Osteopontin SPP1 14140 NM_000582.2 Osteopontin SPP1 14141 NM_000582.2 Osteopontin SPP1 14142 NM_000582.2 Osteopontin SPP1 14143 NM_000582.2 Osteopontin SPP1 14144 NM_000582.2 Osteopontin SPP1 14145 NM_000582.2 Osteopontin SPP1 14146 NM_000582.2 Osteopontin SPP1 14147 NM_000582.2 Osteopontin SPP1 14148 NM_000582.2 Osteopontin SPP1 14149 NM_000582.2 Osteopontin SPP1 14150 NM_000582.2 Osteopontin SPP1 14151 NM_000582.2 Osteopontin SPP1 14152 NM_000582.2 Osteopontin SPP1 14153 NM_000582.2 Osteopontin SPP1 14154 NM_000582.2 Osteopontin SPP1 14155 NM_000582.2 Osteopontin SPP1 14156 NM_000582.2 Osteopontin SPP1 14157 NM_000582.2 Osteopontin SPP1 14158 NM_000582.2 Osteopontin SPP1 14159 NM_000582.2 Osteopontin SPP1 14160 NM_000582.2 Osteopontin SPP1 14161 NM_000582.2 Osteopontin SPP1 14162 NM_000582.2 Osteopontin SPP1 14163 NM_000582.2 Osteopontin SPP1 14164 NM_000582.2 Osteopontin SPP1 14165 NM_000582.2 Osteopontin SPP1 14166 NM_000582.2 Osteopontin SPP1 14167 NM_000582.2 Osteopontin SPP1 14168 NM_000582.2 Osteopontin SPP1 14169 NM_000582.2 Osteopontin SPP1 14170 NM_000582.2 Osteopontin SPP1 14171 NM_000582.2 Osteopontin SPP1 14172 NM_000582.2 Osteopontin SPP1 14173 NM_000582.2 Osteopontin SPP1 14174 NM_000582.2 Osteopontin SPP1 14175 NM_000582.2 Osteopontin SPP1 14176 NM_000582.2 Osteopontin SPP1 14177 NM_000582.2 Osteopontin SPP1 14178 NM_000582.2 Osteopontin SPP1 14179 NM_000582.2 Osteopontin SPP1 14180 NM_000582.2 Osteopontin SPP1 14181 NM_000582.2 Osteopontin SPP1 14182 NM_000582.2 Osteopontin SPP1 14183 NM_000582.2 Osteopontin SPP1 14184 NM_000582.2 Osteopontin SPP1 14185 NM_000582.2 Osteopontin SPP1 14186 NM_000582.2 Osteopontin SPP1 14187 NM_000582.2 Osteopontin SPP1

TABLE 2 SEQ Oligo ID ID Number # AntiSense Backbone AntiSense Chemistry AntiSense Sequence NO: APOB-10167-20- 12138 ooooooooooooooooooo 00000000000000000000m AUUGGUAUUCAGUGUGAUG 1 12138 APOB-10167-20- 12139 ooooooooooooooooooo 00000000000000000000m AUUCGUAUUGAGUCUGAUC 2 12139 MAP4K4-2931- 12293 ooooooooooooooooooo Pf000fffff0f0000fff0 UAGACUUCCACAGAACUCU 3 16-12293 MAP4K4-2931- 12383 ooooooooooooooooooo 0000000000000000000 UAGACUUCCACAGAACUCU 4 16-12383 MAP4K4-2931- 12384 ooooooooooooooooooo P0000000000000000000 UAGACUUCCACAGAACUCU 5 16-12384 MAP4K4-2931- 12385 ooooooooooooooooooo Pf000fffff0f0000fff0 UAGACUUCCACAGAACUCU 6 16-12385 MAP4K4-2931- 12386 oooooooooosssssssso Pf000fffff0f0000fff0 UAGACUUCCACAGAACUCU 7 16-12386 MAP4K4-2931- 12387 oooooooooosssssssso P0000000000000000000 UAGACUUCCACAGAACUCU 8 16-12387 MAP4K4-2931- 12388 ooooooooooooooooo 00000000000000000 UAGACUUCCACAGAACU 9 15-12388 APOB--21-12434 12434 ooooooooooooooooooo 00000000000000000000m AUUGGUAUUCAGUGUGAUG 10 oo AC APOB--21-12435 12435 ooooooooooooooooooo 00000000000000000000m AUUCGUAUUGAGUCUGAUC oo AC 11 MAP4K4-2931- 12451 oooooooooosssssssso Pf000fffff0f0000ffmm UAGACUUCCACAGAACUCU 12 16-12451 MAP4K4-2931- 12452 oooooooooosssssssso Pm000fffff0000ffmm UAGACUUCCACAGAACUCU 13 16-12452 MAP4K4-2931- 12453 oooooosssssssssssso Pm000fffff0f0000ffmm UAGACUUCCACAGAACUCU 14 16-12453 MAP4K4-2931- 12454 oooooooooooosssssssso Pm000fffff0f0000ffffmm UAGACUUCCACAGAACUCUU 15 17-12454 C MAP4K4-2931- 12455 oooooooosssssssssssso Pm000fffff0f0000ffffmm UAGACUUCCACAGAACUCUU 16 17-12455 C MAP4K4-2931- 12456 oooooooooooosssssssss Pm000fffff0f0000ffffff UAGACUUCCACAGAACUCUU 17 19-12456 ssso 00mm CAAAG APOB-10167-21- 12505 ooooooooooooooooooo 00000000000000000000m AUUGGUAUUCAGUGUGAUG 18 12505 os AC APOB-10167-21- 12506 ooooooooooooooooooo 00000000000000000000m AUUCGUAUUGAGUCUGAUC 19 12506 os AC MAP4K4-2931- 12539 ooooooooooossssssss Pf000fffff0f0000fff0 UAGACUUCCACAGAACUCU 20 16-12539 APOB-10167-21- 12505.2 ooooooooooooooooooo 00000000000000000000m AUUGGUAUUCAGUGUGAUG 21 12505.2 oo AC APOB-10167-21- 12506.2 ooooooooooooooooooo 00000000000000000000m AUUCGUAUUGAGUCUGAUC 22 12506.2 oo AC MAP4K4-2931- 12386.2 oooooooooosssssssso Pf000fffff0f0000fff0 UAGACUUCCACAGAACUCU 23 16-12386.2 MAP4K4--16- 12983 oooooooooooosssssso Pm000fffff0m0000mmm0 uagacuuccacagaacucu 24 12983 MAP4K4--16- 12984 oooooooooooossssss Pm000fffff0m0000mmm0 uagacuuccacagaacucu 25 12984 MAP4K4--16- 12985 oooooooooooosssssso Pm000fffff0m0000mmm0 uagacuuccacagaacucu 26 12985 MAP4K4--16- 12986 oooooooooosssssssso Pf000fffff0f0000fff0 UAGACUUCCACAGAACUCU 27 12986 MAP4K4--16- 12987 ooooooooooooossssss P0000f00ff0m0000m0m0 UagacUUccacagaacUcU 28 12987 MAP4K4--16- 12988 ooooooooooooossssss P0000f00ff0m0000m0m0 UagacUUccacagaacUcu 29 12988 MAP4K4--16- 12989 ooooooooooooossssss P0000ff0ff0m0000m0m0 UagacuUccacagaacUcu 30 12989 MAP4K4--16- 12990 ooooooooooooossssss Pf0000ff000000000m00 uagaCuuCCaCagaaCuCu 31 12990 MAP4K4--16- 12991 ooooooooooooossssss Pf0000fff00m00000mm0 uagaCuucCacagaaCucu 32 12991 MAP4K4--16- 12992 ooooooooooooossssss Pf000fffff0000000m00 uagacuuccaCagaaCuCu 33 12992 MAP4K4--16- 12993 ooooooooooooossssss P0000000000000000000 UagaCUUCCaCagaaCUCU 34 12993 MAP4K4--16- 12994 ooooooooooooossssss P0000f0f0f0000000m00 UagacUuCcaCagaaCuCu 35 12994 MAP4K4--16- 12995 oooooooooooosssssso Pf000fffff0000000000 uagacuuccaCagaaCUCU 36 12995 --16-13047 13047 oooooooooooossssss Pm000000000m0000mm UAGACUUCCACAGAACUCU 37 m0 PP1B-16-13136 13136 oooooooooooossssss Pm0fffff0f00mm000mm0 UGUUUUUGUAGCCAAAUCC 38 SOD1-530-16- 13163 oooooooooooosssssso Pm0ffffffff0mmmmm0m0 UACUUUCUUCAUUUCCACC 39 13163 SOD1-523-16- 13164 oooooooooooosssssso Pmff0fffff0fmmmm0mm0 UUCAUUUCCACCUUUGCCC 40 13164 SOD1-535-16- 13165 oooooooooooosssssso Pmfff0f0ffffmmmm0mm0 CUUUGUACUUUCUUCAUUU 41 13165 SOD1-536-16- 13166 oooooooooooosssssso Pmffff0f0fffmmmmm0m0 UCUUUGUACUUUCUUCAUU 42 13166 SOD1-396-16- 13167 oooooooooooosssssso Pmf00f00ff0f0mm0mmm0 UCAGCAGUCACAUUGCCCA 43 13167 SOD1-385-16- 13168 oooooooooooosssssso Pmff0fff000fmmmm00m0 AUUGCCCAAGUCUCCAACA 44 13168 SOD1-195-16- 13169 oooooooooooosssssso Pmfff0fff0000mm00m00 UUCUGCUCGAAAUUGAUGA 45 13169 pGL3-1172-16- 13170 oooooooooooosssssso Pm00ff0f0ffm0ff00mm0 AAAUCGUAUUUGUCAAUCA 46 13170 pGL3-1172-16- 13171 ooooooooooooossssss Pm00ff0f0ffm0ff00mm0 AAAUCGUAUUUGUCAAUCA 47 13171 MAP4k4-2931- 13189 ooooooooooooooooooo 0000000000000000000 UAGACUUCCACAGAACUCU 48 19-13189 MAP4K4--16- 13766 oooooooooooosssssso Pm000fffff0m0000mmm0 UAGACUUCCACAGAACUCU 49 13766 MAP4K4--16- 13939 oooooooooooosssssso m000f0ffff0m0m00m0m UAGACAUCCUACACAGCAC 50 13939 APOB-4314-16- 13940 oooooooooooosssssso Pm0fffffff000mmmmm00 UGUUUCUCCAGAUCCUUGC 51 13940 APOB-4314-17- 13941 oooooooooooosssssso Pm0fffffff000mmmmm00 UGUUUCUCCAGAUCCUUGC 52 13941 APOB--16-13942 13942 oooooooooooosssssso Pm00f000f000mmm0mm UAGCAGAUGAGUCCAUUUG 53 m0 APOB--18-13943 13943 oooooooooooooooossss Pm00f000f000mmm0mm UAGCAGAUGAGUCCAUUUG 54 sso m00000 GAGA APOB--17-13944 13944 oooooooooooosssssso Pm00f000f000mmm0mm UAGCAGAUGAGUCCAUUUG 55 mo APOB--19-13945 13945 oooooooooooooooossss Pm00f000f000mmm0mm UAGCAGAUGAGUCCAUUUG 56 sso m00000 GAGA APOB-4314-16- 13946 oooooooooooosssssso Pmf0ff0ffffmmm000mm0 AUGUUGUUUCUCCAGAUCC 57 13946 APOB-4314-17- 13947 oooooooooooosssssso Pmf0ff0ffffmmm000mm0 AUGUUGUUUCUCCAGAUCC 58 13947 APOB--16-13948 13948 oooooooooooosssssso Pm0fff000000mmmm0m0 UGUUUGAGGGACUCUGUGA 59 o APOB--17-13949 13949 oooooooooooosssssso Pm0fff000000mmmm0m0 UGUUUGAGGGACUCUGUGA 60 o APOB--16-13950 13950 oooooooooooosssssso Pmff00f0fff00m0m00m0 AUUGGUAUUCAGUGUGAUG 61 APOB--18-13951 13951 oooooooooooooooossss Pmff00f0fff00m0m00m00 AUUGGUAUUCAGUGUGAUG 62 sso m00 ACAC APOB--17-13952 13952 oooooooooooosssssso Pmff00f0fff00m0m00m0 AUUGGUAUUCAGUGUGAUG 63 APOB--19-13953 13953 oooooooooooooooossss Pmff00f0fff00m0m00m00 AUUGGUAUUCAGUGUGAUG 64 sso m00 ACAC MAP4K4--16- 13766.2 oooooooooooosssssso Pm000fffff0m0000mmm0 UAGACUUCCACAGAACUCU 65 13766.2 CTGF-1222-16- 13980 oooooooooooosssssso Pm0f0ffffffm0m00m0m0 UACAUCUUCCUGUAGUACA 66 13980 CTGF-813-16- 13981 oooooooooooosssssso Pm0f0ffff0mmmm0m000 AGGCGCUCCACUCUGUGGU 67 13981 CTGF-747-16- 13982 oooooooooooosssssso Pm0ffffff00mm0m0000 UGUCUUCCAGUCGGUAAGC 68 13982 CTGF-817-16- 13983 oooooooooooosssssso Pm00f000f0fmmm0mmm GAACAGGCGCUCCACUCUG 69 13983 m0 CTGF-1174-16- 13984 oooooooooooosssssso Pm00ff0f00f00m000m00 CAGUUGUAAUGGCAGGCAC 70 13984 CTGF-1005-16- 13985 oooooooooooosssssso Pmff000000mmm000mm0 AGCCAGAAAGCUCAAACUU 71 13985 CTGF-814-16- 13986 oooooooooooosssssso Pm000f0ffff0mmmm0m00 CAGGCGCUCCACUCUGUGG 72 13986 CTGF-816-16- 13987 oooooooooooosssssso Pm0f000f0ffmm0mmmm0 AACAGGCGCUCCACUCUGU 73 13987 0 CTGF-1001-16- 13988 oooooooooooosssssso Pm0000fff000mmm00m0 AGAAAGCUCAAACUUGAUA 74 13988 CTGF-1173-16- 13989 oooooooooooosssssso Pmff0f00f00m000m0m0 AGUUGUAAUGGCAGGCACA 75 13989 CTGF-749-16- 13990 oooooooooooosssssso Pmf0ffffff00mm00m00 CGUGUCUUCCAGUCGGUAA 76 13990 CTGF-792-16- 13991 oooooooooooosssssso Pm00ff000f00mm00mmm GGACCAGGCAGUUGGCUCU 77 13991 0 CTGF-1162-16- 13992 oooooooooooosssssso Pm000f0f000mmmm00m0 CAGGCACAGGUCUUGAUGA 78 13992 0 CTGF-811-16- 13993 oooooooooooosssssso Pmf0ffff0ffmm0m00mm0 GCGCUCCACUCUGUGGUCU 79 13993 CTGF-797-16- 13994 oooooooooooosssssso Pm0fff000ff000m00mm0 GGUCUGGACCAGGCAGUUG 80 13994 CTGF-1175-16- 13995 oooooooooooosssssso Pmf00ff0f00m00m000m0 ACAGUUGUAAUGGCAGGCA 81 13995 CTGF-1172-16- 13996 oooooooooooosssssso Pmff0f00f00m000m0m00 GUUGUAAUGGCAGGCACAG 82 13996 CTGF-1177-16- 13997 oooooooooooosssssso Pm00f00ff0f00m00m000 GGACAGUUGUAAUGGCAGG 83 13997 CTGF-1176-16- 13998 oooooooooooosssssso Pm0f00ff0f00m00m0000 GACAGUUGUAAUGGCAGGC 84 13998 CTGF-812-16- 13999 oooooooooooosssssso Pm0f0ffff0fmmm0m00m0 GGCGCUCCACUCUGUGGUC 85 13999 CTGF-745-16- 14000 oooooooooooosssssso Pmfffff00ff00m000mm0 UCUUCCAGUCGGUAAGCCG 86 14000 CTGF-1230-16- 14001 oooooooooooosssssso Pm0fffff0f0m0mmmmmm UGUCUCCGUACAUCUUCCU 87 14001 0 CTGF-920-16- 14002 oooooooooooosssssso Pmffff0f0000mmm00m0 AGCUUCGCAAGGCCUGACC 88 14002 CTGF-679-16- 14003 oooooooooooosssssso Pm0ffffff0f00m0mmmm0 CACUCCUCGCAGCAUUUCC 89 14003 CTGF-992-16- 14004 oooooooooooosssssso Pm00fff00f000mmm0000 AAACUUGAUAGGCUUGGAG 90 14004 CTGF-1045-16- 14005 oooooooooooosssssso Pmffff0f0000mmm00mm0 ACUCCACAGAAUUUAGCUC 91 14005 CTGF-1231-16- 14006 oooooooooooosssssso Pmf0fffff0f0m0mmmmm0 AUGUCUCCGUACAUCUUCC 92 14006 CTGF-991-16- 14007 oooooooooooosssssso Pm0fff00f000mmm00000 AACUUGAUAGGCUUGGAGA 93 14007 CTGF-998-16- 14008 oooooooooooosssssso Pm00fff000fmm00m0000 AAGCUCAAACUUGAUAGGC 94 14008 CTGF-1049-16- 14009 oooooooooooosssssso Pmf0f0ffff0m0000mmm0 ACAUACUCCACAGAAUUUA 95 14009 CTGF-1044-16- 14010 oooooooooooosssssso Pmfff0f0000mmm00mmm CUCCACAGAAUUUAGCUCG 96 14010 0 CTGF-1327-16- 14011 oooooooooooosssssso Pm0f0ff0ff0000mm0mm0 UGUGCUACUGAAAUCAUUU 97 14011 CTGF-1196-16- 14012 oooooooooooosssssso Pm0000f0ff0mm0mmmm AAAGAUGUCAUUGUCUCCG 98 14012 m0 CTGF-562-16- 14013 oooooooooooosssssso Pmf0f0ff00f0mmm0m000 GUGCACUGGUACUUGCAGC 99 14013 CTGF-752-16- 14014 oooooooooooosssssso Pm00f0f0fffmmm00mm00 AAACGUGUCUUCCAGUCGG 100 14014 CTGF-994-16- 14015 oooooooooooosssssso Pmf000fff00m000mmm00 UCAAACUUGAUAGGCUUGG 101 14015 CTGF-1040-16- 14016 oooooooooooosssssso Pmf0000fff00mmm00m00 ACAGAAUUUAGCUCGGUAU 102 14016 CTGF-1984-16- 14017 oooooooooooosssssso Pmf0f0ffff0mmm0m00m0 UUACAUUCUACCUAUGGUG 103 14017 CTGF-2195-16- 14018 oooooooooooosssssso Pm00ff00ff00mm0m0m00 AAACUGAUCAGCUAUAUAG 104 14018 CTGF-2043-16- 14019 oooooooooooosssssso Pm0fff000f0000mmmmm UAUCUGAGCAGAAUUUCCA 105 14019 0 CTGF-1892-16- 14020 oooooooooooosssssso Pmf00fff000m00mm0m00 UUAACUUAGAUAACUGUAC 106 14020 CTGF-1567-16- 14021 oooooooooooosssssso Pm0ff0fff0f0m0000m00 UAUUACUCGUAUAAGAUGC 107 14021 CTGF-1780-16- 14022 oooooooooooosssssso Pm00ff0fff00mmm00mm0 AAGCUGUCCAGUCUAAUCG 108 14022 CTGF-2162-16- 14023 oooooooooooosssssso Pm00f00000fm0mmm0m UAAUAAAGGCCAUUUGUUC 109 14023 m0 CTGF-1034-16- 14024 oooooooooooosssssso Pmff00fff00m0m0mmmm UUUAGCUCGGUAUGUCUUC 110 14024 0 CTGF-2264-16- 14025 oooooooooooosssssso Pmf0fffff00m000m0000 ACACUCUCAACAAAUAAAC 111 14025 CTGF-1032-16- 14026 oooooooooooosssssso Pm00fff00f0m0mmmmm0 UAGCUCGGUAUGUCUUCAU 112 14026 0 CTGF-1535-16- 14027 oooooooooooosssssso Pm00fffffff0mm00m0m0 UAACCUUUCUGCUGGUACC 113 14027 CTGF-1694-16- 14028 oooooooooooosssssso Pmf000000f00mmm00mm UUAAGGAACAACUUGACUC 114 14028 0 CTGF-1588-16- 14029 oooooooooooosssssso Pmf0f0ffff000m00m000 UUACACUUCAAAUAGCAGG 115 14029 CTGF-928-16- 14030 oooooooooooosssssso Pmff000ff00mmmm0m00 UCCAGGUCAGCUUCGCAAG 116 14030 0 CTGF-1133-16- 14031 oooooooooooosssssso Pmffffff0f00mmmm0mm0 CUUCUUCAUGACCUCGCCG 117 14031 CTGF-912-16- 14032 oooooooooooosssssso Pm000fff00fm0m0m0m00 AAGGCCUGACCAUGCACAG 118 14032 CTGF-753-16- 14033 oooooooooooosssssso Pm000f0f0ffmmmm00mm CAAACGUGUCUUCCAGUCG 119 14033 0 CTGF-918-16- 14034 oooooooooooosssssso Pmfff0f0000mmm00mm0 CUUCGCAAGGCCUGACCAU 120 14034 0 CTGF-744-16- 14035 oooooooooooosssssso Pmffff00ff00m000mm00 CUUCCAGUCGGUAAGCCGC 121 14035 CTGF-466-16- 14036 oooooooooooosssssso Pmf00ffff0f00mm00mm0 CCGAUCUUGCGGUUGGCCG 122 14036 CTGF-917-16- 14037 oooooooooooosssssso Pmff0f0000fmm00mm0m UUCGCAAGGCCUGACCAUG 123 14037 0 CTGF-1038-16- 14038 oooooooooooosssssso Pm00fff00fmm0m0m00 AGAAUUUAGCUCGGUAUGU 124 14038 CTGF-1048-16- 14039 oooooooooooosssssso Pm0f0ffff0f0000mmm00 CAUACUCCACAGAAUUUAG 125 14039 CTGF-1235-16- 14040 oooooooooooosssssso Pm0ff0f0fffmmm0m0m0 UGCCAUGUCUCCGUACAUC 126 14040 CTGF-868-16- 14041 oooooooooooosssssso Pm000f0ff0fm0mm00m00 GAGGCGUUGUCAUUGGUAA 127 14041 CTGF-1131-16- 14042 oooooooooooosssssso Pmffff0f00fmmm0mm0m UCUUCAUGACCUCGCCGUC 128 14042 0 CTGF-1043-16- 14043 oooooooooooosssssso Pmff0f0000fmm00mmm0 UCCACAGAAUUUAGCUCGG 129 14043 0 CTGF-751-16- 14044 oooooooooooosssssso Pm0f0f0ffffmm00mm000 AACGUGUCUUCCAGUCGGU 130 14044 CTGF-1227-16- 14045 oooooooooooosssssso Pmfff0f0f0fmmmmmm0m CUCCGUACAUCUUCCUGUA 131 14045 0 CTGF-867-16- 14046 oooooooooooosssssso Pm0f0ff0ff0mm00m000 AGGCGUUGUCAUUGGUAAC 132 14046 CTGF-1128-16- 14047 oooooooooooosssssso Pmf0f00ffff0mm0mm000 UCAUGACCUCGCCGUCAGG 133 14047 CTGF-756-16- 14048 oooooooooooosssssso Pm0ff000f0f0mmmmmm0 GGCCAAACGUGUCUUCCAG 134 14048 0 CTGF-1234-16- 14049 oooooooooooosssssso Pmff0f0ffffmm0m0mm0 GCCAUGUCUCCGUACAUCU 135 14049 CTGF-916-16- 14050 oooooooooooosssssso Pmf0f0000ffm00mm0m00 UCGCAAGGCCUGACCAUGC 136 14050 CTGF-925-16- 14051 oooooooooooosssssso Pm0ff00fffmm0000m0 AGGUCAGCUUCGCAAGGCC 137 14051 CTGF-1225-16- 14052 oooooooooooosssssso Pmf0f0f0fffmmmm0m000 CCGUACAUCUUCCUGUAGU 138 14052 CTGF-445-16- 14053 oooooooooooosssssso Pm00ff0000fm0m000000 GAGCCGAAGUCACAGAAGA 139 14053 CTGF-446-16- 14054 oooooooooooosssssso Pm000ff0000mm0m00000 GGAGCCGAAGUCACAGAAG 140 14054 CTGF-913-16- 14055 oooooooooooosssssso Pm0000fff00mm0m0m0m CAAGGCCUGACCAUGCACA 141 14055 0 CTGF-997-16- 14056 oooooooooooosssssso Pmfff000ffm00m000m0 AGCUCAAACUUGAUAGGCU 142 14056 CTGF-277-16- 14057 oooooooooooosssssso Pmf0f00ffff00mm00m00 CUGCAGUUCUGGCCGACGG 143 14057 CTGF-1052-16- 14058 oooooooooooosssssso Pm0f0f0f0ffmm0m00000 GGUACAUACUCCACAGAAU 144 14058 CTGF-887-16- 14059 oooooooooooosssssso Pmf0fffffff00mmm0m00 CUGCUUCUCUAGCCUGCAG 145 14059 CTGF-914-16- 14060 oooooooooooosssssso Pmf0000fff00mm0m0m00 GCAAGGCCUGACCAUGCAC 146 14060 CTGF-1039-16- 14061 oooooooooooosssssso Pm0000fff00mmm00m0m CAGAAUUUAGCUCGGUAUG 147 14061 0 CTGF-754-16- 14062 oooooooooooosssssso Pmf000f0f0fmmmmm00m CCAAACGUGUCUUCCAGUC 148 14062 0 CTGF-1130-16- 14063 oooooooooooosssssso Pmfff0f00ffmmmm0mm0 CUUCAUGACCUCGCCGUCA 149 14063 CTGF-919-16- 14064 oooooooooooosssssso Pmffff0f0000mmm00mm0 GCUUCGCAAGGCCUGACCA 150 14064 CTGF-922-16- 14065 oooooooooooosssssso Pmf00ffffM000mmm00 UCAGCUUCGCAAGGCCUGA 151 14065 CTGF-746-16- 14066 oooooooooooosssssso Pmffffff00fm0m000m0 GUCUUCCAGUCGGUAAGCC 152 14066 CTGF-993-16- 14067 oooooooooooosssssso Pm000fff00f000mmm000 CAAACUUGAUAGGCUUGGA 153 14067 CTGF-825-16- 14068 oooooooooooosssssso Pm0ffff0000m000m0m0 AGGUCUUGGAACAGGCGCU 154 14068 CTGF-926-16- 14069 oooooooooooosssssso Pm000ff00ffmmm00000 CAGGUCAGCUUCGCAAGGC 155 14069 CTGF-923-16- 14070 oooooooooooosssssso Pmff00ffff0m0000mmm0 GUCAGCUUCGCAAGGCCUG 156 14070 CTGF-866-16- 14071 oooooooooooosssssso Pm0fffff0ff0mm00m00m0 GGCGUUGUCAUUGGUAACC 157 14071 CTGF-563-16- 14072 oooooooooooosssssso Pmffff0ff00m0mmm0m00 CGUGCACUGGUACUUGCAG 158 14072 CTGF-823-16- 14073 oooooooooooosssssso Pmffff0000f000m0mmm0 GUCUUGGAACAGGCGCUCC 159 14073 CTGF-1233-16- 14074 oooooooooooosssssso Pmf0f0fffff0m0m0mmm0 CCAUGUCUCCGUACAUCUU 160 14074 CTGF-924-16- 14075 oooooooooooosssssso Pm0ff00ffffffm0000mm0 GGUCAGCUUCGCAAGGCCU 161 14075 CTGF-921-16- 14076 oooooooooooosssssso Pm00ffff0f0000mmm000 CAGCUUCGCAAGGCCUGAC 162 14076 CTGF-443-16- 14077 oooooooooooosssssso Pmff0000ffffm00000000 GCCGAAGUCACAGAAGAGG 163 14077 CTGF-1041-16- 14078 oooooooooooosssssso Pm0f0000fffff0mmm00m0 CACAGAAUUUAGCUCGGUA 164 14078 CTGF-1042-16- 14079 oooooooooooosssssso Pmffff0000ffm00mmm000 CCACAGAAUUUAGCUCGGU 165 14079 CTGF-755-16- 14080 oooooooooooosssssso Pmff000f0f0mmmmmm00 GCCAAACGUGUCUUCCAGU 166 14080 0 CTGF-467-16- 14081 oooooooooooosssssso Pmffff00ffff0m0mm00m0 GCCGAUCUUGCGGUUGGCC 167 14081 CTGF-995-16- 14082 oooooooooooosssssso Pmff000fffff0m000mmm0 CUCAAACUUGAUAGGCUUG 168 14082 CTGF-927-16- 14083 oooooooooooosssssso Pmf000ff00fmmm0m0000 CCAGGUCAGCUUCGCAAGG 169 14083 SPP1-1091-16- 14131 oooooooooooosssssso Pmff00ff000m0m0000m0 UUUGACUAAAUGCAAAGUG 170 14131 PP113-16-14188 14188 ooooooooooooossssss Pm0fffff0f00mm000mm0 UGUUUUUGUAGCCAAAUCC 171 PP113-17-14189 14189 ooooooooooooossssss Pm0fffff0f00mm000mm0 UGUUUUUGUAGCCAAAUCC 172 PP113-18-14190 14190 ooooooooooooossssss Pm0fffff0f00mm000mm0 UGUUUUUGUAGCCAAAUCC 173 pGL3-1172-16- 14386 oooooooooooosssssso Pm00ff0f0ffm0mm00mm0 AAAUCGUAUUUGUCAAUCA 174 14386 pGL3-1172-16- 14387 oooooooooooosssssso Pm00ff0f0ffm0mm00mm0 AAAUCGUAUUUGUCAAUCA 175 14387 miR-122--23- 14391 14391 14084 oooooooooooosssssso Pmff00fff0f000000m00 UCUAAUUCAUGAGAAAUAC 616 14085 oooooooooooosssssso Pm00ff00fffm000000m0 UAAUUGACCUCAGAAGAUG 617 14086 oooooooooooosssssso Pmff00ff00fmmm000000 UUUAAUUGACCUCAGAAGA 618 14087 oooooooooooosssssso Pm0ff00ffff000000m00 AAUUGACCUCAGAAGAUGC 619 14088 oooooooooooosssssso Pmf00ff00ffmm0000000 UUAAUUGACCUCAGAAGAU 620 14089 oooooooooooosssssso Pmff00ffff000000m0m0 AUUGACCUCAGAAGAUGCA 621 14090 oooooooooooosssssso Pmf0fff00ff00mmm0mm0 UCAUCCAGCUGACUCGUUU 622 14091 oooooooooooosssssso Pm0fff0ff0000m00m00 AGAUUCAUCAGAAUGGUGA 623 14092 oooooooooooosssssso Pm00ffff00fmm0m000m0 UGACCUCAGUCCAUAAACC 624 14093 oooooooooooosssssso Pm0100f0000mmm0mm00 AAUGGUGAGACUCAUCAGA 625 0 14094 oooooooooooosssssso Pmff00ffff00mmm0m000 UUUGACCUCAGUCCAUAAA 626 14095 oooooooooooosssssso Pmff0f00ff0m0000mmm0 UUCAUGGCUGUGAAAUUCA 627 14096 oooooooooooosssssso Pm00f00f0000mmm0mm0 GAAUGGUGAGACUCAUCAG 628 0 14097 oooooooooooosssssso Pm00ffffff0mmm0m0m00 UGGCUUUCCGCUUAUAUAA 629 14098 oooooooooooosssssso Pmf00ffffff0mmm0m0m0 UUGGCUUUCCGCUUAUAUA 630 14099 oooooooooooosssssso Pmf0fff0f0f00mm0m000 UCAUCCAUGUGGUCAUGGC 631 14100 oooooooooooosssssso Pmf0f00ff0f00mmmmm00 AUGUGGUCAUGGCUUUCGU 632 14101 oooooooooooosssssso Pmf00ff0f00mmmmm0m GUGGUCAUGGCUUUCGUUG 633 m0 14102 oooooooooooosssssso Pmff00fffffmmmm0m00 AUUGGCUUUCCGCUUAUAU 634 14103 oooooooooooosssssso Pm00f0f0000mmmm000m AAAUACGAAAUUUCAGGUG 635 0 14104 oooooooooooosssssso Pm000f0f0000mmmm000 AGAAAUACGAAAUUUCAGG 636 14105 oooooooooooosssssso Pm00ff0f00fmmmm0mm0 UGGUCAUGGCUUUCGUUGG 637 0 14106 oooooooooooosssssso Pmf0ff0fff0m0m00mm00 AUAUCAUCCAUGUGGUCAU 638 14107 oooooooooooosssssso Pm0f0f0000fmmm000m0 AAUACGAAAUUUCAGGUGU 639 0 14108 oooooooooooosssssso Pm0ff000000mm0mmm00 AAUCAGAAGGCGCGUUCAG 640 14109 oooooooooooosssssso Pmfff0f000000m0m0000 AUUCAUGAGAAAUACGAAA 641 14110 oooooooooooosssssso Pmf0fff0f0000000m000 CUAUUCAUGAGAGAAUAAC 642 14111 oooooooooooosssssso Pmfff0ff000mmm0mmm0 UUUCGUUGGACUUACUUGG 643 0 14112 oooooooooooosssssso Pmf0fffff0fm0mm00mm0 UUGCUCUCAUCAUUGGCUU 644 14113 oooooooooooosssssso Pmff00fffffmmmmmmm0 UUCAACUCCUCGCUUUCCA 645 14114 oooooooooooosssssso Pm00ff0ff00mm0m0mm0 UGACUAUCAAUCACAUCGG 646 0 14115 oooooooooooosssssso Pm0f0f0ff0mmm00mmm0 AGAUGCACUAUCUAAUUCA 647 14116 oooooooooooosssssso Pm0f000f0f0m0mmm00m AAUAGAUACACAUUCAACC 648 0 14117 oooooooooooosssssso Pmffffff0f0000m000m0 UUCUUCUAUAGAAUGAACA 649 14118 oooooooooooosssssso Pm0ff0ff000m00mm0m00 AAUUGCUGGACAACCGUGG 650 14119 oooooooooooosssssso Pmf0ffffff0m0m0m0000 UCGCUUUCCAUGUGUGAGG 651 14120 oooooooooooosssssso Pm00fff000fm0mmm0m0 UAAUCUGGACUGCUUGUGG 652 0 14121 oooooooooooosssssso Pmf0f0fff00mm00m0000 ACACAUUCAACCAAUAAAC 653 14122 oooooooooooosssssso Pmfff0ffff0m00mm0mm0 ACUCGUUUCAUAACUGUCC 654 14123 oooooooooooosssssso Pmf00fff000mm0mmm0m AUAAUCUGGACUGCUUGUG 655 0 14124 oooooooooooosssssso Pmffff0fff0m0m00mmm0 UUUCCGCUUAUAUAAUCUG 656 14125 oooooooooooosssssso Pm0fff00ff00m0m00m00 UGUUUAACUGGUAUGGCAC 657 14126 oooooooooooosssssso Pm0f0000f000m0m000m0 UAUAGAAUGAACAUAGACA 658 14127 oooooooooooosssssso Pmffffff00fm0m0mmm0 UUUCCUUGGUCGGCGUUUG 659 14128 oooooooooooosssssso Pmf0f0f0ff0mmm00mmm GUAUGCACCAUUCAACUCC 660 0 14129 oooooooooooosssssso Pmf00ff0ff0m0m0m0mm0 UCGGCCAUCAUAUGUGUCU 661 14130 oooooooooooosssssso Pm0fff000ff0mmm0m000 AAUCUGGACUGCUUGUGGC 662 14132 oooooooooooosssssso Pmf0ff0000f0mmm0mm0 ACAUCGGAAUGCUCAUUGC 663 0 14133 oooooooooooosssssso Pm00fffff00mm0mm00m0 AAGUUCCUGACUAUCAAUC 664 14134 oooooooooooosssssso Pmf00ff000f0m0000m00 UUGACUAAAUGCAAAGUGA 665 14135 oooooooooooosssssso Pm0fff0ff000mm00m00 AGACUCAUCAGACUGGUGA 666 14136 oooooooooooosssssso Pmf0f0f0f0fmm0mm0m00 UCAUAUGUGUCUACUGUGG 667 14137 oooooooooooosssssso Pmf0fffff0fmm0m00m00 AUGUCCUCGUCUGUAGCAU 668 14138 oooooooooooosssssso Pm00fff0f00mm00mmmm GAAUUCACGGCUGACUUUG 669 0 14139 oooooooooooosssssso Pmf0fffff000mmm000m0 UUAUUUCCAGACUCAAAUA 670 14140 oooooooooooosssssso Pm000ff0f000mm000mm GAAGCCACAAACUAAACUA 671 0 14141 oooooooooooosssssso Pmffff0ff000mmm0mmm CUUUCGUUGGACUUACUUG 672 0 14142 oooooooooooosssssso Pmfff0f0000mmmmmm00 GUCUGCGAAACUUCUUAGA 673 0 14143 oooooooooooosssssso Pm0f0fff0ff0mmmmm0m AAUGCUCAUUGCUCUCAUC 674 0 14144 oooooooooooosssssso Pmf0f0ff0ffm00mmm0m0 AUGCACUAUCUAAUUCAUG 675 14145 oooooooooooosssssso Pmff0f0f0f0mm0mmm000 CUUGUAUGCACCAUUCAAC 676 14146 oooooooooooosssssso Pm00fff0fffm0m00mm00 UGACUCGUUUCAUAACUGU 677 14147 oooooooooooosssssso Pmff00f0fffm00mm0mm0 UUCAGCACUCUGGUCAUCC 678 14148 oooooooooooosssssso Pm00fff0f00mm0m00000 AAAUUCAUGGCUGUGGAAU 679 14149 oooooooooooosssssso Pmf0fff00ff00m000mm0 ACAUUCAACCAAUAAACUG 680 14150 oooooooooooosssssso Pm0f0f0fff00mm00m000 UACACAUUCAACCAAUAAA 681 14151 oooooooooooosssssso Pmff00ff0ffmmm000mm0 AUUAGUUAUUUCCAGACUC 682 14152 oooooooooooosssssso Pmffff0fff0m00000000 UUUCUAUUCAUGAGAGAAU 683 14153 oooooooooooosssssso Pmff00ff0ff00m000mm0 UUCGGUUGCUGGCAGGUCC 684 14154 oooooooooooosssssso Pm0f0f0f0000m00m0mm CAUGUGUGAGGUGAUGUCC 685 0 14155 oooooooooooosssssso Pmf0ff0fff00mmmmmm0 GCACCAUUCAACUCCUCGC 686 0 14156 oooooooooooosssssso Pm0fff00ff00mmm0mmm CAUCCAGCUGACUCGUUUC 687 0 14157 oooooooooooosssssso Pmfffff0fff0m0m00mm0 CUUUCCGCUUAUAUAAUCU 688 14158 oooooooooooosssssso Pm0ff0f0ff0000m0mmm0 AAUCACAUCGGAAUGCUCA 689 14159 oooooooooooosssssso Pmf0f0ff00fm0mmmmm0 ACACAUUAGUUAUUUCCAG 690 0 14160 oooooooooooosssssso Pmfff0f0000m000m0m00 UUCUAUAGAAUGAACAUAG 691 14161 oooooooooooosssssso Pm0f00f00f00mmm0m0m UACAGUGAUAGUUUGCAUU 692 0 14162 oooooooooooosssssso Pmf000f00ff00m0mm0m0 AUAAGCAAUUGACACCACC 693 14163 oooooooooooosssssso Pmff0ff00ff0mm000m00 UUUAUUAAUUGCUGGACAA 694 14164 oooooooooooosssssso Pmf0ff0000fmmmm0000 UCAUCAGAGUCGUUCGAGU 695 14165 oooooooooooosssssso Pmf000ff0f0mm0mm0mm AUAAACCACACUAUCACCU 696 0 14166 oooooooooooosssssso Pmf0ff0ff00mmmmmm0 UCAUCAUUGGCUUUCCGCU 697 m0 14167 oooooooooooosssssso Pmfffff00fm0mm00mm0 AGUUCCUGACUAUCAAUCA 698 14168 oooooooooooosssssso Pmfffff00ff00mmmm0000 UUCACGGCUGACUUUGGAA 699 14169 oooooooooooosssssso Pmffff0f00f00m000mm0 UUCUCAUGGUAGUGAGUUU 700 14170 oooooooooooosssssso Pm0ff00fff0mmm00mm00 AAUCAGCCUGUUUAACUGG 701 14171 oooooooooooosssssso Pm0ffff00f0mmmm00mm GGUUUCAGCACUCUGGUCA 702 0 14172 oooooooooooosssssso Pmff0000f0fmm0mm0mm AUCGGAAUGCUCAUUGCUC 703 0 14173 oooooooooooosssssso Pm00ff0f0000mmm0m00 UGGCUGUGGAAUUCACGGC 704 0 14174 oooooooooooosssssso Pm000f00ff00m0mm0mm UAAGCAAUUGACACCACCA 705 0 14175 oooooooooooosssssso Pm00fffff0f00m00m000 CAAUUCUCAUGGUAGUGAG 706 14176 oooooooooooosssssso Pm00fffff0fm000mmm00 UGGCUUUCGUUGGACUUAC 707 14177 oooooooooooosssssso Pm0ff00100fm00mmm0m AAUCAGUGACCAGUUCAUC 708 0 14178 oooooooooooosssssso Pmfff0f000mm0m0mm00 AGUCCAUAAACCACACUAU 709 14179 oooooooooooosssssso Pm00f0ffff00mm0mmm00 CAGCACUCUGGUCAUCCAG 710 14180 oooooooooooosssssso Pm0ff00ff0f0mm0000m0 UAUCAAUCACAUCGGAAUG 711 14181 oooooooooooosssssso Pmfff0f00ff00mmmm000 AUUCACGGCUGACUUUGGA 712 14182 oooooooooooosssssso Pmf000f0f0f0mmm00mm AUAGAUACACAUUCAACCA 713 0 14183 oooooooooooosssssso Pmffff000ffm000m0000 UUUCCAGACUCAAAUAGAU 714 14184 oooooooooooosssssso Pmf00ff0ff000m00mm00 UUAAUUGCUGGACAACCGU 715 14185 oooooooooooosssssso Pm0ff00ff0fm000m00m0 UAUUAAUUGCUGGACAACC 716 14186 oooooooooooosssssso Pmff0fff000mm00m000 AGUCGUUCGAGUCAAUGGA 717 14187 oooooooooooosssssso Pmff0ff00f000mmm0m00 GUUGCUGGCAGGUCCGUGG 718 TABLE 2 Antisense backbone, chemistry, and sequence information. o: phosphodiester; s: phosphorothioate; P: 5′ phosphorylation; 0: 2′-OH; F: 2′-fluoro; m: 2′ O-methyl; +: LNA modification. Capital letters in the sequence signify riobonucleotides, lower case letters signify deoxyribonucleotides.

TABLE 3 Sense backbone, chemistry, and sequence information.  OHang SEQ Oligo Sense Sense ID ID Number Number Chem. Backbone Sense Chemistry Sense Sequence NO: APOB-10167- 12138 chl ooooooooooooo 00000000000000000 GUCAUCACACUGAA 176 20-12138 ooooooso 000 UACCAAU APOB-10167- 12139 chl ooooooooooooo 00000000000000000 GUGAUCAGACUCAA 177 20-12139 ooooooso 000 UACGAAU MAP4K4-2931- 12266 chl oooooooooosso mm0m00000mmm0 CUGUGGAAGUCUA 178 13-12266 MAP4K4-2931- 12293 chl oooooooooosso mm0m00000mmm0 CUGUGGAAGUCUA 179 16-12293 MAP4K4-2931- 12383 chl ooooooooooooo mm0m00000mmm0 CUGUGGAAGUCUA 180 16-12383 MAP4K4-2931- 12384 chl ooooooooooooo mm0m00000mmm0 CUGUGGAAGUCUA 181 16-12384 MAP4K4-2931- 12385 chl ooooooooooooo mm0m00000mmm0 CUGUGGAAGUCUA 182 16-12385 MAP4K4-2931- 12386 chl oooooooooosso 0mm0m00000mmm0 CUGUGGAAGUCUA 183 16-12386 MAP4K4-2931- 12387 chl ooooooooooooo mm0m00000mmm0 CUGUGGAAGUCUA 184 16-12387 MAP4K4-2931- 12388 chl ooooooooooooo mm0m00000mmm0 CUGUGGAAGUCUA 185 15-12388 MAP4K4-2931- 12432 chl ooooooooooooo DY547mm0m00000mmm CUGUGGAAGUCUA 186 13-12432 0 MAP4K4-2931- 12266.2 chl oooooooooooss mm0m00000mmm0 CUGUGGAAGUCUA 187 13-12266.2 APOB--21- 12434 chl ooooooooooooo 00000000000000000 GUCAUCACACUGAA 188 12434 ooooooso 000 UACCAAU APOB--21- 12435 chl ooooooooooooo DY547000000000000 GUGAUCAGACUCAA 189 12435 ooooooso 00000000 UACGAAU MAP4K4-2931- 12451 chl oooooooooooss 0mm0m00000mmm0 CUGUGGAAGUCUA 190 16-12451 MAP4K4-2931- 12452 chl oooooooooooss mm0m00000mmm0 CUGUGGAAGUCUA 191 16-12452 MAP4K4-2931- 12453 chl oooooooooooss mm0m00000mmm0 CUGUGGAAGUCUA 192 16-12453 MAP4K4-2931- 12454 chl oooooooooooss 0mm0m00000mmm0 CUGUGGAAGUCUA 193 17-12454 MAP4K4-2931- 12455 chl oooooooooooss mm0m00000mmm0 CUGUGGAAGUCUA 194 17-12455 MAP4K4-2931- 12456 chl oooooooooooss mm0m00000mmm0 CUGUGGAAGUCUA 195 19-12456 --27-12480 12480 chl ooooooooooooo DY547mm0f000f0055 UCAUAGGUAACCUC 196 oooooooooooss f5f00mm00000m000 UGGUUGAAAGUGA o --27-12481 12481 chl ooooooooooooo DY547mm05f05000f0 CGGCUACAGGUGCU 197 oooooooooooss 5ff0m00000000m00 UAUGAAGAAAGUA o APOB-10167- 12505 chl ooooooooooooo 00000000000000000 GUCAUCACACUGAA 198 21-12505 ooooooos 0000 UACCAAU APOB-10167- 12506 chl ooooooooooooo 00000000000000000 GUGAUCAGACUCAA 199 21-12506 ooooooos 0000 UACGAAU MAP4K4-2931- 12539 chl oooooooooooss DY547mm0m00000mmm CUGUGGAAGUCUA 200 16-12539 0 APOB-10167- 12505.2 chl ooooooooooooo 00000000000000000 GUCAUCACACUGAA 201 21-12505.2 ooooooso 000 UACCAAU APOB-10167- 12506.2 chl ooooooooooooo 00000000000000000 GUGAUCAGACUCAA 202 21-12506.2 ooooooso 000 UACGAAU MAP4K4--13- 12565 Chl ooooooooooooo m0m0000m0mmm0 UGUAGGAUGUCUA 203 12565 MAP4K4-2931- 12386.2 chl ooooooooooooo 0mm0m00000mmm0 CUGUGGAAGUCUA 204 16-12386.2 MAP4K4-2931- 12815 chl ooooooooooooo m0m0m0m0m0m0m0m0m CUGUGGAAGUCUA 205 13-12815 0m0m0m0m0 APOB--13- 12957 Chl oooooooooooss 0mmmmmmmmmmmmm ACUGAAUACCAAU 206 12957 TEG MAP4K4--16- 12983 chl oooooooooooss mm0m00000mmm0 CUGUGGAAGUCUA 207 12983 MAP4K4--16- 12984 Chl ooooooooooooo mm0m00000mmm0 CUGUGGAAGUCUA 208 12984 o MAP4K4--16- 12985 chl oooooooooosso mmmmmmmmmmmmm CUGUGGAAGUCUA 209 12985 MAP4K4--16- 12986 chl oooooooooosso mmmmmmmmmmmmm CUGUGGAAGUCUA 210 12986 MAP4K4--16- 12987 chl oooooooooosso mm0m00000mmm0 CUGUGGAAGUCUA 211 12987 MAP4K4--16- 12988 chl oooooooooosso mm0m00000mmm0 CUGUGGAAGUCUA 212 12988 MAP4K4--16- 12989 chl oooooooooosso mm0m00000mmm0 CUGUGGAAGUCUA 213 12989 MAP4K4--16- 12990 chl oooooooooosso mm0m00000mmm0 CUGUGGAAGUCUA 214 12990 MAP4K4--16- 12991 chl oooooooooosso mm0m00000mmm0 CUGUGGAAGUCUA 215 12991 MAP4K4--16- 12992 chl oooooooooosso mm0m00000mmm0 CUGUGGAAGUCUA 216 12992 MAP4K4--16- 12993 chl oooooooooosso mm0m00000mmm0 CUGUGGAAGUCUA 217 12993 MAP4K4--16- 12994 chl oooooooooosso mm0m00000mmm0 CUGUGGAAGUCUA 218 12994 MAP4K4--16- 12995 chl oooooooooosso mm0m00000mmm0 CUGUGGAAGUCUA 219 12995 MAP4K4-2931- 13012 chl ooooooooooooo 00000000000000000 AGAGUUCUGUGGAA 220 19-13012 oooooo 0000 GUCUA MAP4K4-2931- 13016 chl ooooooooooooo DY547000000000000 AGAGUUCUGUGGAA 221 19-13016 oooooo 000000000 GUCUA PPIB--13- 13021 Chl ooooooooooooo 0mmm00mm0m000 AUUUGGCUACAAA 222 13021 pGL3-1172- 13038 chl ooooooooooooo 00m000m0m00mmm ACAAAUACGAUUU 223 13-13038 pGL3-1172- 13040 chl ooooooooooooo DY5470m000m0m00mm ACAAAUACGAUUU 224 13-13040 m --16-13047 13047 Chl ooooooooooooo mm0m00000mmm0 CUGUGGAAGUCUA 225 o SOD1-530-13- 13090 chl ooooooooooooo 00m00000000m0 AAUGAAGAAAGUA 226 13090 SOD1-523-13- 13091 chl ooooooooooooo 000m00000m000 AGGUGGAAAUGAA 227 13091 SOD1-535-13- 13092 chl ooooooooooooo 000000m0m0000 AGAAAGUACAAAG 228 13092 SOD1-536-13- 13093 chl ooooooooooooo 00000m0m00000 GAAAGUACAAAGA 229 13093 SOD1-396-13- 13094 chl ooooooooooooo 0m0m00mm0mm00 AUGUGACUGCUGA 230 13094 SOD1-385-13- 13095 chl ooooooooooooo 000mmm000m00m AGACUUGGGCAAU 231 13095 SOD1-195-13- 13096 chl ooooooooooooo 0mmmm000m0000 AUUUCGAGCAGAA 232 13096 APOB-4314- 13115 Chl ooooooooooooo 0mmm0000000m0 AUCUGGAGAAACA 233 13-13115 APOB-3384- 13116 Chl ooooooooooooo mm0000m000000 UCAGAACAAGAAA 234 13-13116 APOB-3547- 13117 Chl ooooooooooooo 00mmm0mmm0mm0 GACUCAUCUGCUA 235 13-13117 APOB-4318- 13118 Chl ooooooooooooo 0000000m00m0m GGAGAAACAACAU 236 13-13118 APOB-3741- 13119 Chl ooooooooooooo 00mmmmmm000m0 AGUCCCUCAAACA 237 13-13119 PPIB--16- 13136 Chl ooooooooooooo 00mm0m00000m0 GGCUACAAAAACA 238 13136 o APOB-4314- 13154 chl ooooooooooooo 000mmm0000000m0 AGAUCUGGAGAAAC 239 15-13154 o A APOB-3547- 13155 chl ooooooooooooo m000mmm0mmm0mm0 UGGACUCAUCUGCU 240 15-13155 o A APOB-4318- 13157 chl ooooooooooooo mm0000000m00m0m CUGGAGAAACAACA 241 15-13157 o U APOB-3741- 13158 chl ooooooooooooo 0000mmmmmm0000m0 AGAGUCCCUCAAAC 242 15-13158 o A APOB--13- 13159 chl 000000000000 0mm000m0mm00m ACUGAAUACCAAU 243 13159 APOB--15- 13160 chl ooooooooooooo 0m0mm000m0mm00m ACACUGAAUACCAA 244 13160 o U SOD1-530-16- 13163 chl ooooooooooooo 00m00000000m0 AAUGAAGAAAGUA 245 13163 SOD1-523-16- 13164 chl ooooooooooooo 000m00000m000 AGGUGGAAAUGAA 246 13164 SOD1-535-16- 13165 chl ooooooooooooo 000000m0m0000 AGAAAGUACAAAG 247 13165 SOD1-536-16- 13166 chl ooooooooooooo 00000m0m00000 GAAAGUACAAAGA 248 13166 SOD1-396-16- 13167 chl ooooooooooooo 0m0m00mm0mm00 AUGUGACUGCUGA 249 13167 SOD1-385-16- 13168 chl ooooooooooooo 000mmm000m00m AGACUUGGGCAAU 250 13168 SOD1-195-16- 13169 chl ooooooooooooo 0mmmm000m0000 AUUUCGAGCAGAA 251 13169 pGL3-1172- 13170 chl ooooooooooooo 0m000m0m00mmm ACAAAUACGAUUU 252 16-13170 pGL3-1172- 13171 chl ooooooooooooo DY5470m000m0m00mm ACAAAUACGAUUU 253 16-13171 m MAP4k4-2931- 13189 chl ooooooooooooo 00000000000000000 AGAGUUCUGUGGAA 254 19-13189 oooooo 0000 GUCUA CTGF-1222- 13190 Chl ooooooooooooo 0m0000000m0m0 ACAGGAAGAUGUA 255 13-13190 CTGF-813-13- 13192 Chl ooooooooooooo 000m0000m0mmm GAGUGGAGCGCCU 256 13192 CTGF-747-13- 13194 Chl ooooooooooooo m00mm000000m0 CGACUGGAAGACA 257 13194 CTGF-817-13- 13196 Chl ooooooooooooo 0000m0mmm0mmm GGAGCGCCUGUUC 258 13196 CTGF-1174- 13198 Chl ooooooooooooo 0mm0mm0m00mm0 GCCAUUACAACUG 259 13-13198 CTGF-1005- 13200 Chl ooooooooooooo 000mmmmmm00mm GAGCUUUCUGGCU 260 13-13200 CTGF-814-13- 13202 Chl ooooooooooooo 00m0000m0mmm0 AGUGGAGCGCCUG 261 13202 CTGF-816-13- 13204 Chl ooooooooooooo m0000m0mmm0mm UGGAGCGCCUGUU 262 13204 CTGF-1001- 13206 Chl ooooooooooooo 0mmm000mmmmmm GUUUGAGCUUUCU 263 13-13206 CTGF-1173- 13208 Chl ooooooooooooo m0mm0mm0m00mm UGCCAUUACAACU 264 13-13208 CTGF-749-13- 13210 Chl ooooooooooooo 0mm000000m0m0 ACUGGAAGACACG 265 13210 CTGF-792-13- 13212 Chl ooooooooooooo 00mm0mmm00mmm AACUGCCUGGUCC 266 13212 CTGF-1162- 13214 Chl ooooooooooooo 000mmm0m0mmm0 AGACCUGUGCCUG 267 13-13214 CTGF-811-13- 13216 Chl ooooooooooooo m0000m0000m0m CAGAGUGGAGCGC 268 13216 CTGF-797-13- 13218 Chl ooooooooooooo mmm00mmm000mm CCUGGUCCAGACC 269 13218 CTGF-1175- 13220 Chl ooooooooooooo mm0mm0m00mm0m CCAUUACAACUGU 270 13-13220 CTGF-1172- 13222 Chl ooooooooooooo mm0mm0mm0m0m CUGCCAUUACAAC 271 13-13222 CTGF-1177- 13224 Chl ooooooooooooo 0mm0m00mm0mmm AUUACAACUGUCC 272 13-13224 CTGF-1176- 13226 Chl ooooooooooooo m0mm0m00mm0mm CAUUACAACUGUC 273 13-13226 CTGF-812-13- 13228 Chl ooooooooooooo 0000m0000m0mm AGAGUGGAGCGCC 274 13228 CTGF-745-13- 13230 Chl ooooooooooooo 0mm00mm000000 ACCGACUGGAAGA 275 13230 CTGF-1230- 13232 Chl ooooooooooooo 0m0m0m00000m0 AUGUACGGAGACA 276 13-13232 CTGF-920-13- 13234 Chl ooooooooooooo 0mmmm0m0000mm GCCUUGCGAAGCU 277 13234 CTGF-679-13- 13236 Chl ooooooooooooo 0mm0m000000m0 GCUGCGAGGAGUG 278 13236 CTGF-992-13- 13238 Chl ooooooooooooo 0mmm0mm000mmm GCCUAUCAAGUUU 279 13238 CTGF-1045- 13240 Chl ooooooooooooo 00mmmm0m0000m AAUUCUGUGGAGU 280 13-13240 CTGF-1231- 13242 Chl ooooooooooooo m0m0m00000m0m UGUACGGAGACAU 281 13-13242 CTGF-991-13- 13244 Chl ooooooooooooo 00mmm0mm000mm AGCCUAUCAAGUU 282 13244 CTGF-998-13- 13246 Chl ooooooooooooo m000mmm000mmm CAAGUUUGAGCUU 283 13246 CTGF-1049- 13248 Chl ooooooooooooo mm0m0000m0m0m CUGUGGAGUAUGU 284 13-13248 CTGF-1044- 13250 Chl ooooooooooooo 000mmmm0m0000 AAAUUCUGUGGAG 285 13-13250 CTGF-1327- 13252 Chl ooooooooooooo mmmm00m00m0m0 UUUCAGUAGCACA 286 13-13252 CTGF-1196- 13254 Chl ooooooooooooo m00m00m0mmmmm CAAUGACAUCUUU 287 13-13254 CTGF-562-13- 13256 Chl ooooooooooooo 00m0mm00m0m0m AGUACCAGUGCAC 288 13256 CTGF-752-13- 13258 Chl ooooooooooooo 000000m0m0mmm GGAAGACACGUUU 289 13258 CTGF-994-13- 13260 Chl ooooooooooooo mm0mm000mmm00 CUAUCAAGUUUGA 290 13260 CTGF-1040- 13262 Chl ooooooooooooo 00mm000mmmm0m AGCUAAAUUCUGU 291 13-13262 CTGF-1984- 13264 Chl ooooooooooooo 000m0000m0m00 AGGUAGAAUGUAA 292 13-13264 CTGF-2195- 13266 Chl ooooooooooooo 00mm00mm00mmm AGCUGAUCAGUUU 293 13-13266 CTGF-2043- 13268 Chl ooooooooooooo mmmm0mmm000m0 UUCUGCUCAGAUA 294 13-13268 CTGF-1892- 13270 Chl ooooooooooooo mm0mmm000mm00 UUAUCUAAGUUAA 295 13-13270 CTGF-1567- 13272 Chl ooooooooooooo m0m0m000m00m0 UAUACGAGUAAUA 296 13-13272 CTGF-1780- 13274 Chl ooooooooooooo 00mm000m00mmm GACUGGACAGCUU 297 13-13274 CTGF-2162- 13276 Chl ooooooooooooo 0m00mmmmm0mm0 AUGGCCUUUAUUA 298 13-13276 CTGF-1034- 13278 Chl ooooooooooooo 0m0mm000mm000 AUACCGAGCUAAA 299 13-13278 CTGF-2264- 13280 Chl ooooooooooooo mm0mm00000m0m UUGUUGAGAGUGU 300 13-13280 CTGF-1032- 13282 Chl ooooooooooooo 0m0m0mm000mm0 ACAUACCGAGCUA 301 13-13282 CTGF-1535- 13284 Chl ooooooooooooo 00m0000000mm0 AGCAGAAAGGUUA 302 13-13284 CTGF-1694- 13286 Chl ooooooooooooo 00mm0mmmmmm00 AGUUGUUCCUUAA 303 13-13286 CTGF-1588- 13288 Chl ooooooooooooo 0mmm0000m0m00 AUUUGAAGUGUAA 304 13-13288 CTGF-928-13- 13290 Chl ooooooooooooo 000mm00mmm000 AAGCUGACCUGGA 305 13290 CTGF-1133- 13292 Chl ooooooooooooo 00mm0m0000000 GGUCAUGAAGAAG 306 13-13292 CTGF-912-13- 13294 Chl ooooooooooooo 0m00mm000mmmm AUGGUCAGGCCUU 307 13294 CTGF-753-13- 13296 Chl ooooooooooooo 00000m0m0mmm0 GAAGACACGUUUG 308 13296 CTGF-918-13- 13298 Chl ooooooooooooo 000mmmm0m0000 AGGCCUUGCGAAG 309 13298 CTGF-744-13- 13300 Chl ooooooooooooo m0mm0mm00000 UACCGACUGGAAG 310 13300 CTGF-466-13- 13302 Chl ooooooooooooo 0mm0m0000mm0 ACCGCAAGAUCGG 311 13302 CTGF-917-13- 13304 Chl ooooooooooooo m000mmmm0m000 CAGGCCUUGCGAA 312 13304 CTGF-1038- 13306 Chl ooooooooooooo m000mm000mmmm CGAGCUAAAUUCU 313 13-13306 CTGF-1048- 13308 Chl ooooooooooooo mmm0m0000m0m0 UCUGUGGAGUAUG 314 13-13308 CTGF-1235- 13310 Chl ooooooooooooo m00000m0m00m0 CGGAGACAUGGCA 315 13-13310 CTGF-868-13- 13312 Chl ooooooooooooo 0m00m00m0mmmm AUGACAACGCCUC 316 13312 CTGF-1131- 13314 Chl ooooooooooooo 0000mm0m00000 GAGGUCAUGAAGA 317 13-13314 CTGF-1043- 13316 Chl ooooooooooooo m000mmmm0m000 UAAAUUCUGUGGA 318 13-13316 CTGF-751-13- 13318 Chl ooooooooooooo m000000m0m0mm UGGAAGACACGUU 319 13318 CTGF-1227- 13320 Chl ooooooooooooo 0000m0m0m0000 AAGAUGUACGGAG 320 13-13320 CTGF-867-13- 13322 Chl ooooooooooooo 00m00m00m0mmm AAUGACAACGCCU 321 13322 CTGF-1128- 13324 Chl ooooooooooooo 00m0000mm0m00 GGCGAGGUCAUGA 322 13-13324 CTGF-756-13- 13326 Chl ooooooooooooo 00m0m0mmm00mm GACACGUUUGGCC 323 13326 CTGF-1234- 13328 Chl ooooooooooooo 0m00000m0m00m ACGGAGACAUGGC 324 13-13328 CTGF-916-13- 13330 Chl ooooooooooooo mm000mmmm0m00 UCAGGCCUUGCGA 325 13330 CTGF-925-13- 13332 Chl ooooooooooooo 0m0000mm00mmm GCGAAGCUGACCU 326 13332 CTGF-1225- 13334 Chl ooooooooooooo 000000m0m0m00 GGAAGAUGUACGG 327 13-13334 CTGF-445-13- 13336 Chl ooooooooooooo 0m00mmmm00mmm GUGACUUCGGCUC 328 13336 CTGF-446-13- 13338 Chl ooooooooooooo m00mmmm00mmmm UGACUUCGGCUCC 329 13338 CTGF-913-13- 13340 Chl ooooooooooooo m00mm000mmmm0 UGGUCAGGCCUUG 330 13340 CTGF-997-13- 13342 Chl ooooooooooooo mm000mmm000mm UCAAGUUUGAGCU 331 13342 CTGF-277-13- 13344 Chl ooooooooooooo 0mm0000mm0m00 GCCAGAACUGCAG 332 13344 CTGF-1052- 13346 Chl ooooooooooooo m0000m0m0m0mm UGGAGUAUGUACC 333 13-13346 CTGF-887-13- 13348 Chl ooooooooooooo 0mm0000000m00 GCUAGAGAAGCAG 334 13348 CTGF-914-13- 13350 Chl ooooooooooooo 00mm000mmmm0m GGUCAGGCCUUGC 335 13350 CTGF-1039- 13352 Chl ooooooooooooo 000mm000mmmm0 GAGCUAAAUUCUG 336 13-13352 CTGF-754-13- 13354 Chl ooooooooooooo 0000m0m0mmm00 AAGACACGUUUGG 337 13354 CTGF-1130- 13356 Chl ooooooooooooo m0000mm0m0000 CGAGGUCAUGAAG 338 13-13356 CTGF-919-13- 13358 Chl ooooooooooooo 00mmmm0m0000m GGCCUUGCGAAGC 339 13358 CTGF-922-13- 13360 Chl ooooooooooooo mmm0m0000mm00 CUUGCGAAGCUGA 340 13360 CTGF-746-13- 13362 Chl ooooooooooooo mm00mm000000m CCGACUGGAAGAC 341 13362 CTGF-993-13- 13364 Chl ooooooooooooo mmm0mm000mmm0 CCUAUCAAGUUUG 342 13364 CTGF-825-13- 13366 Chl ooooooooooooo m0mmmm0000mmm UGUUCCAAGACCU 343 13366 CTGF-926-13- 13368 Chl ooooooooooooo m0000mm00mmm0 CGAAGCUGACCUG 344 13368 CTGF-923-13- 13370 Chl ooooooooooooo mm0m0000mm00m UUGCGAAGCUGAC 345 13370 CTGF-866-13- 13372 Chl ooooooooooooo m00m00m00m0mm CAAUGACAACGCC 346 13372 CTGF-563-13- 13374 Chl ooooooooooooo 0m0mm00m0m0m0 GUACCAGUGCACG 347 13374 CTGF-823-13- 13376 Chl ooooooooooooo mmm0mmmm0000m CCUGUUCCAAGAC 348 13376 CTGF-1233- 13378 Chl ooooooooooooo m0m00000m0m00 UACGGAGACAUGG 349 13-13378 CTGF-924-13- 13380 Chl ooooooooooooo m0m0000mm00mm UGCGAAGCUGACC 350 13380 CTGF-921-13- 13382 Chl ooooooooooooo mmmm0m0000mm0 CCUUGCGAAGCUG 351 13382 CTGF-443-13- 13384 Chl ooooooooooooo mm0m00mmmm00m CUGUGACUUCGGC 352 13384 CTGF-1041- 13386 Chl ooooooooooooo 0mm000mmmm0m0 GCUAAAUUCUGUG 353 13-13386 CTGF-1042- 13388 Chl ooooooooooooo mm000mmmm0m00 CUAAAUUCUGUGG 354 13-13388 CTGF-755-13- 13390 Chl ooooooooooooo 000m0m0mmm00m AGACACGUUUGGC 355 13390 CTGF-467-13- 13392 Chl ooooooooooooo mm0m0000mm00m CCGCAAGAUCGGC 356 13392 CTGF-995-13- 13394 Chl ooooooooooooo m0mm000mmm000 UAUCAAGUUUGAG 357 13394 CTGF-927-13- 13396 Chl ooooooooooooo 0000mm00mmm00 GAAGCUGACCUGG 358 13396 SPP1-1025- 13398 Chl ooooooooooooo mmm0m000mm000 CUCAUGAAUUAGA 359 13-13398 SPP1-1049- 13400 Chl ooooooooooooo mm0000mm00mm0 CUGAGGUCAAUUA 360 13-13400 SPP1-1051- 13402 Chl ooooooooooooo 0000mm00mm000 GAGGUCAAUUAAA 361 13-13402 SPP1-1048- 13404 Chl ooooooooooooo mmm0000mm00mm UCUGAGGUCAAUU 362 13-13404 SPP1-1050- 13406 Chl ooooooooooooo m0000mm00mm00 UGAGGUCAAUUAA 363 13-13406 SPP1-1047- 13408 Chl ooooooooooooo mmmm0000mm00m UUCUGAGGUCAAU 364 13-13408 SPP1-800-13- 13410 Chl ooooooooooooo 0mm00mm000m00 GUCAGCUGGAUGA 365 13410 SPP1-492-13- 13412 Chl ooooooooooooo mmmm00m000mmm UUCUGAUGAAUCU 366 13412 SPP1-612-13- 13414 Chl ooooooooooooo m000mm0000mm0 UGGACUGAGGUCA 367 13414 SPP1-481-13- 13416 Chl ooooooooooooo 000mmmm0mm0mm GAGUCUCACCAUU 368 13416 SPP1-614-13- 13418 Chl ooooooooooooo 00mm0000mm000 GACUGAGGUCAAA 369 13418 SPP1-951-13- 13420 Chl ooooooooooooo mm0m00mm0m000 UCACAGCCAUGAA 370 13420 SPP1-482-13- 13422 Chl ooooooooooooo 00mmmm0mm0mmm AGUCUCACCAUUC 371 13422 SPP1-856-13- 13424 Chl ooooooooooooo 000m000000mm0 AAGCGGAAAGCCA 372 13424 SPP1-857-13- 13426 Chl ooooooooooooo 00m000000mm00 AGCGGAAAGCCAA 373 13426 SPP1-365-13- 13428 Chl ooooooooooooo 0mm0m0m000m00 ACCACAUGGAUGA 374 13428 SPP1-359-13- 13430 Chl ooooooooooooo 0mm0m00mm0m0m GCCAUGACCACAU 375 13430 SPP1-357-13- 13432 Chl ooooooooooooo 000mm0m00mm0m AAGCCAUGACCAC 376 13432 SPP1-858-13- 13434 Chl ooooooooooooo 0m000000mm00m GCGGAAAGCCAAU 377 13434 SPP1-1012- 13436 Chl ooooooooooooo 000mmmm0m0mmm AAAUUUCGUAUUU 378 13-13436 SPP1-1014- 13438 Chl ooooooooooooo 0mmmm0m0mmmmm AUUUCGUAUUUCU 379 13-13438 SPP1-356-13- 13440 Chl ooooooooooooo 0000mm0m00mm0 AAAGCCAUGACCA 380 13440 SPP1-368-13- 13442 Chl ooooooooooooo 0m0m000m00m0m ACAUGGAUGAUAU 381 13442 SPP1-1011- 13444 Chl ooooooooooooo 0000mmmm0m0mm GAAAUUUCGUAUU 382 13-13444 SPP1-754-13- 13446 Chl ooooooooooooo 0m0mmmmmm00mm GCGCCUUCUGAUU 383 13446 SPP1-1021- 13448 Chl ooooooooooooo 0mmmmmm0m000m AUUUCUCAUGAAU 384 13-13448 SPP1-1330- 13450 Chl ooooooooooooo mmmmm0m000m00 CUCUCAUGAAUAG 385 13-13450 SPP1-346-13- 13452 Chl ooooooooooooo 000mmm00m0000 AAGUCCAACGAAA 386 13452 SPP1-869-13- 13454 Chl ooooooooooooo 0m00m00000m00 AUGAUGAGAGCAA 387 13454 SPP1-701-13- 13456 Chl ooooooooooooo 0m000000mm000 GCGAGGAGUUGAA 388 13456 SPP1-896-13- 13458 Chl ooooooooooooo m00mm00m00mm0 UGAUUGAUAGUCA 389 13458 SPP1-1035- 13460 Chl ooooooooooooo 000m00m0m0mmm AGAUAGUGCAUCU 390 13-13460 SPP1-1170- 13462 Chl ooooooooooooo 0m0m0m0mmm0mm AUGUGUAUCUAUU 391 13-13462 SPP1-1282- 13464 Chl ooooooooooooo mmmm0m0000000 UUCUAUAGAAGAA 392 13-13464 SPP1-1537- 13466 Chl ooooooooooooo mm0mmm00m00mm UUGUCCAGCAAUU 393 13-13466 SPP1-692-13- 13468 Chl ooooooooooooo 0m0m000000m00 ACAUGGAAAGCGA 394 13468 SPP1-840-13- 13470 Chl ooooooooooooo 0m00mmm000mm0 GCAGUCCAGAUUA 395 13470 SPP1-1163- 13472 Chl ooooooooooooo m00mm000m0m0m UGGUUGAAUGUGU 396 13-13472 SPP1-789-13- 13474 Chl ooooooooooooo mm0m0000m000m UUAUGAAACGAGU 397 13474 SPP1-841-13- 13476 Chl ooooooooooooo m00mmm000mm0m CAGUCCAGAUUAU 398 13476 SPP1-852-13- 13478 Chl ooooooooooooo 0m0m000m00000 AUAUAAGCGGAAA 399 13478 SPP1-209-13- 13480 Chl ooooooooooooo m0mm00mm000m0 UACCAGUUAAACA 400 13480 SPP1-1276- 13482 Chl ooooooooooooo m0mmm0mmmm0m0 UGUUCAUUCUAUA 401 13-13482 SPP1-137-13- 13484 Chl ooooooooooooo mm00mm0000000 CCGACCAAGGAAA 402 13484 SPP1-711-13- 13486 Chl ooooooooooooo 000m00m0m0m0m GAAUGGUGCAUAC 403 13486 SPP1-582-13- 13488 Chl ooooooooooooo 0m0m00m00mm00 AUAUGAUGGCCGA 404 13488 SPP1-839-13- 13490 Chl ooooooooooooo 00m00mmm000mm AGCAGUCCAGAUU 405 13490 SPP1-1091- 13492 Chl ooooooooooooo 0m0mmm00mm000 GCAUUUAGUCAAA 406 13-13492 SPP1-884-13- 13494 Chl ooooooooooooo 00m0mmmm00m0m AGCAUUCCGAUGU 407 13494 SPP1-903-13- 13496 Chl ooooooooooooo m00mm00000mmm UAGUCAGGAACUU 408 13496 SPP1-1090- 13498 Chl ooooooooooooo m0m0mmm00mm00 UGCAUUUAGUCAA 409 13-13498 SPP1-474-13- 13500 Chl ooooooooooooo 0mmm00m000mmm GUCUGAUGAGUCU 410 13500 SPP1-575-13- 13502 Chl ooooooooooooo m000m0m0m0m00 UAGACACAUAUGA 411 13502 SPP1-671-13- 13504 Chl ooooooooooooo m000m00000m0m CAGACGAGGACAU 412 13504 SPP1-924-13- 13506 Chl ooooooooooooo m00mm0m000mmm CAGCCGUGAAUUC 413 13506 SPP1-1185- 13508 Chl ooooooooooooo 00mmm00000m00 AGUCUGGAAAUAA 414 13-13508 SPP1-1221- 13510 Chl ooooooooooooo 00mmm0m00mmmm AGUUUGUGGCUUC 415 13-13510 SPP1-347-13- 13512 Chl ooooooooooooo 00mmm00m00000 AGUCCAACGAAAG 416 13512 SPP1-634-13- 13514 Chl ooooooooooooo 000mmmm0m000m AAGUUUCGCAGAC 417 13514 SPP1-877-13- 13516 Chl ooooooooooooo 00m00m000m0mm AGCAAUGAGCAUU 418 13516 SPP1-1033- 13518 Chl ooooooooooooo mm000m00m0m0m UUAGAUAGUGCAU 419 13-13518 SPP1-714-13- 13520 Chl ooooooooooooo m00m0m0m0m000 UGGUGCAUACAAG 420 13520 SPP1-791-13- 13522 Chl ooooooooooooo 0m0000m000mm0 AUGAAACGAGUCA 421 13522 SPP1-813-13- 13524 Chl ooooooooooooo mm0000m0mm000 CCAGAGUGCUGAA 422 13524 SPP1-939-13- 13526 Chl ooooooooooooo m00mm0m000mmm CAGCCAUGAAUUU 423 13526 SPP1-1161- 13528 Chl ooooooooooooo 0mm00mm000m0m AUUGGUUGAAUGU 424 13-13528 SPP1-1164- 13530 Chl ooooooooooooo 00mm000m0m0m0 GGUUGAAUGUGUA 425 13-13530 SPP1-1190- 13532 Chl ooooooooooooo 00000m00mm00m GGAAAUAACUAAU 426 13-13532 SPP1-1333- 13534 Chl ooooooooooooo mm0m000m00000 UCAUGAAUAGAAA 427 13-13534 SPP1-537-13- 13536 Chl ooooooooooooo 0mm00m00mm000 GCCAGCAACCGAA 428 13536 SPP1-684-13- 13538 Chl ooooooooooooo m0mmmm0m0m0m0 CACCUCACACAUG 429 13538 SPP1-707-13- 13540 Chl ooooooooooooo 00mm000m00m0m AGUUGAAUGGUGC 430 13540 SPP1-799-13- 13542 Chl ooooooooooooo 00mm00mm000m0 AGUCAGCUGGAUG 431 13542 SPP1-853-13- 13544 Chl ooooooooooooo m0m000m000000 UAUAAGCGGAAAG 432 13544 SPP1-888-13- 13546 Chl ooooooooooooo mmmm00m0m00mm UUCCGAUGUGAUU 433 13546 SPP1-1194- 13548 Chl ooooooooooooo 0m00mm00m0m0m AUAACUAAUGUGU 434 13-13548 SPP1-1279- 13550 Chl ooooooooooooo mm0mmmm0m0000 UCAUUCUAUAGAA 435 13-13550 SPP1-1300- 13552 Chl ooooooooooooo 00mm0mm0mm0m0 AACUAUCACUGUA 436 13-13552 SPP1-1510- 13554 Chl ooooooooooooo 0mm00mm0mmm0m GUCAAUUGCUUAU 437 13-13554 SPP1-1543- 13556 Chl ooooooooooooo 00m00mm00m000 AGCAAUUAAUAAA 438 13-13556 SPP1-434-13- 13558 Chl ooooooooooooo 0m00mmmm00m00 ACGACUCUGAUGA 439 13558 SPP1-600-13- 13560 Chl ooooooooooooo m00m0m00mmm0m UAGUGUGGUUUAU 440 13560 SPP1-863-13- 13562 Chl ooooooooooooo 000mm00m00m00 AAGCCAAUGAUGA 441 13562 SPP1-902-13- 13564 Chl ooooooooooooo 0m00mm00000mm AUAGUCAGGAACU 442 13564 SPP1-921-13- 13566 Chl ooooooooooooo 00mm00mm0m000 AGUCAGCCGUGAA 443 13566 SPP1-154-13- 13568 Chl ooooooooooooo 0mm0mm0m00000 ACUACCAUGAGAA 444 13568 SPP1-217-13- 13570 Chl ooooooooooooo 000m000mm00mm AAACAGGCUGAUU 445 13570 SPP1-816-13- 13572 Chl ooooooooooooo 000m0mm0000mm GAGUGCUGAAACC 446 13572 SPP1-882-13- 13574 Chl ooooooooooooo m000m0mmmm00m UGAGCAUUCCGAU 447 13574 SPP1-932-13- 13576 Chl ooooooooooooo 00mmmm0m00mm0 AAUUCCACAGCCA 448 13576 SPP1-1509- 13578 Chl ooooooooooooo m0mm00mm0mmm0 UGUCAAUUGCUUA 449 13-13578 SPP1-157-13- 13580 Chl ooooooooooooo 0mm0m00000mm0 ACCAUGAGAAUUG 450 13580 SPP1-350-13- 13582 Chl ooooooooooooo mm00m00000mm0 CCAACGAAAGCCA 451 13582 SPP1-511-13- 13584 Chl ooooooooooooo mm00mm0mm00mm CUGGUCACUGAUU 452 13584 SPP1-605-13- 13586 Chl ooooooooooooo m00mmm0m000mm UGGUUUAUGGACU 453 13586 SPP1-811-13- 13588 Chl ooooooooooooo 00mm0000m0mm0 GACCAGAGUGCUG 454 13588 SPP1-892-13- 13590 Chl ooooooooooooo 00m0m00mm00m0 GAUGUGAUUGAUA 455 13590 SPP1-922-13- 13592 Chl ooooooooooooo 0mm00mm0m000m GUCAGCCGUGAAU 456 13592 SPP1-1169- 13594 Chl ooooooooooooo 00m0m0m0mmm0m AAUGUGUAUCUAU 457 13-13594 SPP1-1182- 13596 Chl ooooooooooooo mm000mmm00000 UUGAGUCUGGAAA 458 13-13596 SPP1-1539- 13598 Chl ooooooooooooo 0mmm00m00mm00 GUCCAGCAAUUAA 459 13-13598 SPP1-1541- 13600 Chl ooooooooooooo mm00m00mm00m0 CCAGCAAUUAAUA 460 13-13600 SPP1-427-13- 13602 Chl ooooooooooooo 00mmm000m00mm GACUCGAACGACU 461 13602 SPP1-533-13- 13604 Chl ooooooooooooo 0mmm0mm00m00m ACCUGCCAGCAAC 462 13604 APOB--13- 13763 Chl ooooooooooooo 0m+00+m0+m0+m ACtGAaUAcCAaU 463 13763 TEG APOB--13- 13764 Chl ooooooooooooo 0mm000m0mm00m ACUGAAUACCAAU 464 13764 TEG MAP4K4--16- 13766 Chl ooooooooooooo DY547mm0m00000mmm CUGUGGAAGUCUA 465 13766 0 PPIB--13- 13767 Chl ooooooooooooo mmmmmmmmmmmmm GGCUACAAAAACA 466 13767 PPIB--15- 13768 Chl ooooooooooooo mm00mm0m00000m0 UUGGCUACAAAAAC 467 13768 oo A PPIB--17- 13769 Chl ooooooooooooo 0mmm00mm0m00000m0 AUUUGGCUACAAAA 468 13769 oooo ACA MAP4K4--16- 13939 Chl ooooooooooooo m0m0000m0mmm0 UGUAGGAUGUCUA 469 13939 APOB-4314- 13940 Chl ooooooooooooo 0mmm0000000m0 AUCUGGAGAAACA 470 16-13940 APOB-4314- 13941 Chl ooooooooooooo 000mmm0000000m0 AGAUCUGGAGAAAC 471 17-13941 oo A APOB--16- 13942 Chl ooooooooooooo 00mmm0mmm0mm0 GACUCAUCUGCUA 472 13942 APOB--18- 13943 Chl ooooooooooooo 00mmm0mmm0mm0 GACUCAUCUGCUA 473 13943 APOB--17- 13944 Chl ooooooooooooo m000mmm0mmm0mm0 UGGACUCAUCUGCU 474 13944 oo A APOB--19- 13945 Chl ooooooooooooo m000mmm0mmm0mm0 UGGACUCAUCUGCU 475 13945 oo A APOB-4314- 13946 Chl ooooooooooooo 0000000m00m0m GGAGAAACAACAU 476 16-13946 APOB-4314- 13947 Chl ooooooooooooo mm0000000m00m0m CUGGAGAAACAACA 477 17-13947 oo U APOB--16- 13948 Chl ooooooooooooo 00mmmmmm000m0 AGUCCCUCAAACA 478 13948 APOB--17- 13949 Chl ooooooooooooo 0000mmmmmm000m0 AGAGUCCCUCAAAC 479 13949 oo A APOB--16- 13950 Chl ooooooooooooo 0mm000m0mm00m ACUGAAUACCAAU 480 13950 APOB--18- 13951 Chl ooooooooooooo 0mm000m0mm00m ACUGAAUACCAAU 481 13951 APOB--17- 13952 Chl ooooooooooooo 0m0mm000m0mm00m ACACUGAAUACCAA 482 13952 oo U APOB--19- 13953 Chl ooooooooooooo 0m0mm000m0mm00m ACACUGAAUACCAA 483 13953 oo U MAP4K4--16- 13766.2 Chl ooooooooooooo DY547mm0m00000mmm CUGUGGAAGUCUA 484 13766.2 0 CTGF-1222- 13980 Chl ooooooooooooo 0m0000000m0m0 ACAGGAAGAUGUA 485 16-13980 CTGF-813-16- 13981 Chl ooooooooooooo 000m0000mmmm GAGUGGAGCGCCU 486 13981 CTGF-747-16- 13982 Chl ooooooooooooo m0mm000000m0 CGACUGGAAGACA 487 13982 CTGF-817-16- 13983 Chl ooooooooooooo 0000mmmm0mmm GGAGCGCCUGUUC 488 13983 CTGF-1174- 13984 Chl ooooooooooooo 0mm0mm0m00mm0 GCCAUUACAACUG 489 16-13984 CTGF-1005- 13985 Chl ooooooooooooo 000mmmmmm00mm GAGCUUUCUGGCU 490 16-13985 CTGF-814-16- 13986 Chl ooooooooooooo 00m0000mmmm0 AGUGGAGCGCCUG 491 13986 CTGF-816-16- 13987 Chl ooooooooooooo m0000mmmm0mm UGGAGCGCCUGUU 492 13987 CTGF-1001- 13988 Chl ooooooooooooo 0mmm000mmmmmm GUUUGAGCUUUCU 493 16-13988 CTGF-1173- 13989 Chl ooooooooooooo m0mm0mm0m00mm UGCCAUUACAACU 494 16-13989 CTGF-749-16- 13990 Chl ooooooooooooo 0mm000000m0m ACUGGAAGACACG 495 13990 CTGF-792-16- 13991 Chl ooooooooooooo 00mm0mmm00mmm AACUGCCUGGUCC 496 13991 CTGF-1162- 13992 Chl ooooooooooooo 000mmm0m0mmm0 AGACCUGUGCCUG 497 16-13992 CTGF-811-16- 13993 Chl ooooooooooooo m0000m0000mm CAGAGUGGAGCGC 498 13993 CTGF-797-16- 13994 Chl ooooooooooooo mmm00mmm000mm CCUGGUCCAGACC 499 13994 CTGF-1175- 13995 Chl ooooooooooooo mm0mm0m00mm0m CCAUUACAACUGU 500 16-13995 CTGF-1172- 13996 Chl ooooooooooooo mm0mm0mm0m00m CUGCCAUUACAAC 501 16-13996 CTGF-1177- 13997 Chl ooooooooooooo 0mm0m00mm0mmm AUUACAACUGUCC 502 16-13997 CTGF-1176- 13998 Chl ooooooooooooo m0mm0m00mm0mm CAUUACAACUGUC 503 16-13998 CTGF-812-16- 13999 Chl ooooooooooooo 0000m0000mmm AGAGUGGAGCGCC 504 13999 CTGF-745-16- 14000 Chl ooooooooooooo 0mm0mm000000 ACCGACUGGAAGA 505 14000 CTGF-1230- 14001 Chl ooooooooooooo 0m0m0m0000m0 AUGUACGGAGACA 506 16-14001 CTGF-920-16- 14002 Chl ooooooooooooo 0mmmm0m000mm GCCUUGCGAAGCU 507 14002 CTGF-679-16- 14003 Chl ooooooooooooo 0mm0m00000m0 GCUGCGAGGAGUG 508 14003 CTGF-992-16- 14004 Chl ooooooooooooo 0mmm0mm000mmm GCCUAUCAAGUUU 509 14004 CTGF-1045- 14005 Chl ooooooooooooo 00mmmm0m0000m AAUUCUGUGGAGU 510 16-14005 CTGF-1231- 14006 Chl ooooooooooooo m0m0m0000m0m UGUACGGAGACAU 511 16-14006 CTGF-991-16- 14007 Chl ooooooooooooo 00mmm0mm000mm AGCCUAUCAAGUU 512 14007 CTGF-998-16- 14008 Chl ooooooooooooo m000mmm000mmm CAAGUUUGAGCUU 513 14008 CTGF-1049- 14009 Chl ooooooooooooo mm0m0000m0m0m CUGUGGAGUAUGU 514 16-14009 CTGF-1044- 14010 Chl ooooooooooooo 000mmmm0m0000 AAAUUCUGUGGAG 515 16-14010 CTGF-1327- 14011 Chl ooooooooooooo mmmm00m00m0m0 UUUCAGUAGCACA 516 16-14011 CTGF-1196- 14012 Chl ooooooooooooo m00m00m0mmmmm CAAUGACAUCUUU 517 16-14012 CTGF-562-16- 14013 Chl ooooooooooooo 00m0mm00m0m0m AGUACCAGUGCAC 518 14013 CTGF-752-16- 14014 Chl ooooooooooooo 000000m0mmmm GGAAGACACGUUU 519 14014 CTGF-994-16- 14015 Chl ooooooooooooo mm0mm000mmm00 CUAUCAAGUUUGA 520 14015 CTGF-1040- 14016 Chl ooooooooooooo 00mm000mmmm0m AGCUAAAUUCUGU 521 16-14016 CTGF-1984- 14017 Chl ooooooooooooo 000m0000m0m00 AGGUAGAAUGUAA 522 16-14017 CTGF-2195- 14018 Chl ooooooooooooo 00mm00mm00mmm AGCUGAUCAGUUU 523 16-14018 CTGF-2043- 14019 Chl ooooooooooooo mmmm0mmm000m0 UUCUGCUCAGAUA 524 16-14019 CTGF-1892- 14020 Chl ooooooooooooo mm0mmm000mm00 UUAUCUAAGUUAA 525 16-14020 CTGF-1567- 14021 Chl ooooooooooooo m0m0m00m00m0 UAUACGAGUAAUA 526 16-14021 CTGF-1780- 14022 Chl ooooooooooooo 00mm000m00mmm GACUGGACAGCUU 527 16-14022 CTGF-2162- 14023 Chl ooooooooooooo 0m00mmmmm0mm0 AUGGCCUUUAUUA 528 16-14023 CTGF-1034- 14024 Chl ooooooooooooo 0m0mm00mm000 AUACCGAGCUAAA 529 16-14024 CTGF-2264- 14025 Chl ooooooooooooo mm0mm00000m0m UUGUUGAGAGUGU 530 16-14025 CTGF-1032- 14026 Chl ooooooooooooo 0m0m0mm00mm0 ACAUACCGAGCUA 531 16-14026 CTGF-1535- 14027 Chl ooooooooooooo 00m0000000mm0 AGCAGAAAGGUUA 532 16-14027 CTGF-1694- 14028 Chl ooooooooooooo 00mm0mmmmmm00 AGUUGUUCCUUAA 533 16-14028 CTGF-1588- 14029 Chl ooooooooooooo 0mmm0000m0m00 AUUUGAAGUGUAA 534 16-14029 CTGF-928-16- 14030 Chl ooooooooooooo 000mm00mmm000 AAGCUGACCUGGA 535 14030 CTGF-1133- 14031 Chl ooooooooooooo 00mm0m0000000 GGUCAUGAAGAAG 536 16-14031 CTGF-912-16- 14032 Chl ooooooooooooo 0m00mm000mmmm AUGGUCAGGCCUU 537 14032 CTGF-753-16- 14033 Chl ooooooooooooo 00000m0mmmm0 GAAGACACGUUUG 538 14033 CTGF-918-16- 14034 Chl ooooooooooooo 000mmmm0m000 AGGCCUUGCGAAG 539 14034 CTGF-744-16- 14035 Chl ooooooooooooo m0mm0mm00000 UACCGACUGGAAG 540 14035 CTGF-466-16- 14036 Chl ooooooooooooo 0mmm0000mm0 ACCGCAAGAUCGG 541 14036 CTGF-917-16- 14037 Chl ooooooooooooo m000mmmm0m00 CAGGCCUUGCGAA 542 14037 CTGF-1038- 14038 Chl ooooooooooooo m00mm000mmmm CGAGCUAAAUUCU 543 16-14038 CTGF-1048- 14039 Chl ooooooooooooo mmm0m0000m0m0 UCUGUGGAGUAUG 544 16-14039 CTGF-1235- 14040 Chl ooooooooooooo m0000m0m00m0 CGGAGACAUGGCA 545 16-14040 CTGF-868-16- 14041 Chl ooooooooooooo 0m00m00mmmmm AUGACAACGCCUC 546 14041 CTGF-1131- 14042 Chl ooooooooooooo 0000mm0m00000 GAGGUCAUGAAGA 547 16-14042 CTGF-1043- 14043 Chl ooooooooooooo m000mmmm0m000 UAAAUUCUGUGGA 548 16-14043 CTGF-751-16- 14044 Chl ooooooooooooo m000000m0mmm UGGAAGACACGUU 549 14044 CTGF-1227- 14045 Chl ooooooooooooo 0000m0m0m000 AAGAUGUACGGAG 550 16-14045 CTGF-867-16- 14046 Chl ooooooooooooo 00m00m00mmmm AAUGACAACGCCU 551 14046 CTGF-1128- 14047 Chl ooooooooooooo 00m000mm0m00 GGCGAGGUCAUGA 552 16-14047 CTGF-756-16- 14048 Chl ooooooooooooo 00m0m0mmm00mm GACACGUUUGGCC 553 14048 CTGF-1234- 14049 Chl ooooooooooooo 0m00000m0m00m ACGGAGACAUGGC 554 16-14049 CTGF-916-16- 14050 Chl ooooooooooooo mm000mmmm0m00 UCAGGCCUUGCGA 555 14050 CTGF-925-16- 14051 Chl ooooooooooooo 0m0000mm00mmm GCGAAGCUGACCU 556 14051 CTGF-1225- 14052 Chl ooooooooooooo 000000m0m0m00 GGAAGAUGUACGG 557 16-14052 CTGF-445-16- 14053 Chl ooooooooooooo 0m00mmmm00mmm GUGACUUCGGCUC 558 14053 CTGF-446-16- 14054 Chl ooooooooooooo m00mmmm00mmmm UGACUUCGGCUCC 559 14054 CTGF-913-16- 14055 Chl ooooooooooooo m00mm000mmmm0 UGGUCAGGCCUUG 560 14055 CTGF-997-16- 14056 Chl ooooooooooooo mm000mmm000mm UCAAGUUUGAGCU 561 14056 CTGF-277-16- 14057 Chl ooooooooooooo 0mm0000mm0m00 GCCAGAACUGCAG 562 14057 CTGF-1052- 14058 Chl ooooooooooooo m0000m0m0m0mm UGGAGUAUGUACC 563 16-14058 CTGF-887-16- 14059 Chl ooooooooooooo 0mm0000000m00 GCUAGAGAAGCAG 564 14059 CTGF-914-16- 14060 Chl ooooooooooooo 00mm000mmmm0m GGUCAGGCCUUGC 565 14060 CTGF-1039- 14061 Chl ooooooooooooo 000mm000mmmm0 GAGCUAAAUUCUG 566 16-14061 CTGF-754-16- 14062 Chl ooooooooooooo 0000m0m0mmm00 AAGACACGUUUGG 567 14062 CTGF-1130- 14063 Chl ooooooooooooo m0000mm0m0000 CGAGGUCAUGAAG 568 16-14063 CTGF-919-16- 14064 Chl ooooooooooooo 00mmmm0m0000m GGCCUUGCGAAGC 569 14064 CTGF-922-16- 14065 Chl ooooooooooooo mmm0m0000mm00 CUUGCGAAGCUGA 570 14065 CTGF-746-16- 14066 Chl ooooooooooooo mm00mm000000m CCGACUGGAAGAC 571 14066 CTGF-993-16- 14067 Chl ooooooooooooo mmm0mm000mmm0 CCUAUCAAGUUUG 572 14067 CTGF-825-16- 14068 Chl ooooooooooooo m0mmmm0000mmm UGUUCCAAGACCU 573 14068 CTGF-926-16- 14069 Chl ooooooooooooo m0000mm00mmm0 CGAAGCUGACCUG 574 14069 CTGF-923-16- 14070 Chl ooooooooooooo mm0m0000mm00m UUGCGAAGCUGAC 575 14070 CTGF-866-16- 14071 Chl ooooooooooooo m00m00m00m0mm CAAUGACAACGCC 576 14071 CTGF-563-16- 14072 Chl ooooooooooooo 0m0mm00m0m0m0 GUACCAGUGCACG 577 14072 CTGF-823-16- 14073 Chl ooooooooooooo mmm0mmmm0000m CCUGUUCCAAGAC 578 14073 CTGF-1233- 14074 Chl ooooooooooooo m0m00000m0m00 UACGGAGACAUGG 579 16-14074 CTGF-924-16- 14075 Chl ooooooooooooo m0m0000mm00mm UGCGAAGCUGACC 580 14075 CTGF-921-16- 14076 Chl ooooooooooooo mmmm0m0000mm0 CCUUGCGAAGCUG 581 14076 CTGF-443-16- 14077 Chl ooooooooooooo mm0m00mmmm00m CUGUGACUUCGGC 582 14077 CTGF-1041- 14078 Chl ooooooooooooo 0mm000mmmm0m0 GCUAAAUUCUGUG 583 16-14078 CTGF-1042- 14079 Chl ooooooooooooo mm000mmmm0m00 CUAAAUUCUGUGG 584 16-14079 CTGF-755-16- 14080 Chl ooooooooooooo 000m0m0mmm00m AGACACGUUUGGC 585 14080 CTGF-467-16- 14081 Chl ooooooooooooo mm0m0000mm00m CCGCAAGAUCGGC 586 14081 CTGF-995-16- 14082 Chl ooooooooooooo m0mm000mmm000 UAUCAAGUUUGAG 587 14082 CTGF-927-16- 14083 Chl ooooooooooooo 0000mm00mmm00 GAAGCUGACCUGG 588 14083 SPP1-1091- 14131 Chl ooooooooooooo 0m0mmm00mm000 GCAUUUAGUCAAA 589 16-14131 PPIB--16- 14188 Chl ooooooooooooo mmmmmmmmmmmmm GGCUACAAAAACA 590 14188 PPIB--17- 14189 Chl ooooooooooooo mm00mm0m00000m0 UUGGCUACAAAAAC 591 14189 oo A PPIB--18- 14190 Chl ooooooooooooo 0mmm00mm0m00000m0 AUUUGGCUACAAAA 592 14190 oooo ACA pGL3-1172- 14386 chl ooooooooooooo 0m000m0m00mmm ACAAAUACGAUUU 593 16-14386 pGL3-1172- 14387 chl ooooooooooooo DY5470m000m0m00mm ACAAAUACGAUUU 594 16-14387 m MAP4K4-2931- 14390 Chl ooooooooooooo Pmmmmmmmmmmmm000m CUUUGAAGAGUUCU 595 25-14390 oooooooooooo mmmmmmmmm GUGGAAGUCUA miR-122--23- 14391 Chl ssooooooooooo mmmmmmmmmmmmmmmmm ACAAACACCAUUGU 596 14391 oooooossss mmmmmm CACACUCCA 14084 Chl ooooooooooooo mmm0m000mm000 CUCAUGAAUUAGA 719 14085 Chl ooooooooooooo mm0000mm00mm0 CUGAGGUCAAUUA 720 14086 Chl ooooooooooooo 0000mm00mm000 GAGGUCAAUUAAA 721 14087 Chl ooooooooooooo mmm0000mm00mm UCUGAGGUCAAUU 722 14088 Chl ooooooooooooo m0000mm00mm00 UGAGGUCAAUUAA 723 14089 Chl ooooooooooooo mmmm0000mm00m UUCUGAGGUCAAU 724 14090 Chl ooooooooooooo 0mm00mm000m00 GUCAGCUGGAUGA 725 14091 Chl ooooooooooooo mmmm00m000mmm UUCUGAUGAAUCU 726 14092 Chl ooooooooooooo m000mm0000mm0 UGGACUGAGGUCA 727 14093 Chl ooooooooooooo 000mmmm0mm0mm GAGUCUCACCAUU 728 14094 Chl ooooooooooooo 00mm0000mm000 GACUGAGGUCAAA 729 14095 Chl ooooooooooooo mm0m00mm0m000 UCACAGCCAUGAA 730 14096 Chl ooooooooooooo 00mmmm0mm0mmm AGUCUCACCAUUC 731 14097 Chl ooooooooooooo 000m00000mm0 AAGCGGAAAGCCA 732 14098 Chl ooooooooooooo 00m00000mm00 AGCGGAAAGCCAA 733 14099 Chl ooooooooooooo 0mm0m0m000m00 ACCACAUGGAUGA 734 14100 Chl ooooooooooooo 0mm0m00mm0m0m GCCAUGACCACAU 735 14101 Chl ooooooooooooo 000mm0m00mm0m AAGCCAUGACCAC 736 14102 Chl ooooooooooooo 0m00000mm00m GCGGAAAGCCAAU 737 14103 Chl ooooooooooooo 000mmmmm0mmm AAAUUUCGUAUUU 738 14104 Chl ooooooooooooo 0mmmmm0mmmmm AUUUCGUAUUUCU 739 14105 Chl ooooooooooooo 0000mm0m00mm0 AAAGCCAUGACCA 740 14106 Chl ooooooooooooo 0m0m000m00m0m ACAUGGAUGAUAU 741 14107 Chl ooooooooooooo 0000mmmmm0mm GAAAUUUCGUAUU 742 14108 Chl ooooooooooooo 0mmmmmmm00mm GCGCCUUCUGAUU 743 14109 Chl ooooooooooooo 0mmmmmm0m000m AUUUCUCAUGAAU 744 14110 Chl ooooooooooooo mmmmm0m000m00 CUCUCAUGAAUAG 745 14111 Chl ooooooooooooo 000mmm00m000 AAGUCCAACGAAA 746 14112 Chl ooooooooooooo 0m00m00000m00 AUGAUGAGAGCAA 747 14113 Chl ooooooooooooo 0m00000mm000 GCGAGGAGUUGAA 748 14114 Chl ooooooooooooo m00mm00m00mm0 UGAUUGAUAGUCA 749 14115 Chl ooooooooooooo 000m00m0m0mmm AGAUAGUGCAUCU 750 14116 Chl ooooooooooooo 0m0m0m0mmm0mm AUGUGUAUCUAUU 751 14117 Chl ooooooooooooo mmmm0m0000000 UUCUAUAGAAGAA 752 14118 Chl ooooooooooooo mm0mmm00m00mm UUGUCCAGCAAUU 753 14119 Chl ooooooooooooo 0m0m000000m0 ACAUGGAAAGCGA 754 14120 Chl ooooooooooooo 0m00mmm000mm0 GCAGUCCAGAUUA 755 14121 Chl ooooooooooooo m00mm000m0m0m UGGUUGAAUGUGU 756 14122 Chl ooooooooooooo mm0m0000m00m UUAUGAAACGAGU 757 14123 Chl ooooooooooooo m00mmm000mm0m CAGUCCAGAUUAU 758 14124 Chl ooooooooooooo 0m0m000m0000 AUAUAAGCGGAAA 759 14125 Chl ooooooooooooo m0mm00mm000m0 UACCAGUUAAACA 760 14126 Chl ooooooooooooo m0mmm0mmmm0m0 UGUUCAUUCUAUA 761 14127 Chl ooooooooooooo mm0mm0000000 CCGACCAAGGAAA 762 14128 Chl ooooooooooooo 000m00m0m0m0m GAAUGGUGCAUAC 763 14129 Chl ooooooooooooo 0m0m00m00mm0 AUAUGAUGGCCGA 764 14130 Chl ooooooooooooo 00m00mmm000mm AGCAGUCCAGAUU 765 14132 Chl ooooooooooooo 00m0mmmm0m0m AGCAUUCCGAUGU 766 14133 Chl ooooooooooooo m00mm00000mmm UAGUCAGGAACUU 767 14134 Chl ooooooooooooo m0m0mmm00mm00 UGCAUUUAGUCAA 768 14135 Chl ooooooooooooo 0mmm00m000mmm GUCUGAUGAGUCU 769 14136 Chl ooooooooooooo m000m0m0m0m00 UAGACACAUAUGA 770 14137 Chl ooooooooooooo m000m0000m0m CAGACGAGGACAU 771 14138 Chl ooooooooooooo m00mmm000mmm CAGCCGUGAAUUC 772 14139 Chl ooooooooooooo 00mmm00000m00 AGUCUGGAAAUAA 773 14140 Chl ooooooooooooo 00mmm0m00mmmm AGUUUGUGGCUUC 774 14141 Chl ooooooooooooo 00mmm00m0000 AGUCCAACGAAAG 775 14142 Chl ooooooooooooo 000mmmmm000m AAGUUUCGCAGAC 776 14143 Chl ooooooooooooo 00m00m000m0mm AGCAAUGAGCAUU 777 14144 Chl ooooooooooooo mm000m00m0m0m UUAGAUAGUGCAU 778 14145 Chl ooooooooooooo m00m0m0m0m000 UGGUGCAUACAAG 779 14146 Chl ooooooooooooo 0m0000m00mm0 AUGAAACGAGUCA 780 14147 Chl ooooooooooooo mm0000m0mm000 CCAGAGUGCUGAA 781 14148 Chl ooooooooooooo m00mm0m000mmm CAGCCAUGAAUUU 782 14149 Chl ooooooooooooo 0mm00mm000m0m AUUGGUUGAAUGU 783 14150 Chl ooooooooooooo 00mm000m0m0m0 GGUUGAAUGUGUA 784 14151 Chl ooooooooooooo 00000m00mm00m GGAAAUAACUAAU 785 14152 Chl ooooooooooooo mm0m000m00000 UCAUGAAUAGAAA 786 14153 Chl ooooooooooooo 0mm00m00mm00 GCCAGCAACCGAA 787 14154 Chl ooooooooooooo m0mmmm0m0m0m0 CACCUCACACAUG 788 14155 Chl ooooooooooooo 00mm000m00m0m AGUUGAAUGGUGC 789 14156 Chl ooooooooooooo 00mm00mm000m0 AGUCAGCUGGAUG 790 14157 Chl ooooooooooooo m0m000m00000 UAUAAGCGGAAAG 791 14158 Chl ooooooooooooo mmmm0m0m00mm UUCCGAUGUGAUU 792 14159 Chl ooooooooooooo 0m00mm00m0m0m AUAACUAAUGUGU 793 14160 Chl ooooooooooooo mm0mmmm0m0000 UCAUUCUAUAGAA 794 14161 Chl ooooooooooooo 00mm0mm0mm0m0 AACUAUCACUGUA 795 14162 Chl ooooooooooooo 0mm00mm0mmm0m GUCAAUUGCUUAU 796 14163 Chl ooooooooooooo 00m00mm00m000 AGCAAUUAAUAAA 797 14164 Chl ooooooooooooo 0m0mmmm00m00 ACGACUCUGAUGA 798 14165 Chl ooooooooooooo m00m0m00mmm0m UAGUGUGGUUUAU 799 14166 Chl ooooooooooooo 000mm00m00m00 AAGCCAAUGAUGA 800 14167 Chl ooooooooooooo 0m00mm00000mm AUAGUCAGGAACU 801 14168 Chl ooooooooooooo 00mm00mmm000 AGUCAGCCGUGAA 802 14169 Chl ooooooooooooo 0mm0mm0m00000 ACUACCAUGAGAA 803 14170 Chl ooooooooooooo 000m000mm00mm AAACAGGCUGAUU 804 14171 Chl ooooooooooooo 000m0mm0000mm GAGUGCUGAAACC 805 14172 Chl ooooooooooooo m000m0mmmm0m UGAGCAUUCCGAU 806 14173 Chl ooooooooooooo 00mmmm0m00mm0 AAUUCCACAGCCA 807 14174 Chl ooooooooooooo m0mm00mm0mmm0 UGUCAAUUGCUUA 808 14175 Chl ooooooooooooo 0mm0m00000mm0 ACCAUGAGAAUUG 809 14176 Chl ooooooooooooo mm00m0000mm0 CCAACGAAAGCCA 810 14177 Chl ooooooooooooo mm00mm0mm00mm CUGGUCACUGAUU 811 14178 Chl ooooooooooooo m00mmm0m000mm UGGUUUAUGGACU 812 14179 Chl ooooooooooooo 00mm0000m0mm0 GACCAGAGUGCUG 813 14180 Chl ooooooooooooo 00m0m00mm00m0 GAUGUGAUUGAUA 814 14181 Chl ooooooooooooo 0mm00mmm000m GUCAGCCGUGAAU 815 14182 Chl ooooooooooooo 00m0m0m0mmm0m AAUGUGUAUCUAU 816 14183 Chl ooooooooooooo mm000mmm00000 UUGAGUCUGGAAA 817 14184 Chl ooooooooooooo 0mmm00m00mm00 GUCCAGCAAUUAA 818 14185 Chl ooooooooooooo mm00m00mm00m0 CCAGCAAUUAAUA 819 14186 Chl ooooooooooooo 00mmm00m0mm GACUCGAACGACU 820 14187 Chl ooooooooooooo 0mmm0mm00m00m ACCUGCCAGCAAC 821 o: phosphodiester; s: phosphorothioate; P: 5′ phosphorylation; 0: 2′-OH; F: 2′-fluoro; m: 2′ O-methyl; +: LNA modification. Capital letters in the sequence signify ribonucleotides, lower case letters signify deoxyribonucleotides.

TABLE 4 sd-rxRNA miRNA designs SEQ mIRNA Sequence SEQ ID sd-rxRNA SEQ sd-rxRNA mIRNA Name ID NO mature NO Antisense ID NO Sense hsa-let-7a 822 UGAGGUAGUAGGUUGUA 823 UGAGGUAGUAGG 824 AACCUACUACC MIMAT0000062 UAGUU UUGUAUAG UCA hsa-let-7a* 825 CUAUACAAUCUACUGUC 826 CUAUACAAUCUA 827 AGUAGAUUGUA MIMAT0004481 UUUC CUGUCUUU UAG hsa-let-7a-2* 828 CUGUACAGCCUCCUAGC 829 CUGUACAGCCUC 830 AGGAGGCUGUA MIMAT0010195 UUUCC CUAGCUUU CAG hsa-let-7b 831 UGAGGUAGUAGGUUGUG 832 UGAGGUAGUAGG 833 AACCUACUACC MIMAT0000063 UGGUU UUGUGUGG UCA hsa-let-7b* 834 CUAUACAACCUACUGCC 835 CUAUACAACCUA 836 AGUAGGUUGUA MIMAT0004482 UUCCC CUGCCUUC UAG hsa-let-7c 837 UGAGGUAGUAGGUUGUA 838 UGAGGUAGUAGG 839 AACCUACUACC MIMAT0000064 UGGUU UUGUAUGG UCA hsa-let-7c* 840 UAGAGUUACACCCUGGG 841 UAGAGUUACACC 842 AGGGUGUAACU MIMAT0004483 AGUUA CUGGGAGU CUA hsa-let-7d 843 AGAGGUAGUAGGUUGCA 844 AGAGGUAGUAGG 845 AACCUACUACC MIMAT0000065 UAGUU UUGCAUAG UCU hsa-let-7d* 846 CUAUACGACCUGCUGCC 847 CUAUACGACCUG 848 AGCAGGUCGUA MIMAT0004484 UUUCU CUGCCUUU UAG hsa-let-7e 849 UGAGGUAGGAGGUUGUA 850 UGAGGUAGGAGG 851 AACCUCCUACC MIMAT0000066 UAGUU UUGUAUAG UCA hsa-let-7e* 852 CUAUACGGCCUCCUAGC 853 CUAUACGGCCUC 854 AGGAGGCCGUA MIMAT0004485 UUUCC CUAGCUUU UAG hsa-let-7f 855 UGAGGUAGUAGAUUGUA 856 UGAGGUAGUAGA 857 AAUCUACUACC MIMAT0000067 UAGUU UUGUAUAG UCA hsa-let-7f-1* 858 CUAUACAAUCUAUUGCC 859 CUAUACAAUCUA 860 AAUAGAUUGUA MIMAT0004486 UUCCC UUGCCUUC UAG hsa-let-7f-2* 861 CUAUACAGUCUACUGUC 862 CUAUACAGUCUA 863 AGUAGACUGUA MIMAT0004487 UUUCC CUGUCUUU UAG hsa-let-7g 864 UGAGGUAGUAGUUUGUA 865 UGAGGUAGUAGU 866 AAACUACUACC MIMAT0000414 CAGUU UUGUACAG UCA hsa-let-7g* 867 CUGUACAGGCCACUGCC 868 CUGUACAGGCCA 869 AGUGGCCUGUA MIMAT0004584 UUGC CUGCCUUG CAG hsa-let-7i 870 UGAGGUAGUAGUUUGUG 871 UGAGGUAGUAGU 872 AAACUACUACC MIMAT0000415 CUGUU UUGUGCUG UCA hsa-let-7i* 873 CUGCGCAAGCUACUGCC 874 CUGCGCAAGCUA 875 AGUAGCUUGCG MIMAT0004585 UUGCU CUGCCUUG CAG hsa-miR-1 876 UGGAAUGUAAAGAAGUA 877 UGGAAUGUAAAG 878 UUCUUUACAUU MIMAT0000416 UGUAU AAGUAUGU CCA hsa-miR-100 879 AACCCGUAGAUCCGAAC 880 AACCCGUAGAUC 881 CGGAUCUACGG MIMAT0000098 UUGUG CGAACUUG GUU hsa-miR-100* 882 CAAGCUUGUAUCUAUAG 883 CAAGCUUGUAUC 884 UAGAUACAAGC MIMAT0004512 GUAUG UAUAGGUA UUG hsa-miR-101 885 UACAGUACUGUGAUAAC 886 UACAGUACUGUG 887 AUCACAGUACU MIMAT0000099 UGAA AUAACUGA GUA hsa-miR-101* 888 CAGUUAUCACAGUGCUG 889 CAGUUAUCACAG 890 CACUGUGAUAA MIMAT0004513 AUGCU UGCUGAUG CUG hsa-miR-103 891 AGCAGCAUUGUACAGGG 892 AGCAGCAUUGUA 893 UGUACAAUGCU MIMAT0000101 CUAUGA CAGGGCUA GCU hsa-miR-103-2* 894 AGCUUCUUUACAGUGCU 895 AGCUUCUUUACA 896 ACUGUAAAGAA MIMAT0009196 GCCUUG GUGCUGCC GCU hsa-miR-103-as 897 UCAUAGCCCUGUACAAU 898 UCAUAGCCCUGU 899 GUACAGGGCUA MIMAT0007402 GCUGCU ACAAUGCU UGA hsa-miR-105 900 UCAAAUGCUCAGACUCC 901 UCAAAUGCUCAG 902 GUCUGAGCAUU MIMAT0000102 UGUGGU ACUCCUGU UGA hsa-miR-105* 903 ACGGAUGUUUGAGCAUG 904 ACGGAUGUUUGA 905 GCUCAAACAUC MIMAT0004516 UGCUA GCAUGUGC CGU hsa-miR-106a 906 AAAAGUGCUUACAGUGC 907 AAAAGUGCUUAC 908 CUGUAAGCACU MIMAT0000103 AGGUAG AGUGCAGG UUU hsa-miR-106a* 909 CUGCAAUGUAAGCACUU 910 CUGCAAUGUAAG 911 UGCUUACAUUG MIMAT0004517 CUUAC CACUUCUU CAG hsa-miR-106b 912 UAAAGUGCUGACAGUGC 913 UAAAGUGCUGAC 914 CUGUCAGCACU MIMAT0000680 AGAU AGUGCAGA UUA hsa-miR-106b* 915 CCGCACUGUGGGUACUU 916 CCGCACUGUGGG 917 UACCCACAGUG MIMAT0004672 GCUGC UACUUGCU CGG hsa-miR-107 918 AGCAGCAUUGUACAGGG 919 AGCAGCAUUGUA 920 UGUACAAUGCU MIMAT0000104 CUAUCA CAGGGCUA GCU hsa-miR-10a 921 UACCCUGUAGAUCCGAA 922 UACCCUGUAGAU 923 GGAUCUACAGG MIMAT0000253 UUUGUG CCGAAUUU GUA hsa-miR-10a* 924 CAAAUUCGUAUCUAGGG 925 CAAAUUCGUAUC 926 UAGAUACGAAU MIMAT0004555 GAAUA UAGGGGAA UUG hsa-miR-10b 927 UACCCUGUAGAACCGAA 928 UACCCUGUAGAA 929 GGUUCUACAGG MIMAT0000254 UUUGUG CCGAAUUU GUA hsa-miR-10b* 930 ACAGAUUCGAUUCUAGG 931 ACAGAUUCGAUU 932 AGAAUCGAAUC MIMAT0004556 GGAAU CUAGGGGA UGU hsa-miR-1178 933 UUGCUCACUGUUCUUCC 934 UUGCUCACUGUU 935 AGAACAGUGAG MIMAT0005823 CUAG CUUCCCUA CAA hsa-miR-1179 936 AAGCAUUCUUUCAUUGG 937 AAGCAUUCUUUC 938 AUGAAAGAAUG MIMAT0005824 UUGG AUUGGUUG CUU hsa-miR-1180 939 UUUCCGGCUCGCGUGGG 940 UUUCCGGCUCGC 941 ACGCGAGCCGG MIMAT0005825 UGUGU GUGGGUGU AAA hsa-miR-1181 942 CCGUCGCCGCCACCCGA 943 CCGUCGCCGCCA 944 GGUGGCGGCGA MIMAT0005826 GCCG CCCGAGCC CGG hsa-miR-1182 945 GAGGGUCUUGGGAGGGA 946 GAGGGUCUUGGG 947 CUCCCAAGACC MIMAT0005827 UGUGAC AGGGAUGU CUC hsa-miR-1183 948 CACUGUAGGUGAUGGUG 949 CACUGUAGGUGA 950 CAUCACCUACA MIMAT0005828 AGAGUGGGCA UGGUGAGA GUG hsa-miR-1184 951 CCUGCAGCGACUUGAUG 952 CCUGCAGCGACU 953 CAAGUCGCUGC MIMAT0005829 GCUUCC UGAUGGCU AGG hsa-miR-1185 954 AGAGGAUACCCUUUGUA 955 AGAGGAUACCCU 956 AAAGGGUAUCC MIMAT0005798 UGUU UUGUAUGU UCU hsa-miR-1193 957 GGGAUGGUAGACCGGUG 958 GGGAUGGUAGAC 959 CGGUCUACCAU MIMAT0015049 ACGUGC CGGUGACG CCC hsa-miR-1197 960 UAGGACACAUGGUCUAC 961 UAGGACACAUGG 962 GACCAUGUGUC MIMAT0005955 UUCU UCUACUUC CUA hsa-miR-1200 963 CUCCUGAGCCAUUCUGA 964 CUCCUGAGCCAU 965 GAAUGGCUCAG MIMAT0005863 GCCUC UCUGAGCC GAG hsa-miR-1202 966 GUGCCAGCUGCAGUGGG 967 GUGCCAGCUGCA 968 ACUGCAGCUGG MIMAT0005865 GGAG GUGGGGGA CAC hsa-miR-1203 969 CCCGGAGCCAGGAUGCA 970 CCCGGAGCCAGG 971 AUCCUGGCUCC MIMAT0005866 GCUC AUGCAGCU GGG hsa-miR-1204 972 UCGUGGCCUGGUCUCCA 973 UCGUGGCCUGGU 974 AGACCAGGCCA MIMAT0005868 UUAU CUCCAUUA CGA hsa-miR-1205 975 UCUGCAGGGUUUGCUUU 976 UCUGCAGGGUUU 977 GCAAACCCUGC MIMAT0005869 GAG GCUUUGAG AGA hsa-miR-1206 978 UGUUCAUGUAGAUGUUU 979 UGUUCAUGUAGA 980 CAUCUACAUGA MIMAT0005870 AAGC UGUUUAAG ACA hsa-miR-1207- 981 UCAGCUGGCCCUCAUUU 982 UCAGCUGGCCCU 983 UGAGGGCCAGC 3p C CAUUUC UGA MIMAT0005872 hsa-miR-1207- 984 UGGCAGGGAGGCUGGGA 985 UGGCAGGGAGGC 986 CAGCCUCCCUG 5p GGGG UGGGAGGG CCA MIMAT0005871 hsa-miR-1208 987 UCACUGUUCAGACAGGC 988 UCACUGUUCAGA 989 UGUCUGAACAG MIMAT0005873 GGA CAGGCGGA UGA hsa-miR-122 990 UGGAGUGUGACAAUGGU 991 UGGAGUGUGACA 992 AUUGUCACACU MIMAT0000421 GUUUG AUGGUGUU CCA hsa-miR-122* 993 AACGCCAUUAUCACACU 994 AACGCCAUUAUC 995 GUGAUAAUGGC MIMAT0004590 AAAUA ACACUAAA GUU hsa-miR-1224- 996 CCCCACCUCCUCUCUCC 997 CCCCACCUCCUC 998 GAGAGGAGGUG 3p UCAG UCUCCUCA GGG MIMAT0005459 hsa-miR-1224- 999 GUGAGGACUCGGGAGGU 1000 GUGAGGACUCGG 1001 UCCCGAGUCCU 5p GG GAGGUGG CAC MIMAT0005458 hsa-miR-1225- 1002 UGAGCCCCUGUGCCGCC 1003 UGAGCCCCUGUG 1004 GGCACAGGGGC 3p CCCAG CCGCCCCC UCA MIMAT0005573 hsa-miR-1225- 1005 GUGGGUACGGCCCAGUG 1006 GUGGGUACGGCC 1007 UGGGCCGUACC 5p GGGGG CAGUGGGG CAC MIMAT0005572 hsa-miR-1226 1008 UCACCAGCCCUGUGUUC 1009 UCACCAGCCCUG 1010 CACAGGGCUGG MIMAT0005577 CCUAG UGUUCCCU UGA hsa-miR-1226* 1011 GUGAGGGCAUGCAGGCC 1012 GUGAGGGCAUGC 1013 CUGCAUGCCCU MIMAT0005576 UGGAUGGGG AGGCCUGG CAC hsa-miR-1227 1014 CGUGCCACCCUUUUCCC 1015 CGUGCCACCCUU 1016 AAAAGGGUGGC MIMAT0005580 CAG UUCCCCAG ACG hsa-miR-1228 1017 UCACACCUGCCUCGCCC 1018 UCACACCUGCCU 1019 CGAGGCAGGUG MIMAT0005583 CCC CGCCCCCC UGA hsa-miR-1228* 1020 GUGGGCGGGGGCAGGUG 1021 GUGGGCGGGGGC 1022 CUGCCCCCGCC MIMAT0005582 UGUG AGGUGUGU CAC hsa-miR-1229 1023 CUCUCACCACUGCCCUC 1024 CUCUCACCACUG 1025 GGCAGUGGUGA MIMAT0005584 CCACAG CCCUCCCA GAG hsa-miR-1231 1026 GUGUCUGGGCGGACAGC 1027 GUGUCUGGGCGG 1028 GUCCGCCCAGA MIMAT0005586 UGC ACAGCUGC CAC hsa-miR-1233 1029 UGAGCCCUGUCCUCCCG 1030 UGAGCCCUGUCC 1031 GAGGACAGGGC MIMAT0005588 CAG UCCCGCAG UCA hsa-miR-1234 1032 UCGGCCUGACCACCCAC 1033 UCGGCCUGACCA 1034 GGUGGUCAGGC MIMAT0005589 CCCAC CCCACCCC CGA hsa-miR-1236 1035 CCUCUUCCCCUUGUCUC 1036 CCUCUUCCCCUU 1037 ACAAGGGGAAG MIMAT0005591 UCCAG GUCUCUCC AGG hsa-miR-1237 1038 UCCUUCUGCUCCGUCCC 1039 UCCUUCUGCUCC 1040 ACGGAGCAGAA MIMAT0005592 CCAG GUCCCCCA GGA hsa-miR-1238 1041 CUUCCUCGUCUGUCUGC 1042 CUUCCUCGUCUG 1043 GACAGACGAGG MIMAT0005593 CCC UCUGCCCC AAG hsa-miR-124 1044 UAAGGCACGCGGUGAAU 1045 UAAGGCACGCGG 1046 CACCGCGUGCC MIMAT0000422 GCC UGAAUGCC UUA hsa-miR-124* 1047 CGUGUUCACAGCGGACC 1048 CGUGUUCACAGC 1049 CCGCUGUGAAC MIMAT0004591 UUGAU GGACCUUG ACG hsa-miR-1243 1050 AACUGGAUCAAUUAUAG 1051 AACUGGAUCAAU 1052 UAAUUGAUCCA MIMAT0005894 GAGUG UAUAGGAG GUU hsa-miR-1244 1053 AAGUAGUUGGUUUGUAU 1054 AAGUAGUUGGUU 1055 CAAACCAACUA MIMAT0005896 GAGAUGGUU UGUAUGAG CUU hsa-miR-1245 1056 AAGUGAUCUAAAGGCCU 1057 AAGUGAUCUAAA 1058 CCUUUAGAUCA MIMAT0005897 ACAU GGCCUACA CUU hsa-miR-1246 1059 AAUGGAUUUUUGGAGCA 1060 AAUGGAUUUUUG 1061 UCCAAAAAUCC MIMAT0005898 GG GAGCAGG AUU hsa-miR-1247 1062 ACCCGUCCCGUUCGUCC 1063 ACCCGUCCCGUU 1064 CGAACGGGACG MIMAT0005899 CCGGA CGUCCCCG GGU hsa-miR-1248 1065 ACCUUCUUGUAUAAGCA 1066 ACCUUCUUGUAU 1067 UUAUACAAGAA MIMAT0005900 CUGUGCUAAA AAGCACUG GGU hsa-miR-1249 1068 ACGCCCUUCCCCCCCUU 1069 ACGCCCUUCCCC 1070 GGGGGGAAGGG MIMAT0005901 CUUCA CCCUUCUU CGU hsa-miR-1250 1071 ACGGUGCUGGAUGUGGC 1072 ACGGUGCUGGAU 1073 ACAUCCAGCAC MIMAT0005902 CUUU GUGGCCUU CGU hsa-miR-1251 1074 ACUCUAGCUGCCAAAGG 1075 ACUCUAGCUGCC 1076 UUGGCAGCUAG MIMAT0005903 CGCU AAAGGCGC AGU hsa-miR-1252 1077 AGAAGGAAAUUGAAUUC 1078 AGAAGGAAAUUG 1079 UUCAAUUUCCU MIMAT0005944 AUUUA AAUUCAUU UCU hsa-miR-1253 1080 AGAGAAGAAGAUCAGCC 1081 AGAGAAGAAGAU 1082 UGAUCUUCUUC MIMAT0005904 UGCA CAGCCUGC UCU hsa-miR-1254 1083 AGCCUGGAAGCUGGAGC 1084 AGCCUGGAAGCU 1085 CCAGCUUCCAG MIMAT0005905 CUGCAGU GGAGCCUG GCU hsa-miR-1255a 1086 AGGAUGAGCAAAGAAAG 1087 AGGAUGAGCAAA 1088 UCUUUGCUCAU MIMAT0005906 UAGAUU GAAAGUAG CCU hsa-miR-1255b 1089 CGGAUGAGCAAAGAAAG 1090 CGGAUGAGCAAA 1091 UCUUUGCUCAU MIMAT0005945 UGGUU GAAAGUGG CCG hsa-miR-1256 1092 AGGCAUUGACUUCUCAC 1093 AGGCAUUGACUU 1094 AGAAGUCAAUG MIMAT0005907 UAGCU CUCACUAG CCU hsa-miR-1257 1095 AGUGAAUGAUGGGUUCU 1096 AGUGAAUGAUGG 1097 ACCCAUCAUUC MIMAT0005908 GACC GUUCUGAC ACU hsa-miR-1258 1098 AGUUAGGAUUAGGUCGU 1099 AGUUAGGAUUAG 1100 ACCUAAUCCUA MIMAT0005909 GGAA GUCGUGGA ACU hsa-miR-125a- 1101 ACAGGUGAGGUUCUUGG 1102 ACAGGUGAGGUU 1103 AGAACCUCACC 3p GAGCC CUUGGGAG UGU MIMAT0004602 hsa-miR-125a- 1104 UCCCUGAGACCCUUUAA 1105 UCCCUGAGACCC 1106 AAGGGUCUCAG 5p CCUGUGA UUUAACCU GGA MIMAT0000443 hsa-miR-125b 1107 UCCCUGAGACCCUAACU 1108 UCCCUGAGACCC 1109 UAGGGUCUCAG MIMAT0000423 UGUGA UAACUUGU GGA hsa-miR-125b- 1110 ACGGGUUAGGCUCUUGG 1111 ACGGGUUAGGCU 1112 AGAGCCUAACC 1* GAGCU CUUGGGAG CGU MIMAT0004592 hsa-miR-125b- 1113 UCACAAGUCAGGCUCUU 1114 UCACAAGUCAGG 1115 AGCCUGACUUG 2* GGGAC CUCUUGGG UGA MIMAT0004603 hsa-miR-126 1116 UCGUACCGUGAGUAAUA 1117 UCGUACCGUGAG 1118 UACUCACGGUA MIMAT0000445 AUGCG UAAUAAUG CGA hsa-miR-126* 1119 CAUUAUUACUUUUGGUA 1120 CAUUAUUACUUU 1121 CAAAAGUAAUA MIMAT0000444 CGCG UGGUACGC AUG hsa-miR-1260 1122 AUCCCACCUCUGCCACC 1123 AUCCCACCUCUG 1124 GGCAGAGGUGG MIMAT0005911 A CCACCA GAU hsa-miR-1260b 1125 AUCCCACCACUGCCACC 1126 AUCCCACCACUG 1127 GGCAGUGGUGG MIMAT0015041 AU CCACCAU GAU hsa-miR-1261 1128 AUGGAUAAGGCUUUGGC 1129 AUGGAUAAGGCU 1130 AAAGCCUUAUC MIMAT0005913 UU UUGGCUU CAU hsa-miR-1262 1131 AUGGGUGAAUUUGUAGA 1132 AUGGGUGAAUUU 1133 ACAAAUUCACC MIMAT0005914 AGGAU GUAGAAGG CAU hsa-miR-1263 1134 AUGGUACCCUGGCAUAC 1135 AUGGUACCCUGG 1136 UGCCAGGGUAC MIMAT0005915 UGAGU CAUACUGA CAU hsa-miR-1264 1137 CAAGUCUUAUUUGAGCA 1138 CAAGUCUUAUUU 1139 UCAAAUAAGAC MIMAT0005791 CCUGUU GAGCACCU UUG hsa-miR-1265 1140 CAGGAUGUGGUCAAGUG 1141 CAGGAUGUGGUC 1142 UUGACCACAUC MIMAT0005918 UUGUU AAGUGUUG CUG hsa-miR-1266 1143 CCUCAGGGCUGUAGAAC 1144 CCUCAGGGCUGU 1145 CUACAGCCCUG MIMAT0005920 AGGGCU AGAACAGG AGG hsa-miR-1267 1146 CCUGUUGAAGUGUAAUC 1147 CCUGUUGAAGUG 1148 UACACUUCAAC MIMAT0005921 CCCA UAAUCCCC AGG hsa-miR-1268 1149 CGGGCGUGGUGGUGGGG 1150 CGGGCGUGGUGG 1151 CACCACCACGC MIMAT0005922 G UGGGGG CCG hsa-miR-1269 1152 CUGGACUGAGCCGUGCU 1153 CUGGACUGAGCC 1154 ACGGCUCAGUC MIMAT0005923 ACUGG GUGCUACU CAG hsa-miR-1270 1155 CUGGAGAUAUGGAAGAG 1156 CUGGAGAUAUGG 1157 UUCCAUAUCUC MIMAT0005924 CUGUGU AAGAGCUG CAG hsa-miR-1271 1158 CUUGGCACCUAGCAAGC 1159 CUUGGCACCUAG 1160 UGCUAGGUGCC MIMAT0005796 ACUCA CAAGCACU AAG hsa-miR-1272 1161 GAUGAUGAUGGCAGCAA 1162 GAUGAUGAUGGC 1163 CUGCCAUCAUC MIMAT0005925 AUUCUGAAA AGCAAAUU AUC hsa-miR-1273 1164 GGGCGACAAAGCAAGAC 1165 GGGCGACAAAGC 1166 UUGCUUUGUCG MIMAT0005926 UCUUUCUU AAGACUCU CCC hsa-miR-1273c 1167 GGCGACAAAACGAGACC 1168 GGCGACAAAACG 1169 CUCGUUUUGUC MIMAT0015017 CUGUC AGACCCUG GCC hsa-miR-1273d 1170 GAACCCAUGAGGUUGAG 1171 GAACCCAUGAGG 1172 AACCUCAUGGG MIMAT0015090 GCUGCAGU UUGAGGCU UUC hsa-miR-1273e 1173 UUGCUUGAACCCAGGAA 1174 UUGCUUGAACCC 1175 CUGGGUUCAAG MIMAT0018079 GUGGA AGGAAGUG CAA hsa-miR-127-3p 1176 UCGGAUCCGUCUGAGCU 1177 UCGGAUCCGUCU 1178 UCAGACGGAUC MIMAT0000446 UGGCU GAGCUUGG CGA hsa-miR-1274a 1179 GUCCCUGUUCAGGCGCC 1180 GUCCCUGUUCAG 1181 GCCUGAACAGG MIMAT0005927 A GCGCCA GAC hsa-miR-1274b 1182 UCCCUGUUCGGGCGCCA 1183 UCCCUGUUCGGG 1184 CGCCCGAACAG MIMAT0005938 CGCCA GGA hsa-miR-1275 1185 GUGGGGGAGAGGCUGUC 1186 GUGGGGGAGAGG 1187 AGCCUCUCCCC MIMAT0005929 CUGUC CAC hsa-miR-127-5p 1188 CUGAAGCUCAGAGGGCU 1189 CUGAAGCUCAGA 1190 CCUCUGAGCUU MIMAT0004604 CUGAU GGGCUCUG CAG hsa-miR-1276 1191 UAAAGAGCCCUGUGGAG 1192 UAAAGAGCCCUG 1193 CACAGGGCUCU MIMAT0005930 ACA UGGAGACA UUA hsa-miR-1277 1194 UACGUAGAUAUAUAUGU 1195 UACGUAGAUAUA 1196 UAUAUAUCUAC MIMAT0005933 AUUUU UAUGUAUU GUA hsa-miR-1278 1197 UAGUACUGUGCAUAUCA 1198 UAGUACUGUGCA 1199 UAUGCACAGUA MIMAT0005936 UCUAU UAUCAUCU CUA hsa-miR-1279 1200 UCAUAUUGCUUCUUUCU 1201 UCAUAUUGCUUC 1202 AAGAAGCAAUA MIMAT0005937 UUUCU UGA hsa-miR-128 1203 UCACAGUGAACCGGUCU 1204 UCACAGUGAACC 1205 CCGGUUCACUG MIMAT0000424 CUUU GGUCUCUU UGA hsa-miR-1280 1206 UCCCACCGCUGCCACCC 1207 UCCCACCGCUGC 1208 UGGCAGCGGUG MIMAT0005946 CACCC GGA hsa-miR-1281 1209 UCGCCUCCUCCUCUCCC 1210 UCGCCUCCUCCU 1211 AGAGGAGGAGG MIMAT0005939 CUCCC CGA hsa-miR-1282 1212 UCGUUUGCCUUUUUCUG 1213 UCGUUUGCCUUU 1214 AAAAAGGCAAA MIMAT0005940 CUU UUCUGCUU CGA hsa-miR-1283 1215 UCUACAAAGGAAAGCGC 1216 UCUACAAAGGAA 1217 CUUUCCUUUGU MIMAT0005799 UUUCU AGCGCUUU AGA hsa-miR-1284 1218 UCUAUACAGACCCUGGC 1219 UCUAUACAGACC 1220 AGGGUCUGUAU MIMAT0005941 UUUUC CUGGCUUU AGA hsa-miR-1285 1221 UCUGGGCAACAAAGUGA 1222 UCUGGGCAACAA 1223 CUUUGUUGCCC MIMAT0005876 GACCU AGUGAGAC AGA hsa-miR-1286 1224 UGCAGGACCAAGAUGAG 1225 UGCAGGACCAAG 1226 AUCUUGGUCCU MIMAT0005877 CCCU AUGAGCCC GCA hsa-miR-1287 1227 UGCUGGAUCAGUGGUUC 1228 UGCUGGAUCAGU 1229 CCACUGAUCCA MIMAT0005878 GAGUC GGUUCGAG GCA hsa-miR-1288 1230 UGGACUGCCCUGAUCUG 1231 UGGACUGCCCUG 1232 AUCAGGGCAGU MIMAT0005942 GAGA AUCUGGAG CCA hsa-miR-1289 1233 UGGAGUCCAGGAAUCUG 1234 UGGAGUCCAGGA 1235 AUUCCUGGACU MIMAT0005879 CAUUUU AUCUGCAU CCA hsa-miR-129* 1236 AAGCCCUUACCCCAAAA 1237 AAGCCCUUACCC 1238 UGGGGUAAGGG MIMAT0004548 AGUAU CAAAAAGU CUU hsa-miR-1290 1239 UGGAUUUUUGGAUCAGG 1240 UGGAUUUUUGGA 1241 GAUCCAAAAAU MIMAT0005880 GA UCAGGGA CCA hsa-miR-1291 1242 UGGCCCUGACUGAAGAC 1243 UGGCCCUGACUG 1244 UUCAGUCAGGG MIMAT0005881 CAGCAGU AAGACCAG CCA hsa-miR-1292 1245 UGGGAACGGGUUCCGGC 1246 UGGGAACGGGUU 1247 GGAACCCGUUC MIMAT0005943 AGACGCUG CCGGCAGA CCA hsa-miR-1293 1248 UGGGUGGUCUGGAGAUU 1249 UGGGUGGUCUGG 1250 CUCCAGACCAC MIMAT0005883 UGUGC AGAUUUGU CCA hsa-miR-129-3p 1251 AAGCCCUUACCCCAAAA 1252 AAGCCCUUACCC 1253 UGGGGUAAGGG MIMAT0004605 AGCAU CAAAAAGC CUU hsa-miR-1294 1254 UGUGAGGUUGGCAUUGU 1255 UGUGAGGUUGGC 1256 AUGCCAACCUC MIMAT0005884 UGUCU AUUGUUGU ACA hsa-miR-1295 1257 UUAGGCCGCAGAUCUGG 1258 UUAGGCCGCAGA 1259 GAUCUGCGGCC MIMAT0005885 GUGA UCUGGGUG UAA hsa-miR-129-5p 1260 CUUUUUGCGGUCUGGGC 1261 CUUUUUGCGGUC 1262 CAGACCGCAAA MIMAT0000242 UUGC UGGGCUUG AAG hsa-miR-1296 1263 UUAGGGCCCUGGCUCCA 1264 UUAGGGCCCUGG 1265 AGCCAGGGCCC MIMAT0005794 UCUCC CUCCAUCU UAA hsa-miR-1297 1266 UUCAAGUAAUUCAGGUG 1267 UUCAAGUAAUUC 1268 CUGAAUUACUU MIMAT0005886 AGGUG GAA hsa-miR-1298 1269 UUCAUUCGGCUGUCCAG 1270 UUCAUUCGGCUG 1271 GACAGCCGAAU MIMAT0005800 AUGUA UCCAGAUG GAA hsa-miR-1299 1272 UUCUGGAAUUCUGUGUG 1273 UUCUGGAAUUCU 1274 ACAGAAUUCCA MIMAT0005887 AGGGA GUGUGAGG GAA hsa-miR-1301 1275 UUGCAGCUGCCUGGGAG 1276 UUGCAGCUGCCU 1277 CCAGGCAGCUG MIMAT0005797 UGACUUC GGGAGUGA CAA hsa-miR-1302 1278 UUGGGACAUACUUAUGC 1279 UUGGGACAUACU 1280 UAAGUAUGUCC MIMAT0005890 UAAA UAUGCUAA CAA hsa-miR-1303 1281 UUUAGAGACGGGGUCUU 1282 UUUAGAGACGGG 1283 ACCCCGUCUCU MIMAT0005891 GCUCU GUCUUGCU AAA hsa-miR-1304 1284 UUUGAGGCUACAGUGAG 1285 UUUGAGGCUACA 1286 ACUGUAGCCUC MIMAT0005892 AUGUG GUGAGAUG AAA hsa-miR-1305 1287 UUUUCAACUCUAAUGGG 1288 UUUUCAACUCUA 1289 AUUAGAGUUGA MIMAT0005893 AGAGA AUGGGAGA AAA hsa-miR-1306 1290 ACGUUGGCUCUGGUGGU 1291 ACGUUGGCUCUG 1292 ACCAGAGCCAA MIMAT0005950 G GUGGUG CGU hsa-miR-1307 1293 ACUCGGCGUGGCGUCGG 1294 ACUCGGCGUGGC 1295 ACGCCACGCCG MIMAT0005951 UCGUG GUCGGUCG AGU hsa-miR-130a 1296 CAGUGCAAUGUUAAAAG 1297 CAGUGCAAUGUU 1298 UUAACAUUGCA MIMAT0000425 GGCAU AAAAGGGC CUG hsa-miR-130a* 1299 UUCACAUUGUGCUACUG 1300 UUCACAUUGUGC 1301 UAGCACAAUGU MIMAT0004593 UCUGC UACUGUCU GAA hsa-miR-130b 1302 CAGUGCAAUGAUGAAAG 1303 CAGUGCAAUGAU 1304 UCAUCAUUGCA MIMAT0000691 GGCAU GAAAGGGC CUG hsa-miR-130b* 1305 ACUCUUUCCCUGUUGCA 1306 ACUCUUUCCCUG 1307 AACAGGGAAAG MIMAT0004680 CUAC UUGCACUA AGU hsa-miR-132 1308 UAACAGUCUACAGCCAU 1309 UAACAGUCUACA 1310 GCUGUAGACUG MIMAT0000426 GGUCG GCCAUGGU UUA hsa-miR-132* 1311 ACCGUGGCUUUCGAUUG 1312 ACCGUGGCUUUC 1313 UCGAAAGCCAC MIMAT0004594 UUACU GAUUGUUA GGU hsa-miR-1321 1314 CAGGGAGGUGAAUGUGA 1315 CAGGGAGGUGAA 1316 CAUUCACCUCC MIMAT0005952 U UGUGAU CUG hsa-miR-1322 1317 GAUGAUGCUGCUGAUGC 1318 GAUGAUGCUGCU 1319 UCAGCAGCAUC MIMAT0005953 UG GAUGCUG AUC hsa-miR-1323 1320 UCAAAACUGAGGGGCAU 1321 UCAAAACUGAGG 1322 CCCCUCAGUUU MIMAT0005795 UUUCU GGCAUUUU UGA hsa-miR-1324 1323 CCAGACAGAAUUCUAUG 1324 CCAGACAGAAUU 1325 AGAAUUCUGUC MIMAT0005956 CACUUUC CUAUGCAC UGG hsa-miR-133a 1326 UUUGGUCCCCUUCAACC 1327 UUUGGUCCCCUU 1328 UGAAGGGGACC MIMAT0000427 AGCUG CAACCAGC AAA hsa-miR-133b 1329 UUUGGUCCCCUUCAACC 1330 UUUGGUCCCCUU 1331 UGAAGGGGACC MIMAT0000770 AGCUA CAACCAGC AAA hsa-miR-134 1332 UGUGACUGGUUGACCAG 1333 UGUGACUGGUUG 1334 GUCAACCAGUC MIMAT0000447 AGGGG ACCAGAGG ACA hsa-miR-135a 1335 UAUGGCUUUUUAUUCCU 1336 UAUGGCUUUUUA 1337 AAUAAAAAGCC MIMAT0000428 AUGUGA UUCCUAUG AUA hsa-miR-135a* 1338 UAUAGGGAUUGGAGCCG 1339 UAUAGGGAUUGG 1340 CUCCAAUCCCU MIMAT0004595 UGGCG AGCCGUGG AUA hsa-miR-135b 1341 UAUGGCUUUUCAUUCCU 1342 UAUGGCUUUUCA 1343 AAUGAAAAGCC MIMAT0000758 AUGUGA UUCCUAUG AUA hsa-miR-135b* 1344 AUGUAGGGCUAAAAGCC 1345 AUGUAGGGCUAA 1346 UUUUAGCCCUA MIMAT0004698 AUGGG AAGCCAUG CAU hsa-miR-136 1347 ACUCCAUUUGUUUUGAU 1348 ACUCCAUUUGUU 1349 AAAACAAAUGG MIMAT0000448 GAUGGA UUGAUGAU AGU hsa-miR-136* 1350 CAUCAUCGUCUCAAAUG 1351 CAUCAUCGUCUC 1352 UUGAGACGAUG MIMAT0004606 AGUCU AAAUGAGU AUG hsa-miR-137 1353 UUAUUGCUUAAGAAUAC 1354 UUAUUGCUUAAG 1355 UUCUUAAGCAA MIMAT0000429 GCGUAG AAUACGCG UAA hsa-miR-138 1356 AGCUGGUGUUGUGAAUC 1357 AGCUGGUGUUGU 1358 UCACAACACCA MIMAT0000430 AGGCCG GAAUCAGG GCU hsa-miR-138-1* 1359 GCUACUUCACAACACCA 1360 GCUACUUCACAA 1361 UGUUGUGAAGU MIMAT0004607 GGGCC CACCAGGG AGC hsa-miR-138-2* 1362 GCUAUUUCACGACACCA 1363 GCUAUUUCACGA 1364 UGUCGUGAAAU MIMAT0004596 GGGUU CACCAGGG AGC hsa-miR-139-3p 1365 GGAGACGCGGCCCUGUU 1366 GGAGACGCGGCC 1367 AGGGCCGCGUC MIMAT0004552 GGAGU CUGUUGGA UCC hsa-miR-139-5p 1368 UCUACAGUGCACGUGUC 1369 UCUACAGUGCAC 1370 ACGUGCACUGU MIMAT0000250 UCCAG GUGUCUCC AGA hsa-miR-140-3p 1371 UACCACAGGGUAGAACC 1372 UACCACAGGGUA 1373 UCUACCCUGUG MIMAT0004597 ACGG GAACCACG GUA hsa-miR-140-5p 1374 CAGUGGUUUUACCCUAU 1375 CAGUGGUUUUAC 1376 GGGUAAAACCA MIMAT0000431 GGUAG CCUAUGGU CUG hsa-miR-141 1377 UAACACUGUCUGGUAAA 1378 UAACACUGUCUG 1379 ACCAGACAGUG MIMAT0000432 GAUGG GUAAAGAU UUA hsa-miR-141* 1380 CAUCUUCCAGUACAGUG 1381 CAUCUUCCAGUA 1382 UGUACUGGAAG MIMAT0004598 UUGGA CAGUGUUG AUG hsa-miR-142-3p 1383 UGUAGUGUUUCCUACUU 1384 UGUAGUGUUUCC 1385 UAGGAAACACU MIMAT0000434 UAUGGA UACUUUAU ACA hsa-miR-142-5p 1386 CAUAAAGUAGAAAGCAC 1387 CAUAAAGUAGAA 1388 CUUUCUACUUU MIMAT0000433 UACU AGCACUAC AUG hsa-miR-143 1389 UGAGAUGAAGCACUGUA 1390 UGAGAUGAAGCA 1391 AGUGCUUCAUC MIMAT0000435 GCUC CUGUAGCU UCA hsa-miR-143* 1392 GGUGCAGUGCUGCAUCU 1393 GGUGCAGUGCUG 1394 UGCAGCACUGC MIMAT0004599 CUGGU CAUCUCUG ACC hsa-miR-144 1395 UACAGUAUAGAUGAUGU 1396 UACAGUAUAGAU 1397 UCAUCUAUACU MIMAT0000436 ACU GAUGUACU GUA hsa-miR-144* 1398 GGAUAUCAUCAUAUACU 1399 GGAUAUCAUCAU 1400 AUAUGAUGAUA MIMAT0004600 GUAAG AUACUGUA UCC hsa-miR-145 1401 GUCCAGUUUUCCCAGGA 1402 GUCCAGUUUUCC 1403 UGGGAAAACUG MIMAT0000437 AUCCCU CAGGAAUC GAC hsa-miR-145* 1404 GGAUUCCUGGAAAUACU 1405 GGAUUCCUGGAA 1406 AUUUCCAGGAA MIMAT0004601 GUUCU AUACUGUU UCC hsa-miR-1468 1407 CUCCGUUUGCCUGUUUC 1408 CUCCGUUUGCCU 1409 ACAGGCAAACG MIMAT0006789 GCUG GUUUCGCU GAG hsa-miR-1469 1410 CUCGGCGCGGGGCGCGG 1411 CUCGGCGCGGGG 1412 CGCCCCGCGCC MIMAT0007347 GCUCC CGCGGGCU GAG hsa-miR-146a 1413 UGAGAACUGAAUUCCAU 1414 UGAGAACUGAAU 1415 GAAUUCAGUUC MIMAT0000449 GGGUU UCCAUGGG UCA hsa-miR-146a* 1416 CCUCUGAAAUUCAGUUC 1417 CCUCUGAAAUUC 1418 CUGAAUUUCAG MIMAT0004608 UUCAG AGUUCUUC AGG hsa-miR-146b- 1419 UGCCCUGUGGACUCAGU 1420 UGCCCUGUGGAC 1421 GAGUCCACAGG 3p UCUGG UCAGUUCU GCA MIMAT0004766 hsa-miR-146b- 1422 UGAGAACUGAAUUCCAU 1423 UGAGAACUGAAU 1424 GAAUUCAGUUC 5p AGGCU UCCAUAGG UCA MIMAT0002809 hsa-miR-147 1425 GUGUGUGGAAAUGCUUC 1426 GUGUGUGGAAAU 1427 GCAUUUCCACA MIMAT0000251 UGC GCUUCUGC CAC hsa-miR-1470 1428 GCCCUCCGCCCGUGCAC 1429 GCCCUCCGCCCG 1430 CACGGGCGGAG MIMAT0007348 CCCG UGCACCCC GGC hsa-miR-1471 1431 GCCCGCGUGUGGAGCCA 1432 GCCCGCGUGUGG 1433 CUCCACACGCG MIMAT0007349 GGUGU AGCCAGGU GGC hsa-miR-147b 1434 GUGUGCGGAAAUGCUUC 1435 GUGUGCGGAAAU 1436 GCAUUUCCGCA MIMAT0004928 UGCUA GCUUCUGC CAC hsa-miR-148a 1437 UCAGUGCACUACAGAAC 1438 UCAGUGCACUAC 1439 CUGUAGUGCAC MIMAT0000243 UUUGU AGAACUUU UGA hsa-miR-148a* 1440 AAAGUUCUGAGACACUC 1441 AAAGUUCUGAGA 1442 UGUCUCAGAAC MIMAT0004549 CGACU CACUCCGA UUU hsa-miR-148b 1443 UCAGUGCAUCACAGAAC 1444 UCAGUGCAUCAC 1445 CUGUGAUGCAC MIMAT0000759 UUUGU AGAACUUU UGA hsa-miR-148b* 1446 AAGUUCUGUUAUACACU 1447 AAGUUCUGUUAU 1448 GUAUAACAGAA MIMAT0004699 CAGGC ACACUCAG CUU hsa-miR-149 1449 UCUGGCUCCGUGUCUUC 1450 UCUGGCUCCGUG 1451 GACACGGAGCC MIMAT0000450 ACUCCC UCUUCACU AGA hsa-miR-149* 1452 AGGGAGGGACGGGGGCU 1453 AGGGAGGGACGG 1454 CCCCGUCCCUC MIMAT0004609 GUGC GGGCUGUG CCU hsa-miR-150 1455 UCUCCCAACCCUUGUAC 1456 UCUCCCAACCCU 1457 CAAGGGUUGGG MIMAT0000451 CAGUG UGUACCAG AGA hsa-miR-150* 1458 CUGGUACAGGCCUGGGG 1459 CUGGUACAGGCC 1460 CAGGCCUGUAC MIMAT0004610 GACAG UGGGGGAC CAG hsa-miR-151-3p 1461 CUAGACUGAAGCUCCUU 1462 CUAGACUGAAGC 1463 GAGCUUCAGUC MIMAT0000757 GAGG UCCUUGAG UAG hsa-miR-151-5p 1464 UCGAGGAGCUCACAGUC 1465 UCGAGGAGCUCA 1466 UGUGAGCUCCU MIMAT0004697 UAGU CAGUCUAG CGA hsa-miR-152 1467 UCAGUGCAUGACAGAAC 1468 UCAGUGCAUGAC 1469 CUGUCAUGCAC MIMAT0000438 UUGG AGAACUUG UGA hsa-miR-153 1470 UUGCAUAGUCACAAAAG 1471 UUGCAUAGUCAC 1472 UUGUGACUAUG MIMAT0000439 UGAUC AAAAGUGA CAA hsa-miR-1537 1473 AAAACCGUCUAGUUACA 1474 AAAACCGUCUAG 1475 AACUAGACGGU MIMAT0007399 GUUGU UUACAGUU UUU hsa-miR-1538 1476 CGGCCCGGGCUGCUGCU 1477 CGGCCCGGGCUG 1478 AGCAGCCCGGG MIMAT0007400 GUUCCU CUGCUGUU CCG hsa-miR-1539 1479 UCCUGCGCGUCCCAGAU 1480 UCCUGCGCGUCC 1481 UGGGACGCGCA MIMAT0007401 GCCC CAGAUGCC GGA hsa-miR-154 1482 UAGGUUAUCCGUGUUGC 1483 UAGGUUAUCCGU 1484 ACACGGAUAAC MIMAT0000452 CUUCG GUUGCCUU CUA hsa-miR-154* 1485 AAUCAUACACGGUUGAC 1486 AAUCAUACACGG 1487 AACCGUGUAUG MIMAT0000453 CUAUU UUGACCUA AUU hsa-miR-155 1488 UUAAUGCUAAUCGUGAU 1489 UUAAUGCUAAUC 1490 ACGAUUAGCAU MIMAT0000646 AGGGGU GUGAUAGG UAA hsa-miR-155* 1491 CUCCUACAUAUUAGCAU 1492 CUCCUACAUAUU 1493 CUAAUAUGUAG MIMAT0004658 UAACA AGCAUUAA GAG hsa-miR-15a 1494 UAGCAGCACAUAAUGGU 1495 UAGCAGCACAUA 1496 AUUAUGUGCUG MIMAT0000068 UUGUG AUGGUUUG CUA hsa-miR-15a* 1497 CAGGCCAUAUUGUGCUG 1498 CAGGCCAUAUUG 1499 CACAAUAUGGC MIMAT0004488 CCUCA UGCUGCCU CUG hsa-miR-15b 1500 UAGCAGCACAUCAUGGU 1501 UAGCAGCACAUC 1502 AUGAUGUGCUG MIMAT0000417 UUACA AUGGUUUA CUA hsa-miR-15b* 1503 CGAAUCAUUAUUUGCUG 1504 CGAAUCAUUAUU 1505 CAAAUAAUGAU MIMAT0004586 CUCUA UGCUGCUC UCG hsa-miR-16 1506 UAGCAGCACGUAAAUAU 1507 UAGCAGCACGUA 1508 UUUACGUGCUG MIMAT0000069 UGGCG AAUAUUGG CUA hsa-miR-16-1* 1509 CCAGUAUUAACUGUGCU 1510 CCAGUAUUAACU 1511 ACAGUUAAUAC MIMAT0004489 GCUGA GUGCUGCU UGG hsa-miR-16-2* 1512 CCAAUAUUACUGUGCUG 1513 CCAAUAUUACUG 1514 CACAGUAAUAU MIMAT0004518 CUUUA UGCUGCUU UGG hsa-miR-17 1515 CAAAGUGCUUACAGUGC 1516 CAAAGUGCUUAC 1517 CUGUAAGCACU MIMAT0000070 AGGUAG AGUGCAGG UUG hsa-miR-17* 1518 ACUGCAGUGAAGGCACU 1519 ACUGCAGUGAAG 1520 GCCUUCACUGC MIMAT0000071 UGUAG GCACUUGU AGU hsa-miR-181a 1521 AACAUUCAACGCUGUCG 1522 AACAUUCAACGC 1523 CAGCGUUGAAU MIMAT0000256 GUGAGU UGUCGGUG GUU hsa-miR-181a* 1524 ACCAUCGACCGUUGAUU 1525 ACCAUCGACCGU 1526 CAACGGUCGAU MIMAT0000270 GUACC UGAUUGUA GGU hsa-miR-181a- 1527 ACCACUGACCGUUGACU 1528 ACCACUGACCGU 1529 CAACGGUCAGU 2* GUACC UGACUGUA GGU MIMAT0004558 hsa-miR-181b 1530 AACAUUCAUUGCUGUCG 1531 AACAUUCAUUGC 1532 CAGCAAUGAAU MIMAT0000257 GUGGGU UGUCGGUG GUU hsa-miR-181c 1533 AACAUUCAACCUGUCGG 1534 AACAUUCAACCU 1535 ACAGGUUGAAU MIMAT0000258 UGAGU GUCGGUGA GUU hsa-miR-181c* 1536 AACCAUCGACCGUUGAG 1537 AACCAUCGACCG 1538 AACGGUCGAUG MIMAT0004559 UGGAC UUGAGUGG GUU hsa-miR-181d 1539 AACAUUCAUUGUUGUCG 1540 AACAUUCAUUGU 1541 CAACAAUGAAU MIMAT0002821 GUGGGU UGUCGGUG GUU hsa-miR-182 1542 UUUGGCAAUGGUAGAAC 1543 UUUGGCAAUGGU 1544 CUACCAUUGCC MIMAT0000259 UCACACU AGAACUCA AAA hsa-miR-182* 1545 UGGUUCUAGACUUGCCA 1546 UGGUUCUAGACU 1547 CAAGUCUAGAA MIMAT0000260 ACUA UGCCAACU CCA hsa-miR-1825 1548 UCCAGUGCCCUCCUCUC 1549 UCCAGUGCCCUC 1550 AGGAGGGCACU MIMAT0006765 C CUCUCC GGA hsa-miR-1827 1551 UGAGGCAGUAGAUUGAA 1552 UGAGGCAGUAGA 1553 AAUCUACUGCC MIMAT0006767 U UUGAAU UCA hsa-miR-183 1554 UAUGGCACUGGUAGAAU 1555 UAUGGCACUGGU 1556 CUACCAGUGCC MIMAT0000261 UCACU AGAAUUCA AUA hsa-miR-183* 1557 GUGAAUUACCGAAGGGC 1558 GUGAAUUACCGA 1559 CUUCGGUAAUU MIMAT0004560 CAUAA AGGGCCAU CAC hsa-miR-184 1560 UGGACGGAGAACUGAUA 1561 UGGACGGAGAAC 1562 CAGUUCUCCGU MIMAT0000454 AGGGU UGAUAAGG CCA hsa-miR-185 1563 UGGAGAGAAAGGCAGUU 1564 UGGAGAGAAAGG 1565 UGCCUUUCUCU MIMAT0000455 CCUGA CAGUUCCU CCA hsa-miR-185* 1566 AGGGGCUGGCUUUCCUC 1567 AGGGGCUGGCUU 1568 GAAAGCCAGCC MIMAT0004611 UGGUC UCCUCUGG CCU hsa-miR-186 1569 CAAAGAAUUCUCCUUUU 1570 CAAAGAAUUCUC 1571 AGGAGAAUUCU MIMAT0000456 GGGCU CUUUUGGG UUG hsa-miR-186* 1572 GCCCAAAGGUGAAUUUU 1573 GCCCAAAGGUGA 1574 AUUCACCUUUG MIMAT0004612 UUGGG AUUUUUUG GGC hsa-miR-187 1575 UCGUGUCUUGUGUUGCA 1576 UCGUGUCUUGUG 1577 AACACAAGACA MIMAT0000262 GCCGG UUGCAGCC CGA hsa-miR-187* 1578 GGCUACAACACAGGACC 1579 GGCUACAACACA 1580 CCUGUGUUGUA MIMAT0004561 CGGGC GGACCCGG GCC hsa-miR-188-3p 1581 CUCCCACAUGCAGGGUU 1582 CUCCCACAUGCA 1583 CCUGCAUGUGG MIMAT0004613 UGCA GGGUUUGC GAG hsa-miR-188-5p 1584 CAUCCCUUGCAUGGUGG 1585 CAUCCCUUGCAU 1586 CCAUGCAAGGG MIMAT0000457 AGGG GGUGGAGG AUG hsa-miR-18a 1587 UAAGGUGCAUCUAGUGC 1588 UAAGGUGCAUCU 1589 CUAGAUGCACC MIMAT0000072 AGAUAG AGUGCAGA UUA hsa-miR-18a* 1590 ACUGCCCUAAGUGCUCC 1591 ACUGCCCUAAGU 1592 GCACUUAGGGC MIMAT0002891 UUCUGG GCUCCUUC AGU hsa-miR-18b 1593 UAAGGUGCAUCUAGUGC 1594 UAAGGUGCAUCU 1595 CUAGAUGCACC MIMAT0001412 AGUUAG AGUGCAGU UUA hsa-miR-18b* 1596 UGCCCUAAAUGCCCCUU 1597 UGCCCUAAAUGC 1598 GGGCAUUUAGG MIMAT0004751 CUGGC CCCUUCUG GCA hsa-miR-190 1599 UGAUAUGUUUGAUAUAU 1600 UGAUAUGUUUGA 1601 UAUCAAACAUA MIMAT0000458 UAGGU UAUAUUAG UCA hsa-miR-1908 1602 CGGCGGGGACGGCGAUU 1603 CGGCGGGGACGG 1604 CGCCGUCCCCG MIMAT0007881 GGUC CGAUUGGU CCG hsa-miR-1909 1605 CGCAGGGGCCGGGUGCU 1606 CGCAGGGGCCGG 1607 ACCCGGCCCCU MIMAT0007883 CACCG GUGCUCAC GCG hsa-miR-1909* 1608 UGAGUGCCGGUGCCUGC 1609 UGAGUGCCGGUG 1610 GGCACCGGCAC MIMAT0007882 CCUG CCUGCCCU UCA hsa-miR-190b 1611 UGAUAUGUUUGAUAUUG 1612 UGAUAUGUUUGA 1613 UAUCAAACAUA MIMAT0004929 GGUU UAUUGGGU UCA hsa-miR-191 1614 CAACGGAAUCCCAAAAG 1615 CAACGGAAUCCC 1616 UUGGGAUUCCG MIMAT0000440 CAGCUG AAAAGCAG UUG hsa-miR-191* 1617 GCUGCGCUUGGAUUUCG 1618 GCUGCGCUUGGA 1619 AAUCCAAGCGC MIMAT0001618 UCCCC UUUCGUCC AGC hsa-miR-1910 1620 CCAGUCCUGUGCCUGCC 1621 CCAGUCCUGUGC 1622 AGGCACAGGAC MIMAT0007884 GCCU CUGCCGCC UGG hsa-miR-1911 1623 UGAGUACCGCCAUGUCU 1624 UGAGUACCGCCA 1625 CAUGGCGGUAC MIMAT0007885 GUUGGG UGUCUGUU UCA hsa-miR-1911* 1626 CACCAGGCAUUGUGGUC 1627 CACCAGGCAUUG 1628 CACAAUGCCUG MIMAT0007886 UCC UGGUCUCC GUG hsa-miR-1912 1629 UACCCAGAGCAUGCAGU 1630 UACCCAGAGCAU 1631 GCAUGCUCUGG MIMAT0007887 GUGAA GCAGUGUG GUA hsa-miR-1913 1632 UCUGCCCCCUCCGCUGC 1633 UCUGCCCCCUCC 1634 GCGGAGGGGGC MIMAT0007888 UGCCA GCUGCUGC AGA hsa-miR-1914 1635 CCCUGUGCCCGGCCCAC 1636 CCCUGUGCCCGG 1637 GGCCGGGCACA MIMAT0007889 UUCUG CCCACUUC GGG hsa-miR-1914* 1638 GGAGGGGUCCCGCACUG 1639 GGAGGGGUCCCG 1640 UGCGGGACCCC MIMAT0007890 GGAGG CACUGGGA UCC hsa-miR-1915 1641 CCCCAGGGCGACGCGGC 1642 CCCCAGGGCGAC 1643 GCGUCGCCCUG MIMAT0007892 GGG GCGGCGGG GGG hsa-miR-1915* 1644 ACCUUGCCUUGCUGCCC 1645 ACCUUGCCUUGC 1646 CAGCAAGGCAA MIMAT0007891 GGGCC UGCCCGGG GGU hsa-miR-192 1647 CUGACCUAUGAAUUGAC 1648 CUGACCUAUGAA 1649 AAUUCAUAGGU MIMAT0000222 AGCC UUGACAGC CAG hsa-miR-192* 1650 CUGCCAAUUCCAUAGGU 1651 CUGCCAAUUCCA 1652 UAUGGAAUUGG MIMAT0004543 CACAG UAGGUCAC CAG hsa-miR-193a- 1653 AACUGGCCUACAAAGUC 1654 AACUGGCCUACA 1655 UUUGUAGGCCA 3p CCAGU AAGUCCCA GUU MIMAT0000459 hsa-miR-193a- 1656 UGGGUCUUUGCGGGCGA 1657 UGGGUCUUUGCG 1658 CCCGCAAAGAC 5p GAUGA GGCGAGAU CCA MIMAT0004614 hsa-miR-193b 1659 AACUGGCCCUCAAAGUC 1660 AACUGGCCCUCA 1661 UUUGAGGGCCA MIMAT0002819 CCGCU AAGUCCCG GUU hsa-miR-193b* 1662 CGGGGUUUUGAGGGCGA 1663 CGGGGUUUUGAG 1664 CCCUCAAAACC MIMAT0004767 GAUGA GGCGAGAU CCG hsa-miR-194 1665 UGUAACAGCAACUCCAU 1666 UGUAACAGCAAC 1667 GAGUUGCUGUU MIMAT0000460 GUGGA UCCAUGUG ACA hsa-miR-194* 1668 CCAGUGGGGCUGCUGUU 1669 CCAGUGGGGCUG 1670 AGCAGCCCCAC MIMAT0004671 AUCUG CUGUUAUC UGG hsa-miR-195 1671 UAGCAGCACAGAAAUAU 1672 UAGCAGCACAGA 1673 UUUCUGUGCUG MIMAT0000461 UGGC AAUAUUGG CUA hsa-miR-195* 1674 CCAAUAUUGGCUGUGCU 1675 CCAAUAUUGGCU 1676 ACAGCCAAUAU MIMAT0004615 GCUCC GUGCUGCU UGG hsa-miR-196a 1677 UAGGUAGUUUCAUGUUG 1678 UAGGUAGUUUCA 1679 CAUGAAACUAC MIMAT0000226 UUGGG UGUUGUUG CUA hsa-miR-196a* 1680 CGGCAACAAGAAACUGC 1681 CGGCAACAAGAA 1682 GUUUCUUGUUG MIMAT0004562 CUGAG ACUGCCUG CCG hsa-miR-196b 1683 UAGGUAGUUUCCUGUUG 1684 UAGGUAGUUUCC 1685 CAGGAAACUAC MIMAT0001080 UUGGG UGUUGUUG CUA hsa-miR-196b* 1686 UCGACAGCACGACACUG 1687 UCGACAGCACGA 1688 UGUCGUGCUGU MIMAT0009201 CCUUC CACUGCCU CGA hsa-miR-197 1689 UUCACCACCUUCUCCAC 1690 UUCACCACCUUC 1691 GAGAAGGUGGU MIMAT0000227 CCAGC UCCACCCA GAA hsa-miR-1972 1692 UCAGGCCAGGCACAGUG 1693 UCAGGCCAGGCA 1694 UGUGCCUGGCC MIMAT0009447 GCUCA CAGUGGCU UGA hsa-miR-1973 1695 ACCGUGCAAAGGUAGCA 1696 ACCGUGCAAAGG 1697 UACCUUUGCAC MIMAT0009448 UA UAGCAUA GGU hsa-miR-1976 1698 CCUCCUGCCCUCCUUGC 1699 CCUCCUGCCCUC 1700 AGGAGGGCAGG MIMAT0009451 UGU CUUGCUGU AGG hsa-miR-198 1701 GGUCCAGAGGGGAGAUA 1702 GGUCCAGAGGGG 1703 CUCCCCUCUGG MIMAT0000228 GGUUC AGAUAGGU ACC hsa-miR-199a- 1704 ACAGUAGUCUGCACAUU 1705 ACAGUAGUCUGC 1706 GUGCAGACUAC 3p GGUUA ACAUUGGU UGU MIMAT0000232 hsa-miR-199a- 1707 CCCAGUGUUCAGACUAC 1708 CCCAGUGUUCAG 1709 GUCUGAACACU 5p CUGUUC ACUACCUG GGG MIMAT0000231 hsa-miR-199b- 1710 ACAGUAGUCUGCACAUU 1711 ACAGUAGUCUGC 1712 GUGCAGACUAC 3p GGUUA ACAUUGGU UGU MIMAT0004563 hsa-miR-199b- 1713 CCCAGUGUUUAGACUAU 1714 CCCAGUGUUUAG 1715 GUCUAAACACU 5p CUGUUC ACUAUCUG GGG MIMAT0000263 hsa-miR-19a 1716 UGUGCAAAUCUAUGCAA 1717 UGUGCAAAUCUA 1718 CAUAGAUUUGC MIMAT0000073 AACUGA UGCAAAAC ACA hsa-miR-19a* 1719 AGUUUUGCAUAGUUGCA 1720 AGUUUUGCAUAG 1721 AACUAUGCAAA MIMAT0004490 CUACA UUGCACUA ACU hsa-miR-19b 1722 UGUGCAAAUCCAUGCAA 1723 UGUGCAAAUCCA 1724 CAUGGAUUUGC MIMAT0000074 AACUGA UGCAAAAC ACA hsa-miR-19b-1* 1725 AGUUUUGCAGGUUUGCA 1726 AGUUUUGCAGGU 1727 AAACCUGCAAA MIMAT0004491 UCCAGC UUGCAUCC ACU hsa-miR-19b-2* 1728 AGUUUUGCAGGUUUGCA 1729 AGUUUUGCAGGU 1730 AAACCUGCAAA MIMAT0004492 UUUCA UUGCAUUU ACU hsa-miR-200a 1731 UAACACUGUCUGGUAAC 1732 UAACACUGUCUG 1733 ACCAGACAGUG MIMAT0000682 GAUGU GUAACGAU UUA hsa-miR-200a* 1734 CAUCUUACCGGACAGUG 1735 CAUCUUACCGGA 1736 UGUCCGGUAAG MIMAT0001620 CUGGA CAGUGCUG AUG hsa-miR-200b 1737 UAAUACUGCCUGGUAAU 1738 UAAUACUGCCUG 1739 ACCAGGCAGUA MIMAT0000318 GAUGA GUAAUGAU UUA hsa-miR-200b* 1740 CAUCUUACUGGGCAGCA 1741 CAUCUUACUGGG 1742 UGCCCAGUAAG MIMAT0004571 UUGGA CAGCAUUG AUG hsa-miR-200c 1743 UAAUACUGCCGGGUAAU 1744 UAAUACUGCCGG 1745 ACCCGGCAGUA MIMAT0000617 GAUGGA GUAAUGAU UUA hsa-miR-200c* 1746 CGUCUUACCCAGCAGUG 1747 CGUCUUACCCAG 1748 UGCUGGGUAAG MIMAT0004657 UUUGG CAGUGUUU ACG hsa-miR-202 1749 AGAGGUAUAGGGCAUGG 1750 AGAGGUAUAGGG 1751 UGCCCUAUACC MIMAT0002811 GAA CAUGGGAA UCU hsa-miR-202* 1752 UUCCUAUGCAUAUACUU 1753 UUCCUAUGCAUA 1754 UAUAUGCAUAG MIMAT0002810 CUUUG UACUUCUU GAA hsa-miR-203 1755 GUGAAAUGUUUAGGACC 1756 GUGAAAUGUUUA 1757 CCUAAACAUUU MIMAT0000264 ACUAG GGACCACU CAC hsa-miR-204 1758 UUCCCUUUGUCAUCCUA 1759 UUCCCUUUGUCA 1760 GAUGACAAAGG MIMAT0000265 UGCCU UCCUAUGC GAA hsa-miR-205 1761 UCCUUCAUUCCACCGGA 1762 UCCUUCAUUCCA 1763 GGUGGAAUGAA MIMAT0000266 GUCUG CCGGAGUC GGA hsa-miR-205* 1764 GAUUUCAGUGGAGUGAA 1765 GAUUUCAGUGGA 1766 ACUCCACUGAA MIMAT0009197 GUUC GUGAAGUU AUC hsa-miR-2052 1767 UGUUUUGAUAACAGUAA 1768 UGUUUUGAUAAC 1769 CUGUUAUCAAA MIMAT0009977 UGU AGUAAUGU ACA hsa-miR-2053 1770 GUGUUAAUUAAACCUCU 1771 GUGUUAAUUAAA 1772 GGUUUAAUUAA MIMAT0009978 AUUUAC CCUCUAUU CAC hsa-miR-2054 1773 CUGUAAUAUAAAUUUAA 1774 CUGUAAUAUAAA 1775 AAUUUAUAUUA MIMAT0009979 UUUAUU UUUAAUUU CAG hsa-miR-206 1776 UGGAAUGUAAGGAAGUG 1777 UGGAAUGUAAGG 1778 UUCCUUACAUU MIMAT0000462 UGUGG AAGUGUGU CCA hsa-miR-208a 1779 AUAAGACGAGCAAAAAG 1780 AUAAGACGAGCA 1781 UUUGCUCGUCU MIMAT0000241 CUUGU AAAAGCUU UAU hsa-miR-208b 1782 AUAAGACGAACAAAAGG 1783 AUAAGACGAACA 1784 UUUGUUCGUCU MIMAT0004960 UUUGU AAAGGUUU UAU hsa-miR-20a 1785 UAAAGUGCUUAUAGUGC 1786 UAAAGUGCUUAU 1787 CUAUAAGCACU MIMAT0000075 AGGUAG AGUGCAGG UUA hsa-miR-20a* 1788 ACUGCAUUAUGAGCACU 1789 ACUGCAUUAUGA 1790 GCUCAUAAUGC MIMAT0004493 UAAAG GCACUUAA AGU hsa-miR-20b 1791 CAAAGUGCUCAUAGUGC 1792 CAAAGUGCUCAU 1793 CUAUGAGCACU MIMAT0001413 AGGUAG AGUGCAGG UUG hsa-miR-20b* 1794 ACUGUAGUAUGGGCACU 1795 ACUGUAGUAUGG 1796 GCCCAUACUAC MIMAT0004752 UCCAG GCACUUCC AGU hsa-miR-21 1797 UAGCUUAUCAGACUGAU 1798 UAGCUUAUCAGA 1799 AGUCUGAUAAG MIMAT0000076 GUUGA CUGAUGUU CUA hsa-miR-21* 1800 CAACACCAGUCGAUGGG 1801 CAACACCAGUCG 1802 AUCGACUGGUG MIMAT0004494 CUGU AUGGGCUG UUG hsa-miR-210 1803 CUGUGCGUGUGACAGCG 1804 CUGUGCGUGUGA 1805 UGUCACACGCA MIMAT0000267 GCUGA CAGCGGCU CAG hsa-miR-211 1806 UUCCCUUUGUCAUCCUU 1807 UUCCCUUUGUCA 1808 GAUGACAAAGG MIMAT0000268 CGCCU UCCUUCGC GAA hsa-miR-2110 1809 UUGGGGAAACGGCCGCU 1810 UUGGGGAAACGG 1811 GGCCGUUUCCC MIMAT0010133 GAGUG CCGCUGAG CAA hsa-miR-2113 1812 AUUUGUGCUUGGCUCUG 1813 AUUUGUGCUUGG 1814 AGCCAAGCACA MIMAT0009206 UCAC CUCUGUCA AAU hsa-miR-2114 1815 UAGUCCCUUCCUUGAAG 1816 UAGUCCCUUCCU 1817 CAAGGAAGGGA MIMAT0011156 CGGUC UGAAGCGG CUA hsa-miR-2114* 1818 CGAGCCUCAAGCAAGGG 1819 CGAGCCUCAAGC 1820 UUGCUUGAGGC MIMAT0011157 ACUU AAGGGACU UCG hsa-miR-2115 1821 AGCUUCCAUGACUCCUG 1822 AGCUUCCAUGAC 1823 GAGUCAUGGAA MIMAT0011158 AUGGA UCCUGAUG GCU hsa-miR-2115* 1824 CAUCAGAAUUCAUGGAG 1825 CAUCAGAAUUCA 1826 CAUGAAUUCUG MIMAT0011159 GCUAG UGGAGGCU AUG hsa-miR-2116 1827 GGUUCUUAGCAUAGGAG 1828 GGUUCUUAGCAU 1829 CUAUGCUAAGA MIMAT0011160 GUCU AGGAGGUC ACC hsa-miR-2116* 1830 CCUCCCAUGCCAAGAAC 1831 CCUCCCAUGCCA 1832 CUUGGCAUGGG MIMAT0011161 UCCC AGAACUCC AGG hsa-miR-2117 1833 UGUUCUCUUUGCCAAGG 1834 UGUUCUCUUUGC 1835 UGGCAAAGAGA MIMAT0011162 ACAG CAAGGACA ACA hsa-miR-212 1836 UAACAGUCUCCAGUCAC 1837 UAACAGUCUCCA 1838 ACUGGAGACUG MIMAT0000269 GGCC GUCACGGC UUA hsa-miR-214 1839 ACAGCAGGCACAGACAG 1840 ACAGCAGGCACA 1841 UCUGUGCCUGC MIMAT0000271 GCAGU GACAGGCA UGU hsa-miR-214* 1842 UGCCUGUCUACACUUGC 1843 UGCCUGUCUACA 1844 AGUGUAGACAG MIMAT0004564 UGUGC CUUGCUGU GCA hsa-miR-215 1845 AUGACCUAUGAAUUGAC 1846 AUGACCUAUGAA 1847 AAUUCAUAGGU MIMAT0000272 AGAC UUGACAGA CAU hsa-miR-216a 1848 UAAUCUCAGCUGGCAAC 1849 UAAUCUCAGCUG 1850 GCCAGCUGAGA MIMAT0000273 UGUGA GCAACUGU UUA hsa-miR-216b 1851 AAAUCUCUGCAGGCAAA 1852 AAAUCUCUGCAG 1853 GCCUGCAGAGA MIMAT0004959 UGUGA GCAAAUGU UUU hsa-miR-217 1854 UACUGCAUCAGGAACUG 1855 UACUGCAUCAGG 1856 UUCCUGAUGCA MIMAT0000274 AUUGGA AACUGAUU GUA hsa-miR-218 1857 UUGUGCUUGAUCUAACC 1858 UUGUGCUUGAUC 1859 UAGAUCAAGCA MIMAT0000275 AUGU UAACCAUG CAA hsa-miR-218-1* 1860 AUGGUUCCGUCAAGCAC 1861 AUGGUUCCGUCA 1862 CUUGACGGAAC MIMAT0004565 CAUGG AGCACCAU CAU hsa-miR-218-2* 1863 CAUGGUUCUGUCAAGCA 1864 CAUGGUUCUGUC 1865 UUGACAGAACC MIMAT0004566 CCGCG AAGCACCG AUG hsa-miR-219-1- 1866 AGAGUUGAGUCUGGACG 1867 AGAGUUGAGUCU 1868 CCAGACUCAAC 3p UCCCG GGACGUCC UCU MIMAT0004567 hsa-miR-219-2- 1869 AGAAUUGUGGCUGGACA 1870 AGAAUUGUGGCU 1871 CCAGCCACAAU 3p UCUGU GGACAUCU UCU MIMAT0004675 hsa-miR-219-5p 1872 UGAUUGUCCAAACGCAA 1873 UGAUUGUCCAAA 1874 CGUUUGGACAA MIMAT0000276 UUCU CGCAAUUC UCA hsa-miR-22 1875 AAGCUGCCAGUUGAAGA 1876 AAGCUGCCAGUU 1877 UCAACUGGCAG MIMAT0000077 ACUGU GAAGAACU CUU hsa-miR-22* 1878 AGUUCUUCAGUGGCAAG 1879 AGUUCUUCAGUG 1880 GCCACUGAAGA MIMAT0004495 CUUUA GCAAGCUU ACU hsa-miR-221 1881 AGCUACAUUGUCUGCUG 1882 AGCUACAUUGUC 1883 CAGACAAUGUA MIMAT0000278 GGUUUC UGCUGGGU GCU hsa-miR-221* 1884 ACCUGGCAUACAAUGUA 1885 ACCUGGCAUACA 1886 AUUGUAUGCCA MIMAT0004568 GAUUU AUGUAGAU GGU hsa-miR-222 1887 AGCUACAUCUGGCUACU 1888 AGCUACAUCUGG 1889 AGCCAGAUGUA MIMAT0000279 GGGU CUACUGGG GCU hsa-miR-222* 1890 CUCAGUAGCCAGUGUAG 1891 CUCAGUAGCCAG 1892 CACUGGCUACU MIMAT0004569 AUCCU UGUAGAUC GAG hsa-miR-223 1893 UGUCAGUUUGUCAAAUA 1894 UGUCAGUUUGUC 1895 UUGACAAACUG MIMAT0000280 CCCCA AAAUACCC ACA hsa-miR-223* 1896 CGUGUAUUUGACAAGCU 1897 CGUGUAUUUGAC 1898 UUGUCAAAUAC MIMAT0004570 GAGUU AAGCUGAG ACG hsa-miR-224 1899 CAAGUCACUAGUGGUUC 1900 CAAGUCACUAGU 1901 CCACUAGUGAC MIMAT0000281 CGUU GGUUCCGU UUG hsa-miR-224* 1902 AAAAUGGUGCCCUAGUG 1903 AAAAUGGUGCCC 1904 UAGGGCACCAU MIMAT0009198 ACUACA UAGUGACU UUU hsa-miR-2276 1905 UCUGCAAGUGUCAGAGG 1906 UCUGCAAGUGUC 1907 CUGACACUUGC MIMAT0011775 CGAGG AGAGGCGA AGA hsa-miR-2277- 1908 UGACAGCGCCCUGCCUG 1909 UGACAGCGCCCU 1910 GCAGGGCGCUG 3p GCUC GCCUGGCU UCA MIMAT0011777 hsa-miR-2277- 1911 AGCGCGGGCUGAGCGCU 1912 AGCGCGGGCUGA 1913 GCUCAGCCCGC 5p GCCAGUC GCGCUGCC GCU MIMAT0017352 hsa-miR-2278 1914 GAGAGCAGUGUGUGUUG 1915 GAGAGCAGUGUG 1916 CACACACUGCU MIMAT0011778 CCUGG UGUUGCCU CUC hsa-miR-2355- 1917 AUUGUCCUUGCUGUUUG 1918 AUUGUCCUUGCU 1919 ACAGCAAGGAC 3p GAGAU GUUUGGAG AAU MIMAT0017950 hsa-miR-2355- 1920 AUCCCCAGAUACAAUGG 1921 AUCCCCAGAUAC 1922 UUGUAUCUGGG 5p ACAA AAUGGACA GAU MIMAT0016895 hsa-miR-23a 1923 AUCACAUUGCCAGGGAU 1924 AUCACAUUGCCA 1925 CCUGGCAAUGU MIMAT0000078 UUCC GGGAUUUC GAU hsa-miR-23a* 1926 GGGGUUCCUGGGGAUGG 1927 GGGGUUCCUGGG 1928 UCCCCAGGAAC MIMAT0004496 GAUUU GAUGGGAU CCC hsa-miR-23b 1929 AUCACAUUGCCAGGGAU 1930 AUCACAUUGCCA 1931 CCUGGCAAUGU MIMAT0000418 UACC GGGAUUAC GAU hsa-miR-23b* 1932 UGGGUUCCUGGCAUGCU 1933 UGGGUUCCUGGC 1934 AUGCCAGGAAC MIMAT0004587 GAUUU AUGCUGAU CCA hsa-miR-23c 1935 AUCACAUUGCCAGUGAU 1936 AUCACAUUGCCA 1937 ACUGGCAAUGU MIMAT0018000 UACCC GUGAUUAC GAU hsa-miR-24 1938 UGGCUCAGUUCAGCAGG 1939 UGGCUCAGUUCA 1940 GCUGAACUGAG MIMAT0000080 AACAG GCAGGAAC CCA hsa-miR-24-1* 1941 UGCCUACUGAGCUGAUA 1942 UGCCUACUGAGC 1943 CAGCUCAGUAG MIMAT0000079 UCAGU UGAUAUCA GCA hsa-miR-24-2* 1944 UGCCUACUGAGCUGAAA 1945 UGCCUACUGAGC 1946 CAGCUCAGUAG MIMAT0004497 CACAG UGAAACAC GCA hsa-miR-25 1947 CAUUGCACUUGUCUCGG 1948 CAUUGCACUUGU 1949 AGACAAGUGCA MIMAT0000081 UCUGA CUCGGUCU AUG hsa-miR-25* 1950 AGGCGGAGACUUGGGCA 1951 AGGCGGAGACUU 1952 CCAAGUCUCCG MIMAT0004498 AUUG GGGCAAUU CCU hsa-miR-26a 1953 UUCAAGUAAUCCAGGAU 1954 UUCAAGUAAUCC 1955 CUGGAUUACUU MIMAT0000082 AGGCU AGGAUAGG GAA hsa-miR-26a-1* 1956 CCUAUUCUUGGUUACUU 1957 CCUAUUCUUGGU 1958 UAACCAAGAAU MIMAT0004499 GCACG UACUUGCA AGG hsa-miR-26a-2* 1959 CCUAUUCUUGAUUACUU 1960 CCUAUUCUUGAU 1961 UAAUCAAGAAU MIMAT0004681 GUUUC UACUUGUU AGG hsa-miR-26b 1962 UUCAAGUAAUUCAGGAU 1963 UUCAAGUAAUUC 1964 CUGAAUUACUU MIMAT0000083 AGGU AGGAUAGG GAA hsa-miR-26b* 1965 CCUGUUCUCCAUUACUU 1966 CCUGUUCUCCAU 1967 UAAUGGAGAAC MIMAT0004500 GGCUC UACUUGGC AGG hsa-miR-27a 1968 UUCACAGUGGCUAAGUU 1969 UUCACAGUGGCU 1970 UUAGCCACUGU MIMAT0000084 CCGC AAGUUCCG GAA hsa-miR-27a* 1971 AGGGCUUAGCUGCUUGU 1972 AGGGCUUAGCUG 1973 AGCAGCUAAGC MIMAT0004501 GAGCA CUUGUGAG CCU hsa-miR-27b 1974 UUCACAGUGGCUAAGUU 1975 UUCACAGUGGCU 1976 UUAGCCACUGU MIMAT0000419 CUGC AAGUUCUG GAA hsa-miR-27b* 1977 AGAGCUUAGCUGAUUGG 1978 AGAGCUUAGCUG 1979 AUCAGCUAAGC MIMAT0004588 UGAAC AUUGGUGA UCU hsa-miR-28-3p 1980 CACUAGAUUGUGAGCUC 1981 CACUAGAUUGUG 1982 CUCACAAUCUA MIMAT0004502 CUGGA AGCUCCUG GUG hsa-miR-28-5p 1983 AAGGAGCUCACAGUCUA 1984 AAGGAGCUCACA 1985 ACUGUGAGCUC MIMAT0000085 UUGAG GUCUAUUG CUU hsa-miR-2861 1986 GGGGCCUGGCGGUGGGC 1987 GGGGCCUGGCGG 1988 CACCGCCAGGC MIMAT0013802 GG UGGGCGG CCC hsa-miR-2909 1989 GUUAGGGCCAACAUCUC 1990 GUUAGGGCCAAC 1991 AUGUUGGCCCU MIMAT0013863 UUGG AUCUCUUG AAC hsa-miR-296-3p 1992 GAGGGUUGGGUGGAGGC 1993 GAGGGUUGGGUG 1994 UCCACCCAACC MIMAT0004679 UCUCC GAGGCUCU CUC hsa-miR-296-5p 1995 AGGGCCCCCCCUCAAUC 1996 AGGGCCCCCCCU 1997 UGAGGGGGGGC MIMAT0000690 CUGU CAAUCCUG CCU hsa-miR-297 1998 AUGUAUGUGUGCAUGUG 1999 AUGUAUGUGUGC 2000 AUGCACACAUA MIMAT0004450 CAUG AUGUGCAU CAU hsa-miR-298 2001 AGCAGAAGCAGGGAGGU 2002 AGCAGAAGCAGG 2003 UCCCUGCUUCU MIMAT0004901 UCUCCCA GAGGUUCU GCU hsa-miR-299-3p 2004 UAUGUGGGAUGGUAAAC 2005 UAUGUGGGAUGG 2006 UACCAUCCCAC MIMAT0000687 CGCUU UAAACCGC AUA hsa-miR-299-5p 2007 UGGUUUACCGUCCCACA 2008 UGGUUUACCGUC 2009 GGGACGGUAAA MIMAT0002890 UACAU CCACAUAC CCA hsa-miR-29a 2010 UAGCACCAUCUGAAAUC 2011 UAGCACCAUCUG 2012 UUCAGAUGGUG MIMAT0000086 GGUUA AAAUCGGU CUA hsa-miR-29a* 2013 ACUGAUUUCUUUUGGUG 2014 ACUGAUUUCUUU 2015 CAAAAGAAAUC MIMAT0004503 UUCAG UGGUGUUC AGU hsa-miR-29b 2016 UAGCACCAUUUGAAAUC 2017 UAGCACCAUUUG 2018 UUCAAAUGGUG MIMAT0000100 AGUGUU AAAUCAGU CUA hsa-miR-29b-1* 2019 GCUGGUUUCAUAUGGUG 2020 GCUGGUUUCAUA 2021 CAUAUGAAACC MIMAT0004514 GUUUAGA UGGUGGUU AGC hsa-miR-29b-2* 2022 CUGGUUUCACAUGGUGG 2023 CUGGUUUCACAU 2024 CCAUGUGAAAC MIMAT0004515 CUUAG GGUGGCUU CAG hsa-miR-29c 2025 UAGCACCAUUUGAAAUC 2026 UAGCACCAUUUG 2027 UUCAAAUGGUG MIMAT0000681 GGUUA AAAUCGGU CUA hsa-miR-29c* 2028 UGACCGAUUUCUCCUGG 2029 UGACCGAUUUCU 2030 GGAGAAAUCGG MIMAT0004673 UGUUC CCUGGUGU UCA hsa-miR-300 2031 UAUACAAGGGCAGACUC 2032 UAUACAAGGGCA 2033 UCUGCCCUUGU MIMAT0004903 UCUCU GACUCUCU AUA hsa-miR-301a 2034 CAGUGCAAUAGUAUUGU 2035 CAGUGCAAUAGU 2036 AUACUAUUGCA MIMAT0000688 CAAAGC AUUGUCAA CUG hsa-miR-301b 2037 CAGUGCAAUGAUAUUGU 2038 CAGUGCAAUGAU 2039 AUAUCAUUGCA MIMAT0004958 CAAAGC AUUGUCAA CUG hsa-miR-302a 2040 UAAGUGCUUCCAUGUUU 2041 UAAGUGCUUCCA 2042 CAUGGAAGCAC MIMAT0000684 UGGUGA UGUUUUGG UUA hsa-miR-302a* 2043 ACUUAAACGUGGAUGUA 2044 ACUUAAACGUGG 2045 AUCCACGUUUA MIMAT0000683 CUUGCU AUGUACUU AGU hsa-miR-302b 2046 UAAGUGCUUCCAUGUUU 2047 UAAGUGCUUCCA 2048 CAUGGAAGCAC MIMAT0000715 UAGUAG UGUUUUAG UUA hsa-miR-302b* 2049 ACUUUAACAUGGAAGUG 2050 ACUUUAACAUGG 2051 UUCCAUGUUAA MIMAT0000714 CUUUC AAGUGCUU AGU hsa-miR-302c 2052 UAAGUGCUUCCAUGUUU 2053 UAAGUGCUUCCA 2054 CAUGGAAGCAC MIMAT0000717 CAGUGG UGUUUCAG UUA hsa-miR-302c* 2055 UUUAACAUGGGGGUACC 2056 UUUAACAUGGGG 2057 ACCCCCAUGUU MIMAT0000716 UGCUG GUACCUGC AAA hsa-miR-302d 2058 UAAGUGCUUCCAUGUUU 2059 UAAGUGCUUCCA 2060 CAUGGAAGCAC MIMAT0000718 GAGUGU UGUUUGAG UUA hsa-miR-302d* 2061 ACUUUAACAUGGAGGCA 2062 ACUUUAACAUGG 2063 CUCCAUGUUAA MIMAT0004685 CUUGC AGGCACUU AGU hsa-miR-302e 2064 UAAGUGCUUCCAUGCUU 2065 UAAGUGCUUCCA 2066 CAUGGAAGCAC MIMAT0005931 UGCUU UUA hsa-miR-302f 2067 UAAUUGCUUCCAUGUUU 2068 UAAUUGCUUCCA 2069 CAUGGAAGCAA MIMAT0005932 UGUUU UUA hsa-miR-3065- 2070 UCAGCACCAGGAUAUUG 2071 UCAGCACCAGGA 2072 UAUCCUGGUGC 3p UUGGAG UAUUGUUG UGA MIMAT0015378 hsa-miR-3065- 2073 UCAACAAAAUCACUGAU 2074 UCAACAAAAUCA 2075 AGUGAUUUUGU 5p GCUGGA CUGAUGCU UGA MIMAT0015066 hsa-miR-3074 2076 GAUAUCAGCUCAGUAGG 2077 GAUAUCAGCUCA 2078 ACUGAGCUGAU MIMAT0015027 CACCG GUAGGCAC AUC hsa-miR-30a 2079 UGUAAACAUCCUCGACU 2080 UGUAAACAUCCU 2081 CGAGGAUGUUU MIMAT0000087 GGAAG CGACUGGA ACA hsa-miR-30a* 2082 CUUUCAGUCGGAUGUUU 2083 CUUUCAGUCGGA 2084 CAUCCGACUGA MIMAT0000088 GCAGC UGUUUGCA AAG hsa-miR-30b 2085 UGUAAACAUCCUACACU 2086 UGUAAACAUCCU 2087 GUAGGAUGUUU MIMAT0000420 CAGCU ACACUCAG ACA hsa-miR-30b* 2088 CUGGGAGGUGGAUGUUU 2089 CUGGGAGGUGGA 2090 CAUCCACCUCC MIMAT0004589 ACUUC UGUUUACU CAG hsa-miR-30c 2091 UGUAAACAUCCUACACU 2092 UGUAAACAUCCU 2093 GUAGGAUGUUU MIMAT0000244 CUCAGC ACACUCUC ACA hsa-miR-30c-1* 2094 CUGGGAGAGGGUUGUUU 2095 CUGGGAGAGGGU 2096 CAACCCUCUCC MIMAT0004674 ACUCC UGUUUACU CAG hsa-miR-30c-2* 2097 CUGGGAGAAGGCUGUUU 2098 CUGGGAGAAGGC 2099 CAGCCUUCUCC MIMAT0004550 ACUCU UGUUUACU CAG hsa-miR-30d 2100 UGUAAACAUCCCCGACU 2101 UGUAAACAUCCC 2102 CGGGGAUGUUU MIMAT0000245 GGAAG CGACUGGA ACA hsa-miR-30d* 2103 CUUUCAGUCAGAUGUUU 2104 CUUUCAGUCAGA 2105 CAUCUGACUGA MIMAT0004551 GCUGC UGUUUGCU AAG hsa-miR-30e 2106 UGUAAACAUCCUUGACU 2107 UGUAAACAUCCU 2108 CAAGGAUGUUU MIMAT0000692 GGAAG UGACUGGA ACA hsa-miR-30e* 2109 CUUUCAGUCGGAUGUUU 2110 CUUUCAGUCGGA 2111 CAUCCGACUGA MIMAT0000693 ACAGC UGUUUACA AAG hsa-miR-31 2112 AGGCAAGAUGCUGGCAU 2113 AGGCAAGAUGCU 2114 CCAGCAUCUUG MIMAT0000089 AGCU GGCAUAGC CCU hsa-miR-31* 2115 UGCUAUGCCAACAUAUU 2116 UGCUAUGCCAAC 2117 AUGUUGGCAUA MIMAT0004504 GCCAU AUAUUGCC GCA hsa-miR-3115 2118 AUAUGGGUUUACUAGUU 2119 AUAUGGGUUUAC 2120 UAGUAAACCCA MIMAT0014977 GGU UAGUUGGU UAU hsa-miR-3116 2121 UGCCUGGAACAUAGUAG 2122 UGCCUGGAACAU 2123 CUAUGUUCCAG MIMAT0014978 GGACU AGUAGGGA GCA hsa-miR-3117 2124 AUAGGACUCAUAUAGUG 2125 AUAGGACUCAUA 2126 UAUAUGAGUCC MIMAT0014979 CCAG UAGUGCCA UAU hsa-miR-3118 2127 UGUGACUGCAUUAUGAA 2128 UGUGACUGCAUU 2129 AUAAUGCAGUC MIMAT0014980 AAUUCU AUGAAAAU ACA hsa-miR-3119 2130 UGGCUUUUAACUUUGAU 2131 UGGCUUUUAACU 2132 AAAGUUAAAAG MIMAT0014981 GGC UUGAUGGC CCA hsa-miR-3120 2133 CACAGCAAGUGUAGACA 2134 CACAGCAAGUGU 2135 CUACACUUGCU MIMAT0014982 GGCA AGACAGGC GUG hsa-miR-3121 2136 UAAAUAGAGUAGGCAAA 2137 UAAAUAGAGUAG 2138 GCCUACUCUAU MIMAT0014983 GGACA GCAAAGGA UUA hsa-miR-3122 2139 GUUGGGACAAGAGGACG 2140 GUUGGGACAAGA 2141 CCUCUUGUCCC MIMAT0014984 GUCUU GGACGGUC AAC hsa-miR-3123 2142 CAGAGAAUUGUUUAAUC 2143 CAGAGAAUUGUU 2144 UAAACAAUUCU MIMAT0014985 UAAUC CUG hsa-miR-3124 2145 UUCGCGGGCGAAGGCAA 2146 UUCGCGGGCGAA 2147 CCUUCGCCCGC MIMAT0014986 AGUC GGCAAAGU GAA hsa-miR-3125 2148 UAGAGGAAGCUGUGGAG 2149 UAGAGGAAGCUG 2150 CACAGCUUCCU MIMAT0014988 AGA UGGAGAGA CUA hsa-miR-3126- 2151 CAUCUGGCAUCCGUCAC 2152 CAUCUGGCAUCC 2153 ACGGAUGCCAG 3p ACAGA GUCACACA AUG MIMAT0015377 hsa-miR-3126- 2154 UGAGGGACAGAUGCCAG 2155 UGAGGGACAGAU 2156 GCAUCUGUCCC 5p AAGCA GCCAGAAG UCA MIMAT0014989 hsa-miR-3127 2157 AUCAGGGCUUGUGGAAU 2158 AUCAGGGCUUGU 2159 CCACAAGCCCU MIMAT0014990 GGGAAG GGAAUGGG GAU hsa-miR-3128 2160 UCUGGCAAGUAAAAAAC 2161 UCUGGCAAGUAA 2162 UUUUACUUGCC MIMAT0014991 UCUCAU AAAACUCU AGA hsa-miR-3129 2163 GCAGUAGUGUAGAGAUU 2164 GCAGUAGUGUAG 2165 CUCUACACUAC MIMAT0014992 GGUUU AGAUUGGU UGC hsa-miR-3130- 2166 GCUGCACCGGAGACUGG 2167 GCUGCACCGGAG 2168 GUCUCCGGUGC 3p GUAA ACUGGGUA AGC MIMAT0014994 hsa-miR-3130- 2169 UACCCAGUCUCCGGUGC 2170 UACCCAGUCUCC 2171 CCGGAGACUGG 5p AGCC GGUGCAGC GUA MIMAT0014995 hsa-miR-3131 2172 UCGAGGACUGGUGGAAG 2173 UCGAGGACUGGU 2174 CCACCAGUCCU MIMAT0014996 GGCCUU GGAAGGGC CGA hsa-miR-3132 2175 UGGGUAGAGAAGGAGCU 2176 UGGGUAGAGAAG 2177 UCCUUCUCUAC MIMAT0014997 CAGAGGA GAGCUCAG CCA hsa-miR-3133 2178 UAAAGAACUCUUAAAAC 2179 UAAAGAACUCUU 2180 UUAAGAGUUCU MIMAT0014998 CCAAU AAAACCCA UUA hsa-miR-3134 2181 UGAUGGAUAAAAGACUA 2182 UGAUGGAUAAAA 2183 UCUUUUAUCCA MIMAT0015000 CAUAUU GACUACAU UCA hsa-miR-3135 2184 UGCCUAGGCUGAGACUG 2185 UGCCUAGGCUGA 2186 UCUCAGCCUAG MIMAT0015001 CAGUG GACUGCAG GCA hsa-miR-3136 2187 CUGACUGAAUAGGUAGG 2188 CUGACUGAAUAG 2189 ACCUAUUCAGU MIMAT0015003 GUCAUU GUAGGGUC CAG hsa-miR-3137 2190 UCUGUAGCCUGGGAGCA 2191 UCUGUAGCCUGG 2192 UCCCAGGCUAC MIMAT0015005 AUGGGGU GAGCAAUG AGA hsa-miR-3138 2193 UGUGGACAGUGAGGUAG 2194 UGUGGACAGUGA 2195 CCUCACUGUCC MIMAT0015006 AGGGAGU GGUAGAGG ACA hsa-miR-3139 2196 UAGGAGCUCAACAGAUG 2197 UAGGAGCUCAAC 2198 CUGUUGAGCUC MIMAT0015007 CCUGUU AGAUGCCU CUA hsa-miR-3140 2199 AGCUUUUGGGAAUUCAG 2200 AGCUUUUGGGAA 2201 AAUUCCCAAAA MIMAT0015008 GUAGU UUCAGGUA GCU hsa-miR-3141 2202 GAGGGCGGGUGGAGGAG 2203 GAGGGCGGGUGG 2204 CUCCACCCGCC MIMAT0015010 GA AGGAGGA CUC hsa-miR-3142 2205 AAGGCCUUUCUGAACCU 2206 AAGGCCUUUCUG 2207 UUCAGAAAGGC MIMAT0015011 UCAGA AACCUUCA CUU hsa-miR-3143 2208 AUAACAUUGUAAAGCGC 2209 AUAACAUUGUAA 2210 CUUUACAAUGU MIMAT0015012 UUCUUUCG AGCGCUUC UAU hsa-miR-3144- 2211 AUAUACCUGUUCGGUCU 2212 AUAUACCUGUUC 2213 CCGAACAGGUA 3p CUUUA GGUCUCUU UAU MIMAT0015015 hsa-miR-3144- 2214 AGGGGACCAAAGAGAUA 2215 AGGGGACCAAAG 2216 CUCUUUGGUCC 5p UAUAG AGAUAUAU CCU MIMAT0015014 hsa-miR-3145 2217 AGAUAUUUUGAGUGUUU 2218 AGAUAUUUUGAG 2219 CACUCAAAAUA MIMAT0015016 GGAAUUG UGUUUGGA UCU hsa-miR-3146 2220 CAUGCUAGGAUAGAAAG 2221 CAUGCUAGGAUA 2222 UCUAUCCUAGC MIMAT0015018 AAUGG GAAAGAAU AUG hsa-miR-3147 2223 GGUUGGGCAGUGAGGAG 2224 GGUUGGGCAGUG 2225 CUCACUGCCCA MIMAT0015019 GGUGUGA AGGAGGGU ACC hsa-miR-3148 2226 UGGAAAAAACUGGUGUG 2227 UGGAAAAAACUG 2228 ACCAGUUUUUU MIMAT0015021 UGCUU GUGUGUGC CCA hsa-miR-3149 2229 UUUGUAUGGAUAUGUGU 2230 UUUGUAUGGAUA 2231 CAUAUCCAUAC MIMAT0015022 GUGUAU UGUGUGUG AAA hsa-miR-3150 2232 CUGGGGAGAUCCUCGAG 2233 CUGGGGAGAUCC 2234 GAGGAUCUCCC MIMAT0015023 GUUGG UCGAGGUU CAG hsa-miR-3150b 2235 UGAGGAGAUCGUCGAGG 2236 UGAGGAGAUCGU 2237 CGACGAUCUCC MIMAT0018194 UUGG CGAGGUUG UCA hsa-miR-3151 2238 GGUGGGGCAAUGGGAUC 2239 GGUGGGGCAAUG 2240 CCCAUUGCCCC MIMAT0015024 AGGU GGAUCAGG ACC hsa-miR-3152 2241 UGUGUUAGAAUAGGGGC 2242 UGUGUUAGAAUA 2243 CCUAUUCUAAC MIMAT0015025 AAUAA GGGGCAAU ACA hsa-miR-3153 2244 GGGGAAAGCGAGUAGGG 2245 GGGGAAAGCGAG 2246 UACUCGCUUUC MIMAT0015026 ACAUUU UAGGGACA CCC hsa-miR-3154 2247 CAGAAGGGGAGUUGGGA 2248 CAGAAGGGGAGU 2249 CAACUCCCCUU MIMAT0015028 GCAGA UGGGAGCA CUG hsa-miR-3155 2250 CCAGGCUCUGCAGUGGG 2251 CCAGGCUCUGCA 2252 ACUGCAGAGCC MIMAT0015029 AACU GUGGGAAC UGG hsa-miR-3156 2253 AAAGAUCUGGAAGUGGG 2254 AAAGAUCUGGAA 2255 ACUUCCAGAUC MIMAT0015030 AGACA GUGGGAGA UUU hsa-miR-3157 2256 UUCAGCCAGGCUAGUGC 2257 UUCAGCCAGGCU 2258 CUAGCCUGGCU MIMAT0015031 AGUCU AGUGCAGU GAA hsa-miR-3158 2259 AAGGGCUUCCUCUCUGC 2260 AAGGGCUUCCUC 2261 GAGAGGAAGCC MIMAT0015032 AGGAC UCUGCAGG CUU hsa-miR-3159 2262 UAGGAUUACAAGUGUCG 2263 UAGGAUUACAAG 2264 CACUUGUAAUC MIMAT0015033 GCCAC UGUCGGCC CUA hsa-miR-3160 2265 AGAGCUGAGACUAGAAA 2266 AGAGCUGAGACU 2267 CUAGUCUCAGC MIMAT0015034 GCCCA AGAAAGCC UCU hsa-miR-3161 2268 CUGAUAAGAACAGAGGC 2269 CUGAUAAGAACA 2270 UCUGUUCUUAU MIMAT0015035 CCAGAU GAGGCCCA CAG hsa-miR-3162 2271 UUAGGGAGUAGAAGGGU 2272 UUAGGGAGUAGA 2273 CUUCUACUCCC MIMAT0015036 GGGGAG AGGGUGGG UAA hsa-miR-3163 2274 UAUAAAAUGAGGGCAGU 2275 UAUAAAAUGAGG 2276 GCCCUCAUUUU MIMAT0015037 AAGAC GCAGUAAG AUA hsa-miR-3164 2277 UGUGACUUUAAGGGAAA 2278 UGUGACUUUAAG 2279 CCCUUAAAGUC MIMAT0015038 UGGCG GGAAAUGG ACA hsa-miR-3165 2280 AGGUGGAUGCAAUGUGA 2281 AGGUGGAUGCAA 2282 CAUUGCAUCCA MIMAT0015039 CCUCA UGUGACCU CCU hsa-miR-3166 2283 CGCAGACAAUGCCUACU 2284 CGCAGACAAUGC 2285 AGGCAUUGUCU MIMAT0015040 GGCCUA CUACUGGC GCG hsa-miR-3167 2286 AGGAUUUCAGAAAUACU 2287 AGGAUUUCAGAA 2288 AUUUCUGAAAU MIMAT0015042 GGUGU AUACUGGU CCU hsa-miR-3168 2289 GAGUUCUACAGUCAGAC 2290 GAGUUCUACAGU 2291 UGACUGUAGAA MIMAT0015043 CAGAC CUC hsa-miR-3169 2292 UAGGACUGUGCUUGGCA 2293 UAGGACUGUGCU 2294 CAAGCACAGUC MIMAT0015044 CAUAG UGGCACAU CUA hsa-miR-3170 2295 CUGGGGUUCUGAGACAG 2296 CUGGGGUUCUGA 2297 UCUCAGAACCC MIMAT0015045 ACAGU GACAGACA CAG hsa-miR-3171 2298 AGAUGUAUGGAAUCUGU 2299 AGAUGUAUGGAA 2300 GAUUCCAUACA MIMAT0015046 AUAUAUC UCUGUAUA UCU hsa-miR-3173 2301 AAAGGAGGAAAUAGGCA 2302 AAAGGAGGAAAU 2303 CUAUUUCCUCC MIMAT0015048 GGCCA AGGCAGGC UUU hsa-miR-3174 2304 UAGUGAGUUAGAGAUGC 2305 UAGUGAGUUAGA 2306 UCUCUAACUCA MIMAT0015051 AGAGCC GAUGCAGA CUA hsa-miR-3175 2307 CGGGGAGAGAACGCAGU 2308 CGGGGAGAGAAC 2309 GCGUUCUCUCC MIMAT0015052 GACGU GCAGUGAC CCG hsa-miR-3176 2310 ACUGGCCUGGGACUACC 2311 ACUGGCCUGGGA 2312 AGUCCCAGGCC MIMAT0015053 GG CUACCGG AGU hsa-miR-3177 2313 UGCACGGCACUGGGGAC 2314 UGCACGGCACUG 2315 CCCAGUGCCGU MIMAT0015054 ACGU GGGACACG GCA hsa-miR-3178 2316 GGGGCGCGGCCGGAUCG 2317 GGGGCGCGGCCG 2318 UCCGGCCGCGC MIMAT0015055 GAUCG CCC hsa-miR-3179 2319 AGAAGGGGUGAAAUUUA 2320 AGAAGGGGUGAA 2321 AUUUCACCCCU MIMAT0015056 AACGU AUUUAAAC UCU hsa-miR-3180 2322 UGGGGCGGAGCUUCCGG 2323 UGGGGCGGAGCU 2324 GAAGCUCCGCC MIMAT0018178 AG UCCGGAG CCA hsa-miR-3180- 2325 UGGGGCGGAGCUUCCGG 2326 UGGGGCGGAGCU 2327 GAAGCUCCGCC 3p AGGCC UCCGGAGG CCA MIMAT0015058 hsa-miR-3180- 2328 CUUCCAGACGCUCCGCC 2329 CUUCCAGACGCU 2330 GGAGCGUCUGG 5p CCACGUCG CCGCCCCA AAG MIMAT0015057 hsa-miR-3181 2331 AUCGGGCCCUCGGCGCC 2332 AUCGGGCCCUCG 2333 GCCGAGGGCCC MIMAT0015061 GG GCGCCGG GAU hsa-miR-3182 2334 GCUUCUGUAGUGUAGUC 2335 GCUUCUGUAGUG 2336 UACACUACAGA MIMAT0015062 UAGUC AGC hsa-miR-3183 2337 GCCUCUCUCGGAGUCGC 2338 GCCUCUCUCGGA 2339 ACUCCGAGAGA MIMAT0015063 UCGGA GUCGCUCG GGC hsa-miR-3184 2340 UGAGGGGCCUCAGACCG 2341 UGAGGGGCCUCA 2342 UCUGAGGCCCC MIMAT0015064 AGCUUUU GACCGAGC UCA hsa-miR-3185 2343 AGAAGAAGGCGGUCGGU 2344 AGAAGAAGGCGG 2345 GACCGCCUUCU MIMAT0015065 CUGCGG UCGGUCUG UCU hsa-miR-3186- 2346 UCACGCGGAGAGAUGGC 2347 UCACGCGGAGAG 2348 AUCUCUCCGCG 3p UUUG AUGGCUUU UGA MIMAT0015068 hsa-miR-3186- 2349 CAGGCGUCUGUCUACGU 2350 CAGGCGUCUGUC 2351 UAGACAGACGC 5p GGCUU UACGUGGC CUG MIMAT0015067 hsa-miR-3187 2352 UUGGCCAUGGGGCUGCG 2353 UUGGCCAUGGGG 2354 AGCCCCAUGGC MIMAT0015069 CGG CUGCGCGG CAA hsa-miR-3188 2355 AGAGGCUUUGUGCGGAU 2356 AGAGGCUUUGUG 2357 CGCACAAAGCC MIMAT0015070 ACGGGG CGGAUACG UCU hsa-miR-3189 2358 CCCUUGGGUCUGAUGGG 2359 CCCUUGGGUCUG 2360 AUCAGACCCAA MIMAT0015071 GUAG AUGGGGUA GGG hsa-miR-3190 2361 UGUGGAAGGUAGACGGC 2362 UGUGGAAGGUAG 2363 GUCUACCUUCC MIMAT0015073 CAGAGA ACGGCCAG ACA hsa-miR-3191 2364 UGGGGACGUAGCUGGCC 2365 UGGGGACGUAGC 2366 CAGCUACGUCC MIMAT0015075 AGACAG UGGCCAGA CCA hsa-miR-3192 2367 UCUGGGAGGUUGUAGCA 2368 UCUGGGAGGUUG 2369 UACAACCUCCC MIMAT0015076 GUGGAA UAGCAGUG AGA hsa-miR-3193 2370 UCCUGCGUAGGAUCUGA 2371 UCCUGCGUAGGA 2372 GAUCCUACGCA MIMAT0015077 GGAGU UCUGAGGA GGA hsa-miR-3194 2373 GGCCAGCCACCAGGAGG 2374 GGCCAGCCACCA 2375 CCUGGUGGCUG MIMAT0015078 GCUG GGAGGGCU GCC hsa-miR-3195 2376 CGCGCCGGGCCCGGGUU 2377 CGCGCCGGGCCC 2378 CCGGGCCCGGC MIMAT0015079 GGGUU GCG hsa-miR-3196 2379 CGGGGCGGCAGGGGCCU 2380 CGGGGCGGCAGG 2381 CCCCUGCCGCC MIMAT0015080 C GGCCUC CCG hsa-miR-3197 2382 GGAGGCGCAGGCUCGGA 2383 GGAGGCGCAGGC 2384 GAGCCUGCGCC MIMAT0015082 AAGGCG UCGGAAAG UCC hsa-miR-3198 2385 GUGGAGUCCUGGGGAAU 2386 GUGGAGUCCUGG 2387 CCCCAGGACUC MIMAT0015083 GGAGA GGAAUGGA CAC hsa-miR-3199 2388 AGGGACUGCCUUAGGAG 2389 AGGGACUGCCUU 2390 CUAAGGCAGUC MIMAT0015084 AAAGUU AGGAGAAA CCU hsa-miR-32 2391 UAUUGCACAUUACUAAG 2392 UAUUGCACAUUA 2393 AGUAAUGUGCA MIMAT0000090 UUGCA CUAAGUUG AUA hsa-miR-32* 2394 CAAUUUAGUGUGUGUGA 2395 CAAUUUAGUGUG 2396 CACACACUAAA MIMAT0004505 UAUUU UGUGAUAU UUG hsa-miR-3200- 2397 CACCUUGCGCUACUCAG 2398 CACCUUGCGCUA 2399 AGUAGCGCAAG 3p GUCUG CUCAGGUC GUG MIMAT0015085 hsa-miR-3200- 2400 AAUCUGAGAAGGCGCAC 2401 AAUCUGAGAAGG 2402 CGCCUUCUCAG 5p AAGGU CGCACAAG AUU MIMAT0017392 hsa-miR-3201 2403 GGGAUAUGAAGAAAAAU 2404 GGGAUAUGAAGA 2405 UUUCUUCAUAU MIMAT0015086 AAAAU CCC hsa-miR-3202 2406 UGGAAGGGAGAAGAGCU 2407 UGGAAGGGAGAA 2408 UCUUCUCCCUU MIMAT0015089 UUAAU GAGCUUUA CCA hsa-miR-320a 2409 AAAAGCUGGGUUGAGAG 2410 AAAAGCUGGGUU 2411 UCAACCCAGCU MIMAT0000510 GGCGA GAGAGGGC UUU hsa-miR-320b 2412 AAAAGCUGGGUUGAGAG 2413 AAAAGCUGGGUU 2414 UCAACCCAGCU MIMAT0005792 GGCAA GAGAGGGC UUU hsa-miR-320c 2415 AAAAGCUGGGUUGAGAG 2416 AAAAGCUGGGUU 2417 UCAACCCAGCU MIMAT0005793 GGU GAGAGGGU UUU hsa-miR-320d 2418 AAAAGCUGGGUUGAGAG 2419 AAAAGCUGGGUU 2420 UCAACCCAGCU MIMAT0006764 GA GAGAGGA UUU hsa-miR-320e 2421 AAAGCUGGGUUGAGAAG 2422 AAAGCUGGGUUG 2423 CUCAACCCAGC MIMAT0015072 G AGAAGG UUU hsa-miR-323-3p 2424 CACAUUACACGGUCGAC 2425 CACAUUACACGG 2426 GACCGUGUAAU MIMAT0000755 CUCU UCGACCUC GUG hsa-miR-323-5p 2427 AGGUGGUCCGUGGCGCG 2428 AGGUGGUCCGUG 2429 GCCACGGACCA MIMAT0004696 UUCGC GCGCGUUC CCU hsa-miR-323b- 2430 CCCAAUACACGGUCGAC 2431 CCCAAUACACGG 2432 GACCGUGUAUU 3p CUCUU UCGACCUC GGG MIMAT0015050 hsa-miR-323b- 2433 AGGUUGUCCGUGGUGAG 2434 AGGUUGUCCGUG 2435 ACCACGGACAA 5p UUCGCA GUGAGUUC CCU MIMAT0001630 hsa-miR-324-3p 2436 ACUGCCCCAGGUGCUGC 2437 ACUGCCCCAGGU 2438 GCACCUGGGGC MIMAT0000762 UGG GCUGCUGG AGU hsa-miR-324-5p 2439 CGCAUCCCCUAGGGCAU 2440 CGCAUCCCCUAG 2441 CCCUAGGGGAU MIMAT0000761 UGGUGU GGCAUUGG GCG hsa-miR-325 2442 CCUAGUAGGUGUCCAGU 2443 CCUAGUAGGUGU 2444 GGACACCUACU MIMAT0000771 AAGUGU CCAGUAAG AGG hsa-miR-326 2445 CCUCUGGGCCCUUCCUC 2446 CCUCUGGGCCCU 2447 GAAGGGCCCAG MIMAT0000756 CAG UCCUCCAG AGG hsa-miR-328 2448 CUGGCCCUCUCUGCCCU 2449 CUGGCCCUCUCU 2450 GCAGAGAGGGC MIMAT0000752 UCCGU GCCCUUCC CAG hsa-miR-329 2451 AACACACCUGGUUAACC 2452 AACACACCUGGU 2453 UAACCAGGUGU MIMAT0001629 UCUUU UAACCUCU GUU hsa-miR-330-3p 2454 GCAAAGCACACGGCCUG 2455 GCAAAGCACACG 2456 GCCGUGUGCUU MIMAT0000751 CAGAGA GCCUGCAG UGC hsa-miR-330-5p 2457 UCUCUGGGCCUGUGUCU 2458 UCUCUGGGCCUG 2459 CACAGGCCCAG MIMAT0004693 UAGGC UGUCUUAG AGA hsa-miR-331-3p 2460 GCCCCUGGGCCUAUCCU 2461 GCCCCUGGGCCU 2462 AUAGGCCCAGG MIMAT0000760 AGAA AUCCUAGA GGC hsa-miR-331-5p 2463 CUAGGUAUGGUCCCAGG 2464 CUAGGUAUGGUC 2465 GGGACCAUACC MIMAT0004700 GAUCC CCAGGGAU UAG hsa-miR-335 2466 UCAAGAGCAAUAACGAA 2467 UCAAGAGCAAUA 2468 GUUAUUGCUCU MIMAT0000765 AAAUGU ACGAAAAA UGA hsa-miR-335* 2469 UUUUUCAUUAUUGCUCC 2470 UUUUUCAUUAUU 2471 GCAAUAAUGAA MIMAT0004703 UGACC GCUCCUGA AAA hsa-miR-337-3p 2472 CUCCUAUAUGAUGCCUU 2473 CUCCUAUAUGAU 2474 GCAUCAUAUAG MIMAT0000754 UCUUC GCCUUUCU GAG hsa-miR-337-5p 2475 GAACGGCUUCAUACAGG 2476 GAACGGCUUCAU 2477 GUAUGAAGCCG MIMAT0004695 AGUU ACAGGAGU UUC hsa-miR-338-3p 2478 UCCAGCAUCAGUGAUUU 2479 UCCAGCAUCAGU 2480 UCACUGAUGCU MIMAT0000763 UGUUG GAUUUUGU GGA hsa-miR-338-5p 2481 AACAAUAUCCUGGUGCU 2482 AACAAUAUCCUG 2483 ACCAGGAUAUU MIMAT0004701 GAGUG GUGCUGAG GUU hsa-miR-339-3p 2484 UGAGCGCCUCGACGACA 2485 UGAGCGCCUCGA 2486 CGUCGAGGCGC MIMAT0004702 GAGCCG CGACAGAG UCA hsa-miR-339-5p 2487 UCCCUGUCCUCCAGGAG 2488 UCCCUGUCCUCC 2489 CUGGAGGACAG MIMAT0000764 CUCACG AGGAGCUC GGA hsa-miR-33a 2490 GUGCAUUGUAGUUGCAU 2491 GUGCAUUGUAGU 2492 CAACUACAAUG MIMAT0000091 UGCA UGCAUUGC CAC hsa-miR-33a* 2493 CAAUGUUUCCACAGUGC 2494 CAAUGUUUCCAC 2495 CUGUGGAAACA MIMAT0004506 AUCAC AGUGCAUC UUG hsa-miR-33b 2496 GUGCAUUGCUGUUGCAU 2497 GUGCAUUGCUGU 2498 CAACAGCAAUG MIMAT0003301 UGC UGCAUUGC CAC hsa-miR-33b* 2499 CAGUGCCUCGGCAGUGC 2500 CAGUGCCUCGGC 2501 CUGCCGAGGCA MIMAT0004811 AGCCC AGUGCAGC CUG hsa-miR-340 2502 UUAUAAAGCAAUGAGAC 2503 UUAUAAAGCAAU 2504 UCAUUGCUUUA MIMAT0004692 UGAUU GAGACUGA UAA hsa-miR-340* 2505 UCCGUCUCAGUUACUUU 2506 UCCGUCUCAGUU 2507 GUAACUGAGAC MIMAT0000750 AUAGC ACUUUAUA GGA hsa-miR-342-3p 2508 UCUCACACAGAAAUCGC 2509 UCUCACACAGAA 2510 AUUUCUGUGUG MIMAT0000753 ACCCGU AUCGCACC AGA hsa-miR-342-5p 2511 AGGGGUGCUAUCUGUGA 2512 AGGGGUGCUAUC 2513 CAGAUAGCACC MIMAT0004694 UUGA UGUGAUUG CCU hsa-miR-345 2514 GCUGACUCCUAGUCCAG 2515 GCUGACUCCUAG 2516 GACUAGGAGUC MIMAT0000772 GGCUC UCCAGGGC AGC hsa-miR-346 2517 UGUCUGCCCGCAUGCCU 2518 UGUCUGCCCGCA 2519 CAUGCGGGCAG MIMAT0000773 GCCUCU UGCCUGCC ACA hsa-miR-34a 2520 UGGCAGUGUCUUAGCUG 2521 UGGCAGUGUCUU 2522 CUAAGACACUG MIMAT0000255 GUUGU AGCUGGUU CCA hsa-miR-34a* 2523 CAAUCAGCAAGUAUACU 2524 CAAUCAGCAAGU 2525 AUACUUGCUGA MIMAT0004557 GCCCU AUACUGCC UUG hsa-miR-34b 2526 CAAUCACUAACUCCACU 2527 CAAUCACUAACU 2528 GGAGUUAGUGA MIMAT0004676 GCCAU CCACUGCC UUG hsa-miR-34b* 2529 UAGGCAGUGUCAUUAGC 2530 UAGGCAGUGUCA 2531 AAUGACACUGC MIMAT0000685 UGAUUG UUAGCUGA CUA hsa-miR-34c-3p 2532 AAUCACUAACCACACGG 2533 AAUCACUAACCA 2534 UGUGGUUAGUG MIMAT0004677 CCAGG CACGGCCA AUU hsa-miR-34c-5p 2535 AGGCAGUGUAGUUAGCU 2536 AGGCAGUGUAGU 2537 UAACUACACUG MIMAT0000686 GAUUGC UAGCUGAU CCU hsa-miR-3605- 2538 CCUCCGUGUUACCUGUC 2539 CCUCCGUGUUAC 2540 AGGUAACACGG 3p CUCUAG CUGUCCUC AGG MIMAT0017982 hsa-miR-3605- 2541 UGAGGAUGGAUAGCAAG 2542 UGAGGAUGGAUA 2543 GCUAUCCAUCC 5p GAAGCC GCAAGGAA UCA MIMAT0017981 hsa-miR-3606 2544 UUAGUGAAGGCUAUUUU 2545 UUAGUGAAGGCU 2546 AUAGCCUUCAC MIMAT0017983 AAUU AUUUUAAU UAA hsa-miR-3607- 2547 ACUGUAAACGCUUUCUG 2548 ACUGUAAACGCU 2549 AAAGCGUUUAC 3p AUG UUCUGAUG AGU MIMAT0017985 hsa-miR-3607- 2550 GCAUGUGAUGAAGCAAA 2551 GCAUGUGAUGAA 2552 GCUUCAUCACA 5p UCAGU GCAAAUCA UGC MIMAT0017984 hsa-miR-3609 2553 CAAAGUGAUGAGUAAUA 2554 CAAAGUGAUGAG 2555 UACUCAUCACU MIMAT0017986 CUGGCUG UAAUACUG UUG hsa-miR-3610 2556 GAAUCGGAAAGGAGGCG 2557 GAAUCGGAAAGG 2558 CUCCUUUCCGA MIMAT0017987 CCG AGGCGCCG UUC hsa-miR-3611 2559 UUGUGAAGAAAGAAAUU 2560 UUGUGAAGAAAG 2561 UUCUUUCUUCA MIMAT0017988 CUUA AAAUUCUU CAA hsa-miR-3612 2562 AGGAGGCAUCUUGAGAA 2563 AGGAGGCAUCUU 2564 UCAAGAUGCCU MIMAT0017989 AUGGA GAGAAAUG CCU hsa-miR-3613- 2565 ACAAAAAAAAAAGCCCA 2566 ACAAAAAAAAAA 2567 GCUUUUUUUUU MIMAT0017991 ACCCUUC GCCCAACC UGU hsa-miR-3613- 2568 UGUUGUACUUUUUUUUU 2569 UGUUGUACUUUU 2570 AAAAAAGUACA 5p UGUUC UUUUUUGU ACA MIMAT0017990 hsa-miR-361-3p 2571 UCCCCCAGGUGUGAUUC 2572 UCCCCCAGGUGU 2573 UCACACCUGGG MIMAT0004682 UGAUUU GAUUCUGA GGA hsa-miR-3614- 2574 UAGCCUUCAGAUCUUGG 2575 UAGCCUUCAGAU 2576 AGAUCUGAAGG 3p UGUUUU CUUGGUGU CUA MIMAT0017993 hsa-miR-3614- 2577 CCACUUGGAUCUGAAGG 2578 CCACUUGGAUCU 2579 UCAGAUCCAAG 5p CUGCCC GAAGGCUG UGG MIMAT0017992 hsa-miR-3615 2580 UCUCUCGGCUCCUCGCG 2581 UCUCUCGGCUCC 2582 GAGGAGCCGAG MIMAT0017994 GCUC UCGCGGCU AGA hsa-miR-361-5p 2583 UUAUCAGAAUCUCCAGG 2584 UUAUCAGAAUCU 2585 GGAGAUUCUGA MIMAT0000703 GGUAC CCAGGGGU UAA hsa-miR-3616- 2586 CGAGGGCAUUUCAUGAU 2587 CGAGGGCAUUUC 2588 AUGAAAUGCCC 3p GCAGGC AUGAUGCA UCG MIMAT0017996 hsa-miR-3616- 2589 AUGAAGUGCACUCAUGA 2590 AUGAAGUGCACU 2591 UGAGUGCACUU 5p UAUGU CAUGAUAU CAU MIMAT0017995 hsa-miR-3617 2592 AAAGACAUAGUUGCAAG 2593 AAAGACAUAGUU 2594 GCAACUAUGUC MIMAT0017997 AUGGG GCAAGAUG UUU hsa-miR-3618 2595 UGUCUACAUUAAUGAAA 2596 UGUCUACAUUAA 2597 CAUUAAUGUAG MIMAT0017998 AGAGC UGAAAAGA ACA hsa-miR-3619 2598 UCAGCAGGCAGGCUGGU 2599 UCAGCAGGCAGG 2600 AGCCUGCCUGC MIMAT0017999 GCAGC CUGGUGCA UGA hsa-miR-3620 2601 UCACCCUGCAUCCCGCA 2602 UCACCCUGCAUC 2603 GGGAUGCAGGG MIMAT0018001 CCCAG CCGCACCC UGA hsa-miR-3621 2604 CGCGGGUCGGGGUCUGC 2605 CGCGGGUCGGGG 2606 GACCCCGACCC MIMAT0018002 AGG UCUGCAGG GCG hsa-miR-3622a- 2607 UCACCUGACCUCCCAUG 2608 UCACCUGACCUC 2609 GGGAGGUCAGG 3p CCUGU CCAUGCCU UGA MIMAT0018004 hsa-miR-3622a- 2610 CAGGCACGGGAGCUCAG 2611 CAGGCACGGGAG 2612 AGCUCCCGUGC 5p GUGAG CUCAGGUG CUG MIMAT0018003 hsa-miR-3622b- 2613 UCACCUGAGCUCCCGUG 2614 UCACCUGAGCUC 2615 GGGAGCUCAGG 3p CCUG CCGUGCCU UGA MIMAT0018006 hsa-miR-3622b- 2616 AGGCAUGGGAGGUCAGG 2617 AGGCAUGGGAGG 2618 GACCUCCCAUG 5p UGA UCAGGUGA CCU MIMAT0018005 hsa-miR-362-3p 2619 AACACACCUAUUCAAGG 2620 AACACACCUAUU 2621 UGAAUAGGUGU MIMAT0004683 AUUCA CAAGGAUU GUU hsa-miR-362-5p 2622 AAUCCUUGGAACCUAGG 2623 AAUCCUUGGAAC 2624 AGGUUCCAAGG MIMAT0000705 UGUGAGU CUAGGUGU AUU hsa-miR-363 2625 AAUUGCACGGUAUCCAU 2626 AAUUGCACGGUA 2627 GAUACCGUGCA MIMAT0000707 CUGUA UCCAUCUG AUU hsa-miR-363* 2628 CGGGUGGAUCACGAUGC 2629 CGGGUGGAUCAC 2630 UCGUGAUCCAC MIMAT0003385 AAUUU GAUGCAAU CCG hsa-miR-3646 2631 AAAAUGAAAUGAGCCCA 2632 AAAAUGAAAUGA 2633 GCUCAUUUCAU MIMAT0018065 GCCCA GCCCAGCC UUU hsa-miR-3647- 2634 AGAAAAUUUUUGUGUGU 2635 AGAAAAUUUUUG 2636 CACAAAAAUUU 3p CUGAUC UGUGUCUG UCU MIMAT0018067 hsa-miR-3647- 2637 CUGAAGUGAUGAUUCAC 2638 CUGAAGUGAUGA 2639 AAUCAUCACUU 5p AUUCAU UUCACAUU CAG MIMAT0018066 hsa-miR-3648 2640 AGCCGCGGGGAUCGCCG 2641 AGCCGCGGGGAU 2642 CGAUCCCCGCG MIMAT0018068 AGGG CGCCGAGG GCU hsa-miR-3649 2643 AGGGACCUGAGUGUCUA 2644 AGGGACCUGAGU 2645 ACACUCAGGUC MIMAT0018069 AG GUCUAAG CCU hsa-miR-365 2646 UAAUGCCCCUAAAAAUC 2647 UAAUGCCCCUAA 2648 UUUUAGGGGCA MIMAT0000710 CUUAU AAAUCCUU UUA hsa-miR-365* 2649 AGGGACUUUCAGGGGCA 2650 AGGGACUUUCAG 2651 CCCUGAAAGUC MIMAT0009199 GCUGU GGGCAGCU CCU hsa-miR-3650 2652 AGGUGUGUCUGUAGAGU 2653 AGGUGUGUCUGU 2654 CUACAGACACA MIMAT0018070 CC AGAGUCC CCU hsa-miR-3651 2655 CAUAGCCCGGUCGCUGG 2656 CAUAGCCCGGUC 2657 GCGACCGGGCU MIMAT0018071 UACAUGA GCUGGUAC AUG hsa-miR-3652 2658 CGGCUGGAGGUGUGAGG 2659 CGGCUGGAGGUG 2660 CACACCUCCAG MIMAT0018072 A UGAGGA CCG hsa-miR-3653 2661 CUAAGAAGUUGACUGAA 2662 CUAAGAAGUUGA 2663 AGUCAACUUCU MIMAT0018073 G CUGAAG UAG hsa-miR-3654 2664 GACUGGACAAGCUGAGG 2665 GACUGGACAAGC 2666 CAGCUUGUCCA MIMAT0018074 AA UGAGGAA GUC hsa-miR-3655 2667 GCUUGUCGCUGCGGUGU 2668 GCUUGUCGCUGC 2669 CCGCAGCGACA MIMAT0018075 UGCU GGUGUUGC AGC hsa-miR-3656 2670 GGCGGGUGCGGGGGUGG 2671 GGCGGGUGCGGG 2672 CCCCCGCACCC MIMAT0018076 GGUGG GCC hsa-miR-3657 2673 UGUGUCCCAUUAUUGGU 2674 UGUGUCCCAUUA 2675 AAUAAUGGGAC MIMAT0018077 GAUU UUGGUGAU ACA hsa-miR-3658 2676 UUUAAGAAAACACCAUG 2677 UUUAAGAAAACA 2678 GGUGUUUUCUU MIMAT0018078 GAGAU CCAUGGAG AAA hsa-miR-3659 2679 UGAGUGUUGUCUACGAG 2680 UGAGUGUUGUCU 2681 GUAGACAACAC MIMAT0018080 GGCA ACGAGGGC UCA hsa-miR-3660 2682 ACUGACAGGAGAGCAUU 2683 ACUGACAGGAGA 2684 GCUCUCCUGUC MIMAT0018081 UUGA GCAUUUUG AGU hsa-miR-3661 2685 UGACCUGGGACUCGGAC 2686 UGACCUGGGACU 2687 CGAGUCCCAGG MIMAT0018082 AGCUG CGGACAGC UCA hsa-miR-3662 2688 GAAAAUGAUGAGUAGUG 2689 GAAAAUGAUGAG 2690 UACUCAUCAUU MIMAT0018083 ACUGAUG UAGUGACU UUC hsa-miR-3663- 2691 UGAGCACCACACAGGCC 2692 UGAGCACCACAC 2693 CUGUGUGGUGC 3p GGGCGC AGGCCGGG UCA MIMAT0018085 hsa-miR-3663- 2694 GCUGGUCUGCGUGGUGC 2695 GCUGGUCUGCGU 2696 CCACGCAGACC 5p UCGG GGUGCUCG AGC MTMAT0018084 hsa-miR-3664 2697 AACUCUGUCUUCACUCA 2698 AACUCUGUCUUC 2699 GUGAAGACAGA MIMAT0018086 UGAGU ACUCAUGA GUU hsa-miR-3665 2700 AGCAGGUGCGGGGCGGC 2701 AGCAGGUGCGGG 2702 GCCCCGCACCU MIMAT0018087 G GCGGCG GCU hsa-miR-3666 2703 CAGUGCAAGUGUAGAUG 2704 CAGUGCAAGUGU 2705 CUACACUUGCA MIMAT0018088 CCGA AGAUGCCG CUG hsa-miR-3667- 2706 ACCUUCCUCUCCAUGGG 2707 ACCUUCCUCUCC 2708 AUGGAGAGGAA 3p UCUUU AUGGGUCU GGU MIMAT0018090 hsa-miR-3667- 2709 AAAGACCCAUUGAGGAG 2710 AAAGACCCAUUG 2711 CUCAAUGGGUC 5p AAGGU AGGAGAAG UUU MIMAT0018089 hsa-miR-3668 2712 AAUGUAGAGAUUGAUCA 2713 AAUGUAGAGAUU 2714 UCAAUCUCUAC MIMAT0018091 AAAU GAUCAAAA AUU hsa-miR-3669 2715 ACGGAAUAUGUAUACGG 2716 ACGGAAUAUGUA 2717 UAUACAUAUUC MIMAT0018092 AAUAUA UACGGAAU CGU hsa-miR-367 2718 AAUUGCACUUUAGCAAU 2719 AAUUGCACUUUA 2720 GCUAAAGUGCA MIMAT0000719 GGUGA GCAAUGGU AUU hsa-miR-367* 2721 ACUGUUGCUAAUAUGCA 2722 ACUGUUGCUAAU 2723 AUAUUAGCAAC MIMAT0004686 ACUCU AUGCAACU AGU hsa-miR-3670 2724 AGAGCUCACAGCUGUCC 2725 AGAGCUCACAGC 2726 CAGCUGUGAGC MIMAT0018093 UUCUCUA UGUCCUUC UCU hsa-miR-3671 2727 AUCAAAUAAGGACUAGU 2728 AUCAAAUAAGGA 2729 AGUCCUUAUUU MIMAT0018094 CUGCA CUAGUCUG GAU hsa-miR-3672 2730 AUGAGACUCAUGUAAAA 2731 AUGAGACUCAUG 2732 UACAUGAGUCU MIMAT0018095 CAUCUU UAAAACAU CAU hsa-miR-3673 2733 AUGGAAUGUAUAUACGG 2734 AUGGAAUGUAUA 2735 UAUAUACAUUC MIMAT0018096 AAUA UACGGAAU CAU hsa-miR-3674 2736 AUUGUAGAACCUAAGAU 2737 AUUGUAGAACCU 2738 UUAGGUUCUAC MIMAT0018097 UGGCC AAGAUUGG AAU hsa-miR-3675- 2739 CAUCUCUAAGGAACUCC 2740 CAUCUCUAAGGA 2741 GUUCCUUAGAG 3p CCCAA ACUCCCCC AUG MIMAT0018099 hsa-miR-3675- 2742 UAUGGGGCUUCUGUAGA 2743 UAUGGGGCUUCU 2744 ACAGAAGCCCC 5p GAUUUC GUAGAGAU AUA MIMAT0018098 hsa-miR-3676 2745 CCGUGUUUCCCCCACGC 2746 CCGUGUUUCCCC 2747 UGGGGGAAACA MIMAT0018100 UUU CACGCUUU CGG hsa-miR-3677 2748 CUCGUGGGCUCUGGCCA 2749 CUCGUGGGCUCU 2750 CCAGAGCCCAC MIMAT0018101 CGGCC GGCCACGG GAG hsa-miR-3678- 2751 CUGCAGAGUUUGUACGG 2752 CUGCAGAGUUUG 2753 UACAAACUCUG 3p ACCGG UACGGACC CAG MIMAT0018103 hsa-miR-3678- 2754 UCCGUACAAACUCUGCU 2755 UCCGUACAAACU 2756 AGAGUUUGUAC 5p GUG CUGCUGUG GGA MIMAT0018102 hsa-miR-3679- 2757 CUUCCCCCCAGUAAUCU 2758 CUUCCCCCCAGU 2759 UUACUGGGGGG 3p UCAUC AAUCUUCA AAG MIMAT0018105 hsa-miR-3679- 2760 UGAGGAUAUGGCAGGGA 2761 UGAGGAUAUGGC 2762 CUGCCAUAUCC 5p AGGGGA AGGGAAGG UCA MIMAT0018104 hsa-miR-3680 2763 GACUCACUCACAGGAUU 2764 GACUCACUCACA 2765 CCUGUGAGUGA MIMAT0018106 GUGCA GGAUUGUG GUC hsa-miR-3680* 2766 UUUUGCAUGACCCUGGG 2767 UUUUGCAUGACC 2768 AGGGUCAUGCA MIMAT0018107 AGUAGG CUGGGAGU AAA hsa-miR-3681 2769 UAGUGGAUGAUGCACUC 2770 UAGUGGAUGAUG 2771 UGCAUCAUCCA MIMAT0018108 UGUGC CACUCUGU CUA hsa-miR-3681* 2772 ACACAGUGCUUCAUCCA 2773 ACACAGUGCUUC 2774 AUGAAGCACUG MIMAT0018109 CUACU AUCCACUA UGU hsa-miR-3682 2775 UGAUGAUACAGGUGGAG 2776 UGAUGAUACAGG 2777 CACCUGUAUCA MIMAT0018110 GUAG UGGAGGUA UCA hsa-miR-3683 2778 UGCGACAUUGGAAGUAG 2779 UGCGACAUUGGA 2780 CUUCCAAUGUC MIMAT0018111 UAUCA AGUAGUAU GCA hsa-miR-3684 2781 UUAGACCUAGUACACGU 2782 UUAGACCUAGUA 2783 UGUACUAGGUC MIMAT0018112 CCUU CACGUCCU UAA hsa-miR-3685 2784 UUUCCUACCCUACCUGA 2785 UUUCCUACCCUA 2786 GGUAGGGUAGG MIMAT0018113 AGACU CCUGAAGA AAA hsa-miR-3686 2787 AUCUGUAAGAGAAAGUA 2788 AUCUGUAAGAGA 2789 UUUCUCUUACA MIMAT0018114 AAUGA AAGUAAAU GAU hsa-miR-3687 2790 CCCGGACAGGCGUUCGU 2791 CCCGGACAGGCG 2792 AACGCCUGUCC MIMAT0018115 GCGACGU UUCGUGCG GGG hsa-miR-3688 2793 UAUGGAAAGACUUUGCC 2794 UAUGGAAAGACU 2795 AAAGUCUUUCC MIMAT0018116 ACUCU UUGCCACU AUA hsa-miR-3689a- 2796 CUGGGAGGUGUGAUAUC 2797 CUGGGAGGUGUG 2798 AUCACACCUCC 3p GUGGU AUAUCGUG CAG MIMAT0018118 hsa-miR-3689a- 2799 UGUGAUAUCAUGGUUCC 2800 UGUGAUAUCAUG 2801 ACCAUGAUAUC 5p UGGGA GUUCCUGG ACA MIMAT0018117 hsa-miR-3689b 2802 UGUGAUAUCAUGGUUCC 2803 UGUGAUAUCAUG 2804 ACCAUGAUAUC MIMAT0018180 UGGGA GUUCCUGG ACA hsa-miR-3689b* 2805 CUGGGAGGUGUGAUAUU 2806 CUGGGAGGUGUG 2807 AUCACACCUCC MIMAT0018181 GUGGU AUAUUGUG CAG hsa-miR-3690 2808 ACCUGGACCCAGCGUAG 2809 ACCUGGACCCAG 2810 CGCUGGGUCCA MIMAT0018119 ACAAAG CGUAGACA GGU hsa-miR-3691 2811 AGUGGAUGAUGGAGACU 2812 AGUGGAUGAUGG 2813 CUCCAUCAUCC MIMAT0018120 CGGUAC AGACUCGG ACU hsa-miR-3692 2814 GUUCCACACUGACACUG 2815 GUUCCACACUGA 2816 UGUCAGUGUGG MIMAT0018122 CAGAAGU CACUGCAG AAC hsa-miR-3692* 2817 CCUGCUGGUCAGGAGUG 2818 CCUGCUGGUCAG 2819 UCCUGACCAGC MIMAT0018121 GAUACUG GAGUGGAU AGG hsa-miR-369-3p 2820 AAUAAUACAUGGUUGAU 2821 AAUAAUACAUGG 2822 AACCAUGUAUU MIMAT0000721 CUUU UUGAUCUU AUU hsa-miR-369-5p 2823 AGAUCGACCGUGUUAUA 2824 AGAUCGACCGUG 2825 AACACGGUCGA MIMAT0001621 UUCGC UUAUAUUC UCU hsa-miR-370 2826 GCCUGCUGGGGUGGAAC 2827 GCCUGCUGGGGU 2828 CCACCCCAGCA MIMAT0000722 CUGGU GGAACCUG GGC hsa-miR-3713 2829 GGUAUCCGUUUGGGGAU 2830 GGUAUCCGUUUG 2831 CCCAAACGGAU MIMAT0018164 GGU GGGAUGGU ACC hsa-miR-371-3p 2832 AAGUGCCGCCAUCUUUU 2833 AAGUGCCGCCAU 2834 AGAUGGCGGCA MIMAT0000723 GAGUGU CUUUUGAG CUU hsa-miR-3714 2835 GAAGGCAGCAGUGCUCC 2836 GAAGGCAGCAGU 2837 GCACUGCUGCC MIMAT0018165 CCUGU GCUCCCCU UUC hsa-miR-371-5p 2838 ACUCAAACUGUGGGGGC 2839 ACUCAAACUGUG 2840 CCCACAGUUUG MIMAT0004687 ACU GGGGCACU AGU hsa-miR-372 2841 AAAGUGCUGCGACAUUU 2842 AAAGUGCUGCGA 2843 UGUCGCAGCAC MIMAT0000724 GAGCGU CAUUUGAG UUU hsa-miR-373 2844 GAAGUGCUUCGAUUUUG 2845 GAAGUGCUUCGA 2846 AAUCGAAGCAC MIMAT0000726 GGGUGU UUUUGGGG UUC hsa-miR-373* 2847 ACUCAAAAUGGGGGCGC 2848 ACUCAAAAUGGG 2849 CCCCCAUUUUG MIMAT0000725 UUUCC GGCGCUUU AGU hsa-miR-374a 2850 UUAUAAUACAACCUGAU 2851 UUAUAAUACAAC 2852 AGGUUGUAUUA MIMAT0000727 AAGUG CUGAUAAG UAA hsa-miR-374a* 2853 CUUAUCAGAUUGUAUUG 2854 CUUAUCAGAUUG 2855 UACAAUCUGAU MIMAT0004688 UAAUU UAUUGUAA AAG hsa-miR-374b 2856 AUAUAAUACAACCUGCU 2857 AUAUAAUACAAC 2858 AGGUUGUAUUA MIMAT0004955 AAGUG CUGCUAAG UAU hsa-miR-374b* 2859 CUUAGCAGGUUGUAUUA 2860 CUUAGCAGGUUG 2861 UACAACCUGCU MIMAT0004956 UCAUU UAUUAUCA AAG hsa-miR-374c 2862 AUAAUACAACCUGCUAA 2863 AUAAUACAACCU 2864 GCAGGUUGUAU MIMAT0018443 GUGCU GCUAAGUG UAU hsa-miR-375 2865 UUUGUUCGUUCGGCUCG 2866 UUUGUUCGUUCG 2867 GCCGAACGAAC MIMAT0000728 CGUGA GCUCGCGU AAA hsa-miR-376a 2868 AUCAUAGAGGAAAAUCC 2869 AUCAUAGAGGAA 2870 UUUUCCUCUAU MIMAT0000729 ACGU AAUCCACG GAU hsa-miR-376a* 2871 GUAGAUUCUCCUUCUAU 2872 GUAGAUUCUCCU 2873 GAAGGAGAAUC MIMAT0003386 GAGUA UCUAUGAG UAC hsa-miR-376b 2874 AUCAUAGAGGAAAAUCC 2875 AUCAUAGAGGAA 2876 UUUUCCUCUAU MIMAT0002172 AUGUU AAUCCAUG GAU hsa-miR-376c 2877 AACAUAGAGGAAAUUCC 2878 AACAUAGAGGAA 2879 AUUUCCUCUAU MIMAT0000720 ACGU AUUCCACG GUU hsa-miR-377 2880 AUCACACAAAGGCAACU 2881 AUCACACAAAGG 2882 UGCCUUUGUGU MIMAT0000730 UUUGU CAACUUUU GAU hsa-miR-377* 2883 AGAGGUUGCCCUUGGUG 2884 AGAGGUUGCCCU 2885 CAAGGGCAACC MIMAT0004689 AAUUC UGGUGAAU UCU hsa-miR-378 2886 ACUGGACUUGGAGUCAG 2887 ACUGGACUUGGA 2888 ACUCCAAGUCC MIMAT0000732 AAGG GUCAGAAG AGU hsa-miR-378* 2889 CUCCUGACUCCAGGUCC 2890 CUCCUGACUCCA 2891 CCUGGAGUCAG MIMAT0000731 UGUGU GGUCCUGU GAG hsa-miR-378b 2892 ACUGGACUUGGAGGCAG 2893 ACUGGACUUGGA 2894 CCUCCAAGUCC MIMAT0014999 AA GGCAGAA AGU hsa-miR-378c 2895 ACUGGACUUGGAGUCAG 2896 ACUGGACUUGGA 2897 ACUCCAAGUCC MIMAT0016847 AAGAGUGG GUCAGAAG AGU hsa-miR-379 2898 UGGUAGACUAUGGAACG 2899 UGGUAGACUAUG 2900 UCCAUAGUCUA MIMAT0000733 UAGG GAACGUAG CCA hsa-miR-379* 2901 UAUGUAACAUGGUCCAC 2902 UAUGUAACAUGG 2903 GACCAUGUUAC MIMAT0004690 UAACU UCCACUAA AUA hsa-miR-380 2904 UAUGUAAUAUGGUCCAC 2905 UAUGUAAUAUGG 2906 GACCAUAUUAC MIMAT0000735 AUCUU UCCACAUC AUA hsa-miR-380* 2907 UGGUUGACCAUAGAACA 2908 UGGUUGACCAUA 2909 UCUAUGGUCAA MIMAT0000734 UGCGC GAACAUGC CCA hsa-miR-381 2910 UAUACAAGGGCAAGCUC 2911 UAUACAAGGGCA 2912 CUUGCCCUUGU MIMAT0000736 UCUGU AGCUCUCU AUA hsa-miR-382 2913 GAAGUUGUUCGUGGUGG 2914 GAAGUUGUUCGU 2915 CCACGAACAAC MIMAT0000737 AUUCG GGUGGAUU UUC hsa-miR-383 2916 AGAUCAGAAGGUGAUUG 2917 AGAUCAGAAGGU 2918 UCACCUUCUGA MIMAT0000738 UGGCU GAUUGUGG UCU hsa-miR-384 2919 AUUCCUAGAAAUUGUUC 2920 AUUCCUAGAAAU 2921 CAAUUUCUAGG MIMAT0001075 AUA UGUUCAUA AAU hsa-miR-3907 2922 AGGUGCUCCAGGCUGGC 2923 AGGUGCUCCAGG 2924 AGCCUGGAGCA MIMAT0018179 UCACA CUGGCUCA CCU hsa-miR-3908 2925 GAGCAAUGUAGGUAGAC 2926 GAGCAAUGUAGG 2927 UACCUACAUUG MIMAT0018182 UGUUU UAGACUGU CUC hsa-miR-3909 2928 UGUCCUCUAGGGCCUGC 2929 UGUCCUCUAGGG 2930 GGCCCUAGAGG MIMAT0018183 AGUCU CCUGCAGU ACA hsa-miR-3910 2931 AAAGGCAUAAAACCAAG 2932 AAAGGCAUAAAA 2933 GGUUUUAUGCC MIMAT0018184 ACA CCAAGACA UUU hsa-miR-3911 2934 UGUGUGGAUCCUGGAGG 2935 UGUGUGGAUCCU 2936 CCAGGAUCCAC MIMAT0018185 AGGCA GGAGGAGG ACA hsa-miR-3912 2937 UAACGCAUAAUAUGGAC 2938 UAACGCAUAAUA 2939 CAUAUUAUGCG MIMAT0018186 AUGU UGGACAUG UUA hsa-miR-3913 2940 UUUGGGACUGAUCUUGA 2941 UUUGGGACUGAU 2942 AGAUCAGUCCC MIMAT0018187 UGUCU CUUGAUGU AAA hsa-miR-3914 2943 AAGGAACCAGAAAAUGA 2944 AAGGAACCAGAA 2945 UUUUCUGGUUC MIMAT0018188 GAAGU AAUGAGAA CUU hsa-miR-3915 2946 UUGAGGAAAAGAUGGUC 2947 UUGAGGAAAAGA 2948 CAUCUUUUCCU MIMAT0018189 UUAUU UGGUCUUA CAA hsa-miR-3916 2949 AAGAGGAAGAAAUGGCU 2950 AAGAGGAAGAAA 2951 CAUUUCUUCCU MIMAT0018190 GGUUCUCAG UGGCUGGU CUU hsa-miR-3917 2952 GCUCGGACUGAGCAGGU 2953 GCUCGGACUGAG 2954 UGCUCAGUCCG MIMAT0018191 GGG CAGGUGGG AGC hsa-miR-3918 2955 ACAGGGCCGCAGAUGGA 2956 ACAGGGCCGCAG 2957 AUCUGCGGCCC MIMAT0018192 GACU AUGGAGAC UGU hsa-miR-3919 2958 GCAGAGAACAAAGGACU 2959 GCAGAGAACAAA 2960 CCUUUGUUCUC MIMAT0018193 CAGU GGACUCAG UGC hsa-miR-3920 2961 ACUGAUUAUCUUAACUC 2962 ACUGAUUAUCUU 2963 UUAAGAUAAUC MIMAT0018195 UCUGA AACUCUCU AGU hsa-miR-3921 2964 UCUCUGAGUACCAUAUG 2965 UCUCUGAGUACC 2966 AUGGUACUCAG MIMAT0018196 CCUUGU AUAUGCCU AGA hsa-miR-3922 2967 UCUGGCCUUGACUUGAC 2968 UCUGGCCUUGAC 2969 AAGUCAAGGCC MIMAT0018197 UCUUU UUGACUCU AGA hsa-miR-3923 2970 AACUAGUAAUGUUGGAU 2971 AACUAGUAAUGU 2972 CAACAUUACUA MIMAT0018198 UAGGG UGGAUUAG GUU hsa-miR-3924 2973 AUAUGUAUAUGUGACUG 2974 AUAUGUAUAUGU 2975 UCACAUAUACA MIMAT0018199 CUACU GACUGCUA UAU hsa-miR-3925 2976 AAGAGAACUGAAAGUGG 2977 AAGAGAACUGAA 2978 CUUUCAGUUCU MIMAT0018200 AGCCU AGUGGAGC CUU hsa-miR-3926 2979 UGGCCAAAAAGCAGGCA 2980 UGGCCAAAAAGC 2981 CUGCUUUUUGG MIMAT0018201 GAGA AGGCAGAG CCA hsa-miR-3927 2982 CAGGUAGAUAUUUGAUA 2983 CAGGUAGAUAUU 2984 CAAAUAUCUAC MIMAT0018202 GGCAU UGAUAGGC CUG hsa-miR-3928 2985 GGAGGAACCUUGGAGCU 2986 GGAGGAACCUUG 2987 UCCAAGGUUCC MIMAT0018205 UCGGC GAGCUUCG UCC hsa-miR-3929 2988 GAGGCUGAUGUGAGUAG 2989 GAGGCUGAUGUG 2990 CUCACAUCAGC MIMAT0018206 ACCACU AGUAGACC CUC hsa-miR-3934 2991 UCAGGUGUGGAAACUGA 2992 UCAGGUGUGGAA 2993 GUUUCCACACC MIMAT0018349 GGCAG ACUGAGGC UGA hsa-miR-3935 2994 UGUAGAUACGAGCACCA 2995 UGUAGAUACGAG 2996 UGCUCGUAUCU MIMAT0018350 GCCAC CACCAGCC ACA hsa-miR-3936 2997 UAAGGGGUGUAUGGCAG 2998 UAAGGGGUGUAU 2999 CCAUACACCCC MIMAT0018351 AUGCA GGCAGAUG UUA hsa-miR-3937 3000 ACAGGCGGCUGUAGCAA 3001 ACAGGCGGCUGU 3002 CUACAGCCGCC MIMAT0018352 UGGGGG AGCAAUGG UGU hsa-miR-3938 3003 AAUUCCCUUGUAGAUAA 3004 AAUUCCCUUGUA 3005 UCUACAAGGGA MIMAT0018353 CCCGG GAUAACCC AUU hsa-miR-3939 3006 UACGCGCAGACCACAGG 3007 UACGCGCAGACC 3008 GUGGUCUGCGC MIMAT0018355 AUGUC ACAGGAUG GUA hsa-miR-3940 3009 CAGCCCGGAUCCCAGCC 3010 CAGCCCGGAUCC 3011 UGGGAUCCGGG MIMAT0018356 CACUU CAGCCCAC CUG hsa-miR-3941 3012 UUACACACAACUGAGGA 3013 UUACACACAACU 3014 UCAGUUGUGUG MIMAT0018357 UCAUA GAGGAUCA UAA hsa-miR-3942 3015 AAGCAAUACUGUUACCU 3016 AAGCAAUACUGU 3017 UAACAGUAUUG MIMAT0018358 GAAAU UACCUGAA CUU hsa-miR-3943 3018 UAGCCCCCAGGCUUCAC 3019 UAGCCCCCAGGC 3020 AAGCCUGGGGG MIMAT0018359 UUGGCG UUCACUUG CUA hsa-miR-3944 3021 UUCGGGCUGGCCUGCUG 3022 UUCGGGCUGGCC 3023 CAGGCCAGCCC MIMAT0018360 CUCCGG UGCUGCUC GAA hsa-miR-3945 3024 AGGGCAUAGGAGAGGGU 3025 AGGGCAUAGGAG 3026 CUCUCCUAUGC MIMAT0018361 UGAUAU AGGGUUGA CCU hsa-miR-409-3p 3027 GAAUGUUGCUCGGUGAA 3028 GAAUGUUGCUCG 3029 ACCGAGCAACA MIMAT0001639 CCCCU GUGAACCC UUC hsa-miR-409-5p 3030 AGGUUACCCGAGCAACU 3031 AGGUUACCCGAG 3032 UGCUCGGGUAA MIMAT0001638 UUGCAU CAACUUUG CCU hsa-miR-410 3033 AAUAUAACACAGAUGGC 3034 AAUAUAACACAG 3035 AUCUGUGUUAU MIMAT0002171 CUGU AUGGCCUG AUU hsa-miR-411 3036 UAGUAGACCGUAUAGCG 3037 UAGUAGACCGUA 3038 UAUACGGUCUA MIMAT0003329 UACG UAGCGUAC CUA hsa-miR-411* 3039 UAUGUAACACGGUCCAC 3040 UAUGUAACACGG 3041 GACCGUGUUAC MIMAT0004813 UAACC UCCACUAA AUA hsa-miR-412 3042 ACUUCACCUGGUCCACU 3043 ACUUCACCUGGU 3044 GGACCAGGUGA MIMAT0002170 AGCCGU CCACUAGC AGU hsa-miR-421 3045 AUCAACAGACAUUAAUU 3046 AUCAACAGACAU 3047 UAAUGUCUGUU MIMAT0003339 GGGCGC UAAUUGGG GAU hsa-miR-422a 3048 ACUGGACUUAGGGUCAG 3049 ACUGGACUUAGG 3050 ACCCUAAGUCC MIMAT0001339 AAGGC GUCAGAAG AGU hsa-miR-423-3p 3051 AGCUCGGUCUGAGGCCC 3052 AGCUCGGUCUGA 3053 CCUCAGACCGA MIMAT0001340 CUCAGU GGCCCCUC GCU hsa-miR-423-5p 3054 UGAGGGGCAGAGAGCGA 3055 UGAGGGGCAGAG 3056 CUCUCUGCCCC MIMAT0004748 GACUUU AGCGAGAC UCA hsa-miR-424 3057 CAGCAGCAAUUCAUGUU 3058 CAGCAGCAAUUC 3059 AUGAAUUGCUG MIMAT0001341 UUGAA AUGUUUUG CUG hsa-miR-424* 3060 CAAAACGUGAGGCGCUG 3061 CAAAACGUGAGG 3062 CGCCUCACGUU MIMAT0004749 CUAU CGCUGCUA UUG hsa-miR-425 3063 AAUGACACGAUCACUCC 3064 AAUGACACGAUC 3065 GUGAUCGUGUC MIMAT0003393 CGUUGA ACUCCCGU AUU hsa-miR-425* 3066 AUCGGGAAUGUCGUGUC 3067 AUCGGGAAUGUC 3068 ACGACAUUCCC MIMAT0001343 CGCCC GUGUCCGC GAU hsa-miR-4251 3069 CCUGAGAAAAGGGCCAA 3070 CCUGAGAAAAGG 3071 GCCCUUUUCUC MIMAT0016883 GCCAA AGG hsa-miR-4252 3072 GGCCACUGAGUCAGCAC 3073 GGCCACUGAGUC 3074 CUGACUCAGUG MIMAT0016886 CA AGCACCA GCC hsa-miR-4253 3075 AGGGCAUGUCCAGGGGG 3076 AGGGCAUGUCCA 3077 CCUGGACAUGC MIMAT0016882 U GGGGGU CCU hsa-miR-4254 3078 GCCUGGAGCUACUCCAC 3079 GCCUGGAGCUAC 3080 GAGUAGCUCCA MIMAT0016884 CAUCUC UCCACCAU GGC hsa-miR-4255 3081 CAGUGUUCAGAGAUGGA 3082 CAGUGUUCAGAG 3083 AUCUCUGAACA MIMAT0016885 AUGGA CUG hsa-miR-4256 3084 AUCUGACCUGAUGAAGG 3085 AUCUGACCUGAU 3086 UCAUCAGGUCA MIMAT0016877 U GAAGGU GAU hsa-miR-4257 3087 CCAGAGGUGGGGACUGA 3088 CCAGAGGUGGGG 3089 GUCCCCACCUC MIMAT0016878 G ACUGAG UGG hsa-miR-4258 3090 CCCCGCCACCGCCUUGG 3091 CCCCGCCACCGC 3092 AGGCGGUGGCG MIMAT0016879 CUUGG GGG hsa-miR-4259 3093 CAGUUGGGUCUAGGGGU 3094 CAGUUGGGUCUA 3095 CCUAGACCCAA MIMAT0016880 CAGGA GGGGUCAG CUG hsa-miR-4260 3096 CUUGGGGCAUGGAGUCC 3097 CUUGGGGCAUGG 3098 CUCCAUGCCCC MIMAT0016881 CA AGUCCCA AAG hsa-miR-4261 3099 AGGAAACAGGGACCCA 3100 AGGAAACAGGGA 3101 GGUCCCUGUUU MIMAT0016890 CCCA CCU hsa-miR-4262 3102 GACAUUCAGACUACCUG 3103 GACAUUCAGACU 3104 GUAGUCUGAAU MIMAT0016894 ACCUG GUC hsa-miR-4263 3105 AUUCUAAGUGCCUUGGC 3106 AUUCUAAGUGCC 3107 AAGGCACUUAG MIMAT0016898 C UUGGCC AAU hsa-miR-4264 3108 ACUCAGUCAUGGUCAUU 3109 ACUCAGUCAUGG 3110 GACCAUGACUG MIMAT0016899 UCAUU AGU hsa-miR-4265 3111 CUGUGGGCUCAGCUCUG 3112 CUGUGGGCUCAG 3113 AGCUGAGCCCA MIMAT0016891 GG CUCUGGG CAG hsa-miR-4266 3114 CUAGGAGGCCUUGGCC 3115 CUAGGAGGCCUU 3116 CCAAGGCCUCC MIMAT0016892 GGCC UAG hsa-miR-4267 3117 UCCAGCUCGGUGGCAC 3118 UCCAGCUCGGUG 3119 GCCACCGAGCU MIMAT0016893 GCAC GGA hsa-miR-4268 3120 GGCUCCUCCUCUCAGGA 3121 GGCUCCUCCUCU 3122 UGAGAGGAGGA MIMAT0016896 UGUG CAGGAUGU GCC hsa-miR-4269 3123 GCAGGCACAGACAGCCC 3124 GCAGGCACAGAC 3125 CUGUCUGUGCC MIMAT0016897 UGGC AGCCCUGG UGC hsa-miR-4270 3126 UCAGGGAGUCAGGGGAG 3127 UCAGGGAGUCAG 3128 CCCUGACUCCC MIMAT0016900 GGC GGGAGGGC UGA hsa-miR-4271 3129 GGGGGAAGAAAAGGUGG 3130 GGGGGAAGAAAA 3131 CCUUUUCUUCC MIMAT0016901 GG GGUGGGG CCC hsa-miR-4272 3132 CAUUCAACUAGUGAUUG 3133 CAUUCAACUAGU 3134 UCACUAGUUGA MIMAT0016902 U GAUUGU AUG hsa-miR-4273 3135 GUGUUCUCUGAUGGACA 3136 GUGUUCUCUGAU 3137 CCAUCAGAGAA MIMAT0016903 G GGACAG CAC hsa-miR-4274 3138 CAGCAGUCCCUCCCCCU 3139 CAGCAGUCCCUC 3140 GGGAGGGACUG MIMAT0016906 G CCCCUG CUG hsa-miR-4275 3141 CCAAUUACCACUUCUUU 3142 CCAAUUACCACU 3143 GAAGUGGUAAU MIMAT0016905 UCUUU UGG hsa-miR-4276 3144 CUCAGUGACUCAUGUGC 3145 CUCAGUGACUCA 3146 CAUGAGUCACU MIMAT0016904 UGUGC GAG hsa-miR-4277 3147 GCAGUUCUGAGCACAGU 3148 GCAGUUCUGAGC 3149 GUGCUCAGAAC MIMAT0016908 ACAC ACAGUACA UGC hsa-miR-4278 3150 CUAGGGGGUUUGCCCUU 3151 CUAGGGGGUUUG 3152 GGCAAACCCCC MIMAT0016910 G CCCUUG UAG hsa-miR-4279 3153 CUCUCCUCCCGGCUUC 3154 CUCUCCUCCCGG 3155 AGCCGGGAGGA MIMAT0016909 CUUC GAG hsa-miR-4280 3156 GAGUGUAGUUCUGAGCA 3157 GAGUGUAGUUCU 3158 UCAGAACUACA MIMAT0016911 GAGC GAGCAGAG CUC hsa-miR-4281 3159 GGGUCCCGGGGAGGGGG 3160 GGGUCCCGGGGA 3161 CCUCCCCGGGA MIMAT0016907 G GGGGGG CCC hsa-miR-4282 3162 UAAAAUUUGCAUCCAGG 3163 UAAAAUUUGCAU 3164 GGAUGCAAAUU MIMAT0016912 A CCAGGA UUA hsa-miR-4283 3165 UGGGGCUCAGCGAGUUU 3166 UGGGGCUCAGCG 3167 CUCGCUGAGCC MIMAT0016914 AGUUU CCA hsa-miR-4284 3168 GGGCUCACAUCACCCCA 3169 GGGCUCACAUCA 3170 GGUGAUGUGAG MIMAT0016915 U CCCCAU CCC hsa-miR-4285 3171 GCGGCGAGUCCGACUCA 3172 GCGGCGAGUCCG 3173 GUCGGACUCGC MIMAT0016913 U ACUCAU CGC hsa-miR-4286 3174 ACCCCACUCCUGGUACC 3175 ACCCCACUCCUG 3176 ACCAGGAGUGG MIMAT0016916 GUACC GGU hsa-miR-4287 3177 UCUCCCUUGAGGGCACU 3178 UCUCCCUUGAGG 3179 GCCCUCAAGGG MIMAT0016917 UU GCACUUU AGA hsa-miR-4288 3180 UUGUCUGCUGAGUUUCC 3181 UUGUCUGCUGAG 3182 AACUCAGCAGA MIMAT0016918 UUUCC CAA hsa-miR-4289 3183 GCAUUGUGCAGGGCUAU 3184 GCAUUGUGCAGG 3185 GCCCUGCACAA MIMAT0016920 CA GCUAUCA UGC hsa-miR-429 3186 UAAUACUGUCUGGUAAA 3187 UAAUACUGUCUG 3188 ACCAGACAGUA MIMAT0001536 ACCGU GUAAAACC UUA hsa-miR-4290 3189 UGCCCUCCUUUCUUCCC 3190 UGCCCUCCUUUC 3191 AAGAAAGGAGG MIMAT0016921 UC UUCCCUC GCA hsa-miR-4291 3192 UUCAGCAGGAACAGCU 3193 UUCAGCAGGAAC 3194 CUGUUCCUGCU MIMAT0016922 AGCU GAA hsa-miR-4292 3195 CCCCUGGGCCGGCCUUG 3196 CCCCUGGGCCGG 3197 GGCCGGCCCAG MIMAT0016919 G CCUUGG GGG hsa-miR-4293 3198 CAGCCUGACAGGAACAG 3199 CAGCCUGACAGG 3200 UUCCUGUCAGG MIMAT0016848 AACAG CUG hsa-miR-4294 3201 GGGAGUCUACAGCAGGG 3202 GGGAGUCUACAG 3203 UGCUGUAGACU MIMAT0016849 CAGGG CCC hsa-miR-4295 3204 CAGUGCAAUGUUUUCCU 3205 CAGUGCAAUGUU 3206 AAAACAUUGCA MIMAT0016844 U UUCCUU CUG hsa-miR-4296 3207 AUGUGGGCUCAGGCUCA 3208 AUGUGGGCUCAG 3209 GCCUGAGCCCA MIMAT0016845 GCUCA CAU hsa-miR-4297 3210 UGCCUUCCUGUCUGUG 3211 UGCCUUCCUGUC 3212 CAGACAGGAAG MIMAT0016846 UGUG GCA hsa-miR-4298 3213 CUGGGACAGGAGGAGGA 3214 CUGGGACAGGAG 3215 UCCUCCUGUCC MIMAT0016852 GGCAG GAGGAGGC CAG hsa-miR-4299 3216 GCUGGUGACAUGAGAGG 3217 GCUGGUGACAUG 3218 CUCAUGUCACC MIMAT0016851 C AGAGGC AGC hsa-miR-4300 3219 UGGGAGCUGGACUACUU 3220 UGGGAGCUGGAC 3221 UAGUCCAGCUC MIMAT0016853 C UACUUC CCA hsa-miR-4301 3222 UCCCACUACUUCACUUG 3223 UCCCACUACUUC 3224 GUGAAGUAGUG MIMAT0016850 UGA ACUUGUGA GGA hsa-miR-4302 3225 CCAGUGUGGCUCAGCGA 3226 CCAGUGUGGCUC 3227 CUGAGCCACAC MIMAT0016855 G AGCGAG UGG hsa-miR-4303 3228 UUCUGAGCUGAGGACAG 3229 UUCUGAGCUGAG 3230 UCCUCAGCUCA MIMAT0016856 GACAG GAA hsa-miR-4304 3231 CCGGCAUGUCCAGGGCA 3232 CCGGCAUGUCCA 3233 CCUGGACAUGC MIMAT0016854 GGGCA CGG hsa-miR-4305 3234 CCUAGACACCUCCAGUU 3235 CCUAGACACCUC 3236 UGGAGGUGUCU MIMAT0016857 C CAGUUC AGG hsa-miR-4306 3237 UGGAGAGAAAGGCAGUA 3238 UGGAGAGAAAGG 3239 UGCCUUUCUCU MIMAT0016858 CAGUA CCA hsa-miR-4307 3240 AAUGUUUUUUCCUGUUU 3241 AAUGUUUUUUCC 3242 CAGGAAAAAAC MIMAT0016860 CC UGUUUCC AUU hsa-miR-4308 3243 UCCCUGGAGUUUCUUCU 3244 UCCCUGGAGUUU 3245 AGAAACUCCAG MIMAT0016861 U CUUCUU GGA hsa-miR-4309 3246 CUGGAGUCUAGGAUUCC 3247 CUGGAGUCUAGG 3248 AUCCUAGACUC MIMAT0016859 A AUUCCA CAG hsa-miR-431 3249 UGUCUUGCAGGCCGUCA 3250 UGUCUUGCAGGC 3251 CGGCCUGCAAG MIMAT0001625 UGCA CGUCAUGC ACA hsa-miR-431* 3252 CAGGUCGUCUUGCAGGG 3253 CAGGUCGUCUUG 3254 UGCAAGACGAC MIMAT0004757 CUUCU CAGGGCUU CUG hsa-miR-4310 3255 GCAGCAUUCAUGUCCC 3256 GCAGCAUUCAUG 3257 GACAUGAAUGC MIMAT0016862 UCCC UGC hsa-miR-4311 3258 GAAAGAGAGCUGAGUGU 3259 GAAAGAGAGCUG 3260 CUCAGCUCUCU MIMAT0016863 G AGUGUG UUC hsa-miR-4312 3261 GGCCUUGUUCCUGUCCC 3262 GGCCUUGUUCCU 3263 ACAGGAACAAG MIMAT0016864 CA GUCCCCA GCC hsa-miR-4313 3264 AGCCCCCUGGCCCCAAA 3265 AGCCCCCUGGCC 3266 GGGGCCAGGGG MIMAT0016865 CCC CCAAACCC GCU hsa-miR-4314 3267 CUCUGGGAAAUGGGACA 3268 CUCUGGGAAAUG 3269 CCCAUUUCCCA MIMAT0016868 G GGACAG GAG hsa-miR-4315 3270 CCGCUUUCUGAGCUGGA 3271 CCGCUUUCUGAG 3272 AGCUCAGAAAG MIMAT0016866 C CUGGAC CGG hsa-miR-4316 3273 GGUGAGGCUAGCUGGUG 3274 GGUGAGGCUAGC 3275 CAGCUAGCCUC MIMAT0016867 UGGUG ACC hsa-miR-4317 3276 ACAUUGCCAGGGAGUUU 3277 ACAUUGCCAGGG 3278 CUCCCUGGCAA MIMAT0016872 AGUUU UGU hsa-miR-4318 3279 CACUGUGGGUACAUGCU 3280 CACUGUGGGUAC 3281 AUGUACCCACA MIMAT0016869 AUGCU GUG hsa-miR-4319 3282 UCCCUGAGCAAAGCCAC 3283 UCCCUGAGCAAA 3284 GCUUUGCUCAG MIMAT0016870 GCCAC GGA hsa-miR-432 3285 UCUUGGAGUAGGUCAUU 3286 UCUUGGAGUAGG 3287 GACCUACUCCA MIMAT0002814 GGGUGG UCAUUGGG AGA hsa-miR-432* 3288 CUGGAUGGCUCCUCCAU 3289 CUGGAUGGCUCC 3290 GAGGAGCCAUC MIMAT0002815 GUCU UCCAUGUC CAG hsa-miR-4320 3291 GGGAUUCUGUAGCUUCC 3292 GGGAUUCUGUAG 3293 AGCUACAGAAU MIMAT0016871 U CUUCCU CCC hsa-miR-4321 3294 UUAGCGGUGGACCGCCC 3295 UUAGCGGUGGAC 3296 CGGUCCACCGC MIMAT0016874 UGCG CGCCCUGC UAA hsa-miR-4322 3297 CUGUGGGCUCAGCGCGU 3298 CUGUGGGCUCAG 3299 CGCUGAGCCCA MIMAT0016873 GGGG CGCGUGGG CAG hsa-miR-4323 3300 CAGCCCCACAGCCUCAG 3301 CAGCCCCACAGC 3302 AGGCUGUGGGG MIMAT0016875 A CUCAGA CUG hsa-miR-4324 3303 CCCUGAGACCCUAACCU 3304 CCCUGAGACCCU 3305 UUAGGGUCUCA MIMAT0016876 UAA AACCUUAA GGG hsa-miR-4325 3306 UUGCACUUGUCUCAGUG 3307 UUGCACUUGUCU 3308 UGAGACAAGUG MIMAT0016887 A CAGUGA CAA hsa-miR-4326 3309 UGUUCCUCUGUCUCCCA 3310 UGUUCCUCUGUC 3311 GAGACAGAGGA MIMAT0016888 GAC UCCCAGAC ACA hsa-miR-4327 3312 GGCUUGCAUGGGGGACU 3313 GGCUUGCAUGGG 3314 CCCCCAUGCAA MIMAT0016889 GG GGACUGG GCC hsa-miR-4328 3315 CCAGUUUUCCCAGGAUU 3316 CCAGUUUUCCCA 3317 CCUGGGAAAAC MIMAT0016926 GGAUU UGG hsa-miR-4329 3318 CCUGAGACCCUAGUUCC 3319 CCUGAGACCCUA 3320 ACUAGGGUCUC MIMAT0016923 AC GUUCCAC AGG hsa-miR-433 3321 AUCAUGAUGGGCUCCUC 3322 AUCAUGAUGGGC 3323 GAGCCCAUCAU MIMAT0001627 GGUGU UCCUCGGU GAU hsa-miR-4330 3324 CCUCAGAUCAGAGCCUU 3325 CCUCAGAUCAGA 3326 GCUCUGAUCUG MIMAT0016924 GC GCCUUGC AGG hsa-miR-448 3327 UUGCAUAUGUAGGAUGU 3328 UUGCAUAUGUAG 3329 UCCUACAUAUG MIMAT0001532 CCCAU GAUGUCCC CAA hsa-miR-449a 3330 UGGCAGUGUAUUGUUAG 3331 UGGCAGUGUAUU 3332 ACAAUACACUG MIMAT0001541 CUGGU GUUAGCUG CCA hsa-miR-449b 3333 AGGCAGUGUAUUGUUAG 3334 AGGCAGUGUAUU 3335 ACAAUACACUG MIMAT0003327 CUGGC GUUAGCUG CCU hsa-miR-449b* 3336 CAGCCACAACUACCCUG 3337 CAGCCACAACUA 3338 GGUAGUUGUGG MIMAT0009203 CCACU CCCUGCCA CUG hsa-miR-449c 3339 UAGGCAGUGUAUUGCUA 3340 UAGGCAGUGUAU 3341 CAAUACACUGC MIMAT0010251 GCGGCUGU UGCUAGCG CUA hsa-miR-449c* 3342 UUGCUAGUUGCACUCCU 3343 UUGCUAGUUGCA 3344 AGUGCAACUAG MIMAT0013771 CUCUGU CUCCUCUC CAA hsa-miR-450a 3345 UUUUGCGAUGUGUUCCU 3346 UUUUGCGAUGUG 3347 AACACAUCGCA MIMAT0001545 AAUAU UUCCUAAU AAA hsa-miR-450b- 3348 UUGGGAUCAUUUUGCAU 3349 UUGGGAUCAUUU 3350 CAAAAUGAUCC 3p CCAUA UGCAUCCA CAA MIMAT0004910 hsa-miR-450b- 3351 UUUUGCAAUAUGUUCCU 3352 UUUUGCAAUAUG 3353 AACAUAUUGCA 5p GAAUA UUCCUGAA AAA MIMAT0004909 hsa-miR-451 3354 AAACCGUUACCAUUACU 3355 AAACCGUUACCA 3356 AAUGGUAACGG MIMAT0001631 GAGUU UUACUGAG UUU hsa-miR-452 3357 AACUGUUUGCAGAGGAA 3358 AACUGUUUGCAG 3359 CUCUGCAAACA MIMAT0001635 ACUGA AGGAAACU GUU hsa-miR-452* 3360 CUCAUCUGCAAAGAAGU 3361 CUCAUCUGCAAA 3362 UCUUUGCAGAU MIMAT0001636 AAGUG GAAGUAAG GAG hsa-miR-454 3363 UAGUGCAAUAUUGCUUA 3364 UAGUGCAAUAUU 3365 GCAAUAUUGCA MIMAT0003885 UAGGGU GCUUAUAG CUA hsa-miR-454* 3366 ACCCUAUCAAUAUUGUC 3367 ACCCUAUCAAUA 3368 AAUAUUGAUAG MIMAT0003884 UCUGC UUGUCUCU GGU hsa-miR-455-3p 3369 GCAGUCCAUGGGCAUAU 3370 GCAGUCCAUGGG 3371 UGCCCAUGGAC MIMAT0004784 ACAC CAUAUACA UGC hsa-miR-455-5p 3372 UAUGUGCCUUUGGACUA 3373 UAUGUGCCUUUG 3374 UCCAAAGGCAC MIMAT0003150 CAUCG GACUACAU AUA hsa-miR-466 3375 AUACACAUACACGCAAC 3376 AUACACAUACAC 3377 GCGUGUAUGUG MIMAT0015002 ACACAU GCAACACA UAU hsa-miR-483-3p 3378 UCACUCCUCUCCUCCCG 3379 UCACUCCUCUCC 3380 GAGGAGAGGAG MIMAT0002173 UCUU UCCCGUCU UGA hsa-miR-483-5p 3381 AAGACGGGAGGAAAGAA 3382 AAGACGGGAGGA 3383 UUUCCUCCCGU MIMAT0004761 GGGAG AAGAAGGG CUU hsa-miR-484 3384 UCAGGCUCAGUCCCCUC 3385 UCAGGCUCAGUC 3386 GGGACUGAGCC MIMAT0002174 CCGAU CCCUCCCG UGA hsa-miR-485-3p 3387 GUCAUACACGGCUCUCC 3388 GUCAUACACGGC 3389 GAGCCGUGUAU MIMAT0002176 UCUCU UCUCCUCU GAC hsa-miR-485-5p 3390 AGAGGCUGGCCGUGAUG 3391 AGAGGCUGGCCG 3392 CACGGCCAGCC MIMAT0002175 AAUUC UGAUGAAU UCU hsa-miR-486-3p 3393 CGGGGCAGCUCAGUACA 3394 CGGGGCAGCUCA 3395 ACUGAGCUGCC MIMAT0004762 GGAU GUACAGGA CCG hsa-miR-486-5p 3396 UCCUGUACUGAGCUGCC 3397 UCCUGUACUGAG 3398 AGCUCAGUACA MIMAT0002177 CCGAG CUGCCCCG GGA hsa-miR-487a 3399 AAUCAUACAGGGACAUC 3400 AAUCAUACAGGG 3401 GUCCCUGUAUG MIMAT0002178 CAGUU ACAUCCAG AUU hsa-miR-487b 3402 AAUCGUACAGGGUCAUC 3403 AAUCGUACAGGG 3404 GACCCUGUACG MIMAT0003180 CACUU UCAUCCAC AUU hsa-miR-488 3405 UUGAAAGGCUAUUUCUU 3406 UUGAAAGGCUAU 3407 AAAUAGCCUUU MIMAT0004763 GGUC UUCUUGGU CAA hsa-miR-488* 3408 CCCAGAUAAUGGCACUC 3409 CCCAGAUAAUGG 3410 UGCCAUUAUCU MIMAT0002804 UCAA CACUCUCA GGG hsa-miR-489 3411 GUGACAUCACAUAUACG 3412 GUGACAUCACAU 3413 AUAUGUGAUGU MIMAT0002805 GCAGC AUACGGCA CAC hsa-miR-490-3p 3414 CAACCUGGAGGACUCCA 3415 CAACCUGGAGGA 3416 AGUCCUCCAGG MIMAT0002806 UGCUG CUCCAUGC UUG hsa-miR-490-5p 3417 CCAUGGAUCUCCAGGUG 3418 CCAUGGAUCUCC 3419 CUGGAGAUCCA MIMAT0004764 GGU AGGUGGGU UGG hsa-miR-491-3p 3420 CUUAUGCAAGAUUCCCU 3421 CUUAUGCAAGAU 3422 GAAUCUUGCAU MIMAT0004765 UCUAC UCCCUUCU AAG hsa-miR-491-5p 3423 AGUGGGGAACCCUUCCA 3424 AGUGGGGAACCC 3425 AAGGGUUCCCC MIMAT0002807 UGAGG UUCCAUGA ACU hsa-miR-492 3426 AGGACCUGCGGGACAAG 3427 AGGACCUGCGGG 3428 GUCCCGCAGGU MIMAT0002812 AUUCUU ACAAGAUU CCU hsa-miR-493 3429 UGAAGGUCUACUGUGUG 3430 UGAAGGUCUACU 3431 ACAGUAGACCU MIMAT0003161 CCAGG GUGUGCCA UCA hsa-miR-493* 3432 UUGUACAUGGUAGGCUU 3433 UUGUACAUGGUA 3434 CCUACCAUGUA MIMAT0002813 UCAUU GGCUUUCA CAA hsa-miR-494 3435 UGAAACAUACACGGGAA 3436 UGAAACAUACAC 3437 CCGUGUAUGUU MIMAT0002816 ACCUC GGGAAACC UCA hsa-miR-495 3438 AAACAAACAUGGUGCAC 3439 AAACAAACAUGG 3440 CACCAUGUUUG MIMAT0002817 UUCUU UGCACUUC UUU hsa-miR-496 3441 UGAGUAUUACAUGGCCA 3442 UGAGUAUUACAU 3443 CCAUGUAAUAC MIMAT0002818 AUCUC GGCCAAUC UCA hsa-miR-497 3444 CAGCAGCACACUGUGGU 3445 CAGCAGCACACU 3446 ACAGUGUGCUG MIMAT0002820 UUGU GUGGUUUG CUG hsa-miR-497* 3447 CAAACCACACUGUGGUG 3448 CAAACCACACUG 3449 CACAGUGUGGU MIMAT0004768 UUAGA UGGUGUUA UUG hsa-miR-498 3450 UUUCAAGCCAGGGGGCG 3451 UUUCAAGCCAGG 3452 CCCCUGGCUUG MIMAT0002824 UUUUUC GGGCGUUU AAA hsa-miR-499-3p 3453 AACAUCACAGCAAGUCU 3454 AACAUCACAGCA 3455 CUUGCUGUGAU MIMAT0004772 GUGCU AGUCUGUG GUU hsa-miR-499-5p 3456 UUAAGACUUGCAGUGAU 3457 UUAAGACUUGCA 3458 ACUGCAAGUCU MIMAT0002870 GUUU GUGAUGUU UAA hsa-miR-500a 3459 UAAUCCUUGCUACCUGG 3460 UAAUCCUUGCUA 3461 GGUAGCAAGGA MIMAT0004773 GUGAGA CCUGGGUG UUA hsa-miR-500a* 3462 AUGCACCUGGGCAAGGA 3463 AUGCACCUGGGC 3464 UUGCCCAGGUG MIMAT0002871 UUCUG AAGGAUUC CAU hsa-miR-500b 3465 AAUCCUUGCUACCUGGG 3466 AAUCCUUGCUAC 3467 AGGUAGCAAGG MIMAT0016925 U CUGGGU AUU hsa-miR-501-3p 3468 AAUGCACCCGGGCAAGG 3469 AAUGCACCCGGG 3470 UGCCCGGGUGC MIMAT0004774 AUUCU CAAGGAUU AUU hsa-miR-501-5p 3471 AAUCCUUUGUCCCUGGG 3472 AAUCCUUUGUCC 3473 AGGGACAAAGG MIMAT0002872 UGAGA CUGGGUGA AUU hsa-miR-502-3p 3474 AAUGCACCUGGGCAAGG 3475 AAUGCACCUGGG 3476 UGCCCAGGUGC MIMAT0004775 AUUCA CAAGGAUU AUU hsa-miR-502-5p 3477 AUCCUUGCUAUCUGGGU 3478 AUCCUUGCUAUC 3479 CAGAUAGCAAG MIMAT0002873 GCUA UGGGUGCU GAU hsa-miR-503 3480 UAGCAGCGGGAACAGUU 3481 UAGCAGCGGGAA 3482 UGUUCCCGCUG MIMAT0002874 CUGCAG CAGUUCUG CUA hsa-miR-504 3483 AGACCCUGGUCUGCACU 3484 AGACCCUGGUCU 3485 GCAGACCAGGG MIMAT0002875 CUAUC GCACUCUA UCU hsa-miR-505 3486 CGUCAACACUUGCUGGU 3487 CGUCAACACUUG 3488 AGCAAGUGUUG MIMAT0002876 UUCCU CUGGUUUC ACG hsa-miR-505* 3489 GGGAGCCAGGAAGUAUU 3490 GGGAGCCAGGAA 3491 ACUUCCUGGCU MIMAT0004776 GAUGU GUAUUGAU CCC hsa-miR-506 3492 UAAGGCACCCUUCUGAG 3493 UAAGGCACCCUU 3494 AGAAGGGUGCC MIMAT0002878 UAGA CUGAGUAG UUA hsa-miR-507 3495 UUUUGCACCUUUUGGAG 3496 UUUUGCACCUUU 3497 CAAAAGGUGCA MIMAT0002879 UGAA UGGAGUGA AAA hsa-miR-508-3p 3498 UGAUUGUAGCCUUUUGG 3499 UGAUUGUAGCCU 3500 AAAGGCUACAA MIMAT0002880 AGUAGA UUUGGAGU UCA hsa-miR-508-5p 3501 UACUCCAGAGGGCGUCA 3502 UACUCCAGAGGG 3503 CGCCCUCUGGA MIMAT0004778 CUCAUG CGUCACUC GUA hsa-miR-509-3- 3504 UACUGCAGACGUGGCAA 3505 UACUGCAGACGU 3506 CCACGUCUGCA 5p UCAUG GGCAAUCA GUA MIMAT0004975 hsa-miR-509-3p 3507 UGAUUGGUACGUCUGUG 3508 UGAUUGGUACGU 3509 AGACGUACCAA MIMAT0002881 GGUAG CUGUGGGU UCA hsa-miR-509-5p 3510 UACUGCAGACAGUGGCA 3511 UACUGCAGACAG 3512 CACUGUCUGCA MIMAT0004779 AUCA UGGCAAUC GUA hsa-miR-510 3513 UACUCAGGAGAGUGGCA 3514 UACUCAGGAGAG 3515 CACUCUCCUGA MIMAT0002882 AUCAC UGGCAAUC GUA hsa-miR-511 3516 GUGUCUUUUGCUCUGCA 3517 GUGUCUUUUGCU 3518 AGAGCAAAAGA MIMAT0002808 GUCA CUGCAGUC CAC hsa-miR-512-3p 3519 AAGUGCUGUCAUAGCUG 3520 AAGUGCUGUCAU 3521 CUAUGACAGCA MIMAT0002823 AGGUC AGCUGAGG CUU hsa-miR-512-5p 3522 CACUCAGCCUUGAGGGC 3523 CACUCAGCCUUG 3524 CUCAAGGCUGA MIMAT0002822 ACUUUC AGGGCACU GUG hsa-miR-513a- 3525 UAAAUUUCACCUUUCUG 3526 UAAAUUUCACCU 3527 AAAGGUGAAAU 3p AGAAGG UUCUGAGA UUA MIMAT0004777 hsa-miR-513a- 3528 UUCACAGGGAGGUGUCA 3529 UUCACAGGGAGG 3530 CACCUCCCUGU 5p U UGUCAU GAA MIMAT0002877 hsa-miR-513b 3531 UUCACAAGGAGGUGUCA 3532 UUCACAAGGAGG 3533 CACCUCCUUGU MIMAT0005788 UUUAU UGUCAUUU GAA hsa-miR-513c 3534 UUCUCAAGGAGGUGUCG 3535 UUCUCAAGGAGG 3536 CACCUCCUUGA MIMAT0005789 UUUAU UGUCGUUU GAA hsa-miR-514 3537 AUUGACACUUCUGUGAG 3538 AUUGACACUUCU 3539 ACAGAAGUGUC MIMAT0002883 UAGA GUGAGUAG AAU hsa-miR-514b- 3540 AUUGACACCUCUGUGAG 3541 AUUGACACCUCU 3542 ACAGAGGUGUC 3p UGGA GUGAGUGG AAU MIMAT0015088 hsa-miR-514b- 3543 UUCUCAAGAGGGAGGCA 3544 UUCUCAAGAGGG 3545 CUCCCUCUUGA 5p AUCAU AGGCAAUC GAA MIMAT0015087 hsa-miR-515-3p 3546 GAGUGCCUUCUUUUGGA 3547 GAGUGCCUUCUU 3548 AAAAGAAGGCA MIMAT0002827 GCGUU UUGGAGCG CUC hsa-miR-515-5p 3549 UUCUCCAAAAGAAAGCA 3550 UUCUCCAAAAGA 3551 UUUCUUUUGGA MIMAT0002826 CUUUCUG AAGCACUU GAA hsa-miR-516a- 3552 UGCUUCCUUUCAGAGGG 3553 UGCUUCCUUUCA 3554 UCUGAAAGGAA 3p U GAGGGU GCA MIMAT0006778 hsa-miR-516a- 3555 UUCUCGAGGAAAGAAGC 3556 UUCUCGAGGAAA 3557 UCUUUCCUCGA 5p ACUUUC GAAGCACU GAA MIMAT0004770 hsa-miR-516b 3558 AUCUGGAGGUAAGAAGC 3559 AUCUGGAGGUAA 3560 UCUUACCUCCA MIMAT0002859 ACUUU GAAGCACU GAU hsa-miR-516b* 3561 UGCUUCCUUUCAGAGGG 3562 UGCUUCCUUUCA 3563 UCUGAAAGGAA MIMAT0002860 U GAGGGU GCA hsa-miR-517* 3564 CCUCUAGAUGGAAGCAC 3565 CCUCUAGAUGGA 3566 CUUCCAUCUAG MIMAT0002851 UGUCU AGCACUGU AGG hsa-miR-517a 3567 AUCGUGCAUCCCUUUAG 3568 AUCGUGCAUCCC 3569 AAGGGAUGCAC MIMAT0002852 AGUGU UUUAGAGU GAU hsa-miR-517b 3570 UCGUGCAUCCCUUUAGA 3571 UCGUGCAUCCCU 3572 AAAGGGAUGCA MIMAT0002857 GUGUU UUAGAGUG CGA hsa-miR-517c 3573 AUCGUGCAUCCUUUUAG 3574 AUCGUGCAUCCU 3575 AAAGGAUGCAC MIMAT0002866 AGUGU UUUAGAGU GAU hsa-miR-518a- 3576 GAAAGCGCUUCCCUUUG 3577 GAAAGCGCUUCC 3578 AGGGAAGCGCU 3p CUGGA CUUUGCUG UUC MIMAT0002863 hsa-miR-518a- 3579 CUGCAAAGGGAAGCCCU 3580 CUGCAAAGGGAA 3581 GCUUCCCUUUG 5p UUC GCCCUUUC CAG MIMAT0005457 hsa-miR-518b 3582 CAAAGCGCUCCCCUUUA 3583 CAAAGCGCUCCC 3584 AGGGGAGCGCU MIMAT0002844 GAGGU CUUUAGAG UUG hsa-miR-518c 3585 CAAAGCGCUUCUCUUUA 3586 CAAAGCGCUUCU 3587 AGAGAAGCGCU MIMAT0002848 GAGUGU CUUUAGAG UUG hsa-miR-518c* 3588 UCUCUGGAGGGAAGCAC 3589 UCUCUGGAGGGA 3590 CUUCCCUCCAG MIMAT0002847 UUUCUG AGCACUUU AGA hsa-miR-518d- 3591 CAAAGCGCUUCCCUUUG 3592 CAAAGCGCUUCC 3593 AGGGAAGCGCU 3p GAGC CUUUGGAG UUG MIMAT0002864 hsa-miR-518d- 3594 CUCUAGAGGGAAGCACU 3595 CUCUAGAGGGAA 3596 GCUUCCCUCUA 5p UUCUG GCACUUUC GAG MIMAT0005456 hsa-miR-518e 3597 AAAGCGCUUCCCUUCAG 3598 AAAGCGCUUCCC 3599 AAGGGAAGCGC MIMAT0002861 AGUG UUCAGAGU UUU hsa-miR-518e* 3600 CUCUAGAGGGAAGCGCU 3601 CUCUAGAGGGAA 3602 GCUUCCCUCUA MIMAT0005450 UUCUG GCGCUUUC GAG hsa-miR-518f 3603 GAAAGCGCUUCUCUUUA 3604 GAAAGCGCUUCU 3605 AGAGAAGCGCU MIMAT0002842 GAGG CUUUAGAG UUC hsa-miR-518f* 3606 CUCUAGAGGGAAGCACU 3607 CUCUAGAGGGAA 3608 GCUUCCCUCUA MIMAT0002841 UUCUC GCACUUUC GAG hsa-miR-519a 3609 AAAGUGCAUCCUUUUAG 3610 AAAGUGCAUCCU 3611 AAAGGAUGCAC MIMAT0002869 AGUGU UUUAGAGU UUU hsa-miR-519a* 3612 CUCUAGAGGGAAGCGCU 3613 CUCUAGAGGGAA 3614 GCUUCCCUCUA MIMAT0005452 UUCUG GCGCUUUC GAG hsa-miR-519b- 3615 AAAGUGCAUCCUUUUAG 3616 AAAGUGCAUCCU 3617 AAAGGAUGCAC 3p AGGUU UUUAGAGG UUU MIMAT0002837 hsa-miR-519b- 3618 CUCUAGAGGGAAGCGCU 3619 CUCUAGAGGGAA 3620 GCUUCCCUCUA 5p UUCUG GCGCUUUC GAG MIMAT0005454 hsa-miR-519c- 3621 AAAGUGCAUCUUUUUAG 3622 AAAGUGCAUCUU 3623 AAAAGAUGCAC 3p AGGAU UUUAGAGG UUU MIMAT0002832 hsa-miR-519c- 3624 CUCUAGAGGGAAGCGCU 3625 CUCUAGAGGGAA 3626 GCUUCCCUCUA 5p UUCUG GCGCUUUC GAG MIMAT0002831 hsa-miR-519d 3627 CAAAGUGCCUCCCUUUA 3628 CAAAGUGCCUCC 3629 AGGGAGGCACU MIMAT0002853 GAGUG CUUUAGAG UUG hsa-miR-519e 3630 AAGUGCCUCCUUUUAGA 3631 AAGUGCCUCCUU 3632 AAAAGGAGGCA MIMAT0002829 GUGUU UUAGAGUG CUU hsa-miR-519e* 3633 UUCUCCAAAAGGGAGCA 3634 UUCUCCAAAAGG 3635 UCCCUUUUGGA MIMAT0002828 CUUUC GAGCACUU GAA hsa-miR-520a- 3636 AAAGUGCUUCCCUUUGG 3637 AAAGUGCUUCCC 3638 AAGGGAAGCAC 3p ACUGU UUUGGACU UUU MIMAT0002834 hsa-miR-520a- 3639 CUCCAGAGGGAAGUACU 3640 CUCCAGAGGGAA 3641 ACUUCCCUCUG 5p UUCU GUACUUUC GAG MIMAT0002833 hsa-miR-520b 3642 AAAGUGCUUCCUUUUAG 3643 AAAGUGCUUCCU 3644 AAAGGAAGCAC MIMAT0002843 AGGG UUUAGAGG UUU hsa-miR-520c- 3645 AAAGUGCUUCCUUUUAG 3646 AAAGUGCUUCCU 3647 AAAGGAAGCAC 3p AGGGU UUUAGAGG UUU MIMAT0002846 hsa-miR-520c- 3648 CUCUAGAGGGAAGCACU 3649 CUCUAGAGGGAA 3650 GCUUCCCUCUA 5p UUCUG GCACUUUC GAG MIMAT0005455 hsa-miR-520d- 3651 AAAGUGCUUCUCUUUGG 3652 AAAGUGCUUCUC 3653 AAGAGAAGCAC 3p UGGGU UUUGGUGG UUU MIMAT0002856 hsa-miR-520d- 3654 CUACAAAGGGAAGCCCU 3655 CUACAAAGGGAA 3656 GCUUCCCUUUG 5p UUC GCCCUUUC UAG MIMAT0002855 hsa-miR-520e 3657 AAAGUGCUUCCUUUUUG 3658 AAAGUGCUUCCU 3659 AAAGGAAGCAC MIMAT0002825 AGGG UUUUGAGG UUU hsa-miR-520f 3660 AAGUGCUUCCUUUUAGA 3661 AAGUGCUUCCUU 3662 AAAAGGAAGCA MIMAT0002830 GGGUU UUAGAGGG CUU hsa-miR-520g 3663 ACAAAGUGCUUCCCUUU 3664 ACAAAGUGCUUC 3665 GGGAAGCACUU MIMAT0002858 AGAGUGU CCUUUAGA UGU hsa-miR-520h 3666 ACAAAGUGCUUCCCUUU 3667 ACAAAGUGCUUC 3668 GGGAAGCACUU MIMAT0002867 AGAGU CCUUUAGA UGU hsa-miR-521 3669 AACGCACUUCCCUUUAG 3670 AACGCACUUCCC 3671 AAGGGAAGUGC MIMAT0002854 AGUGU UUUAGAGU GUU hsa-miR-522 3672 AAAAUGGUUCCCUUUAG 3673 AAAAUGGUUCCC 3674 AAGGGAACCAU MIMAT0002868 AGUGU UUUAGAGU UUU hsa-miR-522* 3675 CUCUAGAGGGAAGCGCU 3676 CUCUAGAGGGAA 3677 GCUUCCCUCUA MIMAT0005451 UUCUG GCGCUUUC GAG hsa-miR-523 3678 GAACGCGCUUCCCUAUA 3679 GAACGCGCUUCC 3680 AGGGAAGCGCG MIMAT0002840 GAGGGU CUAUAGAG UUC hsa-miR-523* 3681 CUCUAGAGGGAAGCGCU 3682 CUCUAGAGGGAA 3683 GCUUCCCUCUA MIMAT0005449 UUCUG GCGCUUUC GAG hsa-miR-524-3p 3684 GAAGGCGCUUCCCUUUG 3685 GAAGGCGCUUCC 3686 AGGGAAGCGCC MIMAT0002850 GAGU CUUUGGAG UUC hsa-miR-524-5p 3687 CUACAAAGGGAAGCACU 3688 CUACAAAGGGAA 3689 GCUUCCCUUUG MIMAT0002849 UUCUC GCACUUUC UAG hsa-miR-525-3p 3690 GAAGGCGCUUCCCUUUA 3691 GAAGGCGCUUCC 3692 AGGGAAGCGCC MIMAT0002839 GAGCG CUUUAGAG UUC hsa-miR-525-5p 3693 CUCCAGAGGGAUGCACU 3694 CUCCAGAGGGAU 3695 GCAUCCCUCUG MIMAT0002838 UUCU GCACUUUC GAG hsa-miR-526a 3696 CUCUAGAGGGAAGCACU 3697 CUCUAGAGGGAA 3698 GCUUCCCUCUA MIMAT0002845 UUCUG GCACUUUC GAG hsa-miR-526b 3699 CUCUUGAGGGAAGCACU 3700 CUCUUGAGGGAA 3701 GCUUCCCUCAA MIMAT0002835 UUCUGU GCACUUUC GAG hsa-miR-526b* 3702 GAAAGUGCUUCCUUUUA 3703 GAAAGUGCUUCC 3704 AAGGAAGCACU MIMAT0002836 GAGGC UUUUAGAG UUC hsa-miR-527 3705 CUGCAAAGGGAAGCCCU 3706 CUGCAAAGGGAA 3707 GCUUCCCUUUG MIMAT0002862 UUC GCCCUUUC CAG hsa-miR-532-3p 3708 CCUCCCACACCCAAGGC 3709 CCUCCCACACCC 3710 UUGGGUGUGGG MIMAT0004780 UUGCA AAGGCUUG AGG hsa-miR-532-5p 3711 CAUGCCUUGAGUGUAGG 3712 CAUGCCUUGAGU 3713 ACACUCAAGGC MIMAT0002888 ACCGU GUAGGACC AUG hsa-miR-539 3714 GGAGAAAUUAUCCUUGG 3715 GGAGAAAUUAUC 3716 AGGAUAAUUUC MIMAT0003163 UGUGU CUUGGUGU UCC hsa-miR-541 3717 UGGUGGGCACAGAAUCU 3718 UGGUGGGCACAG 3719 UUCUGUGCCCA MIMAT0004920 GGACU AAUCUGGA CCA hsa-miR-541* 3720 AAAGGAUUCUGCUGUCG 3721 AAAGGAUUCUGC 3722 CAGCAGAAUCC MIMAT0004919 GUCCCACU UGUCGGUC UUU hsa-miR-542-3p 3723 UGUGACAGAUUGAUAAC 3724 UGUGACAGAUUG 3725 AUCAAUCUGUC MIMAT0003389 UGAAA AUAACUGA ACA hsa-miR-542-5p 3726 UCGGGGAUCAUCAUGUC 3727 UCGGGGAUCAUC 3728 AUGAUGAUCCC MIMAT0003340 ACGAGA AUGUCACG CGA hsa-miR-543 3729 AAACAUUCGCGGUGCAC 3730 AAACAUUCGCGG 3731 CACCGCGAAUG MIMAT0004954 UUCUU UGCACUUC UUU hsa-miR-544 3732 AUUCUGCAUUUUUAGCA 3733 AUUCUGCAUUUU 3734 UAAAAAUGCAG MIMAT0003164 AGUUC UAGCAAGU AAU hsa-miR-544b 3735 ACCUGAGGUUGUGCAUU 3736 ACCUGAGGUUGU 3737 GCACAACCUCA MIMAT0015004 UCUAA GCAUUUCU GGU hsa-miR-545 3738 UCAGCAAACAUUUAUUG 3739 UCAGCAAACAUU 3740 UAAAUGUUUGC MIMAT0003165 UGUGC UAUUGUGU UGA hsa-miR-545* 3741 UCAGUAAAUGUUUAUUA 3742 UCAGUAAAUGUU 3743 UAAACAUUUAC MIMAT0004785 GAUGA UAUUAGAU UGA hsa-miR-548a- 3744 CAAAACUGGCAAUUACU 3745 CAAAACUGGCAA 3746 AAUUGCCAGUU 3p UUUGC UUACUUUU UUG MIMAT0003251 hsa-miR-548a- 3747 AAAAGUAAUUGCGAGUU 3748 AAAAGUAAUUGC 3749 UCGCAAUUACU 5p UUACC GAGUUUUA UUU MIMAT0004803 hsa-miR-548aa 3750 AAAAACCACAAUUACUU 3751 AAAAACCACAAU 3752 UAAUUGUGGUU MIMAT0018447 UUGCACCA UACUUUUG UUU hsa-miR-548b- 3753 CAAGAACCUCAGUUGCU 3754 CAAGAACCUCAG 3755 AACUGAGGUUC 3p UUUGU UUGCUUUU UUG MIMAT0003254 hsa-miR-548b- 3756 AAAAGUAAUUGUGGUUU 3757 AAAAGUAAUUGU 3758 CCACAAUUACU 5p UGGCC GGUUUUGG UUU MIMAT0004798 hsa-miR-548c- 3759 CAAAAAUCUCAAUUACU 3760 CAAAAAUCUCAA 3761 AAUUGAGAUUU 3p UUUGC UUACUUUU UUG MIMAT0003285 hsa-miR-548c- 3762 AAAAGUAAUUGCGGUUU 3763 AAAAGUAAUUGC 3764 CCGCAAUUACU 5p UUGCC GGUUUUUG UUU MIMAT0004806 hsa-miR-548d- 3765 CAAAAACCACAGUUUCU 3766 CAAAAACCACAG 3767 AACUGUGGUUU 3p UUUGC UUUCUUUU UUG MIMAT0003323 hsa-miR-548d- 3768 AAAAGUAAUUGUGGUUU 3769 AAAAGUAAUUGU 3770 CCACAAUUACU 5p UUGCC GGUUUUUG UUU MIMAT0004812 hsa-miR-548e 3771 AAAAACUGAGACUACUU 3772 AAAAACUGAGAC 3773 UAGUCUCAGUU MIMAT0005874 UUGCA UACUUUUG UUU hsa-miR-548f 3774 AAAAACUGUAAUUACUU 3775 AAAAACUGUAAU 3776 UAAUUACAGUU MIMAT0005895 UU UACUUUU UUU hsa-miR-548g 3777 AAAACUGUAAUUACUUU 3778 AAAACUGUAAUU 3779 GUAAUUACAGU MIMAT0005912 UGUAC ACUUUUGU UUU hsa-miR-548h 3780 AAAAGUAAUCGCGGUUU 3781 AAAAGUAAUCGC 3782 CCGCGAUUACU MIMAT0005928 UUGUC GGUUUUUG UUU hsa-miR-548i 3783 AAAAGUAAUUGCGGAUU 3784 AAAAGUAAUUGC 3785 CCGCAAUUACU MIMAT0005935 UUGCC GGAUUUUG UUU hsa-miR-548j 3786 AAAAGUAAUUGCGGUCU 3787 AAAAGUAAUUGC 3788 CCGCAAUUACU MIMAT0005875 UUGGU GGUCUUUG UUU hsa-miR-548k 3789 AAAAGUACUUGCGGAUU 3790 AAAAGUACUUGC 3791 CCGCAAGUACU MIMAT0005882 UUGCU GGAUUUUG UUU hsa-miR-548l 3792 AAAAGUAUUUGCGGGUU 3793 AAAAGUAUUUGC 3794 CCGCAAAUACU MIMAT0005889 UUGUC GGGUUUUG UUU hsa-miR-548m 3795 CAAAGGUAUUUGUGGUU 3796 CAAAGGUAUUUG 3797 CACAAAUACCU MIMAT0005917 UUUG UGGUUUUU UUG hsa-miR-548n 3798 CAAAAGUAAUUGUGGAU 3799 CAAAAGUAAUUG 3800 CACAAUUACUU MIMAT0005916 UUUGU UGGAUUUU UUG hsa-miR-548o 3801 CCAAAACUGCAGUUACU 3802 CCAAAACUGCAG 3803 AACUGCAGUUU MIMAT0005919 UUUGC UUACUUUU UGG hsa-miR-548p 3804 UAGCAAAAACUGCAGUU 3805 UAGCAAAAACUG 3806 UGCAGUUUUUG MIMAT0005934 ACUUU CAGUUACU CUA hsa-miR-548q 3807 GCUGGUGCAAAAGUAAU 3808 GCUGGUGCAAAA 3809 ACUUUUGCACC MIMAT0011163 GGCGG GUAAUGGC AGC hsa-miR-548s 3810 AUGGCCAAAACUGCAGU 3811 AUGGCCAAAACU 3812 GCAGUUUUGGC MIMAT0014987 UAUUUU GCAGUUAU CAU hsa-miR-548t 3813 CAAAAGUGAUCGUGGUU 3814 CAAAAGUGAUCG 3815 CACGAUCACUU MIMAT0015009 UUUG UGGUUUUU UUG hsa-miR-548u 3816 CAAAGACUGCAAUUACU 3817 CAAAGACUGCAA 3818 AAUUGCAGUCU MIMAT0015013 UUUGCG UUACUUUU UUG hsa-miR-548v 3819 AGCUACAGUUACUUUUG 3820 AGCUACAGUUAC 3821 AAGUAACUGUA MIMAT0015020 CACCA UUUUGCAC GCU hsa-miR-548w 3822 AAAAGUAACUGCGGUUU 3823 AAAAGUAACUGC 3824 CCGCAGUUACU MIMAT0015060 UUGCCU GGUUUUUG UUU hsa-miR-548x 3825 UAAAAACUGCAAUUACU 3826 UAAAAACUGCAA 3827 AAUUGCAGUUU MIMAT0015081 UUCA UUACUUUC UUA hsa-miR-548y 3828 AAAAGUAAUCACUGUUU 3829 AAAAGUAAUCAC 3830 CAGUGAUUACU MIMAT0018354 UUGCC UGUUUUUG UUU hsa-miR-548z 3831 CAAAAACCGCAAUUACU 3832 CAAAAACCGCAA 3833 AAUUGCGGUUU MIMAT0018446 UUUGCA UUACUUUU UUG hsa-miR-549 3834 UGACAACUAUGGAUGAG 3835 UGACAACUAUGG 3836 AUCCAUAGUUG MIMAT0003333 CUCU AUGAGCUC UCA hsa-miR-550a 3837 AGUGCCUGAGGGAGUAA 3838 AGUGCCUGAGGG 3839 CUCCCUCAGGC MIMAT0004800 GAGCCC AGUAAGAG ACU hsa-miR-550a* 3840 UGUCUUACUCCCUCAGG 3841 UGUCUUACUCCC 3842 GAGGGAGUAAG MIMAT0003257 CACAU UCAGGCAC ACA hsa-miR-550b 3843 UCUUACUCCCUCAGGCA 3844 UCUUACUCCCUC 3845 CUGAGGGAGUA MIMAT0018445 CUG AGGCACUG AGA hsa-miR-551a 3846 GCGACCCACUCUUGGUU 3847 GCGACCCACUCU 3848 CAAGAGUGGGU MIMAT0003214 UCCA UGGUUUCC CGC hsa-miR-551b 3849 GCGACCCAUACUUGGUU 3850 GCGACCCAUACU 3851 CAAGUAUGGGU MIMAT0003233 UCAG UGGUUUCA CGC hsa-miR-551b* 3852 GAAAUCAAGCGUGGGUG 3853 GAAAUCAAGCGU 3854 CCACGCUUGAU MIMAT0004794 AGACC GGGUGAGA UUC hsa-miR-552 3855 AACAGGUGACUGGUUAG 3856 AACAGGUGACUG 3857 ACCAGUCACCU MIMAT0003215 ACAA GUUAGACA GUU hsa-miR-553 3858 AAAACGGUGAGAUUUUG 3859 AAAACGGUGAGA 3860 AAUCUCACCGU MIMAT0003216 UUUU UUUUGUUU UUU hsa-miR-554 3861 GCUAGUCCUGACUCAGC 3862 GCUAGUCCUGAC 3863 GAGUCAGGACU MIMAT0003217 CAGU UCAGCCAG AGC hsa-miR-555 3864 AGGGUAAGCUGAACCUC 3865 AGGGUAAGCUGA 3866 GUUCAGCUUAC MIMAT0003219 UGAU ACCUCUGA CCU hsa-miR-556-3p 3867 AUAUUACCAUUAGCUCA 3868 AUAUUACCAUUA 3869 GCUAAUGGUAA MIMAT0004793 UCUUU GCUCAUCU UAU hsa-miR-556-5p 3870 GAUGAGCUCAUUGUAAU 3871 GAUGAGCUCAUU 3872 ACAAUGAGCUC MIMAT0003220 AUGAG GUAAUAUG AUC hsa-miR-557 3873 GUUUGCACGGGUGGGCC 3874 GUUUGCACGGGU 3875 CCACCCGUGCA MIMAT0003221 UUGUCU GGGCCUUG AAC hsa-miR-558 3876 UGAGCUGCUGUACCAAA 3877 UGAGCUGCUGUA 3878 GGUACAGCAGC MIMAT0003222 AU CCAAAAU UCA hsa-miR-559 3879 UAAAGUAAAUAUGCACC 3880 UAAAGUAAAUAU 3881 GCAUAUUUACU MIMAT0003223 AAAA GCACCAAA UUA hsa-miR-561 3882 CAAAGUUUAAGAUCCUU 3883 CAAAGUUUAAGA 3884 GAUCUUAAACU MIMAT0003225 GAAGU UCCUUGAA UUG hsa-miR-562 3885 AAAGUAGCUGUACCAUU 3886 AAAGUAGCUGUA 3887 GGUACAGCUAC MIMAT0003226 UGC CCAUUUGC UUU hsa-miR-563 3888 AGGUUGACAUACGUUUC 3889 AGGUUGACAUAC 3890 ACGUAUGUCAA MIMAT0003227 CC GUUUCCC CCU hsa-miR-564 3891 AGGCACGGUGUCAGCAG 3892 AGGCACGGUGUC 3893 CUGACACCGUG MIMAT0003228 GC AGCAGGC CCU hsa-miR-566 3894 GGGCGCCUGUGAUCCCA 3895 GGGCGCCUGUGA 3896 GAUCACAGGCG MIMAT0003230 AC UCCCAAC CCC hsa-miR-567 3897 AGUAUGUUCUUCCAGGA 3898 AGUAUGUUCUUC 3899 UGGAAGAACAU MIMAT0003231 CAGAAC CAGGACAG ACU hsa-miR-568 3900 AUGUAUAAAUGUAUACA 3901 AUGUAUAAAUGU 3902 AUACAUUUAUA MIMAT0003232 CAC AUACACAC CAU hsa-miR-569 3903 AGUUAAUGAAUCCUGGA 3904 AGUUAAUGAAUC 3905 AGGAUUCAUUA MIMAT0003234 AAGU CUGGAAAG ACU hsa-miR-570 3906 CGAAAACAGCAAUUACC 3907 CGAAAACAGCAA 3908 AAUUGCUGUUU MIMAT0003235 UUUGC UUACCUUU UCG hsa-miR-571 3909 UGAGUUGGCCAUCUGAG 3910 UGAGUUGGCCAU 3911 AGAUGGCCAAC MIMAT0003236 UGAG CUGAGUGA UCA hsa-miR-572 3912 GUCCGCUCGGCGGUGGC 3913 GUCCGCUCGGCG 3914 ACCGCCGAGCG MIMAT0003237 CCA GUGGCCCA GAC hsa-miR-573 3915 CUGAAGUGAUGUGUAAC 3916 CUGAAGUGAUGU 3917 ACACAUCACUU MIMAT0003238 UGAUCAG GUAACUGA CAG hsa-miR-574-3p 3918 CACGCUCAUGCACACAC 3919 CACGCUCAUGCA 3920 UGUGCAUGAGC MIMAT0003239 CCACA CACACCCA GUG hsa-miR-574-5p 3921 UGAGUGUGUGUGUGUGA 3922 UGAGUGUGUGUG 3923 CACACACACAC MIMAT0004795 GUGUGU UGUGAGUG UCA hsa-miR-575 3924 GAGCCAGUUGGACAGGA 3925 GAGCCAGUUGGA 3926 UGUCCAACUGG MIMAT0003240 GC CAGGAGC CUC hsa-miR-576-3p 3927 AAGAUGUGGAAAAAUUG 3928 AAGAUGUGGAAA 3929 UUUUUCCACAU MIMAT0004796 GAAUC AAUUGGAA CUU hsa-miR-576-5p 3930 AUUCUAAUUUCUCCACG 3931 AUUCUAAUUUCU 3932 GGAGAAAUUAG MIMAT0003241 UCUUU CCACGUCU AAU hsa-miR-577 3933 UAGAUAAAAUAUUGGUA 3934 UAGAUAAAAUAU 3935 CAAUAUUUUAU MIMAT0003242 CCUG UGGUACCU CUA hsa-miR-578 3936 CUUCUUGUGCUCUAGGA 3937 CUUCUUGUGCUC 3938 UAGAGCACAAG MIMAT0003243 UUGU UAGGAUUG AAG hsa-miR-579 3939 UUCAUUUGGUAUAAACC 3940 UUCAUUUGGUAU 3941 UUAUACCAAAU MIMAT0003244 GCGAUU AAACCGCG GAA hsa-miR-580 3942 UUGAGAAUGAUGAAUCA 3943 UUGAGAAUGAUG 3944 UUCAUCAUUCU MIMAT0003245 UUAGG AAUCAUUA CAA hsa-miR-581 3945 UCUUGUGUUCUCUAGAU 3946 UCUUGUGUUCUC 3947 UAGAGAACACA MIMAT0003246 CAGU UAGAUCAG AGA hsa-miR-582-3p 3948 UAACUGGUUGAACAACU 3949 UAACUGGUUGAA 3950 UGUUCAACCAG MIMAT0004797 GAACC CAACUGAA UUA hsa-miR-582-5p 3951 UUACAGUUGUUCAACCA 3952 UUACAGUUGUUC 3953 UUGAACAACUG MIMAT0003247 GUUACU AACCAGUU UAA hsa-miR-583 3954 CAAAGAGGAAGGUCCCA 3955 CAAAGAGGAAGG 3956 GACCUUCCUCU MIMAT0003248 UUAC UCCCAUUA UUG hsa-miR-584 3957 UUAUGGUUUGCCUGGGA 3958 UUAUGGUUUGCC 3959 CAGGCAAACCA MIMAT0003249 CUGAG UGGGACUG UAA hsa-miR-585 3960 UGGGCGUAUCUGUAUGC 3961 UGGGCGUAUCUG 3962 UACAGAUACGC MIMAT0003250 UA UAUGCUA CCA hsa-miR-586 3963 UAUGCAUUGUAUUUUUA 3964 UAUGCAUUGUAU 3965 AAAUACAAUGC MIMAT0003252 GGUCC UUUUAGGU AUA hsa-miR-587 3966 UUUCCAUAGGUGAUGAG 3967 UUUCCAUAGGUG 3968 AUCACCUAUGG MIMAT0003253 UCAC AUGAGUCA AAA hsa-miR-588 3969 UUGGCCACAAUGGGUUA 3970 UUGGCCACAAUG 3971 CCCAUUGUGGC MIMAT0003255 GAAC GGUUAGAA CAA hsa-miR-589 3972 UGAGAACCACGUCUGCU 3973 UGAGAACCACGU 3974 AGACGUGGUUC MIMAT0004799 CUGAG CUGCUCUG UCA hsa-miR-589* 3975 UCAGAACAAAUGCCGGU 3976 UCAGAACAAAUG 3977 GGCAUUUGUUC MIMAT0003256 UCCCAGA CCGGUUCC UGA hsa-miR-590-3p 3978 UAAUUUUAUGUAUAAGC 3979 UAAUUUUAUGUA 3980 UAUACAUAAAA MIMAT0004801 UAGU UAAGCUAG UUA hsa-miR-590-5p 3981 GAGCUUAUUCAUAAAAG 3982 GAGCUUAUUCAU 3983 UUAUGAAUAAG MIMAT0003258 UGCAG AAAAGUGC CUC hsa-miR-591 3984 AGACCAUGGGUUCUCAU 3985 AGACCAUGGGUU 3986 AGAACCCAUGG MIMAT0003259 UGU CUCAUUGU UCU hsa-miR-592 3987 UUGUGUCAAUAUGCGAU 3988 UUGUGUCAAUAU 3989 GCAUAUUGACA MIMAT0003260 GAUGU GCGAUGAU CAA hsa-miR-593 3990 UGUCUCUGCUGGGGUUU 3991 UGUCUCUGCUGG 3992 CCCCAGCAGAG MIMAT0004802 CU GGUUUCU ACA hsa-miR-593* 3993 AGGCACCAGCCAGGCAU 3994 AGGCACCAGCCA 3995 CCUGGCUGGUG MIMAT0003261 UGCUCAGC GGCAUUGC CCU hsa-miR-595 3996 GAAGUGUGCCGUGGUGU 3997 GAAGUGUGCCGU 3998 CCACGGCACAC MIMAT0003263 GUCU GGUGUGUC UUC hsa-miR-596 3999 AAGCCUGCCCGGCUCCU 4000 AAGCCUGCCCGG 4001 AGCCGGGCAGG MIMAT0003264 CGGG CUCCUCGG CUU hsa-miR-597 4002 UGUGUCACUCGAUGACC 4003 UGUGUCACUCGA 4004 CAUCGAGUGAC MIMAT0003265 ACUGU UGACCACU ACA hsa-miR-598 4005 UACGUCAUCGUUGUCAU 4006 UACGUCAUCGUU 4007 ACAACGAUGAC MIMAT0003266 CGUCA GUCAUCGU GUA hsa-miR-599 4008 GUUGUGUCAGUUUAUCA 4009 GUUGUGUCAGUU 4010 UAAACUGACAC MIMAT0003267 AAC UAUCAAAC AAC hsa-miR-600 4011 ACUUACAGACAAGAGCC 4012 ACUUACAGACAA 4013 UCUUGUCUGUA MIMAT0003268 UUGCUC GAGCCUUG AGU hsa-miR-601 4014 UGGUCUAGGAUUGUUGG 4015 UGGUCUAGGAUU 4016 ACAAUCCUAGA MIMAT0003269 AGGAG GUUGGAGG CCA hsa-miR-602 4017 GACACGGGCGACAGCUG 4018 GACACGGGCGAC 4019 CUGUCGCCCGU MIMAT0003270 CGGCCC AGCUGCGG GUC hsa-miR-603 4020 CACACACUGCAAUUACU 4021 CACACACUGCAA 4022 AAUUGCAGUGU MIMAT0003271 UUUGC UUACUUUU GUG hsa-miR-604 4023 AGGCUGCGGAAUUCAGG 4024 AGGCUGCGGAAU 4025 GAAUUCCGCAG MIMAT0003272 AC UCAGGAC CCU hsa-miR-605 4026 UAAAUCCCAUGGUGCCU 4027 UAAAUCCCAUGG 4028 CACCAUGGGAU MIMAT0003273 UCUCCU UGCCUUCU UUA hsa-miR-606 4029 AAACUACUGAAAAUCAA 4030 AAACUACUGAAA 4031 AUUUUCAGUAG MIMAT0003274 AGAU AUCAAAGA UUU hsa-miR-607 4032 GUUCAAAUCCAGAUCUA 4033 GUUCAAAUCCAG 4034 AUCUGGAUUUG MIMAT0003275 UAAC AUCUAUAA AAC hsa-miR-608 4035 AGGGGUGGUGUUGGGAC 4036 AGGGGUGGUGUU 4037 CCAACACCACC MIMAT0003276 AGCUCCGU GGGACAGC CCU hsa-miR-609 4038 AGGGUGUUUCUCUCAUC 4039 AGGGUGUUUCUC 4040 GAGAGAAACAC MIMAT0003277 UCU UCAUCUCU CCU hsa-miR-610 4041 UGAGCUAAAUGUGUGCU 4042 UGAGCUAAAUGU 4043 ACACAUUUAGC MIMAT0003278 GGGA GUGCUGGG UCA hsa-miR-611 4044 GCGAGGACCCCUCGGGG 4045 GCGAGGACCCCU 4046 CGAGGGGUCCU MIMAT0003279 UCUGAC CGGGGUCU CGC hsa-miR-612 4047 GCUGGGCAGGGCUUCUG 4048 GCUGGGCAGGGC 4049 AAGCCCUGCCC MIMAT0003280 AGCUCCUU UUCUGAGC AGC hsa-miR-613 4050 AGGAAUGUUCCUUCUUU 4051 AGGAAUGUUCCU 4052 GAAGGAACAUU MIMAT0003281 GCC UCUUUGCC CCU hsa-miR-614 4053 GAACGCCUGUUCUUGCC 4054 GAACGCCUGUUC 4055 AAGAACAGGCG MIMAT0003282 AGGUGG UUGCCAGG UUC hsa-miR-615-3p 4056 UCCGAGCCUGGGUCUCC 4057 UCCGAGCCUGGG 4058 GACCCAGGCUC MIMAT0003283 CUCUU UCUCCCUC GGA hsa-miR-615-5p 4059 GGGGGUCCCCGGUGCUC 4060 GGGGGUCCCCGG 4061 CACCGGGGACC MIMAT0004804 GGAUC UGCUCGGA CCC hsa-miR-616 4062 AGUCAUUGGAGGGUUUG 4063 AGUCAUUGGAGG 4064 ACCCUCCAAUG MIMAT0004805 AGCAG GUUUGAGC ACU hsa-miR-616* 4065 ACUCAAAACCCUUCAGU 4066 ACUCAAAACCCU 4067 GAAGGGUUUUG MIMAT0003284 GACUU UCAGUGAC AGU hsa-miR-617 4068 AGACUUCCCAUUUGAAG 4069 AGACUUCCCAUU 4070 CAAAUGGGAAG MIMAT0003286 GUGGC UGAAGGUG UCU hsa-miR-618 4071 AAACUCUACUUGUCCUU 4072 AAACUCUACUUG 4073 GACAAGUAGAG MIMAT0003287 CUGAGU UCCUUCUG UUU hsa-miR-619 4074 GACCUGGACAUGUUUGU 4075 GACCUGGACAUG 4076 AACAUGUCCAG MIMAT0003288 GCCCAGU UUUGUGCC GUC hsa-miR-620 4077 AUGGAGAUAGAUAUAGA 4078 AUGGAGAUAGAU 4079 AUAUCUAUCUC MIMAT0003289 AAU AUAGAAAU CAU hsa-miR-621 4080 GGCUAGCAACAGCGCUU 4081 GGCUAGCAACAG 4082 CGCUGUUGCUA MIMAT0003290 ACCU CGCUUACC GCC hsa-miR-622 4083 ACAGUCUGCUGAGGUUG 4084 ACAGUCUGCUGA 4085 CCUCAGCAGAC MIMAT0003291 GAGC GGUUGGAG UGU hsa-miR-623 4086 AUCCCUUGCAGGGGCUG 4087 AUCCCUUGCAGG 4088 CCCCUGCAAGG MIMAT0003292 UUGGGU GGCUGUUG GAU hsa-miR-624 4089 CACAAGGUAUUGGUAUU 4090 CACAAGGUAUUG 4091 ACCAAUACCUU MIMAT0004807 ACCU GUAUUACC GUG hsa-miR-624* 4092 UAGUACCAGUACCUUGU 4093 UAGUACCAGUAC 4094 AGGUACUGGUA MIMAT0003293 GUUCA CUUGUGUU CUA hsa-miR-625 4095 AGGGGGAAAGUUCUAUA 4096 AGGGGGAAAGUU 4097 AGAACUUUCCC MIMAT0003294 GUCC CUAUAGUC CCU hsa-miR-625* 4098 GACUAUAGAACUUUCCC 4099 GACUAUAGAACU 4100 AAAGUUCUAUA MIMAT0004808 CCUCA UUCCCCCU GUC hsa-miR-626 4101 AGCUGUCUGAAAAUGUC 4102 AGCUGUCUGAAA 4103 AUUUUCAGACA MIMAT0003295 UU AUGUCUU GCU hsa-miR-627 4104 GUGAGUCUCUAAGAAAA 4105 GUGAGUCUCUAA 4106 UCUUAGAGACU MIMAT0003296 GAGGA GAAAAGAG CAC hsa-miR-628-3p 4107 UCUAGUAAGAGUGGCAG 4108 UCUAGUAAGAGU 4109 CCACUCUUACU MIMAT0003297 UCGA GGCAGUCG AGA hsa-miR-628-5p 4110 AUGCUGACAUAUUUACU 4111 AUGCUGACAUAU 4112 AAAUAUGUCAG MIMAT0004809 AGAGG UUACUAGA CAU hsa-miR-629 4113 UGGGUUUACGUUGGGAG 4114 UGGGUUUACGUU 4115 CCAACGUAAAC MIMAT0004810 AACU GGGAGAAC CCA hsa-miR-629* 4116 GUUCUCCCAACGUAAGC 4117 GUUCUCCCAACG 4118 UACGUUGGGAG MIMAT0003298 CCAGC UAAGCCCA AAC hsa-miR-630 4119 AGUAUUCUGUACCAGGG 4120 AGUAUUCUGUAC 4121 UGGUACAGAAU MIMAT0003299 AAGGU CAGGGAAG ACU hsa-miR-631 4122 AGACCUGGCCCAGACCU 4123 AGACCUGGCCCA 4124 UCUGGGCCAGG MIMAT0003300 CAGC GACCUCAG UCU hsa-miR-632 4125 GUGUCUGCUUCCUGUGG 4126 GUGUCUGCUUCC 4127 CAGGAAGCAGA MIMAT0003302 GA UGUGGGA CAC hsa-miR-633 4128 CUAAUAGUAUCUACCAC 4129 CUAAUAGUAUCU 4130 GUAGAUACUAU MIMAT0003303 AAUAAA ACCACAAU UAG hsa-miR-634 4131 AACCAGCACCCCAACUU 4132 AACCAGCACCCC 4133 UUGGGGUGCUG MIMAT0003304 UGGAC AACUUUGG GUU hsa-miR-635 4134 ACUUGGGCACUGAAACA 4135 ACUUGGGCACUG 4136 UUCAGUGCCCA MIMAT0003305 AUGUCC AAACAAUG AGU hsa-miR-636 4137 UGUGCUUGCUCGUCCCG 4138 UGUGCUUGCUCG 4139 GACGAGCAAGC MIMAT0003306 CCCGCA UCCCGCCC ACA hsa-miR-637 4140 ACUGGGGGCUUUCGGGC 4141 ACUGGGGGCUUU 4142 CGAAAGCCCCC MIMAT0003307 UCUGCGU CGGGCUCU AGU hsa-miR-638 4143 AGGGAUCGCGGGCGGGU 4144 AGGGAUCGCGGG 4145 CGCCCGCGAUC MIMAT0003308 GGCGGCCU CGGGUGGC CCU hsa-miR-639 4146 AUCGCUGCGGUUGCGAG 4147 AUCGCUGCGGUU 4148 GCAACCGCAGC MIMAT0003309 CGCUGU GCGAGCGC GAU hsa-miR-640 4149 AUGAUCCAGGAACCUGC 4150 AUGAUCCAGGAA 4151 GGUUCCUGGAU MIMAT0003310 CUCU CCUGCCUC CAU hsa-miR-641 4152 AAAGACAUAGGAUAGAG 4153 AAAGACAUAGGA 4154 UAUCCUAUGUC MIMAT0003311 UCACCUC UAGAGUCA UUU hsa-miR-642a 4155 GUCCCUCUCCAAAUGUG 4156 GUCCCUCUCCAA 4157 AUUUGGAGAGG MIMAT0003312 UCUUG AUGUGUCU GAC hsa-miR-642b 4158 AGACACAUUUGGAGAGG 4159 AGACACAUUUGG 4160 CUCCAAAUGUG MIMAT0018444 GACCC AGAGGGAC UCU hsa-miR-643 4161 ACUUGUAUGCUAGCUCA 4162 ACUUGUAUGCUA 4163 GCUAGCAUACA MIMAT0003313 GGUAG GCUCAGGU AGU hsa-miR-644 4164 AGUGUGGCUUUCUUAGA 4165 AGUGUGGCUUUC 4166 AAGAAAGCCAC MIMAT0003314 GC UUAGAGC ACU hsa-miR-645 4167 UCUAGGCUGGUACUGCU 4168 UCUAGGCUGGUA 4169 AGUACCAGCCU MIMAT0003315 GA CUGCUGA AGA hsa-miR-646 4170 AAGCAGCUGCCUCUGAG 4171 AAGCAGCUGCCU 4172 AGAGGCAGCUG MIMAT0003316 GC CUGAGGC CUU hsa-miR-647 4173 GUGGCUGCACUCACUUC 4174 GUGGCUGCACUC 4175 GUGAGUGCAGC MIMAT0003317 CUUC ACUUCCUU CAC hsa-miR-648 4176 AAGUGUGCAGGGCACUG 4177 AAGUGUGCAGGG 4178 UGCCCUGCACA MIMAT0003318 GU CACUGGU CUU hsa-miR-649 4179 AAACCUGUGUUGUUCAA 4180 AAACCUGUGUUG 4181 AACAACACAGG MIMAT0003319 GAGUC UUCAAGAG UUU hsa-miR-650 4182 AGGAGGCAGCGCUCUCA 4183 AGGAGGCAGCGC 4184 GAGCGCUGCCU MIMAT0003320 GGAC UCUCAGGA CCU hsa-miR-651 4185 UUUAGGAUAAGCUUGAC 4186 UUUAGGAUAAGC 4187 AAGCUUAUCCU MIMAT0003321 UUUUG UUGACUUU AAA hsa-miR-652 4188 AAUGGCGCCACUAGGGU 4189 AAUGGCGCCACU 4190 CUAGUGGCGCC MIMAT0003322 UGUG AGGGUUGU AUU hsa-miR-653 4191 GUGUUGAAACAAUCUCU 4192 GUGUUGAAACAA 4193 GAUUGUUUCAA MIMAT0003328 ACUG UCUCUACU CAC hsa-miR-654-3p 4194 UAUGUCUGCUGACCAUC 4195 UAUGUCUGCUGA 4196 GGUCAGCAGAC MIMAT0004814 ACCUU CCAUCACC AUA hsa-miR-654-5p 4197 UGGUGGGCCGCAGAACA 4198 UGGUGGGCCGCA 4199 UCUGCGGCCCA MIMAT0003330 UGUGC GAACAUGU CCA hsa-miR-655 4200 AUAAUACAUGGUUAACC 4201 AUAAUACAUGGU 4202 UAACCAUGUAU MIMAT0003331 UCUUU UAACCUCU UAU hsa-miR-656 4203 AAUAUUAUACAGUCAAC 4204 AAUAUUAUACAG 4205 GACUGUAUAAU MIMAT0003332 CUCU UCAACCUC AUU hsa-miR-657 4206 GGCAGGUUCUCACCCUC 4207 GGCAGGUUCUCA 4208 GGUGAGAACCU MIMAT0003335 UCUAGG CCCUCUCU GCC hsa-miR-658 4209 GGCGGAGGGAAGUAGGU 4210 GGCGGAGGGAAG 4211 UACUUCCCUCC MIMAT0003336 CCGUUGGU UAGGUCCG GCC hsa-miR-659 4212 CUUGGUUCAGGGAGGGU 4213 CUUGGUUCAGGG 4214 CUCCCUGAACC MIMAT0003337 CCCCA AGGGUCCC AAG hsa-miR-660 4215 UACCCAUUGCAUAUCGG 4216 UACCCAUUGCAU 4217 AUAUGCAAUGG MIMAT0003338 AGUUG AUCGGAGU GUA hsa-miR-661 4218 UGCCUGGGUCUCUGGCC 4219 UGCCUGGGUCUC 4220 CAGAGACCCAG MIMAT0003324 UGCGCGU UGGCCUGC GCA hsa-miR-662 4221 UCCCACGUUGUGGCCCA 4222 UCCCACGUUGUG 4223 GCCACAACGUG MIMAT0003325 GCAG GCCCAGCA GGA hsa-miR-663 4224 AGGCGGGGCGCCGCGGG 4225 AGGCGGGGCGCC 4226 GCGGCGCCCCG MIMAT0003326 ACCGC GCGGGACC CCU hsa-miR-663b 4227 GGUGGCCCGGCCGUGCC 4228 GGUGGCCCGGCC 4229 ACGGCCGGGCC MIMAT0005867 UGAGG GUGCCUGA ACC hsa-miR-664 4230 UAUUCAUUUAUCCCCAG 4231 UAUUCAUUUAUC 4232 GGGAUAAAUGA MIMAT0005949 CCUACA CCCAGCCU AUA hsa-miR-664* 4233 ACUGGCUAGGGAAAAUG 4234 ACUGGCUAGGGA 4235 UUUCCCUAGCC MIMAT0005948 AUUGGAU AAAUGAUU AGU hsa-miR-665 4236 ACCAGGAGGCUGAGGCC 4237 ACCAGGAGGCUG 4238 CUCAGCCUCCU MIMAT0004952 CCU AGGCCCCU GGU hsa-miR-668 4239 UGUCACUCGGCUCGGCC 4240 UGUCACUCGGCU 4241 CGAGCCGAGUG MIMAT0003881 CACUAC CGGCCCAC ACA hsa-miR-670 4242 GUCCCUGAGUGUAUGUG 4243 GUCCCUGAGUGU 4244 AUACACUCAGG MIMAT0010357 GUG AUGUGGUG GAC hsa-miR-671-3p 4245 UCCGGUUCUCAGGGCUC 4246 UCCGGUUCUCAG 4247 CCCUGAGAACC MIMAT0004819 CACC GGCUCCAC GGA hsa-miR-671-5p 4248 AGGAAGCCCUGGAGGGG 4249 AGGAAGCCCUGG 4250 CUCCAGGGCUU MIMAT0003880 CUGGAG AGGGGCUG CCU hsa-miR-675 4251 UGGUGCGGAGAGGGCCC 4252 UGGUGCGGAGAG 4253 CCCUCUCCGCA MIMAT0004284 ACAGUG GGCCCACA CCA hsa-miR-675* 4254 CUGUAUGCCCUCACCGC 4255 CUGUAUGCCCUC 4256 GUGAGGGCAUA MIMAT0006790 UCA ACCGCUCA CAG hsa-miR-676 4257 CUGUCCUAAGGUUGUUG 4258 CUGUCCUAAGGU 4259 CAACCUUAGGA MIMAT0018204 AGUU UGUUGAGU CAG hsa-miR-676* 4260 UCUUCAACCUCAGGACU 4261 UCUUCAACCUCA 4262 CCUGAGGUUGA MIMAT0018203 UGCA GGACUUGC AGA hsa-miR-7 4263 UGGAAGACUAGUGAUUU 4264 UGGAAGACUAGU 4265 UCACUAGUCUU MIMAT0000252 UGUUGU GAUUUUGU CCA hsa-miR-708 4266 AAGGAGCUUACAAUCUA 4267 AAGGAGCUUACA 4268 AUUGUAAGCUC MIMAT0004926 GCUGGG AUCUAGCU CUU hsa-miR-708* 4269 CAACUAGACUGUGAGCU 4270 CAACUAGACUGU 4271 UCACAGUCUAG MIMAT0004927 UCUAG GAGCUUCU UUG hsa-miR-7-1* 4272 CAACAAAUCACAGUCUG 4273 CAACAAAUCACA 4274 ACUGUGAUUUG MIMAT0004553 CCAUA GUCUGCCA UUG hsa-miR-711 4275 GGGACCCAGGGAGAGAC 4276 GGGACCCAGGGA 4277 UCUCCCUGGGU MIMAT0012734 GUAAG GAGACGUA CCC hsa-miR-718 4278 CUUCCGCCCCGCCGGGC 4279 CUUCCGCCCCGC 4280 CGGCGGGGCGG MIMAT0012735 GUCG CGGGCGUC AAG hsa-miR-7-2* 4281 CAACAAAUCCCAGUCUA 4282 CAACAAAUCCCA 4283 ACUGGGAUUUG MIMAT0004554 CCUAA GUCUACCU UUG hsa-miR-720 4284 UCUCGCUGGGGCCUCCA 4285 UCUCGCUGGGGC 4286 AGGCCCCAGCG MIMAT0005954 CUCCA AGA hsa-miR-744 4287 UGCGGGGCUAGGGCUAA 4288 UGCGGGGCUAGG 4289 GCCCUAGCCCC MIMAT0004945 CAGCA GCUAACAG GCA hsa-miR-744* 4290 CUGUUGCCACUAACCUC 4291 CUGUUGCCACUA 4292 GUUAGUGGCAA MIMAT0004946 AACCU ACCUCAAC CAG hsa-miR-758 4293 UUUGUGACCUGGUCCAC 4294 UUUGUGACCUGG 4295 GACCAGGUCAC MIMAT0003879 UAACC UCCACUAA AAA hsa-miR-759 4296 GCAGAGUGCAAACAAUU 4297 GCAGAGUGCAAA 4298 UGUUUGCACUC MIMAT0010497 UUGAC CAAUUUUG UGC hsa-miR-760 4299 CGGCUCUGGGUCUGUGG 4300 CGGCUCUGGGUC 4301 CAGACCCAGAG MIMAT0004957 GGA UGUGGGGA CCG hsa-miR-761 4302 GCAGCAGGGUGAAACUG 4303 GCAGCAGGGUGA 4304 UUUCACCCUGC MIMAT0010364 ACACA AACUGACA UGC hsa-miR-762 4305 GGGGCUGGGGCCGGGGC 4306 GGGGCUGGGGCC 4307 CCGGCCCCAGC MIMAT0010313 CGAGC GGGGCCGA CCC hsa-miR-764 4308 GCAGGUGCUCACUUGUC 4309 GCAGGUGCUCAC 4310 AAGUGAGCACC MIMAT0010367 CUCCU UUGUCCUC UGC hsa-miR-765 4311 UGGAGGAGAAGGAAGGU 4312 UGGAGGAGAAGG 4313 UUCCUUCUCCU MIMAT0003945 GAUG AAGGUGAU CCA hsa-miR-766 4314 ACUCCAGCCCCACAGCC 4315 ACUCCAGCCCCA 4316 UGUGGGGCUGG MIMAT0003888 UCAGC CAGCCUCA AGU hsa-miR-767-3p 4317 UCUGCUCAUACCCCAUG 4318 UCUGCUCAUACC 4319 GGGGUAUGAGC MIMAT0003883 GUUUCU CCAUGGUU AGA hsa-miR-767-5p 4320 UGCACCAUGGUUGUCUG 4321 UGCACCAUGGUU 4322 ACAACCAUGGU MIMAT0003882 AGCAUG GUCUGAGC GCA hsa-miR-769-3p 4323 CUGGGAUCUCCGGGGUC 4324 CUGGGAUCUCCG 4325 CCCGGAGAUCC MIMAT0003887 UUGGUU GGGUCUUG CAG hsa-miR-769-5p 4326 UGAGACCUCUGGGUUCU 4327 UGAGACCUCUGG 4328 ACCCAGAGGUC MIMAT0003886 GAGCU GUUCUGAG UCA hsa-miR-770-5p 4329 UCCAGUACCACGUGUCA 4330 UCCAGUACCACG 4331 CACGUGGUACU MIMAT0003948 GGGCCA UGUCAGGG GGA hsa-miR-802 4332 CAGUAACAAAGAUUCAU 4333 CAGUAACAAAGA 4334 AAUCUUUGUUA MIMAT0004185 CCUUGU UUCAUCCU CUG hsa-miR-873 4335 GCAGGAACUUGUGAGUC 4336 GCAGGAACUUGU 4337 UCACAAGUUCC MIMAT0004953 UCCU GAGUCUCC UGC hsa-miR-874 4338 CUGCCCUGGCCCGAGGG 4339 CUGCCCUGGCCC 4340 UCGGGCCAGGG MIMAT0004911 ACCGA GAGGGACC CAG hsa-miR-875-3p 4341 CCUGGAAACACUGAGGU 4342 CCUGGAAACACU 4343 UCAGUGUUUCC MIMAT0004923 UGUG GAGGUUGU AGG hsa-miR-875-5p 4344 UAUACCUCAGUUUUAUC 4345 UAUACCUCAGUU 4346 AAAACUGAGGU MIMAT0004922 AGGUG UUAUCAGG AUA hsa-miR-876-3p 4347 UGGUGGUUUACAAAGUA 4348 UGGUGGUUUACA 4349 UUUGUAAACCA MIMAT0004925 AUUCA AAGUAAUU CCA hsa-miR-876-5p 4350 UGGAUUUCUUUGUGAAU 4351 UGGAUUUCUUUG 4352 CACAAAGAAAU MIMAT0004924 CACCA UGAAUCAC CCA hsa-miR-877 4353 GUAGAGGAGAUGGCGCA 4354 GUAGAGGAGAUG 4355 GCCAUCUCCUC MIMAT0004949 GGG GCGCAGGG UAC hsa-miR-877* 4356 UCCUCUUCUCCCUCCUC 4357 UCCUCUUCUCCC 4358 GAGGGAGAAGA MIMAT0004950 CCAG UCCUCCCA GGA hsa-miR-885-3p 4359 AGGCAGCGGGGUGUAGU 4360 AGGCAGCGGGGU 4361 ACACCCCGCUG MIMAT0004948 GGAUA GUAGUGGA CCU hsa-miR-885-5p 4362 UCCAUUACACUACCCUG 4363 UCCAUUACACUA 4364 GGUAGUGUAAU MIMAT0004947 CCUCU CCCUGCCU GGA hsa-miR-887 4365 GUGAACGGGCGCCAUCC 4366 GUGAACGGGCGC 4367 UGGCGCCCGUU MIMAT0004951 CGAGG CAUCCCGA CAC hsa-miR-888 4368 UACUCAAAAAGCUGUCA 4369 UACUCAAAAAGC 4370 CAGCUUUUUGA MIMAT0004916 GUCA UGUCAGUC GUA hsa-miR-888* 4371 GACUGACACCUCUUUGG 4372 GACUGACACCUC 4373 AAGAGGUGUCA MIMAT0004917 GUGAA UUUGGGUG GUC hsa-miR-889 4374 UUAAUAUCGGACAACCA 4375 UUAAUAUCGGAC 4376 UUGUCCGAUAU MIMAT0004921 UUGU AACCAUUG UAA hsa-miR-890 4377 UACUUGGAAAGGCAUCA 4378 UACUUGGAAAGG 4379 UGCCUUUCCAA MIMAT0004912 GUUG CAUCAGUU GUA hsa-miR-891a 4380 UGCAACGAACCUGAGCC 4381 UGCAACGAACCU 4382 UCAGGUUCGUU MIMAT0004902 ACUGA GAGCCACU GCA hsa-miR-891b 4383 UGCAACUUACCUGAGUC 4384 UGCAACUUACCU 4385 UCAGGUAAGUU MIMAT0004913 AUUGA GAGUCAUU GCA hsa-miR-892a 4386 CACUGUGUCCUUUCUGC 4387 CACUGUGUCCUU 4388 GAAAGGACACA MIMAT0004907 GUAG UCUGCGUA GUG hsa-miR-892b 4389 CACUGGCUCCUUUCUGG 4390 CACUGGCUCCUU 4391 GAAAGGAGCCA MIMAT0004918 GUAGA UCUGGGUA GUG hsa-miR-9 4392 UCUUUGGUUAUCUAGCU 4393 UCUUUGGUUAUC 4394 UAGAUAACCAA MIMAT0000441 GUAUGA UAGCUGUA AGA hsa-miR-9* 4395 AUAAAGCUAGAUAACCG 4396 AUAAAGCUAGAU 4397 UUAUCUAGCUU MIMAT0000442 AAAGU AACCGAAA UAU hsa-miR-920 4398 GGGGAGCUGUGGAAGCA 4399 GGGGAGCUGUGG 4400 UUCCACAGCUC MIMAT0004970 GUA AAGCAGUA CCC hsa-miR-921 4401 CUAGUGAGGGACAGAAC 4402 CUAGUGAGGGAC 4403 CUGUCCCUCAC MIMAT0004971 CAGGAUUC AGAACCAG UAG hsa-miR-922 4404 GCAGCAGAGAAUAGGAC 4405 GCAGCAGAGAAU 4406 CUAUUCUCUGC MIMAT0004972 UACGUC AGGACUAC UGC hsa-miR-924 4407 AGAGUCUUGUGAUGUCU 4408 AGAGUCUUGUGA 4409 CAUCACAAGAC MIMAT0004974 UGC UGUCUUGC UCU hsa-miR-92a 4410 UAUUGCACUUGUCCCGG 4411 UAUUGCACUUGU 4412 GGACAAGUGCA MIMAT0000092 CCUGU CCCGGCCU AUA hsa-miR-92a-1* 4413 AGGUUGGGAUCGGUUGC 4414 AGGUUGGGAUCG 4415 ACCGAUCCCAA MIMAT0004507 AAUGCU GUUGCAAU CCU hsa-miR-92a-2* 4416 GGGUGGGGAUUUGUUGC 4417 GGGUGGGGAUUU 4418 ACAAAUCCCCA MIMAT0004508 AUUAC GUUGCAUU CCC hsa-miR-92b 4419 UAUUGCACUCGUCCCGG 4420 UAUUGCACUCGU 4421 GGACGAGUGCA MIMAT0003218 CCUCC CCCGGCCU AUA hsa-miR-92b* 4422 AGGGACGGGACGCGGUG 4423 AGGGACGGGACG 4424 CGCGUCCCGUC MIMAT0004792 CAGUG CGGUGCAG CCU hsa-miR-93 4425 CAAAGUGCUGUUCGUGC 4426 CAAAGUGCUGUU 4427 CGAACAGCACU MIMAT0000093 AGGUAG CGUGCAGG UUG hsa-miR-93* 4428 ACUGCUGAGCUAGCACU 4429 ACUGCUGAGCUA 4430 GCUAGCUCAGC MIMAT0004509 UCCCG GCACUUCC AGU hsa-miR-933 4431 UGUGCGCAGGGAGACCU 4432 UGUGCGCAGGGA 4433 UCUCCCUGCGC MIMAT0004976 CUCCC GACCUCUC ACA hsa-miR-934 4434 UGUCUACUACUGGAGAC 4435 UGUCUACUACUG 4436 UCCAGUAGUAG MIMAT0004977 ACUGG GAGACACU ACA hsa-miR-935 4437 CCAGUUACCGCUUCCGC 4438 CCAGUUACCGCU 4439 GAAGCGGUAAC MIMAT0004978 UACCGC UCCGCUAC UGG hsa-miR-936 4440 ACAGUAGAGGGAGGAAU 4441 ACAGUAGAGGGA 4442 CCUCCCUCUAC MIMAT0004979 CGCAG GGAAUCGC UGU hsa-miR-937 4443 AUCCGCGCUCUGACUCU 4444 AUCCGCGCUCUG 4445 GUCAGAGCGCG MIMAT0004980 CUGCC ACUCUCUG GAU hsa-miR-938 4446 UGCCCUUAAAGGUGAAC 4447 UGCCCUUAAAGG 4448 CACCUUUAAGG MIMAT0004981 CCAGU UGAACCCA GCA hsa-miR-939 4449 UGGGGAGCUGAGGCUCU 4450 UGGGGAGCUGAG 4451 GCCUCAGCUCC MIMAT0004982 GGGGGUG GCUCUGGG CCA hsa-miR-940 4452 AAGGCAGGGCCCCCGCU 4453 AAGGCAGGGCCC 4454 GGGGGCCCUGC MIMAT0004983 CCCC CCGCUCCC CUU hsa-miR-941 4455 CACCCGGCUGUGUGCAC 4456 CACCCGGCUGUG 4457 CACACAGCCGG MIMAT0004984 AUGUGC UGCACAUG GUG hsa-miR-942 4458 UCUUCUCUGUUUUGGCC 4459 UCUUCUCUGUUU 4460 CAAAACAGAGA MIMAT0004985 AUGUG UGGCCAUG AGA hsa-miR-943 4461 CUGACUGUUGCCGUCCU 4462 CUGACUGUUGCC 4463 ACGGCAACAGU MIMAT0004986 CCAG GUCCUCCA CAG hsa-miR-944 4464 AAAUUAUUGUACAUCGG 4465 AAAUUAUUGUAC 4466 AUGUACAAUAA MIMAT0004987 AUGAG AUCGGAUG UUU hsa-miR-95 4467 UUCAACGGGUAUUUAUU 4468 UUCAACGGGUAU 4469 AAAUACCCGUU MIMAT0000094 GAGCA UUAUUGAG GAA hsa-miR-96 4470 UUUGGCACUAGCACAUU 4471 UUUGGCACUAGC 4472 GUGCUAGUGCC MIMAT0000095 UUUGCU ACAUUUUU AAA hsa-miR-96* 4473 AAUCAUGUGCAGUGCCA 4474 AAUCAUGUGCAG 4475 CACUGCACAUG MIMAT0004510 AUAUG UGCCAAUA AUU hsa-miR-98 4476 UGAGGUAGUAAGUUGUA 4477 UGAGGUAGUAAG 4478 AACUUACUACC MIMAT0000096 UUGUU UUGUAUUG UCA hsa-miR-99a 4479 AACCCGUAGAUCCGAUC 4480 AACCCGUAGAUC 4481 CGGAUCUACGG MIMAT0000097 UUGUG CGAUCUUG GUU hsa-miR-99a* 4482 CAAGCUCGCUUCUAUGG 4483 CAAGCUCGCUUC 4484 UAGAAGCGAGC MIMAT0004511 GUCUG UAUGGGUC UUG hsa-miR-99b 4485 CACCCGUAGAACCGACC 4486 CACCCGUAGAAC 4487 CGGUUCUACGG MIMAT0000689 UUGCG CGACCUUG GUG hsa-miR-99b* 4488 CAAGCUCGUGUCUGUGG 4489 CAAGCUCGUGUC 4490 CAGACACGAGC MIMAT0004678 GUCCG UGUGGGUC UUG

TABLE 5 Examples of chemical modification patterns miRNA Name Example of modified AS strand Example of modified sense strand hsa-let-7a 5′Pm0005f0f05f05f00f05f005f05f05m0*5m0* m0m00m00m0m000m00m0*m0*m0TEGChol MIMAT0000062 0*5m0*f0*5m0*0 hsa-let-7a* 5′Pm0005f0f05f005f05f05f0005f00*5m0*0*5 m0m0m0m00m00m00m00m0*m0*m0TEGChol MIMAT0004481 m0*5m0*0*0 hsa-let-7a-2* 5′Pm05f05f05f05f005f05f05f00005f00*5m0* m0m0m0m0m0m000m0m000*0*m0TEGChol MIMAT0010195 5m0*0*** hsa-let-7b 5′Pm0000f0000f005f05f05f05m0*0*5m0*0*f m0m000m0m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0000063 0*5m0*0 hsa-let-7b* 5′Pm0005f0f0000f05f0005f00*0*5m0*5m0*f m0m0m0m00m0m0m0m0m00m0*m0*m0TEGChol MIMAT0004482 0*0*0 hsa-let-7c 5′Pm005f05f0f05f000f005f05f05f05m0*5m0* m0m000m0m0m0m00m000*m0*m0TEGChol MIMAT0000064 5m0*5m0*5m0*5m0*0 hsa-let-7c* 5′Pm0005f05f05f05f005f0005f05f00*0*0*5m m0m00m0m0m0m000m00m0*m0*m0TEGChol MIMAT0004483 0*** hsa-let-7d 5′Pm005f05f0f05f05f05f0f0000f05m0*0*5m0 m0m0m0m0m0m0000m000*m0*m0TEGChol MIMAT0000065 *5m0*5m0*5m0* hsa-let-7d* 5′Pm005f00f00005f05f000f05m0*0*5m0*5m m0m0m0m00m0m0m0m0m0m00*m0*m0TEGChol MIMAT0004484 0*5m0*0*0 hsa-let-7e 5′Pm0005f0f005f05f05f005f00f00*0*5m0*0* m0m0m00m0m000m0m00m0*m0*m0TEGChol MIMAT0000066 f0*5m0*0 hsa-let-7e* 5′Pm05f000f0000f00005f05m0*0*5m0*5m0 m0m0m0m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0004485 *** hsa-let-7f 5′Pm05f000f05f05f05f05f05f000f00*0*0*0*f m0m0m0m00m0000m0m0m0*0*m0TEGChol MIMAT0000067 0*0*0 hsa-let-7f-1* 5′Pm00005f005f05f0f005f005f05m0*5m0*0* m0m0m00m0m000m0m0m0m0*m0*m0TEGChol MIMAT0004486 5m0*5m0*5m0*0 hsa-let-7f-2* 5′Pm0005f0f05f005f05f05f0005f00*5m0*5m m0m0m0m00m00m00m00m0*m0*m0TEGChol MIMAT0004487 0*0*f0*0*0 hsa-let-7g 5′Pm00005f005f05f05f05f05f05f05f05m0*5m m0m0000m000m0m0m0m0*m0*m0TEGChol MIMAT0000414 0*0*0*f0*0*0 hsa-let-7g* 5′Pm0000f05f05f005f005f05f05f00*0*5m0*0 m0m000m0m0m000m0m0m0*m0*m0TEGChol MIMAT0004584 *5m0*0*0 hsa-let-7i 5′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0000415 m0*5m0*5m0*0 hsa-let-7i* 5′Pm05f000f005f05f05f05f000f00*5m0*0*0* m0m0m0m00m000m0m0m0m0*0*m0TEGChol MIMAT0004585 f0*5m0*0 hsa-miR-1 5′Pm00005f05f05f05f05f05f05f005f00*0*0*5 m0m0m000m0000m0m0m0*m0*m0TEGChol MIMAT0000416 m0*5m0*0*0 hsa-miR-100 5′Pm005f05f05f005f05f0f0005f05f00*0*0*0* m0m00m0m0m000m0m000*m0*m0TEGChol MIMAT0000098 5m0*0*0 hsa-miR-100* 5′Pm005f05f0f05f005f05f05f005f05f05m0*5 m0m00m00m00m00m000*m0*m0TEGChol MIMAT0004512 m0*0*0*5m0*5m0*0 hsa-miR-101 5′Pm0000f005f05f05f05f05f005f00*5m0*0*5 m0m0m000m000m0m0m0m0*m0*m0TEGChol MIMAT0000099 m0*5m0*5m0*0 hsa-miR-101* 5′Pm05f000f005f00f05f0005f05m0*5m0*0*5 m0m0m0m00m0m00m0m0m0m0*0*m0TEGChol MIMAT0004513 m0*f0*5m0*0 hsa-miR-103 5′Pm005f05f0f05f000f0005f05f00*5m0*5m0 m0m00m0m0m0m0m00m000*m0*m0TEGChol MIMAT0000101 *0*f0*0*0 hsa-miR-103-2* 5′Pm05f05f05f0f005f05f05f05f05f05f05f00*0 m0m0000m000m0m000*0*m0TEGChol MIMAT0009196 *0*0*f0*5m0*0 hsa-miR-103-as 5′Pm0005f05f05f05f05f0f0000f05m0*0*5m0 m0m0m0m0m0m0000m00m0*m0*m0TEGChol MIMAT0007402 *5m0*f0*5m0*0 hsa-miR-105 5′Pm0000f05f05f05f0f0005f0f05m0*5m0*5m m0m00m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0000102 0*0*f0*0* hsa-miR-105* 5′Pm0005f0f05f05f05f05f05f000f00*0*5m0* m0m0m0m00m0000m00m0*m0*m0TEGChol MIMAT0004516 5m0*5m0*5m0*0 hsa-miR-106a 5′Pm05f000f05f0005f05f005f0f00*5m0*0*0* m0m00m00m0m0m00m0m0m0*0*m0TEGChol MIMAT0000103 5m0*0*0 hsa-miR-106a* 5′Pm0005f0f005f005f005f05f0f05m0*5m0*0 m0m000m0m0m00m0m00m0*m0*m0TEGChol MIMAT0004517 *0*5m0*5m0*0 hsa-miR-106b 5′Pm0000f05f005f05f05f05f05f05f05m0*5m0 m0m0000m00m00m0m0m0*m0*m0TEGChol MIMAT0000680 *5m0*0*f0*0*0 hsa-miR-106b* 5′Pm0000f05f05f05f05f05f000f00*0*5m0*0* m0m0m0m00m0000m0m0m0*m0*m0TEGChol MIMAT0004672 f0*5m0*0 hsa-miR-107 5′Pm0005f0f05f005f05f05f005f0f00*0*0*5m m0m00m00m00m00m00m0*m0*m0TEGChol MIMAT0000104 0*5m0*5m0* hsa-miR-10a 5′Pm0005f0f00005f05f05f05f0f00*0*0*0*5m m0m0000m0m0m0m0m00m0*m0*m0TEGChol MIMAT0000253 0*0*0 hsa-miR-10a* 5′Pm0005f0f0000f05f05f05f0f00*0*5m0*0*f m0m0000m0m0m0m0m00m0*m0*m0TEGChol MIMAT0004555 0*5m0*0 hsa-miR-10b 5′Pm0005f0f05f005f0f00005f05m0*5m0*0*5 m0m0m0m0m0m00m00m00m0*m0*m0TEGChol MIMAT0000254 m0*f0*5m0*0 hsa-miR-10b* 5′Pm05f05f005f005f05f05f00005f05m0*5m0 m0m0m0m0m0m000m0m0m00*0*m0TEGChol MIMAT0004556 *5m0*0*5m0*5m0*0 hsa-miR-1178 5′Pm00005f05f05f05f05f005f005f05m0*0*5 m0m0m00m0m0000m0m0m0*m0*m0TEGChol MIMAT0005823 m0*5m0*5m0*5m0*0 hsa-miR-1179 5′Pm005f05f0f00005f05f000f05m0*5m0*0*5 m0m0m0m00m0m0m0m0m000*m0*m0TEGChol MIMAT0005824 m0*f0*0*0 hsa-miR-1180 5′Pm05f000f05f000f005f05f05f05m0*5m0*0 m0m000m0m0m0m00m0m0m0*0*m0TEGChol MIMAT0005825 *0*f0*0*0 hsa-miR-1181 5′Pm05f000f005f05f05f0000f00*0*5m0*5m0 m0m0m0m0m0m000m0m0m0m0*0*m0TEGChol MIMAT0005826 *5m0*5m0*0 hsa-miR-1182 5′Pm0000f005f00f05f0005f05m0*0*5m0*5m m0m0m0m00m0m00m0m0m0m0*m0*m0TEGChol MIMAT0005827 0*5m0*5m0*0 hsa-miR-1183 5′Pm0005f05f005f00f05f05f005f05m0*5m0* m0m0m000m0m00m0m00m0*m0*m0TEGChol MIMAT0005828 5m0*0*5m0*5m0*0 hsa-miR-1184 5′Pm05f05f00f005f00f05f05f05f0f00*0*0*5m m0m0000m0m00m0m0m00*0*m0TEGChol MIMAT0005829 0*f0*0*0 hsa-miR-1185 5′Pm005f00f05f05f05f0f005f05f0f05m0*5m0 m0m000m0m0000m0m00*m0*m0TEGChol MIMAT0005798 *0*0*5m0*0*0 hsa-miR-1193 5′Pm00005f05f0005f05f005f05f05m0*0*0*0 m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0015049 *5m0*0*0 hsa-miR-1197 5′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0005955 m0*5m0*5m0*0 hsa-miR-1200 5′Pm0000f0005f05f05f05f005f00*0*0*0*f0* m0m0m000m00m0m0m0m0m0*m0*m0TEGChol MIMAT0005863 5m0*0 hsa-miR-1202 5′Pm05f05f005f05f05f05f05f0005f05f00*5m0 m0m00m0m0m0000m0m00*0*m0TEGChol MIMAT0005865 *5m0*5m0*f0*5m0*0 hsa-miR-1203 5′Pm00005f0005f0f05f005f05f00*5m0*5m0* m0m00m00m00m0m0m0m0m0*m0*m0TEGChol MIMAT0005866 0*f0*5m0*0 hsa-miR-1204 5′Pm05f0005f05f05f05f0f05f005f05f05m0*0* m0m00m00m0000m0m0m0*0*m0TEGChol MIMAT0005868 5m0*5m0*f0*5m0*0 hsa-miR-1205 5′Pm05f05f005f05f05f05f05f0005f05f00*5m0 m0m00m0m0m0000m0m00*0*m0TEGChol MIMAT0005869 *5m0*5m0*f0*5m0*0 hsa-miR-1206 5′Pm0005f05f0000f005f005f00*0*0*0*f0** m0m0m00m0m0m0m0m0m00m0*m0*m0TEGChol MIMAT0005870 hsa-miR-1207-3p 5′Pm00005f005f05f0f05f05f005f00*5m0*5m m0m0m000m000m0m0m0m0*m0*m0TEGChol MIMAT0005872 0*5m0*f0*5m0*0 hsa-miR-1207-5p 5′Pm0005f0f05f000f0000f00*5m0*5m0*5m0 m0m0m0m0m0m0m0m00m00m0*m0*m0TEGChol MIMAT0005871 *f0*5m0*0 hsa-miR-1208 5′Pm05f05f00f005f00f05f05f05f0f00*0*0*5m m0m0000m0m00m0m0m00*0*m0TEGChol MIMAT0005873 0*f0*0*0 hsa-miR-122 5′Pm05f05f05f0f05f05f05f0f005f00f05m0*0* m0m0m00m0m0000m000*0*m0TEGChol MIMAT0000421 0*5m0*5m0*5m0*0 hsa-miR-122* 5′Pm05f05f05f0f05f05f05f0f05f05f05f0f05m0 m0m0000m0000m000*0*m0TEGChol MIMAT0004590 *5m0*5m0*5m0*f0*5m0*0 hsa-miR-1224-3p 5′Pm0000f05f000f00005f05m0*0*5m0*0*5 m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0005459 m0*0*0 hsa-miR-1224-5p 5′Pm00005f005f005f05f05f05f05f05m0*5m0 m0m0000m0m00m0m0m0m0*m0*m0TEGChol MIMAT0005458 *0*0*f0*0*0 hsa-miR-1225-3p 5′Pm05f05f005f05f05f05f05f05f005f05f00*5 m0m00m00m0000m0m00*0*m0TEGChol MIMAT0005573 m0*5m0*5m0*f0*0*0 hsa-miR-1225-5p 5′Pm05f000f00005f05f0005f05m0*0*0*0*f0 m0m0m0m00m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0005572 ** hsa-miR-1226 5′Pm05f05f00f05f005f0f00005f00*5m0*0*0* m0m0m0m0m0m00m00m0m00*0*m0TEGChol MIMAT0005577 f0*5m0*0 hsa-miR-1226* 5′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0005576 m0*5m0*5m0*0 hsa-miR-1227 5′Pm005f005f00005f005f005f00*5m0*0*5m m0m0m00m0m0m0m0m0m0m00*m0*m0TEGChol MIMAT0005580 0*f0*5m0*0 hsa-miR-1228 5′Pm0005f0f05f05f005f005f005f00*5m0*5m m0m0m00m0m0m000m00m0*m0*m0TEGChol MIMAT0005583 0*0*5m0*5m0*0 hsa-miR-1228* 5′Pm05f05f00f05f000f0005f0f00*5m0*0*0*5 m0m00m0m0m0m0m00m0m00*0*m0TEGChol MIMAT0005582 m0*5m0*0 hsa-miR-1229 5′Pm05f000f05f005f0f005f05f05f00*0*5m0* m0m000m0m00m00m0m0m0*0*m0TEGChol MIMAT0005584 0*f0*0*0 hsa-miR-1231 5′Pm005f05f0f0005f0f0005f05f00*0*0*0*f0* m0m00m0m0m00m0m0m000*m0*m0TEGChol MIMAT0005586 0* hsa-miR-1233 5′Pm005f05f0f0005f0f05f05f005f00*0*5m0* m0m0m000m00m0m0m000*m0*m0TEGChol MIMAT0005588 5m0*5m0*5m0*0 hsa-miR-1234 5′Pm005f05f05f0000f05f005f0f05m0*0*0*5 m0m00m00m0m0m0m0m000*m0*m0TEGChol MIMAT0005589 m0*f0*5m0*0 hsa-miR-1236 5′Pm05f005f0f05f0005f05f05f05f05f05m0*0* m0m0000m0m0m00m00m0*0*m0TEGChol MIMAT0005591 0*5m0*5m0*5m0*0 hsa-miR-1237 5′Pm0000f05f005f05f05f005f0f00*5m0*0*5 m0m00m00m00m00m0m0m0*m0*m0TEGChol MIMAT0005592 m0*f0*0*0 hsa-miR-1238 5′Pm05f005f0f005f005f00005f00*5m0*5m0* m0m0m0m0m0m0m00m0m00m0*0*m0TEGChol MIMAT0005593 5m0*5m0*5m0*0 hsa-miR-124 5′Pm05f000f005f00f05f005f0f05m0*0*0*5m m0m00m00m0m00m0m0m0m0*0*m0TEGChol MIMAT0000422 0*5m0*0*0 hsa-miR-124* 5′Pm0000f0000f0005f0f00*0*5m0*0*f0*0*0 m0m00m0m0m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0004591 hsa-miR-1243 5′Pm005f05f05f05f05f05f05f005f00f00*5m0* m0m0m00m0m0000m000*m0*m0TEGChol MIMAT0005894 0*0*5m0*5m0*0 hsa-miR-1244 5′Pm005f005f005f00f005f05f0f05m0*0*0*0* m0m000m0m0m00m0m0m00*m0*m0TEGChol MIMAT0005896 f0*5m0*0 hsa-miR-1245 5′Pm00005f005f005f05f05f05f05f05m0*5m0 m0m0000m0m00m0m0m0m0*m0*m0TEGChol MIMAT0005897 *0*0*f0*0*0 hsa-miR-1246 5′Pm05f05f05f0f05f05f005f05f005f0f00*5m0 m0m00m00m0m000m000*0*m0TEGChol MIMAT0005898 *0*5m0*5m0*0*0 hsa-miR-1247 5′Pm05f005f05f0005f05f05f05f005f00*5m0* m0m0m000m00m0m0m00m0*0*m0TEGChol MIMAT0005899 5m0*5m0*5m0*5m0*0 hsa-miR-1248 5′Pm05f000f0005f0f05f005f0f00*0*5m0*5m m0m00m00m00m0m0m0m0m0*0*m0TEGChol MIMAT0005900 0*5m0*0*0 hsa-miR-1249 5′Pm0000f05f005f05f0005f0f00*5m0*0*5m0 m0m00m0m0m00m00m0m0m0*m0*m0TEGChol MIMAT0005901 *f0*0*0 hsa-miR-1250 5′Pm005f00f005f005f0000f00*5m0*0*0*** m0m0m0m0m0m0m00m0m0m00*m0*m0TEGChol MIMAT0005902 hsa-miR-1251 5′Pm05f005f0f05f05f005f05f05f05f05f05m0* m0m0000m0m000m00m0*0*m0TEGChol MIMAT0005903 5m0*5m0*5m0*** hsa-miR-1252 5′Pm05f000f0000f005f00f05m0*0*5m0*0*f0 m0m0m00m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0005944 *0*0 hsa-miR-1253 5′Pm05f05f005f05f000f05f05f00f05m0*0*5m m0m0m000m0m0m00m0m00*0*m0TEGChol MIMAT0005904 0*5m0*5m0*5m0*0 hsa-miR-1254 5′Pm0005f05f05f000f05f05f05f05f00*0*5m0 m0m0000m0m0m00m00m0*m0*m0TEGChol MIMAT0005905 *5m0*5m0*0*0 hsa-miR-1255a 5′Pm05f05f05f05f05f05f05f05f05f05f05f05f0 m0m0000m0000m000*0*m0TEGChol MIMAT0005906 5m0*5m0*5m0*5m0*5m0*5m0*0 hsa-miR-1255b 5′Pm0005f0f005f00f0005f0f05m0*0*0*5m0* m0m00m0m0m0m00m0m00m0*m0*m0TEGChol MIMAT0005945 f0*0*0 hsa-miR-1256 5′Pm05f05f005f05f05f05f05f05f05f05f0f05m m0m0000m0000m0m00*0*m0TEGChol MIMAT0005907 0*5m0*0*5m0*5m0*0*0 hsa-miR-1257 5′Pm005f005f05f05f005f005f005f00*5m0*0* m0m0m00m0m0m000m0m00*m0*m0TEGChol MIMAT0005908 5m0*5m0*5m0*0 hsa-miR-1258 5′Pm05f005f05f0005f05f005f005f05m0*5m0 m0m0m00m0m00m0m0m00m0*0*m0TEGChol MIMAT0005909 *5m0*5m0*5m0*5m0*0 hsa-miR-125a-3p 5′Pm05f005f0f05f005f0f005f05f0f00*0*0*0* m0m000m0m00m00m00m0*0*m0TEGChol MIMAT0004602 5m0*5m0*0 hsa-miR-125a-5p 5′Pm05f005f0f005f00f005f05f0f00*5m0*5m0 m0m000m0m0m00m0m00m0*0*m0TEGChol MIMAT0000443 *5m0*5m0*5m0*0 hsa-miR-125b 5′Pm0000f005f05f0f0005f05f05m0*5m0*0*5 m0m00m0m0m000m0m0m0m0*m0*m0TEGChol MIMAT0000423 m0*f0*0*0 hsa-miR-125b-1* 5′Pm0005f0f0005f05f0000f00*5m0*0*5m0*f m0m0m0m0m0m00m0m0m00m0*m0*m0TEGChol MIMAT0004592 0*0*0 hsa-miR-125b-2* 5′Pm0005f0f005f005f05f005f05f00*5m0*5m m0m00m00m0m00m0m00m0*m0*m0TEGChol MIMAT0004603 0*5m0*f0*0*0 hsa-miR-126 5′Pm005f005f05f05f05f0f05f05f005f05m0*0* m0m0m000m0000m0m00*m0*m0TEGChol MIMAT0000445 0*5m0*f0*0*0 hsa-miR-126* 5′Pm05f05f05f05f0000f05f05f05f05f05m0*5 m0m0000m0m0m0m0m000*0*m0TEGChol MIMAT0000444 m0*0*0*5m0*5m0*0 hsa-miR-1260 5′Pm0000f05f0005f00005f05m0*0*5m0*0*5 m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0005911 m0*0*0 hsa-miR-1260b 5′Pm005f005f05f005f05f05f05f05f05f05m0*5 m0m0000m00m00m0m00*m0*m0TEGChol MIMAT0015041 m0*5m0*5m0*5m0*0*0 hsa-miR-1261 5′Pm0005f05f05f05f05f0f0005f05f05m0*5m0 m0m00m0m0m0000m00m0*m0*m0TEGChol MIMAT0005913 *0*5m0*5m0*5m0*0 hsa-miR-1262 5′Pm05f05f00f0000f005f005f05m0*0*5m0*0 m0m0m00m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0005914 *f0*0*0 hsa-miR-1263 5′Pm05f05f005f0005f0f005f05f0f00*0*5m0* m0m000m0m00m0m0m0m00*0*m0TEGChol MIMAT0005915 5m0*5m0*5m0*0 hsa-miR-1264 5′Pm05f05f05f0f05f005f05f05f0005f05m0*5 m0m0m0m00m00m00m000*0*m0TEGChol MIMAT0005791 m0*0*5m0*5m0*5m0*0 hsa-miR-1265 5′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0005918 m0*5m0*5m0*0 hsa-miR-1266 5′Pm0000f0000f0005f0f05m0*0*0*5m0*f0* m0m00m0m0m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0005920 0*0 hsa-miR-1267 5′Pm00005f005f05f0f05f05f05f0f05m0*0*0* m0m0000m000m0m0m0m0*m0*m0TEGChol MIMAT0005921 0*f0*0*0 hsa-miR-1268 5′Pm00005f005f005f005f005f00*5m0*0*0*f m0m0m00m0m0m00m0m0m0m0*m0*m0TEGChol MIMAT0005922 0*5m0*0 hsa-miR-1269 5′Pm05f05f00f05f000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m00m0m00*0*m0TEGChol MIMAT0005923 m0*5m0*5m0*0 hsa-miR-1270 5′Pm05f005f05f0005f0f05f005f05f05m0*0*5 m0m00m00m00m0m0m00m0*0*m0TEGChol MIMAT0005924 m0*5m0*f0*0*0 hsa-miR-1271 5′Pm00005f05f05f00f05f05f005f05m0*5m0* m0m0m000m0m000m0m0m0*m0*m0TEGChol MIMAT0005796 0*5m0*f0*0*0 hsa-miR-1272 5′Pm00005f005f005f05f05f05f05f05m0*5m0 m0m0000m0m00m0m0m0m0*m0*m0TEGChol MIMAT0005925 *0*0*f0*0*0 hsa-miR-1273 5′Pm00005f05f05f005f005f05f0f00*0*0*0*f0 m0m000m0m0m000m0m0m0*m0*m0TEGChol MIMAT0005926 *0*0 hsa-miR-1273c 5′Pm05f05f05f05f05f05f05f0f005f005f00*0* m0m0m00m0m0000m000*0*m0TEGChol MIMAT0015017 0*5m0*5m0*5m0*0 hsa-miR-1273d 5′Pm05f05f00f005f05f0f005f05f05f00*5m0*5 m0m000m0m000m0m0m00*0*m0TEGChol MIMAT0015090 m0*0*5m0*5m0*0 hsa-miR-1273e 5′Pm0000f0005f05f05f05f005f00*5m0*5m0* m0m0m000m00m0m0m0m0m0*m0*m0TEGChol MIMAT0018079 0*f0*0*0 hsa-miR-127-3p 5′Pm05f05f05f0f00005f0005f0f05m0*0*0*5 m0m00m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0000446 m0*f0*0*0 hsa-miR-1274a 5′Pm05f05f05f05f0000f05f05f05f05f00*0*5m m0m0000m0m0m0m0m000*0*m0TEGChol MIMAT0005927 0*5m0*5m0*0*0 hsa-miR-1274b 5′Pm05f05f05f05f0000f05f05f05f0f00*5m0*5 m0m0000m0m0m0m0m000*0*m0TEGChol MIMAT0005938 m0*5m0*5m0*5m0*0 hsa-miR-1275 5′Pm05f05f005f05f005f0f05f05f005f05m0*5 m0m0m000m00m00m0m00*0*m0TEGChol MIMAT0005929 m0*5m0*0*5m0*5m0*0 hsa-miR-127-5p 5′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0004604 m0*5m0*5m0*0 hsa-miR-1276 5′Pm05f05f05f0f05f0005f005f005f05m0*5m0 m0m0m00m0m0m0m00m000*0*m0TEGChol MIMAT0005930 *5m0*5m0*f0*0*0 hsa-miR-1277 5′Pm05f000f005f05f0f05f05f05f05f00*5m0*0 m0m0000m000m0m0m0m0*0*m0TEGChol MIMAT0005933 *5m0*5m0*5m0*0 hsa-miR-1278 5′Pm0005f05f05f000f005f05f05f00*0*0*5m0 m0m000m0m0m0m00m00m0*m0*m0TEGChol MIMAT0005936 *f0*0*0 hsa-miR-1279 5′Pm05f005f0f05f05f05f0f05f05f05f05f00*5 m0m0000m0000m00m0*0*m0TEGChol MIMAT0005937 m0*5m0*5m0*5m0*5m0*0 hsa-miR-128 5′Pm00005f005f00f0000f00*0*0*5m0*5m0* m0m0m0m0m0m0m00m0m0m0m0*m0*m0TEGChol MIMAT0000424 0*0 hsa-miR-1280 5′Pm05f000f05f05f00f005f05f05f05m0*5m0* m0m000m0m0m000m0m0m0*0*m0TEGChol MIMAT0005946 0*0*f0*0*0 hsa-miR-1281 5′Pm05f005f0f05f0005f05f05f005f05m0*0*5 m0m0m000m0m0m00m00m0*0*m0TEGChol MIMAT0005939 m0*5m0*5m0*5m0*0 hsa-miR-1282 5′Pm05f005f0f05f0005f05f05f005f05m0*0*5 m0m0m000m0m0m00m00m0*0*m0TEGChol MIMAT0005940 m0*5m0*5m0*5m0*0 hsa-miR-1283 5′Pm005f005f05f05f05f0f05f005f05f00*0*0* m0m00m00m0000m0m00*m0*m0TEGChol MIMAT0005799 0*f0*0*0 hsa-miR-1284 5′Pm05f05f05f05f005f05f05f05f005f05f00*5 m0m00m00m000m0m000*0*m0TEGChol MIMAT0005941 m0*5m0*5m0*f0*0*0 hsa-miR-1285 5′Pm0000f05f005f05f05f05f05f05f05m0*5m0 m0m0000m00m00m0m0m0*m0*m0TEGChol MIMAT0005876 *5m0*0*f0*0*0 hsa-miR-1286 5′Pm0005f05f0005f05f00005f00*0*0*0*f0*5 m0m0m0m0m0m00m0m0m00m0*m0*m0TEGChol MIMAT0005877 m0* hsa-miR-1287 5′Pm0005f0f05f05f005f05f05f00f05m0*0*0* m0m0m000m0m000m00m0*m0*m0TEGChol MIMAT0005878 0*5m0*5m0*0 hsa-miR-1288 5′Pm05f05f005f0005f0f005f05f0f00*0*5m0* m0m000m0m00m0m0m0m00*0*m0TEGChol MIMAT0005942 5m0*5m0*5m0*0 hsa-miR-1289 5′Pm05f05f05f05f0005f05f05f05f05f05f05m0 m0m0000m00m0m0m000*0*m0TEGChol MIMAT0005879 *0*5m0*0*5m0*5m0*0 hsa-miR-129* 5′Pm05f005f0f0005f05f00005f05m0*5m0*5 m0m0m0m0m0m00m0m0m00m0*0*m0TEGChol MIMAT0004548 m0*5m0*f0*0*0 hsa-miR-1290 5′Pm05f05f00f05f05f05f0f00005f05m0*0*5m m0m0m0m0m0m0000m0m00*0*m0TEGChol MIMAT0005880 0*5m0*f0*0* hsa-miR-1291 5′Pm005f005f0005f0f05f05f00f00*0*0*5m0* m0m0m000m00m0m0m0m00*m0*m0TEGChol MIMAT0005881 f0*5m0*0 hsa-miR-1292 5′Pm0005f0f05f05f05f05f05f05f05f05f05m0* m0m0000m0000m00m0*m0*m0TEGChol MIMAT0005943 0*0*0*f0*5m0*0 hsa-miR-1293 5′Pm05f05f05f05f05f000f0000f00*0*5m0*0* m0m0m0m0m0m0m0m00m000*0*m0TEGChol MIMAT0005883 5m0*5m0*0 hsa-miR-129-3p 5′Pm05f005f0f05f05f005f00005f00*0*5m0*0 m0m0m0m0m0m0m000m00m0*0*m0TEGChol MIMAT0004605 *f0*5m0*0 hsa-miR-1294 5′Pm05f05f05f0f05f0005f005f005f05m0*5m0 m0m0m00m0m0m0m00m000*0*m0TEGChol MIMAT0005884 *5m0*5m0*f0*0*0 hsa-miR-1295 5′Pm0005f05f005f05f05f00005f00*0*5m0*5 m0m0m0m0m0m000m0m00m0*m0*m0TEGChol MIMAT0005885 m0*5m0*5m0*0 hsa-miR-129-5p 5′Pm005f05f0f05f05f005f05f05f05f05f00*0* m0m0000m0m000m000*m0*m0TEGChol MIMAT0000242 5m0*0*5m0*0*0 hsa-miR-1296 5′Pm00005f005f00f05f05f00f00*5m0*5m0*0 m0m0m000m0m00m0m0m0m0*m0*m0TEGChol MIMAT0005794 *** hsa-miR-1297 5′Pm0000f00005f0000f05m0*5m0*5m0*0*f m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEG MIMAT0005886 0*0*0 Chol hsa-miR-1298 5′Pm05f05f05f0f05f05f005f05f005f05f00*5m m0m00m00m0m000m000*0*m0TEGChol MIMAT0005800 0*5m0*5m0*** hsa-miR-1299 5′Pm005f05f05f05f005f0f0005f05f05m0*0*0 m0m00m0m0m00m00m000*m0*m0TEGChol MIMAT0005887 *5m0*5m0*5m0*0 hsa-miR-1301 5′Pm05f0005f05f05f005f00005f05m0*0*0*5 m0m0m0m0m0m0m000m0m0m0*0*m0TEGChol MIMAT0005797 m0*f0*0*0 hsa-miR-1302 5′Pm0000f05f0005f00005f00*0*5m0*0*f0*5 m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0005890 m0*0 hsa-miR-1303 5′Pm00005f0000f05f005f05f00*0*5m0*0*5 m0m00m00m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0005891 m0*5m0*0 hsa-miR-1304 5′Pm00005f005f05f0f05f005f0f00*0*5m0*5 m0m00m00m000m0m0m0m0*m0*m0TEGChol MIMAT0005892 m0*f0*0*0 hsa-miR-1305 5′Pm05f05f05f05f005f05f05f05f05f005f05m0 m0m0m000m000m0m000*0*m0TEGChol MIMAT0005893 *0*5m0*5m0*f0** hsa-miR-1306 5′Pm0000f005f05f0f0005f05f05m0*5m0*0*5 m0m00m0m0m000m0m0m0m0*m0*m0TEGChol MIMAT0005950 m0*f0*0*0 hsa-miR-1307 5′Pm00005f05f05f00f05f05f00f05m0*5m0*0 m0m0m000m0m000m0m0m0*m0*m0TEGChol MIMAT0005951 *0*5m0*0*0 hsa-miR-130a 5′Pm005f005f0005f0f05f000f05m0*0*0*5m0 m0m0m0m00m00m0m0m0m00*m0*m0TEGChol MIMAT0000425 *5m0*5m0*0 hsa-miR-130a* 5′Pm05f005f0f05f000f0005f0f05m0*5m0*5m m0m00m0m0m0m0m00m00m0*0*m0TEGChol MIMAT0004593 0*5m0*5m0*0*0 hsa-miR-130b 5′Pm00005f005f05f05f05f05f05f05f05m0*5m m0m0000m000m0m0m0m0*m0*m0TEGChol MIMAT0000691 0*0*0*f0*5m0*0 hsa-miR-130b* 5′Pm05f005f0f05f0005f05f05f05f05f05m0*0* m0m0000m0m0m00m00m0*0*m0TEGChol MIMAT0004680 0*5m0*5m0*5m0*0 hsa-miR-132 5′Pm05f05f00f05f05f05f0f05f005f0f00*5m0* m0m00m00m0000m0m00*0*m0TEGChol MIMAT0000426 0*5m0*5m0*5m0*0 hsa-miR-132* 5′Pm05f005f05f05f05f05f05f05f05f05f05f05 m0m0000m0000m00m0*0*m0TEGChol MIMAT0004594 m0*5m0*5m0*5m0*** hsa-miR-1321 5′Pm005f005f005f00f0000f00*5m0*5m0*5m m0m0m0m0m0m0m00m0m0m00*m0*m0TEGChol MIMAT0005952 0*5m0*5m0*0 hsa-miR-1322 5′Pm0000f05f000f005f05f05f05m0*5m0*0*0 m0m000m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0005953 *f0*0* hsa-miR-1323 5′Pm0005f05f05f0005f05f05f00f00*5m0*5m m0m0m000m0m0m00m00m0*m0*m0TEGChol MIMAT0005795 0*5m0*5m0*0*0 hsa-miR-1324 5′Pm0005f0f0005f05f005f005f00*0*5m0*0* m0m0m00m0m00m0m0m00m0*m0*m0TEGChol MIMAT0005956 5m0*0*0 hsa-miR-133a 5′Pm05f005f0f05f05f005f00005f00*5m0*5m m0m0m0m0m0m0m000m00m0*0*m0TEGChol MIMAT0000427 0*5m0*f0*5m0*0 hsa-miR-133b 5′Pm005f00f05f005f05f005f005f00*0*0*0*5 m0m0m00m0m00m00m0m00*m0*m0TEGChol MIMAT0000770 m0*5m0*0 hsa-miR-134 5′Pm005f05f05f05f005f05f05f05f05f0f05m0* m0m0000m00m00m000*m0*m0TEGChol MIMAT0000447 5m0*5m0*0*5m0*0*0 hsa-miR-135a 5′Pm05f005f05f05f005f05f05f05f05f05f05m0 m0m0000m00m00m00m0*0*m0TEGChol MIMAT0000428 *5m0*5m0*0*5m0*5m0*0 hsa-miR-135a* 5′Pm05f005f05f05f005f05f05f05f05f05f00*5 m0m0000m00m00m00m0*0*m0TEGChol MIMAT0004595 m0*0*0*f0*0* hsa-miR-135b 5′Pm05f05f005f0000f0000f00*5m0*0*5m0* m0m0m0m0m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0000758 5m0*5m0*0 hsa-miR-135b* 5′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0004698 m0*5m0*5m0*0 hsa-miR-136 5′Pm05f005f0f05f0005f05f05f005f05m0*0*5 m0m0m000m0m0m00m00m0*0*m0TEGChol MIMAT0000448 m0*5m0*5m0*5m0*0 hsa-miR-136* 5′Pm05f05f005f005f00f005f05f05f05m0*0*0 m0m000m0m0m00m0m0m00*0*m0TEGChol MIMAT0004606 *5m0*5m0*5m0*0 hsa-miR-137 5′Pm0000f05f000f005f05f05f05m0*5m0*0*0 m0m000m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0000429 *f0*0*0 hsa-miR-138 5′Pm05f05f05f05f00005f005f05f05f05m0*0* m0m000m0m0m0m0m0m000*0*m0TEGChol MIMAT0000430 5m0*5m0*5m0*5m0*0 hsa-miR-138-1* 5′Pm05f05f05f05f05f05f005f05f05f005f00*5 m0m0m000m0m000m000*0*m0TEGChol MIMAT0004607 m0*0*5m0*5m0*5m0*0 hsa-miR-138-2* 5′Pm05f05f05f0f05f005f0f05f000f00*5m0*5 m0m0m0m00m00m00m000*0*m0TEGChol MIMAT0004596 m0*0*f0*0*0 hsa-miR-139-3p 5′Pm005f005f0005f0f05f0005f05m0*5m0*0* m0m0m0m00m00m0m0m0m00*m0*m0TEGChol MIMAT0004552 5m0*5m0*0*0 hsa-miR-139-5p 5′Pm005f05f0f0005f05f005f00f00*5m0*5m0 m0m0m00m0m00m0m0m000*m0*m0TEGChol MIMAT0000250 *5m0*5m0*5m0*0 hsa-miR-140-3p 5′Pm00005f005f05f05f05f05f05f05f05m0*5m m0m0000m000m0m0m0m0*m0*m0TEGChol MIMAT0004597 0*0*0*f0*0*0 hsa-miR-140-5p 5′Pm05f005f05f0005f05f05f05f005f00*0*0*5 m0m0m000m00m0m0m00m0*0*m0TEGChol MIMAT0000431 m0*5m0*0*0 hsa-miR-141 5′Pm0000f005f05f05f005f00f05m0*5m0*5m m0m0m00m0m000m0m0m0m0*m0*m0TEGChol MIMAT0000432 0*0*5m0*5m0*0 hsa-miR-141* 5′Pm05f005f0f05f000f0005f0f05m0*5m0*5m m0m00m0m0m0m0m00m00m0*0*m0TEGChol MIMAT0004598 0*5m0*5m0*0*0 hsa-miR-142-3p 5′Pm05f0005f005f005f05f005f0f00*0*0*5m0 m0m00m00m0m00m0m0m0m0*0*m0TEGChol MIMAT0000434 *5m0*5m0*0 hsa-miR-142-5p 5′Pm05f000f05f000f05f005f05f00*5m0*5m0 m0m00m00m0m0m00m0m0m0*0*m0TEGChol MIMAT0000433 *5m0*5m0*0*0 hsa-miR-143 5′Pm05f0005f0005f0f05f05f05f0f05m0*5m0* m0m0000m00m0m0m0m0m0*0*m0TEGChol MIMAT0000435 0*5m0*f0*0*0 hsa-miR-143* 5′Pm005f00f005f005f0000f05m0*0*0*5m0*f m0m0m0m0m0m0m00m0m0m00*m0*m0TEGChol MIMAT0004599 0** hsa-miR-144 5′Pm00005f005f05f05f05f05f05f05f05m0*5m m0m0000m000m0m0m0m0*m0*m0TEGChol MIMAT0000436 0*0*0*f0*0*0 hsa-miR-144* 5′Pm00005f05f05f00f05f0005f00*0*0*5m0*f m0m0m0m00m0m000m0m0m0*m0*m0TEGChol MIMAT0004600 0*0* hsa-miR-145 5′Pm005f05f05f05f005f0f0005f05f05m0*0*0 m0m00m0m0m00m00m000*m0*m0TEGChol MIMAT0000437 *0*5m0*5m0*0 hsa-miR-145* 5′Pm0005f0f05f000f05f005f0f00*0*5m0*0*5 m0m00m00m0m0m00m00m0*m0*m0TEGChol MIMAT0004601 m0*5m0*0 hsa-miR-1468 5′Pm00005f05f05f005f005f05f05f00*0*0*0*f m0m000m0m0m000m0m0m0*m0*m0TEGChol MIMAT0006789 0*0*0 hsa-miR-1469 5′Pm0005f05f005f05f0f05f05f005f05m0*0*5 m0m0m000m000m0m00m0*m0*m0TEGChol MIMAT0007347 m0*5m0*f0*0*0 hsa-miR-146a 5′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0000449 m0*5m0*5m0*0 hsa-miR-146a* 5′Pm005f05f0f005f05f05f005f00f00*0*5m0* m0m0m00m0m000m0m000*m0*m0TEGChol MIMAT0004608 5m0*5m0*5m0*0 hsa-miR-146b-3p 5′Pm00005f05f05f05f05f005f00f00*5m0*0*0 m0m0m00m0m0000m0m0m0*m0*m0TEGChol MIMAT0004766 *f0*0*0 hsa-miR-146b-5p 5′Pm00005f005f05f05f05f05f05f05f05m0*5m m0m0000m000m0m0m0m0*m0*m0TEGChol MIMAT0002809 0*0*0*5m0*0*0 hsa-miR-147 5′Pm005f05f0f05f05f05f0f05f000f00*0*0*0*f m0m0m0m00m0000m000*m0*m0TEGChol MIMAT0000251 0*5m0*0 hsa-miR-1470 5′Pm005f05f05f05f005f0f00005f05m0*0*0*0 m0m0m0m0m0m00m00m000*m0*m0TEGChol MIMAT0007348 *5m0*5m0*0 hsa-miR-1471 5′Pm05f05f00f005f05f05f05f05f00f05m0*0*5 m0m0m000m000m0m0m00*0*m0TEGChol MIMAT0007349 m0*5m0*f0*0* hsa-miR-147b 5′Pm05f05f005f05f05f005f0000f00*0*0*5m0 m0m0m0m0m0m0m000m0m00*0*m0TEGChol MIMAT0004928 *f0*0*0 hsa-miR-148a 5′Pm05f05f05f05f05f005f0f005f005f00*0*5m m0m0m00m0m00m00m000*0*m0TEGChol MIMAT0000243 0*5m0*** hsa-miR-148a* 5′Pm0005f0f05f0005f005f05f0f05m0*5m0*5 m0m000m0m0m0m00m00m0*m0*m0TEGChol MIMAT0004549 m0*0*5m0*0*0 hsa-miR-148b 5′Pm05f05f05f05f05f05f05f05f0000f05m0*5 m0m0m0m0m0m0000m000*0*m0TEGChol MIMAT0000759 m0*0*5m0*5m0*5m0*0 hsa-miR-148b* 5′Pm00005f05f05f05f0f00005f00*5m0*5m0* m0m0m0m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0004699 5m0*5m0*0*0 hsa-miR-149 5′Pm05f05f00f005f00f05f000f00*5m0*0*0*f m0m0m0m00m0m00m0m0m00*0*m0TEGChol MIMAT0000450 0*0*0 hsa-miR-149* 5′Pm005f05f05f0005f05f005f005f00*5m0*0* m0m0m00m0m00m0m0m000*m0*m0TEGChol MIMAT0004609 5m0*f0*5m0*0 hsa-miR-150 5′Pm05f000f05f05f05f0f005f05f05f05m0*0*0 m0m000m0m0000m0m0m0*0*m0TEGChol MIMAT0000451 *0*f0*0*0 hsa-miR-150* 5′Pm05f05f05f05f05f05f05f05f05f05f05f0f05 m0m0000m0000m000*0*m0TEGChol MIMAT0004610 m0*0*0*0*5m0*5m0*0 hsa-miR-151-3p 5′Pm05f05f05f05f005f05f05f0005f05f05m0*0 m0m00m0m0m000m0m000*0*m0TEGChol MIMAT0000757 *5m0*5m0*f0*0*0 hsa-miR-151-5p 5′Pm05f05f05f05f005f05f0f005f005f05m0*0* m0m0m00m0m000m0m000*0*m0TEGChol MIMAT0004697 5m0*5m0*5m0*5m0*0 hsa-miR-152 5′Pm05f05f00f05f000f05f005f05f00*0*5m0* m0m00m00m0m0m00m0m00*0*m0TEGChol MIMAT0000438 5m0*f0*0*0 hsa-miR-153 5′Pm0000f0005f05f05f05f00f00*5m0*5m0*0 m0m0m000m00m0m0m0m0m0*m0*m0TEGChol MIMAT0000439 *f0*0*0 hsa-miR-1537 5′Pm0000f0000f05f0005f05m0*0*0*5m0*5 m0m0m0m00m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0007399 m0*5m0*0 hsa-miR-1538 5′Pm05f005f0f05f000f0000f05m0*0*0*5m0* m0m0m0m0m0m0m0m00m00m0*0*m0TEGChol MIMAT0007400 5m0*5m0*0 hsa-miR-1539 5′Pm05f05f05f05f005f05f0f05f05f005f05m0* m0m0m000m000m0m000*0*m0TEGChol MIMAT0007401 0*5m0*5m0*f0*5m0* hsa-miR-154 5′Pm05f05f00f0005f05f0005f0f05m0*5m0*5 m0m00m0m0m00m0m0m0m00*0*m0TEGChol MIMAT0000452 m0*5m0*5m0*5m0*0 hsa-miR-154* 5′Pm00005f005f05f05f005f05f05f00*5m0*0* m0m000m0m000m0m0m0m0*m0*m0TEGChol MIMAT0000453 5m0*f0*0*0 hsa-miR-155 5′Pm0000f05f05f00f005f00f00*0*0*5m0*5m m0m0m00m0m0m000m0m0m0*m0*m0TEGChol MIMAT0000646 0*5m0*0 hsa-miR-155* 5′Pm005f00f0005f05f0000f05m0*0*0*0*5m m0m0m0m0m0m00m0m0m0m00*m0*m0TEGChol MIMAT0004658 0*5m0*0 hsa-miR-15a 5′Pm05f0005f05f05f005f00005f00*5m0*0*5 m0m0m0m0m0m0m000m0m0m0*0*m0TEGChol MIMAT0000068 m0*f0*5m0*0 hsa-miR-15a* 5′Pm0000f05f05f05f0f05f05f00f00*0*0*0*f0 m0m0m000m0000m0m0m0*m0*m0TEGChol MIMAT0004488 *0*0 hsa-miR-15b 5′Pm005f005f0000f005f05f0f00*5m0*5m0*0 m0m000m0m0m0m0m0m0m00*m0*m0TEGChol MIMAT0000417 *f0*0*0 hsa-miR-15b* 5′Pm00005f05f05f05f05f05f05f05f05f00*0*5 m0m0000m0000m0m0m0*m0*m0TEGChol MIMAT0004586 m0*5m0*5m0*5m0*0 hsa-miR-16 5′Pm05f005f0f0000f0000f05m0*5m0*5m0*5 m0m0m0m0m0m0m0m0m0m00m0*0*m0TEGChol MIMAT0000069 m0*5m0*5m0*0 hsa-miR-16-1* 5′Pm05f005f0f05f005f0f05f005f0f05m0*0*5 m0m00m00m00m00m00m0*0*m0TEGChol MIMAT0004489 m0*0*5m0*0*0 hsa-miR-16-2* 5′Pm005f00f00005f0000f00*0*0*5m0*5m0* m0m0m0m0m0m0m0m0m0m0m00*m0*m0TEGChol MIMAT0004518 5m0*0 hsa-miR-17 5′Pm05f05f00f005f05f05f0000f05m0*5m0*0 m0m0m0m0m0m000m0m0m00*0*m0TEGChol MIMAT0000070 *0*f0*0*0 hsa-miR-17* 5′Pm005f005f005f05f05f05f05f00f00*5m0*5 m0m0m000m000m0m0m00*m0*m0TEGChol MIMAT0000071 m0*0*5m0*0*0 hsa-miR-181a 5′Pm005f005f0000f05f0005f00*0*0*5m0*5 m0m0m0m00m0m0m0m0m0m00*m0*m0TEGChol MIMAT0000256 m0*0*0 hsa-miR-181a* 5′Pm05f0005f005f005f05f005f0f00*0*0*5m0 m0m00m00m0m00m0m0m0m0*0*m0TEGChol MIMAT0000270 *5m0*5m0*0 hsa-miR-181a-2* 5′Pm0005f05f05f05f005f05f005f0f05m0*0*5 m0m00m00m0m000m00m0*m0*m0TEGChol MIMAT0004558 m0*5m0*5m0*0*0 hsa-miR-181b 5′Pm05f05f00f05f05f05f05f005f005f05m0*5 m0m0m00m0m0000m0m00*0*m0TEGChol MIMAT0000257 m0*5m0*5m0*f0*5m0*0 hsa-miR-181c 5′Pm0000f0000f05f000f00*0*5m0*5m0*f0* m0m0m0m00m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0000258 5m0*0 hsa-miR-181c* 5′Pm005f05f0f005f05f05f05f05f00f00*0*5m0 m0m0m000m000m0m000*m0*m0TEGChol MIMAT0004559 *5m0*5m0*5m0*0 hsa-miR-181d 5′Pm05f05f05f05f05f0005f05f05f05f05f00*5 m0m0000m0m0m00m000*0*m0TEGChol MIMAT0002821 m0*0*5m0*5m0*0*0 hsa-miR-182 5′Pm005f05f05f0005f05f05f000f00*5m0*5m m0m0m0m00m00m0m0m000*m0*m0TEGChol MIMAT0000259 0*5m0*5m0*5m0*0 hsa-miR-182* 5′Pm0005f05f05f005f05f005f05f05f05m0*0* m0m000m0m00m00m00m0*m0*m0TEGChol MIMAT0000260 5m0*0*5m0*0*0 hsa-miR-1825 5′Pm05f000f05f000f0005f0f00*0*5m0*0*5m m0m00m0m0m0m0m00m0m0m0*0*m0TEGChol MIMAT0006765 0*0*0 hsa-miR-1827 5′Pm005f05f0f005f005f05f05f05f0f00*5m0*5 m0m0000m0m00m0m000*m0*m0TEGChol MIMAT0006767 m0*5m0*5m0*0*0 hsa-miR-183 5′Pm0000f0005f0f0000f00*5m0*0*0*f0*0*0 m0m0m0m0m0m00m0m0m0m0m0*m0*m0TEGChol MIMAT0000261 hsa-miR-183* 5′Pm0005f0f005f00f05f05f05f0f05m0*0*5m0 m0m0000m0m00m0m00m0*m0*m0TEGChol MIMAT0004560 *5m0*5m0*5m0*0 hsa-miR-184 5′Pm05f005f0f05f005f05f05f05f05f0f05m0*5 m0m0000m00m00m00m0*0*m0TEGChol MIMAT0000454 m0*0*5m0*5m0*5m0*0 hsa-miR-185 5′Pm005f05f0f05f005f0f05f0005f00*5m0*5m m0m0m0m00m00m00m000*m0*m0TEGChol MIMAT0000455 0*0*f0*5m0*0 hsa-miR-185* 5′Pm05f0005f05f005f0f00005f05m0*0*5m0* m0m0m0m0m0m00m00m0m0m0*0*m0TEGChol MIMAT0004611 0*5m0*0*0 hsa-miR-186 5′Pm0000f05f05f05f05f005f005f00*0*0*5m0 m0m0m00m0m0000m0m0m0*m0*m0TEGChol MIMAT0000456 *f0*5m0*0 hsa-miR-186* 5′Pm05f005f0f05f005f0f05f005f0f05m0*0*0* m0m00m00m00m00m00m0*0*m0TEGChol MIMAT0004612 5m0*f0*5m0*0 hsa-miR-187 5′Pm005f05f0f0005f05f0005f0f00*5m0*5m0 m0m00m0m0m00m0m0m000*m0*m0TEGChol MIMAT0000262 *5m0*f0*0*0 hsa-miR-187* 5′Pm0000f05f005f0f00005f00*5m0*5m0*0* m0m0m0m0m0m00m00m0m0m0*m0*m0TEGChol MIMAT0004561 5m0*5m0*0 hsa-miR-188-3p 5′Pm0000f05f05f05f05f0000f00*5m0*0*0*f0 m0m0m0m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0004613 *0*0 hsa-miR-188-5p 5′Pm00005f05f005f05f05f05f00f05m0*5m0* m0m0m000m00m00m0m0m0*m0*m0TEGChol MIMAT0000457 5m0*0*f0*0*0 hsa-miR-18a 5′Pm005f00f05f005f0f005f05f0f05m0*5m0*5 m0m000m0m00m00m0m00*m0*m0TEGChol MIMAT0000072 m0*5m0*5m0*0*0 hsa-miR-18a* 5′Pm05f0005f005f00f005f05f05f00*0*0*0*f0 m0m000m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0002891 *0*0 hsa-miR-18b 5′Pm05f05f00f00005f005f05f0f05m0*0*5m0 m0m000m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0001412 *5m0*5m0*0*0 hsa-miR-18b* 5′Pm005f00f05f0005f0005f05f05m0*5m0*0* m0m00m0m0m0m0m00m0m00*m0*m0TEGChol MIMAT0004751 5m0*f0*5m0*0 hsa-miR-190 5′Pm05f000f005f005f005f005f00*5m0*0*0*f m0m0m00m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0000458 0*0*0 hsa-miR-1908 5′Pm05f005f05f05f05f00f0005f05f00*5m0*5 m0m00m0m0m0m000m00m0*0*m0TEGChol MIMAT0007881 m0*0*f0*0*0 hsa-miR-1909 5′Pm05f05f05f05f05f005f0f05f05f05f05f00*0 m0m0000m00m00m000*0*m0TEGChol MIMAT0007883 *0*0*5m0*5m0*0 hsa-miR-1909* 5′Pm05f05f00f0000f0000f05m0*5m0*0*0*** m0m0m0m0m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0007882 hsa-miR-190b 5′Pm005f05f0f05f005f05f05f05f00f05m0*0*0 m0m0m000m00m00m000*m0*m0TEGChol MIMAT0004929 *5m0*f0*0*0 hsa-miR-191 5′Pm005f05f0f05f05f00f005f05f0f00*5m0*0* m0m000m0m0m000m000*m0*m0TEGChol MIMAT0000440 5m0*5m0*0* hsa-miR-191* 5′Pm05f0005f0000f05f05f005f05m0*0*5m0* m0m0m000m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0001618 5m0*f0*5m0*0 hsa-miR-1910 5′Pm0000f05f05f05f0f0000f05m0*5m0*5m0 m0m0m0m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0007884 *0*5m0*0*0 hsa-miR-1911 5′Pm05f05f005f05f005f05f0005f0f05m0*0*5 m0m00m0m0m00m00m0m00*0*m0TEGChol MIMAT0007885 m0*0*f0*5m0*0 hsa-miR-1911* 5′Pm00005f05f05f005f0005f05f00*5m0*5m0 m0m00m0m0m0m000m0m0m0*m0*m0TEGChol MIMAT0007886 *5m0*5m0*5m0*0 hsa-miR-1912 5′Pm05f05f00f005f00f00005f05m0*0*0*5m0 m0m0m0m0m0m0m00m0m0m00*0*m0TEGChol MIMAT0007887 *5m0*5m0*0 hsa-miR-1913 5′Pm0000f05f05f005f005f05f05f05m0*0*0*0 m0m000m0m0m000m0m0m0*m0*m0TEGChol MIMAT0007888 *f0*0*0 hsa-miR-1914 5′Pm0005f05f05f05f05f0f05f05f05f05f00*0* m0m0000m0000m00m0*m0*m0TEGChol MIMAT0007889 0*0*f0*0*0 hsa-miR-1914* 5′Pm05f005f05f05f05f05f05f05f05f05f05f05 m0m0000m0000m00m0*0*m0TEGChol MIMAT0007890 m0*5m0*5m0*0*5m0*5m0*0 hsa-miR-1915 5′Pm05f000f005f05f05f005f005f00*0*0*0*5 m0m0m00m0m000m0m0m0m0*0*m0TEGChol MIMAT0007892 m0*0*0 hsa-miR-1915* 5′Pm05f005f05f05f005f05f005f05f05f05m0*5 m0m000m0m00m00m00m0*0*m0TEGChol MIMAT0007891 m0*5m0*5m0*5m0*5m0*0 hsa-miR-192 5′Pm05f05f05f05f00005f05f05f00f05m0*0*0 m0m0m000m0m0m0m0m000*0*m0TEGChol MIMAT0000222 *0*f0*5m0*0 hsa-miR-192* 5′Pm05f000f05f05f00f0005f05f05m0*5m0*5 m0m00m0m0m0m000m0m0m0*0*m0TEGChol MIMAT0004543 m0*5m0*f0*0*0 hsa-miR-193a-3p 5′Pm005f00f0000f05f000f05m0*0*0*5m0*5 m0m0m0m00m0m0m0m0m0m00*m0*m0TEGChol MIMAT0000459 m0*0*0 hsa-miR-193a-5p 5′Pm0000f005f005f0005f05f00*0*5m0*5m0 m0m00m0m0m0m00m0m0m0m0*m0*m0TEGChol MIMAT0004614 *f0*0*0 hsa-miR-193b 5′Pm0005f0f005f005f0000f00*5m0*0*5m0* m0m0m0m0m0m0m00m0m00m0*m0*m0TEGChol MIMAT0002819 5m0*0*0 hsa-miR-193b* 5′Pm00005f005f05f05f05f05f05f05f05m0*5m m0m0000m000m0m0m0m0*m0*m0TEGChol MIMAT0004767 0*5m0*0*f0*0*0 hsa-miR-194 5′Pm00005f005f005f05f05f00f00*0*0*0*5m m0m0m000m0m00m0m0m0m0*m0*m0TEGChol MIMAT0000460 0** hsa-miR-194* 5′Pm05f05f05f0f00005f05f005f05f05m0*5m0 m0m00m00m0m0m0m0m000*0*m0TEGChol MIMAT0004671 *0*5m0*5m0*0*0 hsa-miR-195 5′Pm05f05f05f0f0005f0f05f05f00f00*0*5m0* m0m0m000m00m0m0m000*0*m0TEGChol MIMAT0000461 0*f0*5m0*0 hsa-miR-195* 5′Pm0005f0f05f05f005f05f05f00f00*0*5m0* m0m0m000m0m000m00m0*m0*m0TEGChol MIMAT0004615 5m0*f0*0*0 hsa-miR-196a 5′Pm05f000f005f005f005f005f00*5m0*0*0*f m0m0m00m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0000226 0*0*0 hsa-miR-196a* 5′Pm05f05f05f05f0005f05f05f05f00f00*0*5m m0m0m000m00m0m0m000*0*m0TEGChol MIMAT0004562 0*5m0*5m0*0*0 hsa-miR-196b 5′Pm05f05f00f05f05f05f05f05f05f05f05f00*0 m0m0000m0000m0m00*0*m0TEGChol MIMAT0001080 *5m0*0*5m0*5m0*0 hsa-miR-196b* 5′Pm00005f0000f0000f00*0*0*0*f0*0*0 m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEG MIMAT0009201 Chol hsa-miR-197 5′Pm0000f05f0005f0005f05f05m0*0*5m0*0 m0m00m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0000227 *5m0*0*0 hsa-miR-1972 5′Pm05f000f05f05f05f0f005f05f05f05m0*5m m0m000m0m0000m0m0m0*0*m0TEGChol MIMAT0009447 0*5m0*5m0*5m0*5m0*0 hsa-miR-1973 5′Pm05f05f005f005f005f0005f05f05m0*5m0 m0m00m0m0m0m00m0m0m00*0*m0TEGChol MIMAT0009448 *5m0*5m0*5m0*5m0*0 hsa-miR-1976 5′Pm0000f05f0005f00005f05m0*0*5m0*0*5 m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0009451 m0*0*0 hsa-miR-198 5′Pm005f005f05f05f005f05f05f005f05m0*5m m0m0m000m0m000m0m00*m0*m0TEGChol MIMAT0000228 0*5m0*0*5m0*5m0*0 hsa-miR-199a-3p 5′Pm0005f0f05f05f005f05f05f00f00*0*5m0* m0m0m000m0m000m00m0*m0*m0TEGChol MIMAT0000232 5m0*f0*0*0 hsa-miR-199a-5p 5′Pm05f05f00f05f05f05f05f005f005f00*0*5m m0m0m00m0m0000m0m00*0*m0TEGChol MIMAT0000231 0*0*f0*5m0*0 hsa-miR-199b-3p 5′Pm05f0005f05f05f05f0f05f005f0f00*5m0*0 m0m00m00m0000m0m0m0*0*m0TEGChol MIMAT0004563 *0*5m0*5m0*0 hsa-miR-199b-5p 5′Pm0005f0f05f05f005f05f05f00f00*0*5m0* m0m0m000m0m000m00m0*m0*m0TEGChol MIMAT0000263 5m0*f0*0*0 hsa-miR-19a 5′Pm05f05f005f0000f05f05f05f0f00*0*0*5m m0m0000m0m0m0m0m0m00*0*m0TEGChol MIMAT0000073 0*5m0*0*0 hsa-miR-19a* 5′Pm05f0005f005f05f0f005f05f0f05m0*0*5m m0m000m0m000m0m0m0m0*0*m0TEGChol MIMAT0004490 0*5m0*f0*5m0*0 hsa-miR-19b 5′Pm005f05f05f05f05f00f0000f05m0*5m0*5 m0m0m0m0m0m0m000m000*m0*m0TEGChol MIMAT0000074 m0*5m0*5m0*5m0*0 hsa-miR-19b-1* 5′Pm00005f0005f05f05f05f005f00*5m0*5m0 m0m0m000m00m0m0m0m0m0*m0*m0TEGChol MIMAT0004491 *0*5m0*5m0*0 hsa-miR-19b-2* 5′Pm0005f0f005f00f0000f05m0*5m0*0*5m0 m0m0m0m0m0m0m00m0m00m0*m0*m0TEGChol MIMAT0004492 *5m0*5m0*0 hsa-miR-200a 5′Pm0005f05f0005f05f05f05f05f05f05m0*5m m0m0000m00m0m0m00m0*m0*m0TEGChol MIMAT0000682 0*0*0*5m0*0*0 hsa-miR-200a* 5′Pm005f005f0000f005f00f00*5m0*5m0*5m m0m0m00m0m0m0m0m0m0m00*m0*m0TEGChol MIMAT0001620 0*5m0*5m0*0 hsa-miR-200b 5′Pm0005f0f05f0005f0005f0f05m0*5m0*0*5 m0m00m0m0m0m0m00m00m0*m0*m0TEGChol MIMAT0000318 m0*5m0*0*0 hsa-miR-200b* 5′Pm0005f0f05f0005f0005f0f05m0*5m0*0*5 m0m00m0m0m0m0m00m00m0*m0*m0TEGChol MIMAT0004571 m0*5m0*0*0 hsa-miR-200c 5′Pm005f00f0005f05f05f05f05f0f05m0*0*0* m0m0000m00m0m0m0m00*m0*m0TEGChol MIMAT0000617 0*f0*0*0 hsa-miR-200c* 5′Pm05f000f00005f05f05f005f00*0*5m0*5m m0m0m000m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0004657 0*5m0*0*0 hsa-miR-202 5′Pm0000f0005f05f0005f0f00*5m0*5m0*5m m0m00m0m0m00m0m0m0m0m0*m0*m0TEGChol MIMAT0002811 0*5m0*0*0 hsa-miR-202* 5′Pm05f0005f005f005f0005f0f00*0*0*5m0* m0m00m0m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0002810 5m0*5m0*0 hsa-miR-203 5′Pm0005f0f05f05f05f0f0000f05m0*0*0*0*** m0m0m0m0m0m0000m00m0*m0*m0TEGChol MIMAT0000264 hsa-miR-204 5′Pm05f005f0f05f000f05f05f005f05m0*0*5m m0m0m000m0m0m00m00m0*0*m0TEGChol MIMAT0000265 0*5m0*5m0*5m0*0 hsa-miR-205 5′Pm0000f05f0005f0005f05f05m0*0*5m0*0 m0m00m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0000266 *5m0*5m0*0 hsa-miR-205* 5′Pm05f005f0f05f05f05f05f05f05f05f05f00*5 m0m0000m0000m00m0*0*m0TEGChol MIMAT0009197 m0*0*5m0*5m0*5m0*0 hsa-miR-2052 5′Pm05f05f00f0000f05f05f005f00*0*5m0*0* m0m0m000m0m0m0m0m0m00*0*m0TEGChol MIMAT0009977 f0*5m0*0 hsa-miR-2053 5′Pm05f05f05f0f05f005f0f00005f05m0*5m0* m0m0m0m0m0m00m00m000*0*m0TEGChol MIMAT0009978 0*0*f0*0*0 hsa-miR-2054 5′Pm05f05f05f0f005f05f05f0005f0f00*0*0*0 m0m00m0m0m000m0m000*0*m0TEGChol MIMAT0009979 *5m0** hsa-miR-206 5′Pm005f05f05f0000f0005f05f00*5m0*5m0* m0m00m0m0m0m0m0m0m000*m0*m0TEGChol MIMAT0000462 0*f0*5m0*0 hsa-miR-208a 5′Pm05f05f00f00005f05f05f05f05f00*0*0*5 m0m0000m0m0m0m0m0m00*0*m0TEGChol MIMAT0000241 m0*5m0*5m0*0 hsa-miR-208b 5′Pm0000f05f05f005f00005f00*0*0*5m0*f0 m0m0m0m0m0m0m000m0m0m0*m0*m0TEGChol MIMAT0004960 *0*0 hsa-miR-20a 5′Pm05f000f0005f0f0000f05m0*5m0*0*0*f0 m0m0m0m0m0m00m0m0m0m0m0*0*m0TEGChol MIMAT0000075 ** hsa-miR-20a* 5′Pm00005f005f05f05f05f05f005f00*5m0*5 m0m0m000m000m0m0m0m0*m0*m0TEGChol MIMAT0004493 m0*5m0*5m0*0*0 hsa-miR-20b 5′Pm05f05f05f0f05f05f005f05f005f05f05m0* m0m00m00m0m000m000*0*m0TEGChol MIMAT0001413 5m0*0*0*** hsa-miR-20b* 5′Pm05f05f005f00005f05f05f05f0f00*5m0*5 m0m0000m0m0m0m0m0m00*0*m0TEGChol MIMAT0004752 m0*0*5m0*0*0 hsa-miR-21 5′Pm005f05f0f005f05f0f05f05f00f00*0*0*0*f m0m0m000m000m0m000*m0*m0TEGChol MIMAT0000076 0*5m0*0 hsa-miR-21* 5′Pm05f005f0f00005f05f05f005f00*5m0*0*0 m0m0m000m0m0m0m0m00m0*0*m0TEGChol MIMAT0004494 *f0*5m0*0 hsa-miR-210 5′Pm05f05f005f005f00f005f05f05f05m0*0*5 m0m000m0m0m00m0m0m00*0*m0TEGChol MIMAT0000267 m0*5m0*f0*5m0*0 hsa-miR-211 5′Pm05f005f0f05f000f05f05f005f05m0*0*5m m0m0m000m0m0m00m00m0*0*m0TEGChol MIMAT0000268 0*5m0*5m0*5m0*0 hsa-miR-2110 5′Pm05f05f005f05f005f0f005f05f0f05m0*0*0 m0m000m0m00m00m0m00*0*m0TEGChol MIMAT0010133 *0*5m0*0*0 hsa-miR-2113 5′Pm00005f05f05f05f05f00005f05m0*0*0*0 m0m0m0m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0009206 *f0*0* hsa-miR-2114 5′Pm0005f0f05f05f05f05f05f05f05f0f05m0*5 m0m0000m0000m00m0*m0*m0TEGChol MIMAT0011156 m0*0*0*5m0*5m0*0 hsa-miR-2114* 5′Pm0005f05f00005f05f05f00f00*0*0*5m0* m0m0m000m0m0m0m0m00m0*m0*m0TEGChol MIMAT0011157 5m0*0*0 hsa-miR-2115 5′Pm0005f05f05f05f00f05f05f00f00*0*0*5m m0m0m000m0m000m00m0*m0*m0TEGChol MIMAT0011158 0*5m0*0*0 hsa-miR-2115* 5′Pm05f05f05f05f05f05f05f05f0005f0f00*5m m0m00m0m0m0000m000*0*m0TEGChol MIMAT0011159 0*5m0*5m0*5m0*5m0*0 hsa-miR-2116 5′Pm00005f0005f05f05f05f05f05f00*5m0*5 m0m0000m00m0m0m0m0m0*m0*m0TEGChol MIMAT0011160 m0*0*5m0*5m0*0 hsa-miR-2116* 5′Pm0000f005f00f005f05f05f05m0*0*0*5m0 m0m000m0m0m00m0m0m0m0*m0*m0TEGChol MIMAT0011161 *f0*0*0 hsa-miR-2117 5′Pm05f05f05f05f0005f05f05f005f0f05m0*0* m0m00m00m00m0m0m000*0*m0TEGChol MIMAT0011162 0*0*5m0*0*0 hsa-miR-212 5′Pm05f05f05f0f0005f0f05f000f05m0*0*5m0 m0m0m0m00m00m0m0m000*0*m0TEGChol MIMAT0000269 *0*5m0*5m0*0 hsa-miR-214 5′Pm0005f0f05f05f05f05f05f05f05f05f05m0* m0m0000m0000m00m0*m0*m0TEGChol MIMAT0000271 0*0*0*f0*0*0 hsa-miR-214* 5′Pm00005f0005f05f05f000f00*0*5m0*5m0 m0m0m0m00m00m0m0m0m0m0*m0*m0TEGChol MIMAT0004564 *5m0*0*0 hsa-miR-215 5′Pm005f005f05f000f05f05f05f0f00*0*5m0* m0m0000m0m0m00m0m00*m0*m0TEGChol MIMAT0000272 5m0*** hsa-miR-216a 5′Pm00005f005f05f05f05f05f005f00*5m0*5 m0m0m000m000m0m0m0m0*m0*m0TEGChol MIMAT0000273 m0*5m0*5m0*0*0 hsa-miR-216b 5′Pm05f05f05f05f0005f0f05f000f00*0*5m0* m0m0m0m00m00m0m0m000*0*m0TEGChol MIMAT0004959 0*5m0*5m0*0 hsa-miR-217 5′Pm05f05f00f0005f0f05f000f00*5m0*5m0* m0m0m0m00m00m0m0m0m00*0*m0TEGChol MIMAT0000274 5m0*5m0*0* hsa-miR-218 5′Pm05f005f0f05f0005f05f005f0f00*0*0*0*5 m0m00m00m0m0m00m00m0*0*m0TEGChol MIMAT0000275 m0*0*0 hsa-miR-218-1* 5′Pm05f0005f0005f0f05f0005f00*5m0*5m0* m0m0m0m00m00m0m0m0m0m0*0*m0TEGChol MIMAT0004565 0*5m0*5m0*0 hsa-miR-218-2* 5′Pm05f05f005f05f005f05f05f05f05f05f05m0 m0m0000m00m00m0m00*0*m0TEGChol MIMAT0004566 *5m0*0*5m0*5m0*5m0*0 hsa-miR-219-1-3p 5′Pm0000f005f00f00005f05m0*5m0*0**** m0m0m0m0m0m0m00m0m0m0m0*m0*m0TEGChol MIMAT0004567 hsa-miR-219-2-3p 5′Pm005f005f05f05f00f005f05f0f05m0*5m0* m0m000m0m0m000m0m00*m0*m0TEGChol MIMAT0004675 5m0*0*** hsa-miR-219-5p 5′Pm0000f005f005f0005f0f00*0*0*0*f0*0*0 m0m00m0m0m0m00m0m0m0m0*m0*m0TEGChol MIMAT0000276 hsa-miR-22 5′Pm0000f05f0005f0000f00*5m0*5m0*5m0 m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0000077 *5m0** hsa-miR-22* 5′Pm00005f05f005f05f05f0005f05m0*0*5m0 m0m0m0m00m00m00m0m0m0*m0*m0TEGChol MIMAT0004495 *0*f0*5m0*0 hsa-miR-221 5′Pm0005f05f05f000f05f05f005f05m0*0*5m m0m0m000m0m0m00m00m0*m0*m0TEGChol MIMAT0000278 0*5m0*f0*5m0*0 hsa-miR-221* 5′Pm00005f005f05f05f05f05f005f00*5m0*5 m0m0m000m000m0m0m0m0*m0*m0TEGChol MIMAT0004568 m0*5m0*5m0*0*0 hsa-miR-222 5′Pm05f000f05f05f00f005f005f00*0*5m0*0* m0m0m00m0m0m000m0m0m0*0*m0TEGChol MIMAT0000279 f0*5m0*0 hsa-miR-222* 5′Pm005f05f05f005f05f05f005f00f00*0*5m0 m0m0m00m0m000m0m000*m0*m0TEGChol MIMAT0004569 *5m0*f0*5m0*0 hsa-miR-223 5′Pm05f05f005f005f00f00005f00*0*5m0*0* m0m0m0m0m0m0m00m0m0m00*0*m0TEGChol MIMAT0000280 5m0*0* hsa-miR-223* 5′Pm0000f05f005f0f0005f05f05m0*0*0*0*f0 m0m00m0m0m00m00m0m0m0*m0*m0TEGChol MIMAT0004570 *0*0 hsa-miR-224 5′Pm05f05f05f05f00005f005f05f05f05m0*0* m0m000m0m0m0m0m0m000*0*m0TEGChol MIMAT0000281 0*5m0*5m0** hsa-miR-224* 5′Pm05f05f05f0f05f005f0f005f05f05f05m0*0 m0m000m0m00m00m000*0*m0TEGChol MIMAT0009198 *0*0*f0*0*0 hsa-miR-2276 5′Pm05f000f005f05f05f05f000f00*0*0*5m0* m0m0m0m00m000m0m0m0m0*0*m0TEGChol MIMAT0011775 f0*0*0 hsa-miR-2277-3p 5′Pm05f05f00f05f005f0f0000f05m0*0*5m0* m0m0m0m0m0m00m00m0m00*0*m0TEGChol MIMAT0011777 5m0*5m0*0*0 hsa-miR-2277-5p 5′Pm0000f05f05f00f05f05f005f00*0*5m0*0* m0m0m000m0m000m0m0m0*m0*m0TEGChol MIMAT0017352 f0*0*0 hsa-miR-2278 5′Pm05f05f005f05f05f00f05f005f0f00*0*5m0 m0m00m00m0m000m0m00*0*m0TEGChol MIMAT0011778 *5m0*f0*5m0*0 hsa-miR-2355-3p 5′Pm05f005f05f005f05f0f05f05f005f05m0*5 m0m0m000m000m0m00m0*0*m0TEGChol MIMAT0017950 m0*0*0*f0*5m0*0 hsa-miR-2355-5p 5′Pm05f05f05f05f05f005f05f05f05f05f05f05 m0m0000m00m00m000*0*m0TEGChol MIMAT0016895 m0*5m0*0*5m0*5m0*0*0 hsa-miR-23a 5′Pm005f05f05f0000f0000f00*0*5m0*0*f0* m0m0m0m0m0m0m0m0m0m000*m0*m0TEGChol MIMAT0000078 0*0 hsa-miR-23a* 5′Pm05f05f05f0f005f05f0f05f0005f05m0*0*5 m0m0m0m00m000m0m000*0*m0TEGChol MIMAT0004496 m0*5m0*** hsa-miR-23b 5′Pm05f0005f0005f05f05f005f0f05m0*0*5m m0m00m00m00m0m0m0m0m0*0*m0TEGChol MIMAT0000418 0*5m0*f0*0*0 hsa-miR-23b* 5′Pm00005f005f05f05f05f05f005f00*5m0*5 m0m0m000m000m0m0m0m0*m0*m0TEGChol MIMAT0004587 m0*5m0*f0*0*0 hsa-miR-23c 5′Pm05f05f05f0f05f005f0f05f05f05f05f00*0* m0m0000m00m00m000*0*m0TEGChol MIMAT0018000 0*5m0*f0*5m0*0 hsa-miR-24 5′Pm05f05f05f05f0005f0f05f000f00*0*5m0* m0m0m0m00m00m0m0m000*0*m0TEGChol MIMAT0000080 0*5m0*5m0*0 hsa-miR-24-1* 5′Pm00005f005f05f05f05f05f005f00*5m0*5 m0m0m000m000m0m0m0m0*m0*m0TEGChol MIMAT0000079 m0*5m0*** hsa-miR-24-2* 5′Pm0005f05f005f05f05f05f05f005f00*5m0* m0m0m000m000m0m00m0*m0*m0TEGChol MIMAT0004497 5m0*5m0*** hsa-miR-25 5′Pm0005f05f05f05f05f0f05f05f05f05f00*0* m0m0000m0000m00m0*m0*m0TEGChol MIMAT0000081 0*0*f0*0*0 hsa-miR-25* 5′Pm05f000f005f005f05f05f05f05f05m0*5m0 m0m0000m0m00m0m0m0m0*0*m0TEGChol MIMAT0004498 *5m0*5m0*f0*0*0 hsa-miR-26a 5′Pm0000f05f05f005f05f05f05f0f00*0*0*0*f m0m0000m0m000m0m0m0*m0*m0TEGChol MIMAT0000082 0*0*0 hsa-miR-26a-1* 5′Pm05f000f05f000f005f05f05f05m0*0*0*5 m0m000m0m0m0m00m0m0m0*0*m0TEGChol MIMAT0004499 m0*5m0*5m0* hsa-miR-26a-2* 5′Pm05f000f05f000f05f05f05f0f05m0*0*0*0 m0m0000m0m0m00m0m0m0*0*m0TEGChol MIMAT0004681 *f0*0*0 hsa-miR-26b 5′Pm005f05f0f05f005f0f05f05f005f05m0*0*0 m0m0m000m00m00m000*m0*m0TEGChol MIMAT0000083 *0*5m0*5m0*0 hsa-miR-26b* 5′Pm0000f05f05f05f05f0000f00*0*0*0*5m0 m0m0m0m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0004500 *0*0 hsa-miR-27a 5′Pm0005f05f05f0005f005f005f00*5m0*0*0 m0m0m00m0m0m0m00m00m0*m0*m0TEGChol MIMAT0000084 *5m0*0*0 hsa-miR-27a* 5′Pm005f05f05f05f005f0f05f05f005f05m0*5 m0m0m000m00m00m000*m0*m0TEGChol MIMAT0004501 m0*0*0*f0*5m0*0 hsa-miR-27b 5′Pm005f05f05f0000f00005f00*5m0*0*5m0 m0m0m0m0m0m0m0m0m0m000*m0*m0TEGChol MIMAT0000419 *f0*0*0 hsa-miR-27b* 5′Pm0005f0f0005f0f005f005f00*5m0*5m0*5 m0m0m00m0m00m0m0m00m0*m0*m0TEGChol MIMAT0004588 m0*5m0*0*0 hsa-miR-28-3p 5′Pm05f005f0f0005f05f05f0005f05m0*5m0* m0m0m0m00m00m0m0m00m0*0*m0TEGChol MIMAT0004502 5m0*0*f0*0* hsa-miR-28-5p 5′Pm0000f05f0005f05f05f00f05m0*0*5m0*0 m0m0m000m0m0m00m0m0m0*m0*m0TEGChol MIMAT0000085 *f0*0*0 hsa-miR-2861 5′Pm05f05f05f0f05f005f05f00005f05m0*0*5 m0m0m0m0m0m00m00m000*0*m0TEGChol MIMAT0013802 m0*5m0*5m0*5m0*0 hsa-miR-2909 5′Pm05f005f0f005f005f05f05f05f0f05m0*5m m0m0000m0m00m0m00m0*0*m0TEGChol MIMAT0013863 0*5m0*0*5m0*5m0*0 hsa-miR-296-3p 5′Pm05f0005f05f05f00f00005f05m0*5m0*0* m0m0m0m0m0m0m000m0m0m0*0*m0TEGChol MIMAT0004679 5m0*5m0*5m0*0 hsa-miR-296-5p 5′Pm05f0005f005f05f05f05f0005f00*5m0*0* m0m0m0m00m000m0m0m0m0*0*m0TEGChol MIMAT0000690 5m0*5m0*0*0 hsa-miR-297 5′Pm05f0005f005f05f0f00005f00*5m0*5m0* m0m0m0m0m0m000m0m0m0m0*0*m0TEGChol MIMAT0004450 0*5m0*5m0*0 hsa-miR-298 5′Pm005f05f0f005f005f05f05f05f05f05m0*5 m0m0000m0m00m0m000*m0*m0TEGChol MIMAT0004901 m0*0*0*f0*5m0*0 hsa-miR-299-3p 5′Pm05f000f0005f0f005f00f00*5m0*5m0*0* m0m0m00m0m00m0m0m0m0m0*0*m0TEGChol MIMAT0000687 5m0*5m0*0 hsa-miR-299-5p 5′Pm005f00f0005f05f0005f0f05m0*5m0*0*5 m0m00m0m0m00m0m0m0m00*m0*m0TEGChol MIMAT0002890 m0*5m0*0*0 hsa-miR-29a 5′Pm00005f005f00f0000f00*0*0*5m0*** m0m0m0m0m0m0m00m0m0m0m0*m0*m0TEGChol MIMAT0000086 hsa-miR-29a* 5′Pm005f05f0f05f000f05f0005f00*0*5m0*0* m0m0m0m00m0m0m00m000*m0*m0TEGChol MIMAT0004503 f0*0*0 hsa-miR-29b 5′Pm0000f0000f0000f00*0*5m0*5m0*5m0* m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEG MIMAT0000100 5m0*0 Chol hsa-miR-29b-1* 5′Pm00005f05f005f05f05f005f0f05m0*5m0* m0m00m00m00m00m0m0m0*m0*m0TEGChol MIMAT0004514 0*5m0*5m0*5m0*0 hsa-miR-29b-2* 5′Pm05f05f00f05f005f05f05f000f05m0*5m0* m0m0m0m00m00m00m0m00*0*m0TEGChol MIMAT0004515 0*5m0*5m0*5m0*0 hsa-miR-29c 5′Pm0000f05f05f00f005f05f0f00*0*0*0*f0*0 m0m000m0m0m000m0m0m0*m0*m0TEGChol MIMAT0000681 *0 hsa-miR-29c* 5′Pm05f000f05f05f005f00005f05m0*5m0*0* m0m0m0m0m0m0m000m0m0m0*0*m0TEGChol MIMAT0004673 0*f0*5m0*0 hsa-miR-300 5′Pm0000f05f005f0f00005f00*0*0*0*5m0*5 m0m0m0m0m0m00m00m0m0m0*m0*m0TEGChol MIMAT0004903 m0*0 hsa-miR-301a 5′Pm005f05f0f05f005f0f0000f05m0*0*5m0* m0m0m0m0m0m00m00m000*m0*m0TEGChol MIMAT0000688 5m0*5m0*0*0 hsa-miR-301b 5′Pm005f05f0f05f005f0f00005f05m0*0*5m0 m0m0m0m0m0m00m00m000*m0*m0TEGChol MIMAT0004958 *5m0*5m0*0*0 hsa-miR-302a 5′Pm05f0005f0000f05f05f005f05m0*0*0*5m m0m0m000m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0000684 0*f0*5m0*0 hsa-miR-302a* 5′Pm0005f0f005f005f00005f00*0*0*0*f0*5 m0m0m0m0m0m0m00m0m00m0*m0*m0TEGChol MIMAT0000683 m0*0 hsa-miR-302b 5′Pm005f005f05f0005f05f05f00f05m0*0*0*0 m0m0m000m0m0m00m0m00*m0*m0TEGChol MIMAT0000715 *5m0*0*0 hsa-miR-302b* 5′Pm0000f05f05f00f005f05f0f00*0*0*0*f0*0 m0m000m0m0m000m0m0m0*m0*m0TEGChol MIMAT0000714 *0 hsa-miR-302c 5′Pm005f00f005f005f05f05f05f05f00*0*5m0 m0m0000m0m00m0m0m00*m0*m0TEGChol MIMAT0000717 *5m0*f0*0*0 hsa-miR-302c* 5′Pm05f000f00005f05f005f05f05m0*5m0*5 m0m00m00m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0000716 m0*5m0*f0*0*0 hsa-miR-302d 5′Pm05f05f05f05f0005f05f00005f00*5m0*5 m0m0m0m0m0m00m0m0m000*0*m0TEGChol MIMAT0000718 m0*5m0*f0*5m0*0 hsa-miR-302d* 5′Pm0000f05f05f00f005f05f0f00*0*0*0*f0*0 m0m000m0m0m000m0m0m0*m0*m0TEGChol MIMAT0004685 *0 hsa-miR-302e 5′Pm005f00f005f005f05f05f05f0f05m0*0*5m m0m0000m0m00m0m0m00*m0*m0TEGChol MIMAT0005931 0*5m0*5m0*0*0 hsa-miR-302f 5′Pm005f05f0f05f005f0f05f0005f05m0*0*0* m0m0m0m00m00m00m000*m0*m0TEGChol MIMAT0005932 5m0*5m0*5m0*0 hsa-miR-3065-3p 5′Pm05f05f00f005f00f05f0005f00*5m0*5m0 m0m0m0m00m0m00m0m0m00*0*m0TEGChol MIMAT0015378 *5m0*5m0*5m0*0 hsa-miR-3065-5p 5′Pm05f000f00005f05f05f05f0f00*5m0*5m0 m0m0000m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0015066 **** hsa-miR-3074 5′Pm05f000f00005f00005f00*5m0*5m0*5m m0m0m0m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0015027 0*f0*5m0*0 hsa-miR-30a 5′Pm005f00f005f005f05f05f05f0f05m0*0*5m m0m0000m0m00m0m0m00*m0*m0TEGChol MIMAT0000087 0*5m0*5m0*5m0*0 hsa-miR-30a* 5′Pm05f000f0000f0005f05f00*5m0*5m0*5m m0m00m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0000088 0*f0*5m0*0 hsa-miR-30b 5′Pm05f000f0000f0005f05f00*5m0*5m0*5m m0m00m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0000420 0*f0*5m0*0 hsa-miR-30b* 5′Pm0000f005f05f05f005f00f05m0*5m0*5m m0m0m00m0m000m0m0m0m0*m0*m0TEGChol MIMAT0004589 0*0*f0*5m0*0 hsa-miR-30c 5′Pm005f00f005f005f05f05f05f05f00*0*5m0 m0m0000m0m00m0m0m00*m0*m0TEGChol MIMAT0000244 *5m0*f0*0*0 hsa-miR-30c-1* 5′Pm0005f05f00005f05f005f0f00*0*5m0*5m m0m00m00m0m0m0m0m00m0*m0*m0TEGChol MIMAT0004674 0*5m0*5m0*0 hsa-miR-30c-2* 5′Pm0005f0f0005f05f005f00f05m0*5m0*5m m0m0m00m0m00m0m0m00m0*m0*m0TEGChol MIMAT0004550 0*0*5m0*5m0*0 hsa-miR-30d 5′Pm05f05f05f05f0005f05f00005f00*5m0*5 m0m0m0m0m0m00m0m0m000*0*m0TEGChol MIMAT0000245 m0*5m0*f0*5m0*0 hsa-miR-30d* 5′Pm005f00f005f005f05f05f05f05f00*0*5m0 m0m0000m0m00m0m0m00*m0*m0TEGChol MIMAT0004551 *5m0*f0*0*0 hsa-miR-30e 5′Pm05f05f05f05f0005f05f00005f00*5m0*5 m0m0m0m0m0m00m0m0m000*0*m0TEGChol MIMAT0000692 m0*5m0*f0*5m0*0 hsa-miR-30e* 5′Pm0005f0f00005f005f05f0f00*5m0*0*5m0 m0m000m0m0m0m0m0m00m0*m0*m0TEGChol MIMAT0000693 *f0*0*0 hsa-miR-31 5′Pm05f000f005f005f05f05f05f05f05m0*5m0 m0m0000m0m00m0m0m0m0*0*m0TEGChol MIMAT0000089 *5m0*5m0*f0*0*0 hsa-miR-31* 5′Pm005f05f0f05f005f05f0005f0f05m0*0*5m m0m00m0m0m00m00m000*m0*m0TEGChol MIMAT0004504 0*5m0*f0*5m0*0 hsa-miR-3115 5′Pm05f005f0f0005f05f05f005f05f00*0*5m0 m0m00m00m00m0m0m00m0*0*m0TEGChol MIMAT0014977 *5m0*f0*0*0 hsa-miR-3116 5′Pm05f05f00f05f05f05f0f005f00f05m0*0*5 m0m0m00m0m0000m0m00*0*m0TEGChol MIMAT0014978 m0**** hsa-miR-3117 5′Pm005f00f05f005f05f0000f00*5m0*0*0*5 m0m0m0m0m0m00m00m0m00*m0*m0TEGChol MIMAT0014979 m0*0*0 hsa-miR-3118 5′Pm005f05f05f0000f05f005f0f00*5m0*0*0* m0m00m00m0m0m0m0m000*m0*m0TEGChol MIMAT0014980 f0*0*0 hsa-miR-3119 5′Pm05f05f05f05f05f005f0f005f05f05f00*0* m0m000m0m00m00m000*0*m0TEGChol MIMAT0014981 0*5m0*5m0*5m0*0 hsa-miR-3120 5′Pm005f005f005f05f05f05f05f05f05f05m0*5 m0m0000m000m0m0m00*m0*m0TEGChol MIMAT0014982 m0*0*0*f0*0*0 hsa-miR-3121 5′Pm00005f05f05f00f0000f00*0*0*5m0*f0* m0m0m0m0m0m0m000m0m0m0*m0*m0TEGChol MIMAT0014983 5m0*0 hsa-miR-3122 5′Pm05f05f05f05f05f05f05f05f05f000f05m0* m0m0m0m00m0000m000*0*m0TEGChol MIMAT0014984 0*5m0*0*5m0*5m0*0 hsa-miR-3123 5′Pm05f0005f005f05f0f05f005f0f05m0*0*5m m0m00m00m000m0m0m0m0*0*m0TEGChol MIMAT0014985 0*0*f0*5m0*0 hsa-miR-3124 5′Pm00005f0005f05f05f05f05f05f05m0*5m0 m0m0000m00m0m0m0m0m0*m0*m0TEGChol MIMAT0014986 *0*0*f0*0*0 hsa-miR-3125 5′Pm05f05f05f05f005f05f05f05f005f05f00*0 m0m00m00m000m0m000*0*m0TEGChol MIMAT0014988 *0*5m0*f0*5m0*0 hsa-miR-3126-3p 5′Pm05f0005f005f05f0f005f05f0f05m0*0*0* m0m000m0m000m0m0m0m0*0*m0TEGChol MIMAT0015377 5m0*f0*0*0 hsa-miR-3126-5p 5′Pm0005f0f0005f05f05f05f00f05m0*5m0*5 m0m0m000m00m0m0m00m0*m0*m0TEGChol MIMAT0014989 m0*0*5m0*5m0*0 hsa-miR-3127 5′Pm0000f05f05f00f005f05f0f00*0*0*0*f0*0* m0m000m0m0m000m0m0m0*m0*m0TEGChol MIMAT0014990 hsa-miR-3128 5′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0014991 m0*5m0*5m0*0 hsa-miR-3129 5′Pm0005f0f05f005f05f05f05f05f05f05m0*0* m0m0000m00m00m00m0*m0*m0TEGChol MIMAT0014992 5m0*0*f0*0*0 hsa-miR-3130-3p 5′Pm05f000f05f05f05f0f005f005f00*5m0*0* m0m0m00m0m0000m0m0m0*0*m0TEGChol MIMAT0014994 5m0*5m0*5m0*0 hsa-miR-3130-5p 5′Pm05f000f005f05f05f05f0005f05m0*5m0* m0m0m0m00m000m0m0m0m0*0*m0TEGChol MIMAT0014995 5m0*0*5m0*5m0*0 hsa-miR-3131 5′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0014996 m0*5m0*5m0*0 hsa-miR-3132 5′Pm05f05f05f05f05f05f05f0f05f05f05f05f00 m0m0000m0000m000*0*m0TEGChol MIMAT0014997 *0*5m0*5m0*f0*5m0*0 hsa-miR-3133 5′Pm005f05f05f05f05f05f05f05f05f05f05f00* m0m0000m0000m000*m0*m0TEGChol MIMAT0014998 0*0*0*5m0*0*0 hsa-miR-3134 5′Pm05f0005f005f05f0f0005f0f00*5m0*5m0 m0m00m0m0m000m0m0m0m0*0*m0TEGChol MIMAT0015000 *0*5m0*5m0*0 hsa-miR-3135 5′Pm05f000f05f005f0f0005f0f00*5m0*5m0* m0m00m0m0m00m00m0m0m0*0*m0TEGChol MIMAT0015001 5m0*5m0*0*0 hsa-miR-3136 5′Pm0005f05f05f000f00005f05m0*5m0*5m0 m0m0m0m0m0m0m0m00m00m0*m0*m0TEGChol MIMAT0015003 *0*5m0*0*0 hsa-miR-3137 5′Pm00005f05f000f05f05f00f00*0*0*0*f0** m0m0m000m0m0m00m0m0m0*m0*m0TEGChol MIMAT0015005 hsa-miR-3138 5′Pm0005f0f05f005f05f05f000f00*0*0*0*f0* m0m0m0m00m00m00m00m0*m0*m0TEGChol MIMAT0015006 0*0 hsa-miR-3139 5′Pm0000f05f005f05f05f05f05f05f05m0*5m0 m0m0000m00m00m0m0m0*m0*m0TEGChol MIMAT0015007 *5m0*0*f0*0*0 hsa-miR-3140 5′Pm005f005f05f005f0f05f0005f05m0*0*0*5 m0m0m0m00m00m00m0m00*m0*m0TEGChol MIMAT0015008 m0*5m0*5m0*0 hsa-miR-3141 5′Pm005f05f05f0000f00005f00*5m0*5m0*0 m0m0m0m0m0m0m0m0m0m000*m0*m0TEGChol MIMAT0015010 *f0*5m0*0 hsa-miR-3142 5′Pm05f0005f0005f05f05f005f0f05m0*0*5m m0m00m00m00m0m0m0m0m0*0*m0TEGChol MIMAT0015011 0*5m0*f0*0*0 hsa-miR-3143 5′Pm05f000f00005f05f000f00*0*0*0*f0*0*0 m0m0m0m00m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0015012 hsa-miR-3144-3p 5′Pm05f05f00f005f00f05f05f05f0f00*0*5m0* m0m0000m0m00m0m0m00*0*m0TEGChol MIMAT0015015 0*** hsa-miR-3144-5p 5′Pm005f00f05f000f05f05f05f0f00*0*5m0*5 m0m0000m0m0m00m0m00*m0*m0TEGChol MIMAT0015014 m0*f0*5m0*0 hsa-miR-3145 5′Pm05f05f05f05f05f005f05f05f05f005f05m0 m0m0m000m00m00m000*0*m0TEGChol MIMAT0015016 *5m0*0*0*f0*0*0 hsa-miR-3146 5′Pm05f005f0f0000f0000f05m0*0*5m0*5m0 m0m0m0m0m0m0m0m0m0m00m0*0*m0TEGChol MIMAT0015018 *5m0*5m0*0 hsa-miR-3147 5′Pm0000f05f005f05f05f05f05f05f05m0*5m0 m0m0000m00m00m0m0m0*m0*m0TEGChol MIMAT0015019 *5m0*0*f0*0*0 hsa-miR-3148 5′Pm05f05f05f0f05f05f00f0005f05f05m0*5m m0m00m0m0m0m000m000*0*m0TEGChol MIMAT0015021 0*5m0*0*** hsa-miR-3149 5′Pm05f05f05f0f05f000f0000f00*0*5m0*0*f m0m0m0m0m0m0m0m00m000*0*m0TEGChol MIMAT0015022 0*0*0 hsa-miR-3150 5′Pm0000f0000f0000f00*5m0*0*0*f0*0* m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEG MIMAT0015023 Chol hsa-miR-3150b 5′Pm05f05f05f0f05f005f05f05f05f05f05f00*0 m0m0000m00m00m000*0*m0TEGChol MIMAT0018194 *0*5m0*5m0*0*0 hsa-miR-3151 5′Pm05f05f05f0f05f005f0f05f05f00f05m0*5 m0m0m000m00m00m000*0*m0TEGChol MIMAT0015024 m0*5m0*0*f0*0*0 hsa-miR-3152 5′Pm05f05f05f0f0000f0005f0f05m0*0*5m0* m0m00m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0015025 5m0*5m0*5m0*0 hsa-miR-3153 5′Pm005f05f05f005f05f0f05f05f00f00*0*0*5 m0m0m000m000m0m000*m0*m0TEGChol MIMAT0015026 m0*f0*5m0*0 hsa-miR-3154 5′Pm05f0005f05f005f05f005f05f05f05m0*5m m0m000m0m00m00m0m0m0*0*m0TEGChol MIMAT0015028 0*0*5m0*5m0*0*0 hsa-miR-3155 5′Pm05f000f005f05f05f005f005f00*0*5m0*0 m0m0m00m0m000m0m0m0m0*0*m0TEGChol MIMAT0015029 *5m0*5m0*0 hsa-miR-3156 5′Pm0005f05f0005f05f00005f00*0*5m0*5m m0m0m0m0m0m00m0m0m00m0*m0*m0TEGChol MIMAT0015030 0*f0*0*0 hsa-miR-3157 5′Pm0005f0f005f05f05f005f00f05m0*0*5m0 m0m0m00m0m000m0m00m0*m0*m0TEGChol MIMAT0015031 *0*5m0*5m0*0 hsa-miR-3158 5′Pm05f05f005f05f05f00f05f05f005f05m0*5 m0m0m000m0m000m0m00*0*m0TEGChol MIMAT0015032 m0*0*0*f0*5m0*0 hsa-miR-3159 5′Pm05f005f0f005f05f0f05f05f05f0f00*5m0* m0m0000m000m0m00m0*0*m0TEGChol MIMAT0015033 5m0*0*f0*5m0*0 hsa-miR-3160 5′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0015034 m0*5m0*5m0*0 hsa-miR-3161 5′Pm005f005f0005f05f05f05f05f05f05m0*0* m0m0000m00m0m0m0m00*m0*m0TEGChol MIMAT0015035 0*0*f0*5m0* hsa-miR-3162 5′Pm005f00f05f05f05f0f05f05f05f0f00*0*5m m0m0000m0000m0m00*m0*m0TEGChol MIMAT0015036 0*5m0*f0*5m0*0 hsa-miR-3163 5′Pm005f00f0005f05f0000f05m0*5m0*0*0* m0m0m0m0m0m00m0m0m0m00*m0*m0TEGChol MIMAT0015037 5m0*0*0 hsa-miR-3164 5′Pm005f05f05f0005f05f0005f0f00*5m0*5m m0m00m0m0m00m0m0m000*m0*m0TEGChol MIMAT0015038 0*0*5m0** hsa-miR-3165 5′Pm0000f0000f00005f05m0*5m0*5m0*0*5 m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEG MIMAT0015039 m0*5m0*0 Chol hsa-miR-3166 5′Pm05f005f05f05f05f05f05f0005f0f00*0*5m m0m00m0m0m0000m00m0*0*m0TEGChol MIMAT0015040 0*0*f0** hsa-miR-3167 5′Pm05f005f0f0005f05f05f05f05f0f00*0*5m0 m0m0000m00m0m0m00m0*0*m0TEGChol MIMAT0015042 *0*f0*0*0 hsa-miR-3168 5′Pm005f00f05f05f005f005f05f0f05m0*0*0* m0m000m0m0m000m0m00*m0*m0TEGChol MIMAT0015043 0*f0*0*0 hsa-miR-3169 5′Pm05f05f00f005f00f005f005f05m0*5m0*0 m0m0m00m0m0m00m0m0m00*0*m0TEGChol MIMAT0015044 *5m0*f0*5m0*0 hsa-miR-3170 5′Pm0005f0f005f05f05f05f05f05f05f05m0*5 m0m0000m000m0m00m0*m0*m0TEGChol MIMAT0015045 m0*5m0*5m0*f0** hsa-miR-3171 5′Pm05f05f05f05f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0015046 m0*5m0*5m0*0 hsa-miR-3173 5′Pm05f0005f05f005f05f005f05f0f05m0*5m0 m0m000m0m00m00m0m0m0*0*m0TEGChol MIMAT0015048 *5m0*5m0*5m0*5m0*0 hsa-miR-3174 5′Pm05f05f00f005f05f0f005f005f05m0*0*5m m0m0m00m0m000m0m0m00*0*m0TEGChol MIMAT0015051 0*5m0*f0*0* hsa-miR-3175 5′Pm05f0005f0000f0000f00*0*0*5m0*5m0* m0m0m0m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0015052 0*0 hsa-miR-3176 5′Pm05f05f00f05f005f0f05f0005f05m0*0*0* m0m0m0m00m00m00m0m00*0*m0TEGChol MIMAT0015053 5m0*5m0*5m0*0 hsa-miR-3177 5′Pm05f0005f05f005f05f005f05f05f05m0*5m m0m000m0m00m00m0m0m0*0*m0TEGChol MIMAT0015054 0*5m0*5m0*** hsa-miR-3178 5′Pm0000f05f005f05f05f05f05f05f05m0*5m0 m0m0000m00m00m0m0m0*m0*m0TEGChol MIMAT0015055 *5m0*0*f0*0*0 hsa-miR-3179 5′Pm05f05f05f0f05f005f05f05f05f00f05m0*5 m0m0m000m00m00m000*0*m0TEGChol MIMAT0015056 m0*5m0*5m0*5m0*5m0*0 hsa-miR-3180 5′Pm05f005f0f0000f0000f05m0*5m0*5m0*5 m0m0m0m0m0m0m0m0m0m00m0*0*m0TEGChol MIMAT0018178 m0*5m0*5m0*0 hsa-miR-3180-3p 5′Pm05f05f05f05f05f005f0f05f05f05f0f00*0* m0m0000m00m00m000*0*m0TEGChol MIMAT0015058 0*5m0*5m0*5m0*0 hsa-miR-3180-5p 5′Pm05f05f05f0f00005f05f05f05f0f05m0*0*5 m0m0000m0m0m0m0m000*0*m0TEGChol MIMAT0015057 m0*0*f0*0*0 hsa-miR-3181 5′Pm05f05f05f05f005f005f005f05f0f00*5m0* m0m000m0m0m00m0m000*0*m0TEGChol MIMAT0015061 0*5m0*5m0*0*0 hsa-miR-3182 5′Pm0005f0f005f005f005f00f05m0*0*0*5m0 m0m0m00m0m0m00m0m00m0*m0*m0TEGChol MIMAT0015062 *5m0*5m0*0 hsa-miR-3183 5′Pm00005f05f05f05f0f05f05f05f0f00*0*5m0 m0m0000m0000m0m0m0*m0*m0TEGChol MIMAT0015063 *0*5m0*5m0*0 hsa-miR-3184 5′Pm005f005f05f05f05f0f0005f0f05m0*0*0* m0m00m0m0m0000m0m00*m0*m0TEGChol MIMAT0015064 0*f0*5m0*0 hsa-miR-3185 5′Pm005f05f0f05f005f05f05f05f05f05f05m0* m0m0000m00m00m000*m0*m0TEGChol MIMAT0015065 5m0*0*5m0*f0*5m0*0 hsa-miR-3186-3p 5′Pm05f005f0f005f05f05f005f05f05f00*0*0* m0m000m0m000m0m00m0*0*m0TEGChol MIMAT0015068 0*5m0*5m0*0 hsa-miR-3186-5p 5′Pm0005f05f05f05f05f0f005f05f05f05m0*0* m0m000m0m0000m00m0*m0*m0TEGChol MIMAT0015067 0*5m0*f0*0*0 hsa-miR-3187 5′Pm05f05f00f05f0005f05f05f005f00*5m0*0 m0m0m000m0m0m00m0m00*0*m0TEGChol MIMAT0015069 *5m0*** hsa-miR-3188 5′Pm005f00f0000f005f05f05f05m0*0*5m0*5 m0m000m0m0m0m0m0m0m00*m0*m0TEGChol MIMAT0015070 m0*f0*5m0*0 hsa-miR-3189 5′Pm00005f05f005f0f05f05f005f00*5m0*5m m0m0m000m00m00m0m0m0*m0*m0TEGChol MIMAT0015071 0*0*5m0*5m0*0 hsa-miR-3190 5′Pm05f005f05f005f05f0f05f05f00f05m0*5m m0m0m000m000m0m00m0*0*m0TEGChol MIMAT0015073 0*5m0*5m0*f0*0*0 hsa-miR-3191 5′Pm00005f005f005f05f05f005f00*5m0*0*5 m0m0m000m0m00m0m0m0m0*m0*m0TEGChol MIMAT0015075 m0*5m0*0* hsa-miR-3192 5′Pm05f05f005f005f00f0005f05f05m0*5m0* m0m00m0m0m0m00m0m0m00*0*m0TEGChol MIMAT0015076 5m0*5m0*5m0*5m0*0 hsa-miR-3193 5′Pm0005f05f005f05f05f005f00f05m0*0*0*0 m0m0m00m0m000m0m00m0*m0*m0TEGChol MIMAT0015077 *5m0*5m0*0 hsa-miR-3194 5′Pm05f05f005f05f05f05f0f0005f0f05m0*5m m0m00m0m0m0000m0m00*0*m0TEGChol MIMAT0015078 0*0*5m0*5m0*0*0 hsa-miR-3195 5′Pm005f005f05f05f05f05f05f000f00*5m0*0 m0m0m0m00m0000m0m00*m0*m0TEGChol MIMAT0015079 *5m0*5m0*0*0 hsa-miR-3196 5′Pm005f05f0f005f05f05f05f05f05f05f05m0* m0m0000m000m0m000*m0*m0TEGChol MIMAT0015080 5m0*0*0*f0*5m0*0 hsa-miR-3197 5′Pm0000f0005f05f005f05f05f05m0*5m0*0* m0m000m0m00m0m0m0m0m0*m0*m0TEGChol MIMAT0015082 0*5m0*0*0 hsa-miR-3198 5′Pm05f0005f05f05f05f0f0005f0f05m0*0*0* m0m00m0m0m0000m0m0m0*0*m0TEGChol MIMAT0015083 5m0*f0*5m0*0 hsa-miR-3199 5′Pm05f05f00f05f000f05f005f05f05m0*0*0* m0m00m00m0m0m00m0m00*0*m0TEGChol MIMAT0015084 5m0*f0*0*0 hsa-miR-32 5′Pm05f05f00f05f005f05f05f000f05m0*5m0* m0m0m0m00m00m00m0m00*0*m0TEGChol MIMAT0000090 0*5m0*5m0*5m0*0 hsa-miR-32* 5′Pm05f000f00005f005f00f05m0*0*5m0*5m m0m0m00m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0004505 0*f0*5m0*0 hsa-miR-3200-3p 5′Pm05f005f0f005f05f0f05f05f05f0f00*0*0*0 m0m0000m000m0m00m0*0*m0TEGChol MIMAT0015085 *5m0*0*0 hsa-miR-3200-5p 5′Pm005f005f005f05f0f05f005f05f05m0*5m0 m0m00m00m000m0m0m00*m0*m0TEGChol MIMAT0017392 *5m0*0*f0*0*0 hsa-miR-3201 5′Pm05f05f05f05f0005f05f005f05f05f00*0*5 m0m000m0m00m0m0m000*0*m0TEGChol MIMAT0015086 m0*5m0*f0*5m0*0 hsa-miR-3202 5′Pm00005f05f05f005f05f05f05f05f00*5m0* m0m0000m0m000m0m0m0*m0*m0TEGChol MIMAT0015089 0*0*f0*5m0*0 hsa-miR-320a 5′Pm0005f0f0005f0f05f000f00*5m0*5m0*5 m0m0m0m00m00m0m0m00m0*m0*m0TEGChol MIMAT0000510 m0*f0*0*0 hsa-miR-320b 5′Pm0000f005f05f05f05f005f05f00*5m0*5m m0m00m00m000m0m0m0m0*m0*m0TEGChol MIMAT0005792 0*0*f0*5m0*0 hsa-miR-320c 5′Pm005f00f05f000f05f05f00f05m0*0*0*5m m0m0m000m0m0m00m0m00*m0*m0TEGChol MIMAT0005793 0*5m0*0*0 hsa-miR-320d 5′Pm05f000f0005f05f005f05f0f05m0*0*5m0 m0m000m0m00m0m0m0m0m0*0*m0TEGChol MIMAT0006764 *5m0*f0*5m0*0 hsa-miR-320e 5′Pm0005f0f05f05f05f0f05f0005f00*5m0*0* m0m0m0m00m0000m00m0*m0*m0TEGChol MIMAT0015072 5m0*5m0*5m0*0 hsa-miR-323-3p 5′Pm05f05f05f05f00005f05f05f05f05f05m0*5 m0m0000m0m0m0m0m000*0*m0TEGChol MIMAT0000755 m0*5m0*5m0*5m0*0*0 hsa-miR-323-5p 5′Pm005f00f05f005f05f005f00f05m0*5m0*5 m0m0m00m0m00m00m0m00*m0*m0TEGChol MIMAT0004696 m0*5m0*5m0*0*0 hsa-miR-323b-3p 5′Pm05f0005f05f05f05f05f05f05f05f0f05m0* m0m0000m0000m0m0m0*0*m0TEGChol MIMAT0015050 5m0*5m0*5m0*5m0*5m0*0 hsa-miR-323b-5p 5′Pm005f00f05f000f05f005f0f00*0*5m0*0*f m0m00m00m0m0m00m0m00*m0*m0TEGChol MIMAT0001630 0*0*0 hsa-miR-324-3p 5′Pm0005f0f005f005f005f05f0f05m0*0*0*5 m0m000m0m0m00m0m00m0*m0*m0TEGChol MIMAT0000762 m0*5m0*5m0*0 hsa-miR-324-5p 5′Pm005f005f00005f05f05f005f00*5m0*0*0 m0m0m000m0m0m0m0m0m00*m0*m0TEGChol MIMAT0000761 *f0*0*0 hsa-miR-325 5′Pm005f005f005f05f05f0005f05f00*0*5m0* m0m00m0m0m000m0m0m00*m0*m0TEGChol MIMAT0000771 5m0*5m0*5m0*0 hsa-miR-326 5′Pm05f05f05f05f005f05f0f05f05f005f05m0* m0m0m000m000m0m000*0*m0TEGChol MIMAT0000756 5m0*5m0*5m0*5m0*5m0*0 hsa-miR-328 5′Pm05f05f005f0005f0f005f05f05f00*0*5m0 m0m000m0m00m0m0m0m00*0*m0TEGChol MIMAT0000752 *0*f0*5m0*0 hsa-miR-329 5′Pm00005f0000f05f000f05m0*0*0*0*f0*0*0 m0m0m0m00m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0001629 hsa-miR-330-3p 5′Pm005f00f0000f05f05f05f05f05m0*5m0*5 m0m0000m0m0m0m0m0m00*m0*m0TEGChol MIMAT0000751 m0*0*5m0*0*0 hsa-miR-330-5p 5′Pm00005f05f005f05f005f05f05f00*5m0*5 m0m000m0m00m00m0m0m0*m0*m0TEGChol MIMAT0004693 m0*0*5m0*5m0*0 hsa-miR-331-3p 5′Pm0000f05f005f0f005f05f0f00*0*5m0*0*5 m0m000m0m00m00m0m0m0*m0*m0TEGChol MIMAT0000760 m0*5m0*0 hsa-miR-331-5p 5′Pm05f000f005f005f005f00f05m0*5m0*5m m0m0m00m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0004700 0*0*5m0*0*0 hsa-miR-335 5′Pm05f05f05f05f005f00f005f00f05m0*0*0* m0m0m00m0m0m00m0m000*0*m0TEGChol MIMAT0000765 0*5m0*5m0*0 hsa-miR-335* 5′Pm0000f005f005f05f05f05f05f05m0*0*5m m0m0000m0m00m0m0m0m0*m0*m0TEGChol MIMAT0004703 0*0*5m0*0*0 hsa-miR-337-3p 5′Pm0005f0f005f005f005f00f00*5m0*0*5m0 m0m0m00m0m0m00m0m00m0*m0*m0TEGChol MIMAT0000754 *5m0*0*0 hsa-miR-337-5p 5′Pm05f05f00f0005f0f0000f00*0*5m0*0*f0* m0m0m0m0m0m00m0m0m0m00*0*m0TEGChol MIMAT0004695 5m0*0 hsa-miR-338-3p 5′Pm05f05f05f05f00005f05f05f005f00*5m0* m0m0m000m0m0m0m0m000*0*m0TEGChol MIMAT0000763 5m0*5m0*5m0*0*0 hsa-miR-338-5p 5′Pm0000f0005f05f005f05f05f00*0*5m0*5m m0m000m0m00m0m0m0m0m0*m0*m0TEGChol MIMAT0004701 0*** hsa-miR-339-3p 5′Pm005f00f05f005f05f005f00f05m0*5m0*5 m0m0m00m0m00m00m0m00*m0*m0TEGChol MIMAT0004702 m0*5m0*5m0*0*0 hsa-miR-339-5p 5′Pm0000f05f005f0f0000f00*0*5m0*0*5m0 m0m0m0m0m0m00m00m0m0m0*m0*m0TEGChol MIMAT0000764 *0*0 hsa-miR-33a 5′Pm05f05f005f00005f0000f00*5m0*0*0*f0 m0m0m0m0m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0000091 *0*0 hsa-miR-33a* 5′Pm005f05f05f05f005f0f05f0005f05m0*0*5 m0m0m0m00m00m00m000*m0*m0TEGChol MIMAT0004506 m0*0*5m0*5m0*0 hsa-miR-33b 5′Pm05f0005f005f05f0f005f05f0f05m0*0*5m m0m000m0m000m0m0m0m0*0*m0TEGChol MIMAT0003301 0*5m0*f0*5m0*0 hsa-miR-33b* 5′Pm05f05f05f05f05f000f05f05f05f0f05m0*5 m0m0000m0m0m00m000*0*m0TEGChol MIMAT0004811 m0*5m0*5m0*f0*0*0 hsa-miR-340 5′Pm05f05f05f05f005f005f05f05f05f05f00*0 m0m0000m0m00m0m000*0*m0TEGChol MIMAT0004692 *5m0*0*f0*0*0 hsa-miR-340* 5′Pm05f05f05f0f00005f05f005f0f00*0*0*5m m0m00m00m0m0m0m0m000*0*m0TEGChol MIMAT0000750 0*f0*0*0 hsa-miR-342-3p 5′Pm05f000f00005f005f00f05m0*0*5m0*5m m0m0m00m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0000753 0*f0*5m0*0 hsa-miR-342-5p 5′Pm05f05f05f0f0005f05f05f0005f00*5m0*0 m0m0m0m00m00m0m0m000*0*m0TEGChol MIMAT0004694 *0*f0*5m0*0 hsa-miR-345 5′Pm05f000f005f005f005f05f05f00*5m0*0*5 m0m000m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0000772 m0*5m0*0*0 hsa-miR-346 5′Pm05f0005f005f05f0f05f05f005f00*5m0*5 m0m0m000m000m0m0m0m0*0*m0TEGChol MIMAT0000773 m0*0*5m0*5m0*0 hsa-miR-34a 5′Pm05f000f05f005f0f005f05f05f05m0*0*0* m0m000m0m00m00m0m0m0*0*m0TEGChol MIMAT0000255 0*f0*0*0 hsa-miR-34a* 5′Pm00005f05f05f005f0000f05m0*0*0*0*f0 m0m0m0m0m0m0m000m0m0m0*m0*m0TEGChol MIMAT0004557 *5m0*0 hsa-miR-34b 5′Pm005f005f00005f05f05f005f00*5m0*0*0 m0m0m000m0m0m0m0m0m00*m0*m0TEGChol MIMAT0004676 *f0*0*0 hsa-miR-34b* 5′Pm05f000f00005f05f05f005f05m0*5m0*5 m0m0m000m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0000685 m0*5m0*f0** hsa-miR-34c-3p 5′Pm0000f0000f05f05f005f00*0*0*0*f0*0*0 m0m0m000m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0004677 hsa-miR-34c-5p 5′Pm0000f005f05f05f005f05f0f05m0*0*5m0 m0m000m0m000m0m0m0m0*m0*m0TEGChol MIMAT0000686 *0*5m0*5m0*0 hsa-miR-3605-3p 5′Pm05f005f05f05f000f05f000f05m0*0*0*5 m0m0m0m00m0m0m00m00m0*0*m0TEGChol MIMAT0017982 m0*5m0*0*0 hsa-miR-3605-5p 5′Pm05f05f005f0005f05f05f0005f05m0*5m0 m0m0m0m00m00m0m0m0m00*0*m0TEGChol MIMAT0017981 *0*5m0*5m0*0*0 hsa-miR-3606 5′Pm05f005f0f05f005f0f005f00f00*5m0*5m0 m0m0m00m0m00m00m00m0*0*m0TEGChol MIMAT0017983 *5m0*5m0*5m0*0 hsa-miR-3607-3p 5′Pm005f05f05f05f005f0f0005f05f05m0*0*5 m0m00m0m0m00m00m000*m0*m0TEGChol MIMAT0017985 m0*0*5m0*5m0*0 hsa-miR-3607-5p 5′Pm0000f05f005f0f05f005f0f00*0*0*0*f0*5 m0m00m00m00m00m0m0m0*m0*m0TEGChol MIMAT0017984 m0*0 hsa-miR-3609 5′Pm05f000f005f005f00005f00*0*5m0*5m0 m0m0m0m0m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0017986 *5m0*5m0*0 hsa-miR-3610 5′Pm05f000f005f05f0f0005f0f00*5m0*5m0* m0m00m0m0m000m0m0m0m0*0*m0TEGChol MIMAT0017987 0*f0*0*0 hsa-miR-3611 5′Pm0000f005f05f0f05f000f00*0*5m0*0*f0* m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0017988 5m0*0 hsa-miR-3612 5′Pm05f05f05f05f05f05f05f05f05f0005f05m0 m0m0m0m00m0000m000*0*m0TEGChol MIMAT0017989 *5m0*5m0**** hsa-miR-3613-3p 5′Pm005f05f05f05f05f00f00005f00*0*0*5m0 m0m0m0m0m0m0m000m000*m0*m0TEGChol MIMAT0017991 *5m0*5m0*0 hsa-miR-3613-5p 5′Pm00005f05f05f05f0f05f05f05f05f05m0*5 m0m0000m0000m0m0m0*m0*m0TEGChol MIMAT0017990 m0*5m0*0*5m0*0*0 hsa-miR-361-3p 5′Pm005f05f05f05f005f0f0005f05f05m0*0*5 m0m00m0m0m00m00m000*m0*m0TEGChol MIMAT0004682 m0*0*5m0*5m0*0 hsa-miR-3614-3p 5′Pm0005f0f05f05f005f05f05f00f05m0*0*0* m0m0m000m0m000m00m0*m0*m0TEGChol MIMAT0017993 5m0*f0*0*0 hsa-miR-3614-5p 5′Pm005f05f05f05f005f05f00005f00*0*5m0* m0m0m0m0m0m00m00m000*m0*m0TEGChol MIMAT0017992 0*5m0*5m0*0 hsa-miR-3615 5′Pm005f05f05f005f00f005f05f05f00*0*0*5 m0m000m0m0m00m0m000*m0*m0TEGChol MIMAT0017994 m0*5m0*5m0*0 hsa-miR-361-5p 5′Pm0005f0f05f05f005f05f05f00f05m0*0*0* m0m0m000m0m000m00m0*m0*m0TEGChol MIMAT0000703 5m0*f0*0*0 hsa-miR-3616-3p 5′Pm005f00f005f00f05f000f00*0*5m0*5m0* m0m0m0m00m0m00m0m0m00*m0*m0TEGChol MIMAT0017996 5m0*0*0 hsa-miR-3616-5p 5′Pm05f05f05f05f005f005f05f0005f00*5m0* m0m0m0m00m0m00m0m000*0*m0TEGChol MIMAT0017995 5m0*0*5m0*0*0 hsa-miR-3617 5′Pm0005f0f0005f0f05f0005f00*5m0*0*5m0 m0m0m0m00m00m0m0m00m0*m0*m0TEGChol MIMAT0017997 *5m0*5m0*0 hsa-miR-3618 5′Pm005f05f05f0005f0f05f05f05f0f05m0*5m m0m0000m00m0m0m000*m0*m0TEGChol MIMAT0017998 0*0*5m0*f0*5m0*0 hsa-miR-3619 5′Pm05f05f05f0f00005f05f005f0f05m0*0*5m m0m00m00m0m0m0m0m000*0*m0TEGChol MIMAT0017999 0*5m0*5m0*5m0*0 hsa-miR-3620 5′Pm05f0005f05f05f00f05f05f005f05m0*5m0 m0m0m000m0m000m0m0m0*0*m0TEGChol MIMAT0018001 *0*5m0*5m0*5m0*0 hsa-miR-3621 5′Pm05f0005f00005f005f05f05f00*5m0*5m0 m0m000m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0018002 *0*5m0*0*0 hsa-miR-3622a- 5′Pm05f05f05f05f05f05f05f05f05f05f05f0f05 m0m0000m0000m000*0*m0TEGChol 3p m0*5m0*5m0*5m0*5m0*5m0*0 MIMAT0018004 hsa-miR-3622a- 5′Pm0005f0f005f05f0f05f05f05f05f05m0*0*0 m0m0000m000m0m00m0*m0*m0TEGChol 5p *0*f0*5m0* MIMAT0018003 hsa-miR-3622b- 5′Pm05f05f00f00005f0000f05m0*5m0*5m0* m0m0m0m0m0m0m0m0m0m0m00*0*m0TEGChol 3p 5m0*f0*5m0*0 MIMAT0018006 hsa-miR-3622b- 5′Pm05f0005f05f005f0f05f05f05f0f05m0*5m m0m0000m00m00m0m0m0*0*m0TEGChol 5p 0*5m0*5m0*5m0*5m0*0 MIMAT0018005 hsa-miR-362-3p 5′Pm0000f05f005f05f05f005f0f00*5m0*0*5 m0m00m00m00m00m0m0m0*m0*m0TEGChol MIMAT0004683 m0*f0*0*0 hsa-miR-362-5p 5′Pm005f05f05f05f005f05f00005f00*0*5m0* m0m0m0m0m0m00m00m000*m0*m0TEGChol MIMAT0000705 0*5m0*5m0*0 hsa-miR-363 5′Pm05f000f0005f0f005f00f05m0*0*0*0*f0* m0m0m00m0m00m0m0m0m0m0*0*m0TEGChol MIMAT0000707 0*0 hsa-miR-363* 5′Pm05f0005f00005f005f05f05f00*5m0*5m0 m0m000m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0003385 *0*f0*0*0 hsa-miR-3646 5′Pm0005f05f05f05f00f005f05f05f00*5m0*0 m0m000m0m0m000m00m0*m0*m0TEGChol MIMAT0018065 *0*f0*0*0 hsa-miR-3647-3p 5′Pm05f05f005f05f0005f05f000f00*0*5m0*0 m0m0m0m00m0m0m00m0m00*0*m0TEGChol MIMAT0018067 *f0*0*0 hsa-miR-3647-5p 5′Pm0000f05f05f00f05f0005f05m0*0*5m0*5 m0m0m0m00m0m000m0m0m0*m0*m0TEGChol MIMAT0018066 m0*5m0*5m0*0 hsa-miR-3648 5′Pm00005f005f05f0f05f005f0f00*5m0*5m0 m0m00m00m000m0m0m0m0*m0*m0TEGChol MIMAT0018068 *0*f0*5m0*0 hsa-miR-3649 5′Pm0005f0f005f005f005f05f0f05m0*0*0*5 m0m000m0m0m00m0m00m0*m0*m0TEGChol MIMAT0018069 m0*5m0*5m0*0 hsa-miR-365 5′Pm05f05f05f05f05f005f05f005f05f0f05m0* m0m000m0m00m00m000*0*m0TEGChol MIMAT0000710 5m0*5m0*5m0*5m0*0*0 hsa-miR-365* 5′Pm0005f0f05f0005f05f05f05f0f00*0*5m0* m0m0000m0m0m00m00m0*m0*m0TEGChol MIMAT0009199 0*f0*0*0 hsa-miR-3650 5′Pm05f05f05f05f005f005f0005f0f05m0*5m0 m0m00m0m0m0m00m0m000*0*m0TEGChol MIMAT0018070 *5m0*5m0*5m0*5m0*0 hsa-miR-3651 5′Pm0000f0005f0f0005f0f05m0*5m0*0*0*f0 m0m00m0m0m00m0m0m0m0m0*m0*m0TEGChol MIMAT0018071 *0*0 hsa-miR-3652 5′Pm05f0005f05f005f0f005f00f00*5m0*5m0 m0m0m00m0m00m00m0m0m0*0*m0TEGChol MIMAT0018072 *0*f0*0*0 hsa-miR-3653 5′Pm0000f05f0005f05f005f0f00*0*5m0*5m0 m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0018073 *5m0*5m0*0 hsa-miR-3654 5′Pm00005f05f005f0f05f05f005f00*0*5m0*0 m0m0m000m00m00m0m0m0*m0*m0TEGChol MIMAT0018074 *5m0*5m0*0 hsa-miR-3655 5′Pm05f05f00f0005f05f005f00f05m0*0*0*0* m0m0m00m0m00m0m0m0m00*0*m0TEGChol MIMAT0018075 f0*5m0*0 hsa-miR-3656 5′Pm0005f0f05f005f0f00005f00*5m0*5m0*0 m0m0m0m0m0m00m00m00m0*m0*m0TEGChol MIMAT0018076 *f0*5m0* hsa-miR-3657 5′Pm05f05f05f05f0005f05f05f05f00f05m0*0* m0m0m000m00m0m0m000*0*m0TEGChol MIMAT0018077 0*0*f0*0*0 hsa-miR-3658 5′Pm0000f05f05f005f0005f05f00*5m0*5m0* m0m00m0m0m0m000m0m0m0*m0*m0TEGChol MIMAT0018078 5m0*5m0*5m0*0 hsa-miR-3659 5′Pm05f05f00f0005f05f05f005f0f00*0*0*5m m0m00m00m00m0m0m0m00*0*m0TEGChol MIMAT0018080 0*f0*0*0 hsa-miR-3660 5′Pm0000f005f05f0f05f005f05f05m0*0*5m0 m0m00m00m000m0m0m0m0*m0*m0TEGChol MIMAT0018081 *5m0*5m0*5m0*0 hsa-miR-3661 5′Pm005f00f05f005f0f05f0005f05m0*0*0*5 m0m0m0m00m00m00m0m00*m0*m0TEGChol MIMAT0018082 m0*5m0*5m0*0 hsa-miR-3662 5′Pm05f0005f0000f05f000f00*5m0*5m0*0*f m0m0m0m00m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0018083 0*5m0*0 hsa-miR-3663-3p 5′Pm0005f05f05f05f00f0000f00*0*0*0*f0** m0m0m0m0m0m0m000m00m0*m0*m0TEGChol MIMAT0018085 hsa-miR-3663-5p 5′Pm0005f0f05f05f005f05f000f05m0*0*0*5 m0m0m0m00m0m000m00m0*m0*m0TEGChol MIMAT0018084 m0*f0*0*0 hsa-miR-3664 5′Pm00005f0005f0f0005f05f00*0*5m0*0*f0 m0m00m0m0m00m0m0m0m0m0*m0*m0TEGChol MIMAT0018086 *5m0*0 hsa-miR-3665 5′Pm05f000f005f00f005f005f05m0*0*0*5m0 m0m0m00m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0018087 *5m0*5m0*0 hsa-miR-3666 5′Pm0000f005f05f05f05f0005f05m0*0*5m0* m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0018088 5m0*5m0*5m0*0 hsa-miR-3667-3p 5′Pm0000f05f0005f00005f05m0*0*5m0*0*5 m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0018090 m0*0*0 hsa-miR-3667-5p 5′Pm0000f05f05f05f0f05f005f05f05m0*0*0* m0m00m00m0000m0m0m0*m0*m0TEGChol MIMAT0018089 0*f0** hsa-miR-3668 5′Pm0000f05f0005f05f005f0f00*5m0*5m0*5 m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0018091 m0*5m0*0*0 hsa-miR-3669 5′Pm05f05f05f0f0005f05f0000f00*0*5m0*0* m0m0m0m0m0m00m0m0m000*0*m0TEGChol MIMAT0018092 5m0*5m0*0 hsa-miR-367 5′Pm05f05f005f0005f0f0000f05m0*0*5m0*5 m0m0m0m0m0m00m0m0m0m00*0*m0TEGChol MIMAT0000719 m0*5m0*0*0 hsa-miR-367* 5′Pm005f005f05f05f00f05f005f05f00*5m0*5 m0m00m00m0m000m0m00*m0*m0TEGChol MIMAT0004686 m0*0*f0*5m0*0 hsa-miR-3670 5′Pm0005f05f0005f05f005f005f05m0*0*5m0 m0m0m00m0m00m0m0m00m0*m0*m0TEGChol MIMAT0018093 *0*5m0*5m0*0 hsa-miR-3671 5′Pm0000f005f05f05f05f0005f05m0*0*5m0* m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0018094 5m0*5m0*5m0*0 hsa-miR-3672 5′Pm05f05f05f0f05f05f00f0005f0f00*0*0*5m m0m00m0m0m0m000m000*0*m0TEGChol MIMAT0018095 0*5m0*5m0*0 hsa-miR-3673 5′Pm005f005f05f005f0f005f00f00*5m0*5m0 m0m0m00m0m00m00m0m00*m0*m0TEGChol MIMAT0018096 *5m0*f0*5m0*0 hsa-miR-3674 5′Pm0005f0f005f05f05f05f005f0f05m0*0*0* m0m00m00m000m0m00m0*m0*m0TEGChol MIMAT0018097 0*f0*0*0 hsa-miR-3675-3p 5′Pm005f005f05f05f005f05f05f00f00*0*0*5 m0m0m000m0m000m0m00*m0*m0TEGChol MIMAT0018099 m0*f0*0*0 hsa-miR-3675-5p 5′Pm05f05f00f05f000f05f000f00*0*0*5m0*5 m0m0m0m00m0m0m00m0m00*0*m0TEGChol MIMAT0018098 m0*5m0*0 hsa-miR-3676 5′Pm0000f05f005f0f05f0005f05m0*5m0*0*5 m0m0m0m00m00m00m0m0m0*m0*m0TEGChol MIMAT0018100 m0*5m0*5m0*0 hsa-miR-3677 5′Pm005f05f05f05f005f05f05f0005f00*0*5m m0m0m0m00m00m00m000*m0*m0TEGChol MIMAT0018101 0*0*5m0*5m0*0 hsa-miR-3678-3p 5′Pm0005f0f05f05f005f05f005f05f05m0*5m0 m0m00m00m0m000m00m0*m0*m0TEGChol MIMAT0018103 *5m0*5m0*f0*0*0 hsa-miR-3678-5p 5′Pm0000f05f005f0f00005f00*5m0*0*0*f0* m0m0m0m0m0m00m00m0m0m0*m0*m0TEGChol MIMAT0018102 0*0 hsa-miR-3679-3p 5′Pm05f05f05f05f05f05f005f05f05f05f0f05m m0m0000m0m000m000*0*m0TEGChol MIMAT0018105 0*5m0*5m0*5m0*5m0*5m0*0 hsa-miR-3679-5p 5′Pm0005f05f05f005f0f05f05f005f05m0*5m0 m0m0m000m00m00m00m0*m0*m0TEGChol MIMAT0018104 *0*0*f0*0*0 hsa-miR-3680 5′Pm05f05f05f05f005f005f005f005f00*5m0* m0m0m00m0m0m00m0m000*0*m0TEGChol MIMAT0018106 5m0*5m0*5m0*5m0*0 hsa-miR-3680* 5′Pm05f005f05f0005f05f05f05f00f05m0*0*0 m0m0m000m00m0m0m00m0*0*m0TEGChol MIMAT0018107 *5m0*f0** hsa-miR-3681 5′Pm0005f05f05f05f005f005f005f00*0*0*5m m0m0m00m0m0m000m00m0*m0*m0TEGChol MIMAT0018108 0*5m0*0*0 hsa-miR-3681* 5′Pm05f05f005f05f0005f05f005f05f00*0*5m m0m00m00m0m0m00m0m00*0*m0TEGChol MIMAT0018109 0*5m0*f0*5m0*0 hsa-miR-3682 5′Pm0005f05f05f005f05f05f005f0f00*0*0*0* m0m00m00m00m00m00m0*m0*m0TEGChol MIMAT0018110 5m0*0*0 hsa-miR-3683 5′Pm0000f05f0005f05f005f0f00*5m0*5m0*5 m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0018111 m0*5m0*5m0*0 hsa-miR-3684 5′Pm0000f05f0005f0005f0f05m0*5m0*5m0* m0m00m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0018112 5m0*5m0*5m0*0 hsa-miR-3685 5′Pm00005f05f05f005f005f05f05f00*5m0*0* m0m000m0m0m000m0m0m0*m0*m0TEGChol MIMAT0018113 0*f0*5m0*0 hsa-miR-3686 5′Pm0000f005f05f0f05f0005f05m0*5m0*5m m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0018114 0*5m0*5m0*5m0*0 hsa-miR-3687 5′Pm0000f05f05f05f0f005f00f00*5m0*5m0* m0m0m00m0m0000m0m0m0*m0*m0TEGChol MIMAT0018115 5m0*** hsa-miR-3688 5′Pm0000f05f0005f05f005f0f00*5m0*5m0*5 m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0018116 m0*5m0*5m0*0 hsa-miR-3689a- 5′Pm0005f05f005f00f005f05f05f05m0*5m0* m0m000m0m0m00m0m00m0*m0*m0TEGChol 3p 0*5m0*5m0*0*0 MIMAT0018118 hsa-miR-3689a- 5′Pm05f05f05f0f0005f05f005f00f00*0*0*5m m0m0m00m0m00m0m0m000*0*m0TEGChol 5p 0*f0*5m0*0 MIMAT0018117 hsa-miR-3689b 5′Pm00005f005f05f0f05f0005f00*5m0*5m0* m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0018180 5m0*f0*0*0 hsa-miR-3689b* 5′Pm05f005f0f05f05f00f05f005f0f05m0*0*0* m0m00m00m0m000m00m0*0*m0TEGChol MIMAT0018181 5m0*f0*0*0 hsa-miR-3690 5′Pm05f0005f0005f0f05f000f00*0*5m0*5m0 m0m0m0m00m00m0m0m0m0m0*0*m0TEGChol MIMAT0018119 *f0*0*0 hsa-miR-3691 5′Pm0000f005f00f05f005f05f05m0*5m0*5m m0m00m00m0m00m0m0m0m0*m0*m0TEGChol MIMAT0018120 0*0*f0*0*0 hsa-miR-3692 5′Pm05f05f005f05f0005f05f005f05f00*0*5m m0m00m00m0m0m00m0m00*0*m0TEGChol MIMAT0018122 0*5m0*f0*5m0*0 hsa-miR-3692* 5′Pm05f05f00f05f005f05f0005f0f00*5m0*5m m0m00m0m0m00m00m0m00*0*m0TEGChol MIMAT0018121 0*5m0*5m0*0*0 hsa-miR-369-3p 5′Pm0005f05f05f005f0f05f05f005f05m0*5m0 m0m0m000m00m00m00m0*m0*m0TEGChol MIMAT0000721 *5m0*0*5m0** hsa-miR-369-5p 5′Pm005f00f05f005f05f05f05f00f05m0*0*5m m0m0m000m00m00m0m00*m0*m0TEGChol MIMAT0001621 0*5m0*f0*0*0 hsa-miR-370 5′Pm00005f005f05f05f05f0005f00*0*5m0*0 m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0000722 *f0*0*0 hsa-miR-3713 5′Pm05f000f005f005f05f05f00f00*0*5m0*5 m0m0m000m0m00m0m0m0m0*0*m0TEGChol MIMAT0018164 m0*f0*5m0*0 hsa-miR-371-3p 5′Pm05f05f05f05f05f05f05f0f05f05f005f05m m0m0m000m0000m000*0*m0TEGChol MIMAT0000723 0*5m0*5m0*0*5m0*0*0 hsa-miR-3714 5′Pm005f05f05f05f05f005f05f000f00*5m0*5 m0m0m0m00m0m000m000*m0*m0TEGChol MIMAT0018165 m0*5m0*5m0*5m0* hsa-miR-371-5p 5′Pm05f05f05f05f005f05f05f05f05f05f0f00*0 m0m0000m000m0m000*0*m0TEGChol MIMAT0004687 *0*0*5m0*5m0*0 hsa-miR-372 5′Pm05f000f005f05f05f005f00f05m0*0*0*5 m0m0m00m0m000m0m0m0m0*0*m0TEGChol MIMAT0000724 m0*f0*5m0*0 hsa-miR-373 5′Pm05f005f0f05f05f005f0005f05f00*5m0*0 m0m00m0m0m0m000m00m0*0*m0TEGChol MIMAT0000726 *5m0*5m0*0*0 hsa-miR-373* 5′Pm0000f05f05f00f0005f05f00*5m0*5m0*5 m0m00m0m0m0m000m0m0m0*m0*m0TEGChol MIMAT0000725 m0*5m0*5m0*0 hsa-miR-374a 5′Pm0005f0f05f05f05f05f05f005f0f00*5m0*0 m0m00m00m0000m00m0*m0*m0TEGChol MIMAT0000727 *5m0*f0*5m0*0 hsa-miR-374a* 5′Pm05f05f005f005f05f0f0000f05m0*5m0*0 m0m0m0m0m0m000m0m0m00*0*m0TEGChol MIMAT0004688 *0*f0*5m0*0 hsa-miR-374b 5′Pm05f005f0f05f05f005f05f005f05f00*5m0* m0m00m00m0m000m00m0*0*m0TEGChol MIMAT0004955 0*5m0*5m0*0*0 hsa-miR-374b* 5′Pm00005f005f05f05f05f0005f05m0*5m0*5 m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0004956 m0*0*f0*0*0 hsa-miR-374c 5′Pm005f05f05f0005f05f05f05f05f0f00*5m0* m0m0000m00m0m0m000*m0*m0TEGChol MIMAT0018443 0*5m0*f0*0*0 hsa-miR-375 5′Pm05f05f005f05f000f005f005f00*0*5m0*5 m0m0m00m0m0m0m00m0m00*0*m0TEGChol MIMAT0000728 m0*5m0*5m0*0 hsa-miR-376a 5′Pm05f05f00f0005f0f0005f05f05m0*0*0*5 m0m00m0m0m00m0m0m0m00*0*m0TEGChol MIMAT0000729 m0*5m0*5m0*0 hsa-miR-376a* 5′Pm05f05f05f05f05f05f005f05f05f005f05m0 m0m0m000m0m000m000*0*m0TEGChol MIMAT0003386 *5m0*0*5m0*5m0*5m0*0 hsa-miR-376b 5′Pm005f00f05f005f05f005f05f0f00*0*0*5m m0m000m0m00m00m0m00*m0*m0TEGChol MIMAT0002172 0*5m0*0*0 hsa-miR-376c 5′Pm00005f05f000f005f05f0f00*0*0*5m0*5 m0m000m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0000720 m0*0*0 hsa-miR-377 5′Pm0005f05f05f05f05f0f05f05f005f05m0*5 m0m0m000m0000m00m0*m0*m0TEGChol MIMAT0000730 m0*0*0*f0*5m0*0 hsa-miR-377* 5′Pm05f000f0005f05f0005f0f00*0*0*0*f0*0 m0m00m0m0m00m0m0m0m0m0*0*m0TEGChol MIMAT0004689 *0 hsa-miR-378 5′Pm05f05f05f0f00005f0000f00*5m0*0*5m0 m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0000732 *5m0*5m0*0 hsa-miR-378* 5′Pm05f05f05f0f005f005f0005f0f05m0*5m0* m0m00m0m0m0m00m0m000*0*m0TEGChol MIMAT0000731 0*0*5m0*5m0*0 hsa-miR-378b 5′Pm05f0005f00005f05f05f00f05m0*5m0*5 m0m0m000m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0014999 m0*0*5m0** hsa-miR-378c 5′Pm05f005f0f005f005f0005f05f05m0*0*0*5 m0m00m0m0m0m00m0m00m0*0*m0TEGChol MIMAT0016847 m0*f0*0*0 hsa-miR-379 5′Pm0000f05f05f005f0005f05f00*5m0*5m0* m0m00m0m0m0m000m0m0m0*m0*m0TEGChol MIMAT0000733 5m0*5m0*5m0* hsa-miR-379* 5′Pm05f05f05f05f005f05f05f05f05f00f05m0* m0m0m000m000m0m000*0*m0TEGChol MIMAT0004690 0*5m0*5m0*** hsa-miR-380 5′Pm05f05f05f05f05f05f05f0f0000f05m0*0*5 m0m0m0m0m0m0000m000*0*m0TEGChol MIMAT0000735 m0*5m0*5m0*5m0* hsa-miR-380* 5′Pm05f005f05f05f005f05f00005f05m0*5m0 m0m0m0m0m0m00m00m00m0*0*m0TEGChol MIMAT0000734 *5m0*5m0*** hsa-miR-381 5′Pm05f005f05f0000f05f0005f05m0*5m0*5 m0m0m0m00m0m0m0m0m00m0*0*m0TEGChol MIMAT0000736 m0*5m0*f0*5m0*0 hsa-miR-382 5′Pm0005f0f05f05f05f05f0005f0f00*5m0*0* m0m00m0m0m0000m00m0*m0*m0TEGChol MIMAT0000737 5m0*f0*0*0 hsa-miR-383 5′Pm005f005f05f05f005f05f0005f05m0*0*5 m0m0m0m00m0m000m0m00*m0*m0TEGChol MIMAT0000738 m0*5m0*f0*5m0*0 hsa-miR-384 5′Pm00005f0000f0000f00*0*5m0*5m0*5m0 m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEG MIMAT0001075 *0*0 Chol hsa-miR-3907 5′Pm05f005f0f00005f0005f0f00*0*0*5m0*5 m0m00m0m0m0m0m0m0m00m0*0*m0TEGChol MIMAT0018179 m0*0*0 hsa-miR-3908 5′Pm0005f0f05f05f00f05f05f00f00*5m0*0*5 m0m0m000m0m000m00m0*m0*m0TEGChol MIMAT0018182 m0*5m0*0*0 hsa-miR-3909 5′Pm05f05f05f05f05f005f05f05f05f005f05m0 m0m0m000m00m00m000*0*m0TEGChol MIMAT0018183 *0*0*0*f0*5m0*0 hsa-miR-3910 5′Pm0005f0f0005f05f005f00f00*0*5m0*0*5 m0m0m00m0m00m0m0m00m0*m0*m0TEGChol MIMAT0018184 m0*0*0 hsa-miR-3911 5′Pm05f05f005f05f05f05f0f005f05f0f05m0*5 m0m000m0m0000m0m00*0*m0TEGChol MIMAT0018185 m0*5m0*5m0*f0*5m0*0 hsa-miR-3912 5′Pm05f005f0f05f05f05f0f0005f0f00*0*0*0* m0m00m0m0m0000m00m0*0*m0TEGChol MIMAT0018186 5m0*5m0*0 hsa-miR-3913 5′Pm05f05f05f0f05f005f0f0000f05m0*5m0*0 m0m0m0m0m0m00m00m000*0*m0TEGChol MIMAT0018187 *5m0*f0*5m0*0 hsa-miR-3914 5′Pm05f0005f0000f0005f0f00*0*0*5m0*5m m0m00m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0018188 0*0*0 hsa-miR-3915 5′Pm0000f0005f05f0000f05m0*5m0*5m0*5 m0m0m0m0m0m00m0m0m0m0m0*m0*m0TEGChol MIMAT0018189 m0*f0*0*0 hsa-miR-3916 5′Pm0000f05f0005f00005f05m0*0*5m0*0*5 m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0018190 m0*5m0*0 hsa-miR-3917 5′Pm05f05f005f05f000f05f05f005f00*5m0*5 m0m0m000m0m0m00m0m00*0*m0TEGChol MIMAT0018191 m0*0*5m0*0*0 hsa-miR-3918 5′Pm005f05f05f05f05f005f05f005f05f05m0*0 m0m00m00m0m000m000*m0*m0TEGChol MIMAT0018192 *0*0*5m0** hsa-miR-3919 5′Pm05f0005f0000f0005f0f00*0*0*5m0*5m m0m00m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0018193 0*0*0 hsa-miR-3920 5′Pm0005f0f05f0005f005f05f0f00*0*0*0*f0* m0m000m0m0m0m00m00m0*m0*m0TEGChol MIMAT0018195 0*0 hsa-miR-3921 5′Pm005f005f05f05f005f05f005f05f00*5m0* m0m00m00m0m000m0m00*m0*m0TEGChol MIMAT0018196 5m0*0*f0*5m0*0 hsa-miR-3922 5′Pm05f05f005f005f05f0f05f005f05f00*5m0* m0m00m00m000m0m0m00*0*m0TEGChol MIMAT0018197 5m0*0*5m0*5m0*0 hsa-miR-3923 5′Pm05f005f0f005f005f0005f05f05m0*0*5m m0m00m0m0m0m00m0m00m0*0*m0TEGChol MIMAT0018198 0*5m0*f0*0*0 hsa-miR-3924 5′Pm0000f05f005f05f005f05f05f00*5m0*0*0 m0m000m0m00m00m0m0m0*m0*m0TEGChol MIMAT0018199 *5m0*5m0*0 hsa-miR-3925 5′Pm00005f05f05f05f0f05f0005f00*5m0*5m m0m0m0m00m0000m0m0m0*m0*m0TEGChol MIMAT0018200 0*5m0*5m0*0*0 hsa-miR-3926 5′Pm05f0005f005f005f0005f05f00*0*5m0*5 m0m00m0m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0018201 m0*5m0*5m0*0 hsa-miR-3927 5′Pm005f005f005f05f05f00005f00*0*0*0*f0 m0m0m0m0m0m000m0m0m00*m0*m0TEGChol MIMAT0018202 *5m0*0 hsa-miR-3928 5′Pm00005f05f005f0f005f05f0f05m0*5m0*5 m0m000m0m00m00m0m0m0*m0*m0TEGChol MIMAT0018205 m0*5m0*5m0*0*0 hsa-miR-3929 5′Pm0000f05f0005f05f005f0f00*5m0*5m0*5 m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0018206 m0*5m0*5m0*0 hsa-miR-3934 5′Pm00005f005f005f05f005f0f00*5m0*0*5m m0m00m00m0m00m0m0m0m0*m0*m0TEGChol MIMAT0018349 0*f0*5m0*0 hsa-miR-3935 5′Pm0005f05f05f005f05f05f0005f05m0*5m0 m0m0m0m00m00m00m00m0*m0*m0TEGChol MIMAT0018350 *5m0*5m0*5m0*0*0 hsa-miR-3936 5′Pm005f005f05f005f0f05f0005f05m0*0*0*5 m0m0m0m00m00m00m0m00*m0*m0TEGChol MIMAT0018351 m0*5m0*5m0*0 hsa-miR-3937 5′Pm05f005f05f005f005f0000f05m0*5m0*0* m0m0m0m0m0m0m00m0m00m0*0*m0TEGChol MIMAT0018352 5m0*5m0*0* hsa-miR-3938 5′Pm0005f0f05f0005f0005f0f00*0*0*0*f0*0 m0m00m0m0m0m0m00m00m0*m0*m0TEGChol MIMAT0018353 *0 hsa-miR-3939 5′Pm05f05f00f05f000f05f05f005f00*5m0*5m m0m0m000m0m0m00m0m00*0*m0TEGChol MIMAT0018355 0*0*5m0*5m0*0 hsa-miR-3940 5′Pm0000f0005f05f05f05f05f0f00*0*0*5m0* m0m0000m00m0m0m0m0m0*m0*m0TEGChol MIMAT0018356 5m0*5m0*0 hsa-miR-3941 5′Pm05f05f00f05f05f05f05f05f0005f05m0*5 m0m0m0m00m0000m0m00*0*m0TEGChol MIMAT0018357 m0*0*0*f0*0*0 hsa-miR-3942 5′Pm05f0005f005f00f05f05f05f0f05m0*5m0* m0m0000m0m00m0m0m0m0*0*m0TEGChol MIMAT0018358 0*0*f0*5m0*0 hsa-miR-3943 5′Pm005f05f05f05f0005f0000f05m0*0*0*0*f m0m0m0m0m0m0m0m00m000*m0*m0TEGChol MIMAT0018359 0*5m0*0 hsa-miR-3944 5′Pm0005f0f0005f0f0000f00*5m0*5m0*0*5 m0m0m0m0m0m00m0m0m00m0*m0*m0TEGChol MIMAT0018360 m0*0*0 hsa-miR-3945 5′Pm005f05f0f05f005f05f05f005f05f05m0*5 m0m00m00m00m00m000*m0*m0TEGChol MIMAT0018361 m0*0*0*5m0*5m0*0 hsa-miR-409-3p 5′Pm005f05f05f00005f05f000f00*5m0*5m0* m0m0m0m00m0m0m0m0m000*m0*m0TEGChol MIMAT0001639 0*5m0*0*0 hsa-miR-409-5p 5′Pm05f05f005f05f05f005f05f05f00f05m0*5 m0m0m000m0m000m0m00*0*m0TEGChol MIMAT0001638 m0*5m0*0*5m0*0*0 hsa-miR-410 5′Pm005f05f05f05f05f05f0f05f05f05f05f05m m0m0000m0000m000*m0*m0TEGChol MIMAT0002171 0*0*0*0*5m0*0*0 hsa-miR-411 5′Pm005f005f005f05f05f00005f00*0*0*0*f0 m0m0m0m0m0m000m0m0m00*m0*m0TEGChol MIMAT0003329 *5m0*0 hsa-miR-411* 5′Pm0005f0f05f05f005f05f05f00f05m0*0*0* m0m0m000m0m000m00m0*m0*m0TEGChol MIMAT0004813 0*f0*5m0*0 hsa-miR-412 5′Pm0000f05f005f0f05f0005f00*0*0*5m0*f0 m0m0m0m00m00m00m0m0m0*m0*m0TEGChol MIMAT0002170 *5m0*0 hsa-miR-421 5′Pm05f05f005f0000f0000f00*5m0*5m0*5m m0m0m0m0m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0003339 0*f0*5m0*0 hsa-miR-422a 5′Pm05f000f05f05f05f05f05f05f05f05f05m0* m0m0000m0000m0m0m0*0*m0TEGChol MIMAT0001339 5m0*0*5m0*f0*0*0 hsa-miR-423-3p 5′Pm005f05f05f005f05f05f005f005f00*5m0* m0m0m00m0m000m0m000*m0*m0TEGChol MIMAT0001340 5m0*5m0*f0*5m0*0 hsa-miR-423-5p 5′Pm0005f05f005f05f0f05f005f0f05m0*5m0* m0m00m00m000m0m00m0*m0*m0TEGChol MIMAT0004748 0*0*f0*5m0*0 hsa-miR-424 5′Pm05f05f005f0000f0000f00*5m0*5m0*5m m0m0m0m0m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0001341 0*f0*5m0*0 hsa-miR-424* 5′Pm05f000f05f005f05f05f005f05f05m0*0*5 m0m00m00m00m00m0m0m0*0*m0TEGChol MIMAT0004749 m0*5m0*5m0*5m0*0 hsa-miR-425 5′Pm005f005f0000f0000f05m0*5m0*5m0*5 m0m0m0m0m0m0m0m0m0m0m00*m0*m0TEGChol MIMAT0003393 m0*f0*5m0*0 hsa-miR-425* 5′Pm05f05f005f005f00f00005f00*0*5m0*5m m0m0m0m0m0m0m00m0m0m00*0*m0TEGChol MIMAT0001343 0*5m0*5m0*0 hsa-miR-4251 5′Pm0000f0000f0000f00*0*0*5m0*f0*0*0 m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEG MIMAT0016883 Chol hsa-miR-4252 5′Pm0005f0f005f005f05f05f05f0f00*5m0*5m m0m0000m0m00m0m00m0*m0*m0TEGChol MIMAT0016886 0*0*f0*5m0*0 hsa-miR-4253 5′Pm005f05f05f05f05f05f05f05f05f05f05f05 m0m0000m0000m000*m0*m0TEGChol MIMAT0016882 m0*5m0*5m0*5m0*5m0*5m0* hsa-miR-4254 5′Pm005f05f05f05f0005f0005f0f00*5m0*0*0 m0m00m0m0m0m0m00m000*m0*m0TEGChol MIMAT0016884 *5m0*0*0 hsa-miR-4255 5′Pm05f05f05f05f05f005f05f005f05f05f00*0 m0m000m0m00m00m000*0*m0TEGChol MIMAT0016885 *0*5m0*f0*5m0*0 hsa-miR-4256 5′Pm05f005f05f0005f05f00005f05m0*5m0*5 m0m0m0m0m0m00m0m0m00m0*0*m0TEGChol MIMAT0016877 m0*5m0*f0*5m0*0 hsa-miR-4257 5′Pm05f05f05f05f0005f05f05f05f005f00*0*5 m0m0m000m00m0m0m000*0*m0TEGChol MIMAT0016878 m0*5m0*5m0*5m0*0 hsa-miR-4258 5′Pm005f005f05f05f005f0005f0f00*0*5m0*5 m0m00m0m0m0m000m0m00*m0*m0TEGChol MIMAT0016879 m0*5m0*5m0*0 hsa-miR-4259 5′Pm05f05f00f05f000f0005f0f00*5m0*5m0* m0m00m0m0m0m0m00m0m00*0*m0TEGChol MIMAT0016880 *** hsa-miR-4260 5′Pm0000f05f0005f05f005f0f00*0*5m0*5m0 m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0016881 *5m0*5m0*0 hsa-miR-4261 5′Pm0005f05f0000f05f05f00f05m0*5m0*0*5 m0m0m000m0m0m0m0m00m0*m0*m0TEGChol MIMAT0016890 m0*f0*0*0 hsa-miR-4262 5′Pm05f0005f05f000f05f000f05m0*0*0*0*f0 m0m0m0m00m0m0m00m0m0m0*0*m0TEGChol MIMAT0016894 *5m0*0 hsa-miR-4263 5′Pm05f05f05f05f05f05f05f05f05f05f005f05 m0m0m000m0000m000*0*m0TEGChol MIMAT0016898 m0*0*5m0*0*5m0*5m0*0 hsa-miR-4264 5′Pm05f005f0f005f005f00005f05m0*5m0*0* m0m0m0m0m0m0m00m0m00m0*0*m0TEGChol MIMAT0016899 0*5m0*5m0*0 hsa-miR-4265 5′Pm0005f05f0005f0f0005f0f05m0*0*5m0*5 m0m00m0m0m00m0m0m00m0*m0*m0TEGChol MIMAT0016891 m0*f0*5m0*0 hsa-miR-4266 5′Pm05f05f05f05f00005f05f0005f05m0*5m0 m0m0m0m00m0m0m0m0m000*0*m0TEGChol MIMAT0016892 *5m0*0*f0** hsa-miR-4267 5′Pm05f05f005f0005f05f05f000f00*0*5m0*0 m0m0m0m00m00m0m0m0m00*0*m0TEGChol MIMAT0016893 *f0*5m0*0 hsa-miR-4268 5′Pm0000f05f0005f00005f05m0*0*5m0*0*5 m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0016896 m0*0*0 hsa-miR-4269 5′Pm0000f05f0005f05f005f0f00*5m0*5m0*5 m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0016897 m0*5m0*5m0*0 hsa-miR-4270 5′Pm005f00f005f05f05f05f05f005f05m0*5m0 m0m0m000m000m0m0m00*m0*m0TEGChol MIMAT0016900 *5m0*5m0*5m0*5m0*0 hsa-miR-4271 5′Pm005f05f05f005f00f0005f05f00*0*5m0*5 m0m00m0m0m0m00m0m000*m0*m0TEGChol MIMAT0016901 m0*5m0*5m0*0 hsa-miR-4272 5′Pm0005f05f005f05f0f005f05f05f05m0*0*5 m0m000m0m000m0m00m0*m0*m0TEGChol MIMAT0016902 m0*5m0*f0*5m0*0 hsa-miR-4273 5′Pm0005f0f005f05f05f005f00f05m0*5m0*0 m0m0m00m0m000m0m00m0*m0*m0TEGChol MIMAT0016903 *5m0*f0*0*0 hsa-miR-4274 5′Pm05f05f005f0005f05f05f05f05f0f00*5m0* m0m0000m00m0m0m0m00*0*m0TEGChol MIMAT0016906 5m0*0*5m0*5m0*0 hsa-miR-4275 5′Pm0000f00005f00005f00*5m0*0*0*5m0** m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEG MIMAT0016905 Chol hsa-miR-4276 5′Pm005f00f005f00f05f000f00*5m0*0*0*f0* m0m0m0m00m0m00m0m0m00*m0*m0TEGChol MIMAT0016904 0*0 hsa-miR-4277 5′Pm0000f005f05f05f0005f0f00*0*5m0*0*5 m0m00m0m0m000m0m0m0m0*m0*m0TEGChol MIMAT0016908 m0*5m0*0 hsa-miR-4278 5′Pm0005f05f05f0005f0000f00*5m0*0*0*** m0m0m0m0m0m0m0m00m00m0*m0*m0TEGChol MIMAT0016910 hsa-miR-4279 5′Pm005f00f05f005f05f005f00f05m0*0*0*5 m0m0m00m0m00m00m0m00*m0*m0TEGChol MIMAT0016909 m0*5m0*0*0 hsa-miR-4280 5′Pm00005f0005f0f05f05f005f05m0*0*0*5m m0m0m000m00m0m0m0m0m0*m0*m0TEGChol MIMAT0016911 0*5m0*0*0 hsa-miR-4281 5′Pm0000f05f005f05f05f005f0f00*0*5m0*5 m0m00m00m00m00m0m0m0*m0*m0TEGChol MIMAT0016907 m0*5m0*5m0*0 hsa-miR-4282 5′Pm005f05f0f05f05f00f05f05f005f00*5m0*0 m0m0m000m0m000m000*m0*m0TEGChol MIMAT0016912 *0*5m0*5m0*0 hsa-miR-4283 5′Pm0000f05f005f05f05f005f0f00*0*5m0*5 m0m00m00m00m00m0m0m0*m0*m0TEGChol MIMAT0016914 m0*5m0*5m0*0 hsa-miR-4284 5′Pm0000f05f005f0f0000f00*0*5m0*0*5m0 m0m0m0m0m0m00m00m0m0m0*m0*m0TEGChol MIMAT0016915 *0*0 hsa-miR-4285 5′Pm0000f05f05f005f05f05f05f05f00*0*5m0 m0m0000m0m000m0m0m0*m0*m0TEGChol MIMAT0016913 *0*f0*0*0 hsa-miR-4286 5′Pm05f05f05f05f00005f05f005f05f05m0*5m m0m00m00m0m0m0m0m000*0*m0TEGChol MIMAT0016916 0*0*0*f0*5m0*0 hsa-miR-4287 5′Pm005f005f05f05f00f05f05f05f0f05m0*5m m0m0000m0m000m0m00*m0*m0TEGChol MIMAT0016917 0*0*0*5m0*0*0 hsa-miR-4288 5′Pm05f000f005f00f005f00f00*0*0*0*5m0* m0m0m00m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0016918 5m0*0 hsa-miR-4289 5′Pm05f05f00f005f05f05f0000f05m0*5m0*0 m0m0m0m0m0m000m0m0m00*0*m0TEGChol MIMAT0016920 *0*f0*0*0 hsa-miR-429 5′Pm005f05f05f05f05f00f00005f05m0*5m0* m0m0m0m0m0m0m000m000*m0*m0TEGChol MIMAT0001536 0*0*f0*5m0*0 hsa-miR-4290 5′Pm05f005f0f05f0005f05f05f005f05m0*0*5 m0m0m000m0m0m00m00m0*0*m0TEGChol MIMAT0016921 m0*5m0*5m0*5m0*0 hsa-miR-4291 5′Pm0000f005f005f05f05f005f00*0*5m0*5m m0m0m000m0m00m0m0m0m0*m0*m0TEGChol MIMAT0016922 0*5m0*5m0*0 hsa-miR-4292 5′Pm05f000f005f00f005f00f00*0*0*0*5m0* m0m0m00m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0016919 5m0*0 hsa-miR-4293 5′Pm0000f005f00f05f05f005f00*0*0*5m0*5 m0m0m000m0m00m0m0m0m0*m0*m0TEGChol MIMAT0016848 m0*5m0*0 hsa-miR-4294 5′Pm0005f0f005f00f00005f00*0*5m0*5m0* m0m0m0m0m0m0m00m0m00m0*m0*m0TEGChol MIMAT0016849 5m0*5m0*0 hsa-miR-4295 5′Pm0005f0f005f005f0005f05f00*0*5m0*5m m0m00m0m0m0m00m0m00m0*m0*m0TEGChol MIMAT0016844 0*f0*0*0 hsa-miR-4296 5′Pm05f05f05f05f0005f05f05f05f00f00*5m0* m0m0m000m00m0m0m000*0*m0TEGChol MIMAT0016845 5m0*5m0*5m0*0*0 hsa-miR-4297 5′Pm05f005f05f0005f05f005f00f05m0*0*0*0 m0m0m00m0m00m0m0m00m0*0*m0TEGChol MIMAT0016846 *f0*0*0 hsa-miR-4298 5′Pm0005f0f0000f05f05f05f0f05m0*5m0*0* m0m0000m0m0m0m0m00m0*m0*m0TEGChol MIMAT0016852 5m0*f0*5m0*0 hsa-miR-4299 5′Pm0000f05f05f05f0f05f0005f00*0*0*0*** m0m0m0m00m0000m0m0m0*m0*m0TEGChol MIMAT0016851 hsa-miR-4300 5′Pm005f005f05f005f05f05f0005f00*0*5m0* m0m0m0m00m00m00m0m00*m0*m0TEGChol MIMAT0016853 5m0*f0*5m0*0 hsa-miR-4301 5′Pm05f05f00f0005f05f0000f05m0*0*5m0*0 m0m0m0m0m0m00m0m0m0m00*0*m0TEGChol MIMAT0016850 *f0*5m0*0 hsa-miR-4302 5′Pm05f05f05f05f005f005f05f005f05f05m0*0 m0m00m00m0m00m0m000*0*m0TEGChol MIMAT0016855 *5m0*5m0*5m0*5m0*0 hsa-miR-4303 5′Pm0005f0f05f0005f005f05f05f05m0*5m0* m0m000m0m0m0m00m00m0*m0*m0TEGChol MIMAT0016856 5m0*5m0*5m0** hsa-miR-4304 5′Pm0000f005f00f005f00f05m0*0*0*0*f0*0 m0m0m00m0m0m00m0m0m0m0*m0*m0TEGChol MIMAT0016854 *0 hsa-miR-4305 5′Pm005f05f0f05f05f00f05f05f005f05m0*0*0 m0m0m000m0m000m000*m0*m0TEGChol MIMAT0016857 *0*5m0*0*0 hsa-miR-4306 5′Pm005f05f05f005f00f005f05f05f00*0*5m0 m0m000m0m0m00m0m000*m0*m0TEGChol MIMAT0016858 *5m0*5m0*5m0*0 hsa-miR-4307 5′Pm05f005f0f005f05f05f0005f05f05m0*5m0 m0m00m0m0m000m0m00m0*0*m0TEGChol MIMAT0016860 *5m0*0*5m0*5m0*0 hsa-miR-4308 5′Pm005f00f05f005f05f005f05f0f00*5m0*0* m0m000m0m00m00m0m00*m0*m0TEGChol MIMAT0016861 5m0*5m0*0* hsa-miR-4309 5′Pm0005f05f05f05f00f05f05f05f0f05m0*0*5 m0m0000m0m000m00m0*m0*m0TEGChol MIMAT0016859 m0*5m0*5m0*5m0*0 hsa-miR-431 5′Pm0000f05f000f05f000f00*0*0*0*f0*0* m0m0m0m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0001625 hsa-miR-431* 5′Pm00005f05f05f05f05f05f05f00f00*5m0*5 m0m0m000m0000m0m0m0*m0*m0TEGChol MIMAT0004757 m0*5m0*5m0*5m0*0 hsa-miR-4310 5′Pm0000f05f005f05f05f005f0f00*5m0*0*5 m0m00m00m00m00m0m0m0*m0*m0TEGChol MIMAT0016862 m0*f0*0*0 hsa-miR-4311 5′Pm005f05f0f05f005f05f05f005f05f05m0*5 m0m00m00m00m00m000*m0*m0TEGChol MIMAT0016863 m0*0*0*5m0*5m0*0 hsa-miR-4312 5′Pm05f05f005f0000f05f05f05f0f05m0*5m0* m0m0000m0m0m0m0m0m00*0*m0TEGChol MIMAT0016864 5m0*5m0*f0*0*0 hsa-miR-4313 5′Pm005f05f0f0005f05f0005f05f00*5m0*0*0 m0m00m0m0m00m0m0m000*m0*m0TEGChol MIMAT0016865 *f0*0*0 hsa-miR-4314 5′Pm05f000f005f05f0f05f0005f05m0*0*5m0 m0m0m0m00m000m0m0m0m0*0*m0TEGChol MIMAT0016868 *5m0*5m0*5m0*0 hsa-miR-4315 5′Pm05f000f005f05f0f0000f00*5m0*0*5m0* m0m0m0m0m0m000m0m0m0m0*0*m0TEGChol MIMAT0016866 5m0*5m0*0 hsa-miR-4316 5′Pm005f05f0f005f005f05f05f005f05m0*0*0 m0m0m000m0m00m0m000*m0*m0TEGChol MIMAT0016867 *5m0*5m0*5m0*0 hsa-miR-4317 5′Pm05f005f0f0005f05f05f000f05m0*5m0*5 m0m0m0m00m00m0m0m00m0*0*m0TEGChol MIMAT0016872 m0*0*** hsa-miR-4318 5′Pm05f05f00f005f05f05f0000f00*5m0*0*0* m0m0m0m0m0m000m0m0m00*0*m0TEGChol MIMAT0016869 f0*0* hsa-miR-4319 5′Pm05f05f00f005f05f05f0000f05m0*5m0*0 m0m0m0m0m0m000m0m0m00*0*m0TEGChol MIMAT0016870 *0*f0*0*0 hsa-miR-432 5′Pm005f05f05f05f05f05f05f005f05f05f00*5 m0m000m0m0000m000*m0*m0TEGChol MIMAT0002814 m0*0**** hsa-miR-432* 5′Pm05f05f005f005f05f0f05f000f05m0*0*5m m0m0m0m00m000m0m0m00*0*m0TEGChol MIMAT0002815 0*5m0*5m0*0*0 hsa-miR-4320 5′Pm05f0005f0000f005f05f0f05m0*5m0*5m m0m000m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0016871 0*5m0*f0*0*0 hsa-miR-4321 5′Pm0000f05f05f00f0000f05m0*0*5m0*5m0 m0m0m0m0m0m0m000m0m0m0*m0*m0TEGChol MIMAT0016874 *f0*0*0 hsa-miR-4322 5′Pm0005f0f0005f05f005f00f00*0*5m0*0*5 m0m0m00m0m00m0m0m00m0*m0*m0TEGChol MIMAT0016873 m0*0*0 hsa-miR-4323 5′Pm0000f05f005f05f05f005f0f00*5m0*0*5 m0m00m00m00m00m0m0m0*m0*m0TEGChol MIMAT0016875 m0*f0*0*0 hsa-miR-4324 5′Pm05f05f005f0005f0f05f000f05m0*0*5m0 m0m0m0m00m00m0m0m0m00*0*m0TEGChol MIMAT0016876 *5m0*5m0*5m0*0 hsa-miR-4325 5′Pm00005f005f00f05f0005f00*0*0*0*f0** m0m0m0m00m0m00m0m0m0m0*m0*m0TEGChol MIMAT0016887 hsa-miR-4326 5′Pm0005f05f005f05f0f05f0005f00*5m0*5m m0m0m0m00m000m0m00m0*m0*m0TEGChol MIMAT0016888 0*0*f0*5m0*0 hsa-miR-4327 5′Pm05f000f005f00f0000f00*0*0*0*f0*0*0 m0m0m0m0m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0016889 hsa-miR-4328 5′Pm05f000f05f000f005f05f05f05m0*0*5m0 m0m000m0m0m0m00m0m0m0*0*m0TEGChol MIMAT0016926 *0*5m0*0*0 hsa-miR-4329 5′Pm05f0005f005f05f0f05f000f00*5m0*0*5 m0m0m0m00m000m0m0m0m0*0*m0TEGChol MIMAT0016923 m0*5m0*5m0*0 hsa-miR-433 5′Pm05f05f005f00005f005f05f05f05m0*5m0 m0m000m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0001627 *5m0*0*f0*5m0*0 hsa-miR-4330 5′Pm005f005f0005f0f05f0005f05m0*5m0*0* m0m0m0m00m00m0m0m0m00*m0*m0TEGChol MIMAT0016924 5m0*5m0*0*0 hsa-miR-448 5′Pm05f05f00f05f0005f005f00f00*0*0*0*5m m0m0m00m0m0m0m00m0m00*0*m0TEGChol MIMAT0001532 0** hsa-miR-449a 5′Pm005f005f0005f0f05f0005f05m0*5m0*0* m0m0m0m00m00m0m0m0m00*m0*m0TEGChol MIMAT0001541 5m0*f0*5m0*0 hsa-miR-449b 5′Pm0005f05f0005f05f005f00f00*0*5m0*0* m0m0m00m0m00m0m0m00m0*m0*m0TEGChol MIMAT0003327 5m0*0*0 hsa-miR-449b* 5′Pm05f005f0f05f0005f0000f05m0*0*0*0*5 m0m0m0m0m0m0m0m00m00m0*0*m0TEGChol MIMAT0009203 m0*5m0*0 hsa-miR-449c 5′Pm0000f05f005f05f05f05f05f05f05m0*0*0 m0m0000m00m00m0m0m0*m0*m0TEGChol MIMAT0010251 *0*5m0*0*0 hsa-miR-449c* 5′Pm0005f05f05f005f05f00005f05m0*0*0*5 m0m0m0m0m0m00m00m00m0*m0*m0TEGChol MIMAT0013771 m0*f0*5m0*0 hsa-miR-450a 5′Pm0005f0f05f05f00f05f05f00f05m0*0*0*0 m0m0m000m0m000m00m0*m0*m0TEGChol MIMAT0001545 *5m0*5m0*0 hsa-miR-450b-3p 5′Pm05f005f0f05f05f05f0f05f05f05f0f00*5m m0m0000m0000m00m0*0*m0TEGChol MIMAT0004910 0*5m0*5m0*5m0*5m0*0 hsa-miR-450b-5p 5′Pm05f005f0f05f005f0f05f0005f00*0*5m0* m0m0m0m00m00m00m00m0*0*m0TEGChol MIMAT0004909 0*f0*5m0*0 hsa-miR-451 5′Pm05f05f05f05f05f05f05f0f05f05f005f05m m0m0m000m0000m000*0*m0TEGChol MIMAT0001631 0*5m0*5m0*5m0*5m0*0*0 hsa-miR-452 5′Pm0000f05f0005f00005f00*0*5m0*0*5m0 m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0001635 *5m0*0 hsa-miR-452* 5′Pm0005f05f0000f0000f00*0*5m0*0*5m0* m0m0m0m0m0m0m0m0m0m00m0*m0*m0TEGChol MIMAT0001636 5m0*0 hsa-miR-454 5′Pm005f005f0000f005f00f00*5m0*5m0*5m m0m0m00m0m0m0m0m0m0m00*m0*m0TEGChol MIMAT0003885 0*5m0*5m0*0 hsa-miR-454* 5′Pm05f05f00f05f05f05f05f05f05f05f05f00*0 m0m0000m0000m0m00*0*m0TEGChol MIMAT0003884 *5m0*5m0*f0*0*0 hsa-miR-455-3p 5′Pm00005f05f005f05f05f005f0f00*5m0*0*0 m0m00m00m00m00m0m0m0*m0*m0TEGChol MIMAT0004784 *f0*5m0*0 hsa-miR-455-5p 5′Pm05f000f0000f05f0005f05m0*0*5m0*5m m0m0m0m00m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0003150 0*f0*0*0 hsa-miR-466 5′Pm0000f005f05f0f0000f00*0*5m0*0*5m0 m0m0m0m0m0m000m0m0m0m0*m0*m0TEGChol MIMAT0015002 *0*0 hsa-miR-483-3p 5′Pm0000f05f0005f00005f05m0*0*5m0*0*5 m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0002173 m0*0*0 hsa-miR-483-5p 5′Pm05f05f00f05f000f05f005f05f05m0*0*5m m0m00m00m0m0m00m0m00*0*m0TEGChol MIMAT0004761 0*5m0*f0*0*0 hsa-miR-484 5′Pm05f05f05f0f05f005f05f05f0005f05m0*5 m0m0m0m00m00m00m000*0*m0TEGChol MIMAT0002174 m0*5m0*0*5m0*5m0*0 hsa-miR-485-3p 5′Pm0005f05f05f05f05f05f05f05f05f05f00*0 m0m0000m0000m00m0*m0*m0TEGChol MIMAT0002176 *0*0*5m0*0*0 hsa-miR-485-5p 5′Pm05f05f05f0f05f005f05f05f05f05f05f00*0 m0m0000m00m00m000*0*m0TEGChol MIMAT0002175 *0*0*5m0*0*0 hsa-miR-486-3p 5′Pm0005f05f005f00f05f05f05f05f05m0*5m0 m0m0000m0m00m0m00m0*m0*m0TEGChol MIMAT0004762 *0*0*f0*0*0 hsa-miR-486-5p 5′Pm00005f05f05f05f0f0005f0f00*0*0*0*f0* m0m00m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0002177 5m0*0 hsa-miR-487a 5′Pm005f05f05f05f000f00005f00*5m0*5m0* m0m0m0m0m0m0m0m00m000*m0*m0TEGChol MIMAT0002178 0*5m0*5m0*0 hsa-miR-487b 5′Pm0000f005f05f0f0005f05f00*5m0*5m0*5 m0m00m0m0m000m0m0m0m0*m0*m0TEGChol MIMAT0003180 m0*5m0** hsa-miR-488 5′Pm05f05f05f0f05f05f005f05f05f05f0f05m0 m0m0000m0m000m000*0*m0TEGChol MIMAT0004763 *5m0*5m0*0*5m0*0*0 hsa-miR-488* 5′Pm005f05f0f05f000f05f005f0f00*5m0*0*0 m0m00m00m0m0m00m000*m0*m0TEGChol MIMAT0002804 *5m0*5m0*0 hsa-miR-489 5′Pm0005f0f05f05f05f05f00005f00*5m0*5m m0m0m0m0m0m0000m00m0*m0*m0TEGChol MIMAT0002805 0*5m0*f0*0*0 hsa-miR-490-3p 5′Pm0005f0f0000f05f05f005f00*0*5m0*5m0 m0m0m000m0m0m0m0m00m0*m0*m0TEGChol MIMAT0002806 *f0*5m0*0 hsa-miR-490-5p 5′Pm005f05f05f05f05f005f0005f05f05m0*5m m0m00m0m0m0m000m000*m0*m0TEGChol MIMAT0004764 0*5m0*0*f0*5m0*0 hsa-miR-491-3p 5′Pm05f005f0f0000f0000f00*0*5m0*5m0*5 m0m0m0m0m0m0m0m0m0m00m0*0*m0TEGChol MIMAT0004765 m0*5m0*0 hsa-miR-491-5p 5′Pm05f0005f005f00f05f05f05f0f00*5m0*0* m0m0000m0m00m0m0m0m0*0*m0TEGChol MIMAT0002807 0*f0** hsa-miR-492 5′Pm0005f05f0005f0f05f005f05f05m0*0*5m m0m00m00m00m0m0m00m0*m0*m0TEGChol MIMAT0002812 0*0*f0*0*0 hsa-miR-493 5′Pm0005f05f0000f0005f0f00*5m0*5m0*0* m0m00m0m0m0m0m0m0m00m0*m0*m0TEGChol MIMAT0003161 5m0*0*0 hsa-miR-493* 5′Pm05f05f05f0f0005f05f0000f00*5m0*0*0* m0m0m0m0m0m00m0m0m000*0*m0TEGChol MIMAT0002813 ** hsa-miR-494 5′Pm05f05f00f05f005f0f0000f05m0*0*0*5m m0m0m0m0m0m00m00m0m00*0*m0TEGChol MIMAT0002816 0*f0*0*0 hsa-miR-495 5′Pm005f005f05f005f05f005f05f0f05m0*5m0 m0m000m0m00m00m0m00*m0*m0TEGChol MIMAT0002817 *0*5m0*5m0*0*0 hsa-miR-496 5′Pm05f0005f005f005f05f05f00f00*0*5m0*0 m0m0m000m0m00m0m0m0m0*0*m0TEGChol MIMAT0002818 *** hsa-miR-497 5′Pm05f05f05f05f05f000f0005f05f00*5m0*5 m0m00m0m0m0m0m00m000*0*m0TEGChol MIMAT0002820 m0*5m0*f0*5m0*0 hsa-miR-497* 5′Pm0005f0f05f05f05f05f00005f05m0*0*0*5 m0m0m0m0m0m0000m00m0*m0*m0TEGChol MIMAT0004768 m0*5m0*5m0*0 hsa-miR-498 5′Pm05f05f00f005f005f05f05f05f05f00*0*5m m0m0000m0m00m0m0m00*0*m0TEGChol MIMAT0002824 0*5m0*5m0** hsa-miR-499-3p 5′Pm0000f0000f00005f00*0*5m0*0*** m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEG MIMAT0004772 Chol hsa-miR-499-5p 5′Pm0005f0f005f005f00005f00*0*0*5m0*5 m0m0m0m0m0m0m00m0m00m0*m0*m0TEGChol MIMAT0002870 m0*0*0 hsa-miR-500a 5′Pm05f05f00f05f05f05f05f05f05f05f05f00*0 m0m0000m0000m0m00*0*m0TEGChol MIMAT0004773 *5m0*5m0*f0*0*0 hsa-miR-500a* 5′Pm0000f005f005f05f05f05f0f00*0*0*0*f0* m0m0000m0m00m0m0m0m0*m0*m0TEGChol MIMAT0002871 5m0*0 hsa-miR-500b 5′Pm0005f0f005f05f0f005f05f05f00*5m0*0* m0m000m0m000m0m00m0*m0*m0TEGChol MIMAT0016925 5m0*f0*0*0 hsa-miR-501-3p 5′Pm005f05f05f05f05f05f0f00005f05m0*5m0 m0m0m0m0m0m0000m000*m0*m0TEGChol MIMAT0004774 *0*5m0*f0*0*0 hsa-miR-501-5p 5′Pm005f00f05f005f05f005f005f00*0*0*0*5 m0m0m00m0m00m00m0m00*m0*m0TEGChol MIMAT0002872 m0*5m0*0 hsa-miR-502-3p 5′Pm0000f05f005f0f00005f05m0*0*0*0*f0* m0m0m0m0m0m00m00m0m0m0*m0*m0TEGChol MIMAT0004775 5m0*0 hsa-miR-502-5p 5′Pm005f05f05f005f005f00005f00*5m0*5m0 m0m0m0m0m0m0m00m0m000*m0*m0TEGChol MIMAT0002873 *5m0*f0*0*0 hsa-miR-503 5′Pm05f05f005f05f05f005f005f05f05f05m0*0 m0m000m0m0m000m0m00*0*m0TEGChol MIMAT0002874 *5m0*0*f0*5m0*0 hsa-miR-504 5′Pm005f005f05f05f005f05f005f05f00*5m0* m0m00m00m0m000m0m00*m0*m0TEGChol MIMAT0002875 5m0*0*f0*5m0*0 hsa-miR-505 5′Pm005f05f0f00005f05f05f005f00*0*0*0*f0 m0m0m000m0m0m0m0m000*m0*m0TEGChol MIMAT0002876 *5m0*0 hsa-miR-505* 5′Pm005f005f05f005f0f005f05f0f05m0*5m0* m0m000m0m00m00m0m00*m0*m0TEGChol MIMAT0004776 5m0*0*f0*0*0 hsa-miR-506 5′Pm005f05f05f05f05f00f05f005f0f00*0*0*0 m0m00m00m0m000m000*m0*m0TEGChol MIMAT0002878 *f0*5m0*0 hsa-miR-507 5′Pm05f0005f05f0005f05f05f05f05f00*5m0* m0m0000m0m0m00m0m0m0*0*m0TEGChol MIMAT0002879 5m0*5m0*5m0** hsa-miR-508-3p 5′Pm05f05f05f05f05f005f0f05f05f00f00*0*0* m0m0m000m00m00m000*0*m0TEGChol MIMAT0002880 5m0*5m0*5m0*0 hsa-miR-508-5p 5′Pm005f05f0f05f000f05f0005f00*0*5m0*0* m0m0m0m00m0m0m00m000*m0*m0TEGChol MIMAT0004778 f0*5m0*0 hsa-miR-509-3-5p 5′Pm005f005f05f05f05f05f05f05f05f05f00*5 m0m0000m0000m0m00*m0*m0TEGChol MIMAT0004975 m0*5m0*5m0*5m0*5m0* hsa-miR-509-3p 5′Pm05f000f0000f0000f05m0*5m0*5m0*0*f m0m0m0m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0002881 0*5m0*0 hsa-miR-509-5p 5′Pm005f05f05f0000f00005f00*0*5m0*0*f0 m0m0m0m0m0m0m0m0m0m000*m0*m0TEGChol MIMAT0004779 *5m0*0 hsa-miR-510 5′Pm05f05f005f005f05f0f005f05f05f00*5m0* m0m000m0m000m0m0m00*0*m0TEGChol MIMAT0002882 5m0*0*f0*0*0 hsa-miR-511 5′Pm005f05f05f05f05f05f05f005f00f05m0*0* m0m0m00m0m0000m000*m0*m0TEGChol MIMAT0002808 5m0*5m0*f0*5m0*0 hsa-miR-512-3p 5′Pm005f05f0f05f005f05f05f05f05f05f05m0* m0m0000m00m00m000*m0*m0TEGChol MIMAT0002823 5m0*5m0*5m0*5m0*0*0 hsa-miR-512-5p 5′Pm005f05f05f05f05f05f05f05f005f05f00*0 m0m00m00m0000m000*m0*m0TEGChol MIMAT0002822 *0*0*f0*5m0*0 hsa-miR-513a-3p 5′Pm005f00f05f05f00f05f05f00f05m0*5m0*0 m0m0m000m0m000m0m00*m0*m0TEGChol MIMAT0004777 *0*f0*0*0 hsa-miR-513a-5p 5′Pm05f05f05f0f05f000f05f000f00*0*5m0*5 m0m0m0m00m0m0m00m000*0*m0TEGChol MIMAT0002877 m0*5m0*5m0*0 hsa-miR-513b 5′Pm0005f05f05f000f005f05f0f05m0*5m0*0 m0m000m0m0m0m00m00m0*m0*m0TEGChol MIMAT0005788 *0*f0*0*0 hsa-miR-513c 5′Pm05f005f05f05f05f05f05f005f05f05f05m0 m0m000m0m0000m00m0*0*m0TEGChol MIMAT0005789 *0*5m0*0*f0*5m0*0 hsa-miR-514 5′Pm05f000f05f05f00f005f05f0f05m0*0*5m0 m0m000m0m0m000m0m0m0*0*m0TEGChol MIMAT0002883 *5m0*f0*5m0*0 hsa-miR-514b-3p 5′Pm05f000f0005f0f05f000f00*0*0*0*5m0* m0m0m0m00m00m0m0m0m0m0*0*m0TEGChol MIMAT0015088 5m0*0 hsa-miR-514b-5p 5′Pm05f0005f05f000f005f05f0f05m0*0*0*5 m0m000m0m0m0m00m0m0m0*0*m0TEGChol MIMAT0015087 m0*5m0*0*0 hsa-miR-515-3p 5′Pm0005f0f005f05f05f0000f00*5m0*5m0*5 m0m0m0m0m0m000m0m00m0*m0*m0TEGChol MIMAT0002827 m0*f0*5m0*0 hsa-miR-515-5p 5′Pm05f05f05f05f0000f05f05f05f05f05m0*5 m0m0000m0m0m0m0m000*0*m0TEGChol MIMAT0002826 m0*5m0*5m0*5m0** hsa-miR-516a-3p 5′Pm005f00f005f05f05f05f05f00f00*0*5m0* m0m0m000m000m0m0m00*m0*m0TEGChol MIMAT0006778 0*f0*0* hsa-miR-516a-5p 5′Pm0000f005f00f05f05f005f00*0*5m0*5m0 m0m0m000m0m00m0m0m0m0*m0*m0TEGChol MIMAT0004770 *5m0*5m0*0 hsa-miR-516b 5′Pm0000f005f05f0f05f0005f05m0*0*5m0*5 m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0002859 m0*5m0*5m0*0 hsa-miR-516b* 5′Pm05f05f05f0f05f05f05f05f005f05f05f00*5 m0m000m0m0000m000*0*m0TEGChol MIMAT0002860 m0*5m0*5m0*5m0*5m0*0 hsa-miR-517* 5′Pm05f000f005f05f05f0000f05m0*5m0*5m m0m0m0m0m0m000m0m0m0m0*0*m0TEGChol MIMAT0002851 0*5m0*f0** hsa-miR-517a 5′Pm05f05f05f05f05f05f05f0f05f005f0f00*0* m0m00m00m0000m000*0*m0TEGChol MIMAT0002852 5m0*0*5m0*5m0*0 hsa-miR-517b 5′Pm05f005f05f05f05f05f05f05f05f05f05f05 m0m0000m0000m00m0*0*m0TEGChol MIMAT0002857 m0*5m0*5m0*5m0*5m0*5m0*0 hsa-miR-517c 5′Pm05f0005f005f05f0f0005f0f05m0*0*0*5 m0m00m0m0m000m0m0m0m0*0*m0TEGChol MIMAT0002866 m0*5m0*5m0*0 hsa-miR-518a-3p 5′Pm0005f0f005f05f05f05f05f00f05m0*5m0* m0m0m000m000m0m00m0*m0*m0TEGChol MIMAT0002863 0*5m0*f0*0*0 hsa-miR-518a-5p 5′Pm05f000f005f05f05f05f05f00f00*0*5m0* m0m0m000m000m0m0m0m0*0*m0TEGChol MIMAT0005457 5m0*5m0*5m0*0 hsa-miR-518b 5′Pm05f0005f00005f005f00f00*5m0*0*0*f0 m0m0m00m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0002844 *5m0*0 hsa-miR-518c 5′Pm005f05f05f005f05f05f005f005f05m0*5m m0m0m00m0m000m0m000*m0*m0TEGChol MIMAT0002848 0*0*5m0*5m0*0*0 hsa-miR-518c* 5′Pm005f05f0f05f0005f05f005f05f05m0*5m0 m0m00m00m0m0m00m000*m0*m0TEGChol MIMAT0002847 *5m0*0*5m0*0*0 hsa-miR-518d-3p 5′Pm05f0005f05f05f005f00005f05m0*0*0*5 m0m0m0m0m0m0m000m0m0m0*0*m0TEGChol MIMAT0002864 m0*f0*0*0 hsa-miR-518d-5p 5′Pm005f005f00005f0005f0f00*5m0*5m0*0 m0m00m0m0m0m0m0m0m0m00*m0*m0TEGChol MIMAT0005456 *5m0*0*0 hsa-miR-518e 5′Pm005f00f05f05f05f05f05f05f005f05m0*5 m0m0m000m0000m0m00*m0*m0TEGChol MIMAT0002861 m0*5m0*5m0*f0*5m0*0 hsa-miR-518e* 5′Pm005f005f005f05f0f05f0005f05m0*0*5m m0m0m0m00m000m0m0m00*m0*m0TEGChol MIMAT0005450 0*5m0*5m0*5m0*0 hsa-miR-518f 5′Pm0005f05f05f05f00f05f05f00f05m0*0*0* m0m0m000m0m000m00m0*m0*m0TEGChol MIMAT0002842 5m0*5m0*0*0 hsa-miR-518f* 5′Pm0005f05f005f00f0005f05f05m0*0*0*0*f m0m00m0m0m0m00m0m00m0*m0*m0TEGChol MIMAT0002841 0*5m0* hsa-miR-519a 5′Pm0005f05f05f05f05f0f05f000f05m0*0*0* m0m0m0m00m0000m00m0*m0*m0TEGChol MIMAT0002869 0*5m0*0*0 hsa-miR-519a* 5′Pm00005f05f05f05f0f05f0005f00*5m0*5m m0m0m0m00m0000m0m0m0*m0*m0TEGChol MIMAT0005452 0*5m0*5m0*5m0*0 hsa-miR-519b-3p 5′Pm005f05f0f05f005f05f0000f00*5m0*5m0 m0m0m0m0m0m00m00m000*m0*m0TEGChol MIMAT0002837 *0*f0*5m0*0 hsa-miR-519b-5p 5′Pm0005f05f005f05f0f0000f05m0*5m0*0*0 m0m0m0m0m0m000m0m00m0*m0*m0TEGChol MIMAT0005454 *f0*0*0 hsa-miR-519c-3p 5′Pm05f005f0f05f05f05f0f005f05f05f00*0*5 m0m000m0m0000m00m0*0*m0TEGChol MIMAT0002832 m0*5m0*f0*5m0*0 hsa-miR-519c-5p 5′Pm05f05f05f0f0005f05f05f000f05m0*5m0* m0m0m0m00m00m0m0m000*0*m0TEGChol MIMAT0002831 5m0*0*5m0*0*0 hsa-miR-519d 5′Pm05f0005f05f05f05f0f05f05f00f00*5m0*0 m0m0m000m0000m0m0m0*0*m0TEGChol MIMAT0002853 *5m0*5m0*0*0 hsa-miR-519e 5′Pm05f05f05f05f0005f05f005f05f0f00*0*0* m0m000m0m00m0m0m000*0*m0TEGChol MIMAT0002829 0*5m0*0*0 hsa-miR-519e* 5′Pm005f05f05f05f005f0f0005f05f00*5m0*5 m0m00m0m0m00m00m000*m0*m0TEGChol MIMAT0002828 m0*0*5m0*0*0 hsa-miR-520a-3p 5′Pm005f00f00005f05f000f00*5m0*5m0*0* m0m0m0m00m0m0m0m0m0m00*m0*m0TEGChol MIMAT0002834 5m0*0*0 hsa-miR-520a-5p 5′Pm0000f05f0005f005f05f0f00*0*0*5m0*f0 m0m000m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0002833 *0*0 hsa-miR-520b 5′Pm005f00f05f05f05f05f05f05f005f05m0*5 m0m0m000m0000m0m00*m0*m0TEGChol MIMAT0002843 m0*5m0*5m0*f0*5m0*0 hsa-miR-520c-3p 5′Pm05f005f0f00005f05f000f00*0*5m0*5m0 m0m0m0m00m0m0m0m0m00m0*0*m0TEGChol MIMAT0002846 *f0*5m0*0 hsa-miR-520c-5p 5′Pm00005f005f05f05f05f05f05f05f05m0*0* m0m0000m000m0m0m0m0*m0*m0TEGChol MIMAT0005455 5m0*5m0*5m0*5m0*0 hsa-miR-520d-3p 5′Pm05f05f05f05f005f05f05f005f05f05f05m0 m0m000m0m000m0m000*0*m0TEGChol MIMAT0002856 *0*0*5m0*f0*0*0 hsa-miR-520d-5p 5′Pm0000f05f05f05f05f05f000f05m0*5m0*5 m0m0m0m00m0000m0m0m0*m0*m0TEGChol MIMAT0002855 m0*5m0*f0*0*0 hsa-miR-520e 5′Pm005f05f0f05f05f005f05f05f05f0f00*0*5 m0m0000m0m000m000*m0*m0TEGChol MIMAT0002825 m0*0*f0*0*0 hsa-miR-520f 5′Pm0000f0000f05f05f00f00*5m0*5m0*5m0 m0m0m000m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0002830 *f0*5m0*0 hsa-miR-520g 5′Pm005f00f05f05f05f05f005f05f0f00*0*5m0 m0m000m0m0000m0m00*m0*m0TEGChol MIMAT0002858 *0*5m0*5m0*0 hsa-miR-520h 5′Pm00005f05f000f05f05f05f0f00*0*5m0*0* m0m0000m0m0m00m0m0m0*m0*m0TEGChol MIMAT0002867 5m0*5m0*0 hsa-miR-521 5′Pm0000f0000f0005f05f00*0*5m0*5m0*5 m0m00m0m0m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0002854 m0*0*0 hsa-miR-522 5′Pm00005f05f005f0f005f05f0f00*0*5m0*0* m0m000m0m00m00m0m0m0*m0*m0TEGChol MIMAT0002868 5m0*5m0*0 hsa-miR-522* 5′Pm00005f05f000f05f005f0f05m0*0*5m0*5 m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0005451 m0*f0*0*0 hsa-miR-523 5′Pm05f005f05f005f05f05f0000f00*5m0*0*5 m0m0m0m0m0m000m0m00m0*0*m0TEGChol MIMAT0002840 m0*f0*5m0*0 hsa-miR-523* 5′Pm05f000f0005f05f05f05f05f05f00*0*0*0* m0m0000m00m0m0m0m0m0*0*m0TEGChol MIMAT0005449 5m0*5m0*0 hsa-miR-524-3p 5′Pm0005f05f005f05f05f00005f00*5m0*0*0 m0m0m0m0m0m000m0m00m0*m0*m0TEGChol MIMAT0002850 *5m0*5m0*0 hsa-miR-524-5p 5′Pm05f05f00f05f005f05f005f005f00*5m0*5 m0m0m00m0m00m00m0m00*0*m0TEGChol MIMAT0002849 m0*0*f0*0*0 hsa-miR-525-3p 5′Pm0005f05f005f05f0f005f05f0f00*0*0*0*f m0m000m0m000m0m00m0*m0*m0TEGChol MIMAT0002839 0*5m0*0 hsa-miR-525-5p 5′Pm0005f0f05f05f005f05f005f0f00*5m0*5m m0m00m00m0m000m00m0*m0*m0TEGChol MIMAT0002838 0*0*f0*0*0 hsa-miR-526a 5′Pm05f05f00f005f00f0005f05f05m0*5m0*5 m0m00m0m0m0m00m0m0m00*0*m0TEGChol MIMAT0002845 m0*0*f0*0*0 hsa-miR-526b 5′Pm005f05f05f0005f05f05f05f00f00*0*0*5 m0m0m000m00m0m0m000*m0*m0TEGChol MIMAT0002835 m0*f0*5m0*0 hsa-miR-526b* 5′Pm005f05f05f05f05f05f0f005f00f05m0*0*0 m0m0m00m0m0000m000*m0*m0TEGChol MIMAT0002836 *0*5m0*5m0*0 hsa-miR-527 5′Pm0005f0f005f00f00005f05m0*5m0*0*5m m0m0m0m0m0m0m00m0m00m0*m0*m0TEGChol MIMAT0002862 0*5m0*5m0*0 hsa-miR-532-3p 5′Pm005f05f05f0000f005f05f0f00*0*0*5m0* m0m000m0m0m0m0m0m000*m0*m0TEGChol MIMAT0004780 5m0*5m0*0 hsa-miR-532-5p 5′Pm005f005f05f000f005f00f00*0*0*0*f0*0 m0m0m00m0m0m0m00m0m00*m0*m0TEGChol MIMAT0002888 *0 hsa-miR-539 5′Pm00005f05f005f05f05f05f005f00*0*0*0* m0m0m000m00m00m0m0m0*m0*m0TEGChol MIMAT0003163 5m0*5m0*0 hsa-miR-541 5′Pm005f00f0000f00005f00*0*0*5m0*5m0* m0m0m0m0m0m0m0m0m0m0m00*m0*m0TEGChol MIMAT0004920 5m0*0 hsa-miR-541* 5′Pm005f005f00005f05f05f05f0f00*0*0*0*f0 m0m0000m0m0m0m0m0m00*m0*m0TEGChol MIMAT0004919 *0*0 hsa-miR-542-3p 5′Pm00005f05f05f05f0f05f05f05f05f05m0*5 m0m0000m0000m0m0m0*m0*m0TEGChol MIMAT0003389 m0*5m0*0*f0*0*0 hsa-miR-542-5p 5′Pm0005f0f05f005f0f005f005f00*0*0*5m0* m0m0m00m0m00m00m00m0*m0*m0TEGChol MIMAT0003340 f0*5m0*0 hsa-miR-543 5′Pm05f05f00f0005f05f0005f05f05m0*5m0* m0m00m0m0m00m0m0m0m00*0*m0TEGChol MIMAT0004954 0*0*5m0*0*0 hsa-miR-544 5′Pm0005f0f0000f0005f05f00*0*0*0*f0*0*0 m0m00m0m0m0m0m0m0m00m0*m0*m0TEGChol MIMAT0003164 hsa-miR-544b 5′Pm005f05f0f0005f0f005f00f00*0*0*0*f0*0 m0m0m00m0m00m0m0m000*m0*m0TEGChol MIMAT0015004 *0 hsa-miR-545 5′Pm0000f005f05f0f0000f00*5m0*0*0*f0*0 m0m0m0m0m0m000m0m0m0m0*m0*m0TEGChol MIMAT0003165 *0 hsa-miR-545* 5′Pm05f000f0000f00005f00*0*5m0*5m0*5 m0m0m0m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0004785 m0*5m0*0 hsa-miR-548a-3p 5′Pm0000f05f0005f05f005f0f00*5m0*5m0*5 m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0003251 m0*5m0*5m0*0 hsa-miR-548a-5p 5′Pm0000f005f05f0f05f0005f05m0*0*5m0*5 m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0004803 m0*5m0*5m0*0 hsa-miR-548aa 5′Pm05f05f005f0000f00005f00*5m0*5m0*0 m0m0m0m0m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0018447 *5m0** hsa-miR-548b-3p 5′Pm05f0005f005f05f05f005f005f05m0*5m0 m0m0m00m0m000m0m0m0m0*0*m0TEGChol MIMAT0003254 *5m0**** hsa-miR-548b-5p 5′Pm0000f05f0005f05f005f05f00*5m0*5m0* m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0004798 5m0*5m0*5m0*0 hsa-miR-548c-3p 5′Pm0000f0000f05f05f00f00*5m0*0*5m0*f0 m0m0m000m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0003285 ** hsa-miR-548c-5p 5′Pm0000f005f05f0f05f0005f05m0*0*5m0*5 m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0004806 m0*5m0*5m0*0 hsa-miR-548d-3p 5′Pm0005f0f005f05f0f05f000f05m0*0*0*0*5 m0m0m0m00m000m0m00m0*m0*m0TEGChol MIMAT0003323 m0*5m0*0 hsa-miR-548d-5p 5′Pm005f005f05f05f00f0000f00*5m0*0*0*f0 m0m0m0m0m0m0m000m0m00*m0*m0TEGChol MIMAT0004812 *0*0 hsa-miR-548e 5′Pm0000f05f005f05f05f05f05f05f05m0*5m0 m0m0000m00m00m0m0m0*m0*m0TEGChol MIMAT0005874 *5m0*5m0*f0*5m0*0 hsa-miR-548f 5′Pm05f05f005f0000f00005f00*5m0*5m0*0 m0m0m0m0m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0005895 *5m0*5m0*0 hsa-miR-548g 5′Pm0000f0000f00005f00*0*5m0*5m0*f0*0 m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEG MIMAT0005912 *0 Chol hsa-miR-548h 5′Pm005f05f05f05f005f05f05f05f05f05f05m0 m0m0000m00m00m000*m0*m0TEGChol MIMAT0005928 *0*0*0*5m0*0*0 hsa-miR-548i 5′Pm05f05f05f0f05f05f05f05f05f05f05f0f00* m0m0000m0000m000*0*m0TEGChol MIMAT0005935 0*5m0*0*5m0*5m0*0 hsa-miR-548j 5′Pm05f0005f05f05f005f05f05f05f05f00*0*5 m0m0000m0m000m0m0m0*0*m0TEGChol MIMAT0005875 m0*5m0*5m0*5m0*0 hsa-miR-548k 5′Pm005f05f05f05f005f05f05f05f05f0f05m0* m0m0000m00m00m000*m0*m0TEGChol MIMAT0005882 5m0*5m0*5m0*5m0*0* hsa-miR-548l 5′Pm005f05f05f05f05f05f0f005f05f05f05m0* m0m000m0m0000m000*m0*m0TEGChol MIMAT0005889 0*0*0*5m0*5m0*0 hsa-miR-548m 5′Pm05f05f05f05f0000f00005f00*5m0*5m0* m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0005917 0*5m0*5m0*0 hsa-miR-548n 5′Pm0005f0f05f05f05f0f05f05f05f05f05m0*0 m0m0000m0000m00m0*m0*m0TEGChol MIMAT0005916 *5m0*5m0*f0*0*0 hsa-miR-548o 5′Pm05f05f05f0f0000f005f00f00*0*5m0*0*f m0m0m00m0m0m0m0m0m000*0*m0TEGChol MIMAT0005919 0** hsa-miR-548p 5′Pm05f05f00f005f05f05f00005f05m0*5m0* m0m0m0m0m0m000m0m0m00*0*m0TEGChol MIMAT0005934 5m0*5m0*5m0*5m0*0 hsa-miR-548q 5′Pm05f05f00f05f005f05f05f05f05f0f05m0*0 m0m0000m00m00m0m00*0*m0TEGChol MIMAT0011163 *0*0*5m0*0*0 hsa-miR-548s 5′Pm05f05f05f0f0005f05f00005f00*0*0*5m0 m0m0m0m0m0m00m0m0m000*0*m0TEGChol MIMAT0014987 *f0*0*0 hsa-miR-548t 5′Pm0000f05f05f05f05f05f0005f00*5m0*5m m0m0m0m00m0000m0m0m0*m0*m0TEGChol MIMAT0015009 0*5m0*f0*0*0 hsa-miR-548u 5′Pm05f0005f05f05f005f005f05f05f00*0*5m m0m000m0m0m000m0m0m0*0*m0TEGChol MIMAT0015013 0*5m0*5m0*5m0*0 hsa-miR-548v 5′Pm005f05f0f05f005f05f005f05f05f00*5m0* m0m000m0m00m00m000*m0*m0TEGChol MIMAT0015020 5m0*0*f0*0*0 hsa-miR-548w 5′Pm00005f05f000f05f005f0f00*0*5m0*0*f0 m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0015060 *0*0 hsa-miR-548x 5′Pm005f00f005f00f05f05f00f05m0*5m0*0* m0m0m000m0m00m0m0m00*m0*m0TEGChol MIMAT0015081 0*f0*5m0*0 hsa-miR-548y 5′Pm05f05f00f05f005f05f05f05f05f0f05m0*0 m0m0000m00m00m0m00*0*m0TEGChol MIMAT0018354 *0*0*5m0*0*0 hsa-miR-548z 5′Pm00005f0005f0f00005f05m0*5m0*5m0* m0m0m0m0m0m00m0m0m0m0m0*m0*m0TEGChol MIMAT0018446 0*5m0*5m0*0 hsa-miR-549 5′Pm05f05f05f05f0000f0000f00*0*5m0*0*f0 m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0003333 *5m0*0 hsa-miR-550a 5′Pm05f05f00f05f05f05f05f0005f05f05m0*0* m0m00m0m0m0000m0m00*0*m0TEGChol MIMAT0004800 0*5m0*5m0*0*0 hsa-miR-550a* 5′Pm05f005f0f005f05f05f05f005f0f05m0*0*0 m0m00m00m000m0m00m0*0*m0TEGChol MIMAT0003257 *5m0*f0*5m0*0 hsa-miR-550b 5′Pm05f000f05f005f05f05f000f05m0*5m0*5 m0m0m0m00m00m00m0m0m0*0*m0TEGChol MIMAT0018445 m0*5m0*5m0*0*0 hsa-miR-551a 5′Pm05f05f00f05f005f05f05f0005f00*0*0*5 m0m0m0m00m00m00m0m00*0*m0TEGChol MIMAT0003214 m0*f0*5m0*0 hsa-miR-551b 5′Pm05f05f00f05f0005f0005f0f00*0*0*5m0* m0m00m0m0m0m0m00m0m00*0*m0TEGChol MIMAT0003233 5m0*5m0*0 hsa-miR-551b* 5′Pm00005f00005f05f000f05m0*5m0*5m0* m0m0m0m00m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0004794 5m0*5m0*0*0 hsa-miR-552 5′Pm0005f0f05f05f05f05f05f05f05f05f05m0* m0m0000m0000m00m0*m0*m0TEGChol MIMAT0003215 0*0*0*f0*5m0*0 hsa-miR-553 5′Pm05f05f00f05f05f05f0f0000f00*0*0*5m0 m0m0m0m0m0m0000m0m00*0*m0TEGChol MIMAT0003216 *5m0*5m0*0 hsa-miR-554 5′Pm005f05f0f005f005f05f005f0f00*0*5m0* m0m00m00m0m00m0m000*m0*m0TEGChol MIMAT0003217 5m0*f0*0*0 hsa-miR-555 5′Pm005f05f0f05f05f00f0000f05m0*5m0*5m m0m0m0m0m0m0m000m000*m0*m0TEGChol MIMAT0003219 0*0*f0*0*0 hsa-miR-556-3p 5′Pm0005f05f05f05f00f005f05f05f00*5m0*5 m0m000m0m0m000m00m0*m0*m0TEGChol MIMAT0004793 m0*0*f0*5m0*0 hsa-miR-556-5p 5′Pm0000f0000f05f05f00f05m0*0*5m0*0*5 m0m0m000m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0003220 m0*0*0 hsa-miR-557 5′Pm05f05f05f05f05f000f05f005f0f00*5m0*5 m0m00m00m0m0m00m000*0*m0TEGChol MIMAT0003221 m0*5m0*5m0*0*0 hsa-miR-558 5′Pm0005f05f05f05f05f0f0005f05f05m0*5m0 m0m00m0m0m0000m00m0*m0*m0TEGChol MIMAT0003222 *0*0*5m0*0*0 hsa-miR-559 5′Pm05f05f05f0f00005f05f05f05f05f05m0*0* m0m0000m0m0m0m0m000*0*m0TEGChol MIMAT0003223 0*5m0*f0*0*0 hsa-miR-561 5′Pm05f005f05f005f05f0f05f05f00f05m0*5m m0m0m000m000m0m00m0*0*m0TEGChol MIMAT0003225 0*5m0*0*5m0*5m0*0 hsa-miR-562 5′Pm05f005f05f05f05f05f05f00005f05m0*0* m0m0m0m0m0m0000m00m0*0*m0TEGChol MIMAT0003226 0*0*5m0** hsa-miR-563 5′Pm05f000f005f05f0f05f000f05m0*0*0*0*f m0m0m0m00m000m0m0m0m0*0*m0TEGChol MIMAT0003227 0*0*0 hsa-miR-564 5′Pm005f00f0005f05f0005f05f00*0*5m0*0* m0m00m0m0m00m0m0m0m00*m0*m0TEGChol MIMAT0003228 ** hsa-miR-566 5′Pm05f005f05f05f000f05f05f05f0f00*0*0*0 m0m0000m0m0m00m00m0*0*m0TEGChol MIMAT0003230 *5m0*5m0*0 hsa-miR-567 5′Pm005f00f05f0005f0005f0f00*5m0*0*0*f0 m0m00m0m0m0m0m00m0m00*m0*m0TEGChol MIMAT0003231 *5m0*0 hsa-miR-568 5′Pm05f000f00005f0000f00*0*5m0*5m0*5 m0m0m0m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0003232 m0*0*0 hsa-miR-569 5′Pm05f05f05f05f05f0005f05f05f05f05f05m0 m0m0000m0m0m00m000*0*m0TEGChol MIMAT0003234 *0*5m0*0*f0*5m0*0 hsa-miR-570 5′Pm005f05f05f005f05f0f05f005f0f05m0*5m m0m00m00m000m0m000*m0*m0TEGChol MIMAT0003235 0*0*0*f0*0*0 hsa-miR-571 5′Pm05f005f05f0000f05f05f05f05f05m0*0*0 m0m0000m0m0m0m0m00m0*0*m0TEGChol MIMAT0003236 *0*f0*0*0 hsa-miR-572 5′Pm05f05f00f05f005f05f05f05f05f05f05m0* m0m0000m00m00m0m00*0*m0TEGChol MIMAT0003237 5m0*5m0*5m0*5m0** hsa-miR-573 5′Pm05f05f05f05f05f000f0000f00*0*5m0*0* m0m0m0m0m0m0m0m00m000*0*m0TEGChol MIMAT0003238 5m0*5m0*0 hsa-miR-574-3p 5′Pm05f05f005f005f00f005f005f00*5m0*0*5 m0m0m00m0m0m00m0m0m00*0*m0TEGChol MIMAT0003239 m0*f0*5m0*0 hsa-miR-574-5p 5′Pm005f05f05f05f05f05f05f05f05f00f00*0* m0m0m000m0000m000*m0*m0TEGChol MIMAT0004795 0*0*5m0** hsa-miR-575 5′Pm05f05f05f05f0000f0000f00*0*0*5m0*f0 m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0003240 *5m0*0 hsa-miR-576-3p 5′Pm005f05f0f005f00f005f05f05f05m0*0*0* m0m000m0m0m00m0m000*m0*m0TEGChol MIMAT0004796 0*f0*0*0 hsa-miR-576-5p 5′Pm05f000f05f005f05f05f000f05m0*0*5m0 m0m0m0m00m00m00m0m0m0*0*m0TEGChol MIMAT0003241 *0*5m0*0*0 hsa-miR-577 5′Pm0005f05f05f05f05f05f005f05f05f00*0*0 m0m000m0m0000m00m0*m0*m0TEGChol MIMAT0003242 *0*f0*5m0*0 hsa-miR-578 5′Pm05f005f05f005f05f05f00005f00*0*0*5m m0m0m0m0m0m000m0m00m0*0*m0TEGChol MIMAT0003243 0*f0*0*0 hsa-miR-579 5′Pm05f05f05f0f005f005f005f00f05m0*0*5m m0m0m00m0m0m00m0m000*0*m0TEGChol MIMAT0003244 0*0*f0*0*0 hsa-miR-580 5′Pm005f05f05f00005f05f05f05f05f00*0*5m m0m0000m0m0m0m0m000*m0*m0TEGChol MIMAT0003245 0*5m0*5m0*0*0 hsa-miR-581 5′Pm0000f05f005f0f005f00f05m0*0*0*5m0* m0m0m00m0m00m00m0m0m0*m0*m0TEGChol MIMAT0003246 f0*5m0*0 hsa-miR-582-3p 5′Pm05f05f05f0f0000f05f000f00*0*0*5m0*f m0m0m0m00m0m0m0m0m000*0*m0TEGChol MIMAT0004797 0*5m0*0 hsa-miR-582-5p 5′Pm005f05f0f05f005f05f05f0005f05m0*0*5 m0m0m0m00m00m00m000*m0*m0TEGChol MIMAT0003247 m0*5m0*f0*0*0 hsa-miR-583 5′Pm05f05f00f05f005f05f0005f0f05m0*0*5m m0m00m0m0m00m00m0m00*0*m0TEGChol MIMAT0003248 0*5m0*5m0*5m0*0 hsa-miR-584 5′Pm0000f05f0005f00005f05m0*0*0*0*5m0 m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0003249 ** hsa-miR-585 5′Pm05f05f00f05f05f005f05f05f05f0f00*5m0 m0m0000m0m000m0m00*0*m0TEGChol MIMAT0003250 *5m0*5m0*5m0*5m0*0 hsa-miR-586 5′Pm05f05f00f05f0005f05f0005f00*5m0*0*0 m0m0m0m00m0m0m00m0m00*0*m0TEGChol MIMAT0003252 *f0*5m0*0 hsa-miR-587 5′Pm05f000f0000f05f05f05f05f05m0*0*0*0* m0m0000m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0003253 f0*5m0*0 hsa-miR-588 5′Pm05f005f05f005f05f0f0000f00*5m0*5m0 m0m0m0m0m0m000m0m00m0*0*m0TEGChol MIMAT0003255 *5m0*** hsa-miR-589 5′Pm005f05f0f05f000f05f005f0f05m0*0*5m0 m0m00m00m0m0m00m000*m0*m0TEGChol MIMAT0004799 *5m0*** hsa-miR-589* 5′Pm005f00f005f05f05f005f05f0f05m0*0*0* m0m000m0m000m0m0m00*m0*m0TEGChol MIMAT0003256 5m0*f0*5m0*0 hsa-miR-590-3p 5′Pm0000f00005f05f005f05f00*0*0*0*5m0* m0m00m00m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0004801 5m0*0 hsa-miR-590-5p 5′Pm005f05f0f005f05f05f005f05f0f00*0*5m0 m0m000m0m000m0m000*m0*m0TEGChol MIMAT0003258 *0*5m0*5m0*0 hsa-miR-591 5′Pm0000f005f005f05f05f05f0f05m0*0*0*5 m0m0000m0m00m0m0m0m0*m0*m0TEGChol MIMAT0003259 m0*f0*5m0*0 hsa-miR-592 5′Pm005f00f0005f0f005f00f00*0*5m0*5m0* m0m0m00m0m00m0m0m0m00*m0*m0TEGChol MIMAT0003260 f0*0*0 hsa-miR-593 5′Pm005f005f005f05f05f0005f0f00*0*5m0*5 m0m00m0m0m000m0m0m00*m0*m0TEGChol MIMAT0004802 m0*f0*0*0 hsa-miR-593* 5′Pm05f05f05f05f00005f0000f05m0*5m0*0* m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0003261 5m0*** hsa-miR-595 5′Pm05f05f05f0f00005f00005f05m0*0*5m0* m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0003263 5m0*f0*0*0 hsa-miR-596 5′Pm00005f05f005f05f0005f0f00*5m0*5m0* m0m00m0m0m00m00m0m0m0*m0*m0TEGChol MIMAT0003264 5m0*5m0*0*0 hsa-miR-597 5′Pm005f005f05f000f005f00f00*0*0*5m0*f0 m0m0m00m0m0m0m00m0m00*m0*m0TEGChol MIMAT0003265 *0*0 hsa-miR-598 5′Pm005f00f05f005f05f0005f0f00*0*0*5m0* m0m00m0m0m00m00m0m00*m0*m0TEGChol MIMAT0003266 5m0*5m0*0 hsa-miR-599 5′Pm05f000f05f05f005f05f000f00*0*0*5m0* m0m0m0m00m0m000m0m0m0*0*m0TEGChol MIMAT0003267 5m0*0*0 hsa-miR-600 5′Pm05f000f05f0005f05f05f05f05f05m0*5m0 m0m0000m0m0m00m0m0m0*0*m0TEGChol MIMAT0003268 *0*5m0*f0*5m0*0 hsa-miR-601 5′Pm05f05f05f05f00005f005f05f0f05m0*0*5 m0m000m0m0m0m0m0m000*0*m0TEGChol MIMAT0003269 m0*0*5m0*5m0*0 hsa-miR-602 5′Pm05f05f05f0f05f005f0f0005f0f00*0*5m0* m0m00m0m0m00m00m000*0*m0TEGChol MIMAT0003270 5m0*5m0*5m0*0 hsa-miR-603 5′Pm05f000f005f005f005f05f05f00*5m0*0*0 m0m000m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0003271 *5m0*0*0 hsa-miR-604 5′Pm00005f05f05f05f0f05f0005f05m0*5m0* m0m0m0m00m0000m0m0m0*m0*m0TEGChol MIMAT0003272 5m0*5m0*5m0** hsa-miR-605 5′Pm05f05f00f05f05f05f05f0005f05f05m0*0* m0m00m0m0m0000m0m00*0*m0TEGChol MIMAT0003273 0*5m0*5m0*5m0*0 hsa-miR-606 5′Pm005f05f05f05f05f05f05f05f05f00f00*0* m0m0m000m0000m000*m0*m0TEGChol MIMAT0003274 0*0*5m0** hsa-miR-607 5′Pm0000f00005f00005f00*0*0*0*f0*5m0*0 m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEG MIMAT0003275 Chol hsa-miR-608 5′Pm00005f05f005f05f005f005f05m0*0*0*0 m0m0m00m0m00m00m0m0m0*m0*m0TEGChol MIMAT0003276 *f0*5m0* hsa-miR-609 5′Pm05f05f005f05f05f05f0f05f0005f00*5m0* m0m0m0m00m0000m0m00*0*m0TEGChol MIMAT0003277 5m0*0*f0*0*0 hsa-miR-610 5′Pm05f05f05f05f00005f0000f00*5m0*0*5m m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0003278 0*5m0*0*0 hsa-miR-611 5′Pm0000f0000f0005f05f00*0*0*0*f0*5m0*0 m0m00m0m0m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0003279 hsa-miR-612 5′Pm05f0005f0005f0f0005f05f00*5m0*5m0* m0m00m0m0m00m0m0m0m0m0*0*m0TEGChol MIMAT0003280 5m0*5m0*0*0 hsa-miR-613 5′Pm00005f0005f0f05f05f05f05f00*0*5m0*0 m0m0000m00m0m0m0m0m0*m0*m0TEGChol MIMAT0003281 *f0*5m0*0 hsa-miR-614 5′Pm05f05f005f05f05f05f0f05f0005f00*5m0* m0m0m0m00m0000m0m00*0*m0TEGChol MIMAT0003282 5m0*0*f0*0*0 hsa-miR-615-3p 5′Pm0000f05f005f0f005f05f0f05m0*0*0*0*f m0m000m0m00m00m0m0m0*m0*m0TEGChol MIMAT0003283 0*5m0*0 hsa-miR-615-5p 5′Pm005f05f0f005f00f05f005f05f00*0*0*5m m0m00m00m0m00m0m000*m0*m0TEGChol MIMAT0004804 0*5m0*0*0 hsa-miR-616 5′Pm05f05f005f005f005f05f05f05f05f05m0*5 m0m0000m0m00m0m0m00*0*m0TEGChol MIMAT0004805 m0*0*0*f0*0*0 hsa-miR-616* 5′Pm0000f05f005f0f005f05f05f05m0*0*5m0 m0m000m0m00m00m0m0m0*m0*m0TEGChol MIMAT0003284 *5m0*f0*0*0 hsa-miR-617 5′Pm0005f0f005f00f0005f0f00*0*0*5m0*5m m0m00m0m0m0m00m0m00m0*m0*m0TEGChol MIMAT0003286 0*5m0*0 hsa-miR-618 5′Pm05f05f005f0005f0f05f005f0f05m0*0*5m m0m00m00m00m0m0m0m00*0*m0TEGChol MIMAT0003287 0*5m0*5m0*5m0*0 hsa-miR-619 5′Pm005f05f05f005f005f05f0005f00*0*0*0*f m0m0m0m00m0m00m0m000*m0*m0TEGChol MIMAT0003288 0*0*0 hsa-miR-620 5′Pm0005f05f05f05f005f05f05f005f05m0*5m m0m0m000m0m000m00m0*m0*m0TEGChol MIMAT0003289 0*5m0*5m0*5m0*5m0*0 hsa-miR-621 5′Pm05f005f0f05f005f05f05f05f05f05f05m0* m0m0000m00m00m00m0*0*m0TEGChol MIMAT0003290 0*0*0*f0*5m0*0 hsa-miR-622 5′Pm05f0005f00005f00005f05m0*0*0*5m0* m0m0m0m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0003291 f0*5m0*0 hsa-miR-623 5′Pm05f05f005f00005f005f05f0f00*0*0*0*5 m0m000m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0003292 m0*0*0 hsa-miR-624 5′Pm05f05f005f005f005f05f05f05f05f05m0*5 m0m0000m0m00m0m0m00*0*m0TEGChol MIMAT0004807 m0*0*0*f0*0*0 hsa-miR-624* 5′Pm05f005f05f05f05f005f005f05f05f05m0*0 m0m000m0m0m000m00m0*0*m0TEGChol MIMAT0003293 *5m0*0*5m0*5m0*0 hsa-miR-625 5′Pm05f05f05f0f05f005f05f005f00f05m0*5m m0m0m00m0m00m00m000*0*m0TEGChol MIMAT0003294 0*5m0*0*f0*5m0*0 hsa-miR-625* 5′Pm005f00f005f05f0f00005f05m0*5m0*0*5 m0m0m0m0m0m000m0m0m00*m0*m0TEGChol MIMAT0004808 m0*f0*0*0 hsa-miR-626 5′Pm05f005f0f05f005f0f05f005f0f00*5m0*5 m0m00m00m00m00m00m0*0*m0TEGChol MIMAT0003295 m0*0*5m0*5m0*0 hsa-miR-627 5′Pm05f005f05f05f0005f05f05f05f05f05m0*0 m0m0000m0m0m00m00m0*0*m0TEGChol MIMAT0003296 *5m0*0*5m0*5m0*0 hsa-miR-628-3p 5′Pm0000f05f000f05f005f0f05m0*0*5m0*5 m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0003297 m0*f0*0*0 hsa-miR-628-5p 5′Pm0005f0f005f005f05f05f05f0f05m0*5m0* m0m0000m0m00m0m00m0*m0*m0TEGChol MIMAT0004809 5m0*0*f0*5m0*0 hsa-miR-629 5′Pm00005f005f00f00005f05m0*5m0*0*0*f m0m0m0m0m0m0m00m0m0m0m0*m0*m0TEGChol MIMAT0004810 0*5m0*0 hsa-miR-629* 5′Pm005f00f05f000f005f00f00*0*5m0*5m0* m0m0m00m0m0m0m00m0m00*m0*m0TEGChol MIMAT0003298 5m0*5m0*0 hsa-miR-630 5′Pm00005f0000f0005f05f00*0*5m0*0*f0*0 m0m00m0m0m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0003299 *0 hsa-miR-631 5′Pm05f005f05f05f000f05f05f05f05f05m0*0* m0m0000m0m0m00m00m0*0*m0TEGChol MIMAT0003300 5m0*0*5m0*5m0*0 hsa-miR-632 5′Pm005f005f05f005f05f005f05f0f05m0*0*5 m0m000m0m00m00m0m00*m0*m0TEGChol MIMAT0003302 m0*5m0*f0*0*0 hsa-miR-633 5′Pm05f000f05f05f05f05f005f00f05m0*0*0* m0m0m00m0m0000m0m0m0*0*m0TEGChol MIMAT0003303 0*f0*0*0 hsa-miR-634 5′Pm005f005f00005f05f000f05m0*0*5m0*5 m0m0m0m00m0m0m0m0m0m00*m0*m0TEGChol MIMAT0003304 m0*f0*5m0*0 hsa-miR-635 5′Pm0005f0f05f000f00005f05m0*0*0*0*5m m0m0m0m0m0m0m0m00m00m0*m0*m0TEGChol MIMAT0003305 0*0*0 hsa-miR-636 5′Pm005f05f0f05f000f005f00f00*0*5m0*5m m0m0m00m0m0m0m00m000*m0*m0TEGChol MIMAT0003306 0*f0*5m0*0 hsa-miR-637 5′Pm0000f05f05f05f0f0000f05m0*0*0*0*f0* m0m0m0m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0003307 0*0 hsa-miR-638 5′Pm005f05f05f00005f005f005f05m0*5m0*0 m0m0m00m0m0m0m0m0m000*m0*m0TEGChol MIMAT0003308 *5m0*f0*5m0*0 hsa-miR-639 5′Pm0000f0000f00005f00*0*5m0*5m0*5m0 m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEG MIMAT0003309 *5m0*0 Chol hsa-miR-640 5′Pm05f005f0f0005f05f05f0005f00*5m0*0*5 m0m0m0m00m00m0m0m00m0*0*m0TEGChol MIMAT0003310 m0*f0*0*0 hsa-miR-641 5′Pm05f000f0005f05f05f005f0f00*0*5m0*5 m0m00m00m00m0m0m0m0m0*0*m0TEGChol MIMAT0003311 m0*5m0*5m0*0 hsa-miR-642a 5′Pm05f05f05f0f05f05f05f05f05f05f05f05f05 m0m0000m0000m000*0*m0TEGChol MIMAT0003312 m0*5m0*5m0*5m0*5m0*5m0*0 hsa-miR-642b 5′Pm0005f05f05f05f005f0005f05f05m0*5m0 m0m00m0m0m0m000m00m0*m0*m0TEGChol MIMAT0018444 *0*0*f0** hsa-miR-643 5′Pm0000f05f05f00f05f05f05f05f05m0*5m0* m0m0000m0m000m0m0m0*m0*m0TEGChol MIMAT0003313 5m0*5m0*5m0*0*0 hsa-miR-644 5′Pm0005f0f005f05f05f05f005f05f05m0*5m0 m0m00m00m000m0m00m0*m0*m0TEGChol MIMAT0003314 *0*5m0*f0*0*0 hsa-miR-645 5′Pm005f005f005f05f05f005f05f05f00*0*0*0 m0m000m0m000m0m0m00*m0*m0TEGChol MIMAT0003315 *f0*5m0*0 hsa-miR-646 5′Pm0000f05f0005f005f005f00*5m0*5m0*0 m0m0m00m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0003316 *5m0*5m0*0 hsa-miR-647 5′Pm0000f0005f05f05f05f05f05f05m0*5m0* m0m0000m00m0m0m0m0m0*m0*m0TEGChol MIMAT0003317 5m0*5m0*f0*0*0 hsa-miR-648 5′Pm05f000f0005f0f0005f0f05m0*0*0*0*f0* m0m00m0m0m00m0m0m0m0m0*0*m0TEGChol MIMAT0003318 0*0 hsa-miR-649 5′Pm05f05f005f05f05f05f05f005f05f0f05m0* m0m000m0m0000m0m00*0*m0TEGChol MIMAT0003319 5m0*5m0*0*f0*0*0 hsa-miR-650 5′Pm0000f05f05f05f0f00005f05m0*5m0*5m m0m0m0m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0003320 0*5m0*f0*0*0 hsa-miR-651 5′Pm05f05f05f0f00005f05f05f05f0f00*5m0*5 m0m0000m0m0m0m0m000*0*m0TEGChol MIMAT0003321 m0*5m0*5m0*0*0 hsa-miR-652 5′Pm005f05f05f05f05f00f0005f05f05m0*0*0 m0m00m0m0m0m000m000*m0*m0TEGChol MIMAT0003322 *0*5m0*0*0 hsa-miR-653 5′Pm05f005f0f05f05f05f0f05f05f05f05f00*0* m0m0000m0000m00m0*0*m0TEGChol MIMAT0003328 5m0*0*f0** hsa-miR-654-3p 5′Pm05f05f05f05f05f000f05f005f0f00*5m0*0 m0m00m00m0m0m00m000*0*m0TEGChol MIMAT0004814 *0*f0*5m0*0 hsa-miR-654-5p 5′Pm00005f0005f05f005f005f05m0*0*5m0* m0m0m00m0m00m0m0m0m0m0*m0*m0TEGChol MIMAT0003330 5m0*5m0*0*0 hsa-miR-655 5′Pm0000f0005f05f0000f00*5m0*0*0*f0*0*0 m0m0m0m0m0m00m0m0m0m0m0*m0*m0TEGChol MIMAT0003331 hsa-miR-656 5′Pm005f05f0f05f005f0f005f005f05m0*5m0* m0m0m00m0m00m00m000*m0*m0TEGChol MIMAT0003332 0*5m0*5m0*5m0*0 hsa-miR-657 5′Pm05f05f005f005f05f0f05f05f00f00*0*0*5 m0m0m000m000m0m0m00*0*m0TEGChol MIMAT0003335 m0*5m0*5m0*0 hsa-miR-658 5′Pm00005f0000f05f05f05f05f05m0*0*5m0* m0m0000m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0003336 5m0*5m0*5m0*0 hsa-miR-659 5′Pm005f05f05f05f05f05f05f005f05f05f05m0 m0m000m0m0000m000*m0*m0TEGChol MIMAT0003337 *5m0*5m0*0*f0*0*0 hsa-miR-660 5′Pm05f05f05f0f0000f05f000f05m0*5m0*5m m0m0m0m00m0m0m0m0m000*0*m0TEGChol MIMAT0003338 0*5m0*5m0*5m0*0 hsa-miR-661 5′Pm05f005f0f05f05f05f05f005f005f05m0*0* m0m0m00m0m0000m00m0*0*m0TEGChol MIMAT0003324 5m0*0*f0*5m0*0 hsa-miR-662 5′Pm005f05f0f05f0005f005f00f00*0*5m0*5 m0m0m00m0m0m0m00m000*m0*m0TEGChol MIMAT0003325 m0*5m0*0*0 hsa-miR-663 5′Pm0000f05f005f05f05f05f05f05f05m0*5m0 m0m0000m00m00m0m0m0*m0*m0TEGChol MIMAT0003326 *5m0*0*5m0*5m0*0 hsa-miR-663b 5′Pm05f05f00f05f05f00f005f05f0f00*5m0*0* m0m000m0m0m000m0m00*0*m0TEGChol MIMAT0005867 5m0*f0*0*0 hsa-miR-664 5′Pm00005f00005f0000f00*0*0*0*5m0*0*0 m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEG MIMAT0005949 Chol hsa-miR-664* 5′Pm0005f05f0005f0f05f005f0f05m0*5m0*5 m0m00m00m00m0m0m00m0*m0*m0TEGChol MIMAT0005948 m0*5m0*5m0*5m0* hsa-miR-665 5′Pm0005f0f05f0005f005f05f0f00*5m0*0*0* m0m000m0m0m0m00m00m0*m0*m0TEGChol MIMAT0004952 f0*5m0* hsa-miR-668 5′Pm05f05f05f05f005f005f005f00f00*0*5m0 m0m0m00m0m0m00m0m000*0*m0TEGChol MIMAT0003881 *5m0*5m0*0*0 hsa-miR-670 5′Pm005f05f05f05f05f05f0f05f005f0f00*5m0 m0m00m00m0000m000*m0*m0TEGChol MIMAT0010357 *0*0*f0*0*0 hsa-miR-671-3p 5′Pm00005f05f05f05f05f0000f00*5m0*0*0*f m0m0m0m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0004819 0*0*0 hsa-miR-671-5p 5′Pm0005f0f05f05f05f0f05f0005f05m0*5m0* m0m0m0m00m0000m00m0*m0*m0TEGChol MIMAT0003880 5m0*0*f0*5m0* hsa-miR-675 5′Pm0000f05f000f005f005f00*0*5m0*0*5m m0m0m00m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0004284 0*0*0 hsa-miR-675* 5′Pm0005f05f05f005f0f00005f05m0*0*0*0*f m0m0m0m0m0m00m00m00m0*m0*m0TEGChol MIMAT0006790 0*5m0*0 hsa-miR-676 5′Pm0000f05f05f05f05f05f05f05f05f05m0*5 m0m0000m0000m0m0m0*m0*m0TEGChol MIMAT0018204 m0*0*5m0*f0*0*0 hsa-miR-676* 5′Pm0005f0f05f05f005f05f05f00f05m0*0*0* m0m0m000m0m000m00m0*m0*m0TEGChol MIMAT0018203 0*f0*0*0 hsa-miR-7 5′Pm0005f0f00005f005f05f0f05m0*0*0*0*f0 m0m000m0m0m0m0m0m00m0*m0*m0TEGChol MIMAT0000252 *5m0*0 hsa-miR-708 5′Pm05f005f0f0000f0000f05m0*5m0*5m0*5 m0m0m0m0m0m0m0m0m0m00m0*0*m0TEGChol MIMAT0004926 m0*5m0*5m0*0 hsa-miR-708* 5′Pm005f05f05f005f005f0000f00*0*5m0*5m m0m0m0m0m0m0m00m0m000*m0*m0TEGChol MIMAT0004927 0*f0*0* hsa-miR-7-1* 5′Pm0000f05f005f05f05f05f05f05f05m0*5m0 m0m0000m00m00m0m0m0*m0*m0TEGChol MIMAT0004553 *5m0*0*f0*0*0 hsa-miR-711 5′Pm005f00f05f05f05f0f005f05f0f05m0*0*5 m0m000m0m0000m0m00*m0*m0TEGChol MIMAT0012734 m0*5m0*5m0*0*0 hsa-miR-718 5′Pm05f000f0005f05f05f000f00*0*0*5m0*f0 m0m0m0m00m00m0m0m0m0m0*0*m0TEGChol MIMAT0012735 *0* hsa-miR-7-2* 5′Pm0005f05f0000f0005f0f00*0*5m0*0*f0* m0m00m0m0m0m0m0m0m00m0*m0*m0TEGChol MIMAT0004554 0*0 hsa-miR-720 5′Pm05f05f005f005f05f0f05f05f00f00*0*0*5 m0m0m000m000m0m0m00*0*m0TEGChol MIMAT0005954 m0*5m0*0*0 hsa-miR-744 5′Pm005f05f0f005f00f05f0005f00*5m0*5m0 m0m0m0m00m0m00m0m000*m0*m0TEGChol MIMAT0004945 *5m0*f0*5m0*0 hsa-miR-744* 5′Pm0000f05f005f0f05f05f05f0f00*5m0*0*5 m0m0000m00m00m0m0m0*m0*m0TEGChol MIMAT0004946 m0*f0*0*0 hsa-miR-758 5′Pm00005f05f05f05f05f0005f0f05m0*0*5m m0m00m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0003879 0*5m0*f0*0*0 hsa-miR-759 5′Pm05f0005f05f05f005f05f000f00*5m0*5m m0m0m0m00m0m000m0m0m0*0*m0TEGChol MIMAT0010497 0*0*f0*0*0 hsa-miR-760 5′Pm0000f05f05f005f00005f00*5m0*5m0*0 m0m0m0m0m0m0m000m0m0m0*m0*m0TEGChol MIMAT0004957 *f0*5m0*0 hsa-miR-761 5′Pm005f05f05f005f05f05f005f05f05f05m0*5 m0m000m0m000m0m000*m0*m0TEGChol MIMAT0010364 m0*0*0*5m0*5m0*0 hsa-miR-762 5′Pm005f005f005f05f05f05f05f05f05f00*0*0 m0m0000m000m0m0m00*m0*m0TEGChol MIMAT0010313 *0*5m0*0*0 hsa-miR-764 5′Pm05f05f005f005f05f0f05f05f00f05m0*0*0 m0m0m000m000m0m0m00*0*m0TEGChol MIMAT0010367 *5m0*5m0*0*0 hsa-miR-765 5′Pm00005f05f05f005f005f05f05f00*5m0*0* m0m000m0m0m000m0m0m0*m0*m0TEGChol MIMAT0003945 0*f0*5m0*0 hsa-miR-766 5′Pm05f005f05f05f000f05f05f05f0f00*0*0*0 m0m0000m0m0m00m00m0*0*m0TEGChol MIMAT0003888 *f0*5m0*0 hsa-miR-767-3p 5′Pm00005f00005f0000f00*0*0*0*5m0*0*0 m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEG MIMAT0003883 Chol hsa-miR-767-5p 5′Pm00005f05f000f005f05f0f00*0*0*0*f0*5 m0m000m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0003882 m0*0 hsa-miR-769-3p 5′Pm00005f00005f05f005f0f00*5m0*0*5m0 m0m00m00m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0003887 *f0*0*0 hsa-miR-769-5p 5′Pm00005f00005f005f05f05f00*0*5m0*0*f m0m000m0m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0003886 0*0*0 hsa-miR-770-5p 5′Pm05f0005f0000f005f00f00*0*0*5m0*5m m0m0m00m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0003948 0*5m0*0 hsa-miR-802 5′Pm05f05f00f05f05f00f0000f00*0*5m0*0*f m0m0m0m0m0m0m000m0m00*0*m0TEGChol MIMAT0004185 0*5m0*0 hsa-miR-873 5′Pm05f0005f05f05f05f05f05f05f00f00*0*5m m0m0m000m0000m0m0m0*0*m0TEGChol MIMAT0004953 0*5m0*** hsa-miR-874 5′Pm005f05f05f05f05f05f0f005f005f00*0*5m m0m0m00m0m0000m000*m0*m0TEGChol MIMAT0004911 0*0*5m0*5m0*0 hsa-miR-875-3p 5′Pm05f05f00f0005f05f05f05f00f05m0*5m0* m0m0m000m00m0m0m0m00*0*m0TEGChol MIMAT0004923 5m0*5m0*f0*5m0* hsa-miR-875-5p 5′Pm005f00f05f005f05f05f05f05f05f00*5m0* m0m0000m00m00m0m00*m0*m0TEGChol MIMAT0004922 5m0*5m0*5m0*0*0 hsa-miR-876-3p 5′Pm05f05f005f0005f0f0005f05f05m0*5m0* m0m00m0m0m00m0m0m0m00*0*m0TEGChol MIMAT0004925 5m0*5m0*f0*0*0 hsa-miR-876-5p 5′Pm05f05f005f05f05f05f0f0005f0f05m0*5m m0m00m0m0m0000m0m00*0*m0TEGChol MIMAT0004924 0*5m0*5m0*5m0*5m0*0 hsa-miR-877 5′Pm05f005f05f05f05f00f05f05f05f0f00*0*0* m0m0000m0m000m00m0*0*m0TEGChol MIMAT0004949 0*f0*5m0*0 hsa-miR-877* 5′Pm00005f005f00f0000f00*5m0*5m0*0*f0 m0m0m0m0m0m00m0m0m0m0*m0*m0TEGChol MIMAT0004950 *0*0 hsa-miR-885-3p 5′Pm05f05f05f05f05f05f005f0000f00*5m0*5 m0m0m0m0m0m0m000m000*0*m0TEGChol MIMAT0004948 m0*0*5m0*5m0*0 hsa-miR-885-5p 5′Pm005f00f0005f0f0000f00*5m0*0*5m0*5 m0m0m0m0m0m00m0m0m0m00*m0*m0TEGChol MIMAT0004947 m0*0*0 hsa-miR-887 5′Pm0000f05f005f05f05f05f05f05f05m0*5m0 m0m0000m00m00m0m0m0*m0*m0TEGChol MIMAT0004951 *5m0*0*f0*0*0 hsa-miR-888 5′Pm05f05f05f05f0000f0000f00*5m0*0*5m0 m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0004916 *5m0*5m0*0 hsa-miR-888* 5′Pm0000f05f000f005f005f05m0*0*5m0*0*f m0m0m00m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0004917 0*5m0*0 hsa-miR-889 5′Pm05f05f05f0f0005f05f0000f05m0*5m0*5 m0m0m0m0m0m00m0m0m000*0*m0TEGChol MIMAT0004921 m0*5m0*f0*5m0* hsa-miR-890 5′Pm005f00f0005f0f05f05f00f05m0*0*5m0* m0m0m000m00m0m0m0m00*m0*m0TEGChol MIMAT0004912 5m0*f0*5m0*0 hsa-miR-891a 5′Pm05f005f0f05f005f0f05f000f00*5m0*0*5 m0m0m0m00m00m00m00m0*0*m0TEGChol MIMAT0004902 m0*5m0*5m0*0 hsa-miR-891b 5′Pm0005f05f05f0005f05f05f00f05m0*0*0*0 m0m0m000m0m0m00m00m0*m0*m0TEGChol MIMAT0004913 *f0*0*0 hsa-miR-892a 5′Pm0005f0f05f05f00f05f05f05f05f05m0*5m m0m0000m0m000m00m0*m0*m0TEGChol MIMAT0004907 0*0*5m0*5m0*0*0 hsa-miR-892b 5′Pm005f00f005f00f05f000f05m0*5m0*5m0 m0m0m0m00m0m00m0m0m00*m0*m0TEGChol MIMAT0004918 *5m0*f0*0*0 hsa-miR-9 5′Pm05f000f05f05f05f0f05f05f05f0f00*0*5m m0m0000m0000m0m0m0*0*m0TEGChol MIMAT0000441 0*5m0*5m0*0*0 hsa-miR-9* 5′Pm05f005f0f05f000f05f005f0f05m0*0*5m0 m0m00m00m0m0m00m00m0*0*m0TEGChol MIMAT0000442 *0*5m0*0*0 hsa-miR-920 5′Pm05f05f00f0000f05f05f00f00*0*5m0*5m m0m0m000m0m0m0m0m0m00*0*m0TEGChol MIMAT0004970 0*5m0*5m0*0 hsa-miR-921 5′Pm005f05f0f05f05f05f0f005f05f05f00*0*5 m0m000m0m0000m000*m0*m0TEGChol MIMAT0004971 m0*5m0*5m0*0*0 hsa-miR-922 5′Pm05f05f05f05f05f000f05f005f0f05m0*0*5 m0m00m00m0m0m00m000*0*m0TEGChol MIMAT0004972 m0*0*f0*5m0*0 hsa-miR-924 5′Pm0000f0005f05f05f05f00f00*0*5m0*5m0 m0m0m000m00m0m0m0m0m0*m0*m0TEGChol MIMAT0004974 *5m0*5m0*0 hsa-miR-92a 5′Pm005f005f0005f0f05f05f005f00*5m0*5m m0m0m000m00m0m0m0m00*m0*m0TEGChol MIMAT0000092 0*5m0*5m0*5m0*0 hsa-miR-92a-1* 5′Pm0000f05f005f05f05f05f05f05f05m0*5m0 m0m0000m00m00m0m0m0*m0*m0TEGChol MIMAT0004507 *5m0*0*f0*0*0 hsa-miR-92a-2* 5′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0004508 m0*5m0*5m0*0 hsa-miR-92b 5′Pm005f00f05f005f0f0005f0f00*5m0*0*5m m0m00m0m0m00m00m0m00*m0*m0TEGChol MIMAT0003218 0*f0*5m0*0 hsa-miR-92b* 5′Pm05f05f00f00005f005f05f0f00*0*0*5m0* m0m000m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0004792 5m0*0*0 hsa-miR-93 5′Pm00005f05f0005f005f00f00*5m0*0*0*f0 m0m0m00m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0000093 *5m0*0 hsa-miR-93* 5′Pm05f000f00005f0000f00*0*0*5m0*f0*0*0 m0m0m0m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0004509 hsa-miR-933 5′Pm05f05f00f05f05f05f05f05f000f00*5m0*5 m0m0m0m00m0000m0m00*0*m0TEGChol MIMAT0004976 m0*5m0*5m0*0*0 hsa-miR-934 5′Pm005f05f05f005f05f0f0005f05f00*0*5m0 m0m00m0m0m000m0m000*m0*m0TEGChol MIMAT0004977 *0*5m0*5m0*0 hsa-miR-935 5′Pm0005f0f05f05f005f05f005f0f05m0*0*5m m0m00m00m0m000m00m0*m0*m0TEGChol MIMAT0004978 0*5m0*f0*5m0*0 hsa-miR-936 5′Pm0000f05f005f05f005f05f05f00*5m0*0*5 m0m000m0m00m00m0m0m0*m0*m0TEGChol MIMAT0004979 m0*f0*0*0 hsa-miR-937 5′Pm05f05f05f05f05f005f05f05f000f05m0*0* m0m0m0m00m00m00m000*0*m0TEGChol MIMAT0004980 5m0*5m0*f0** hsa-miR-938 5′Pm05f000f05f005f0f0000f05m0*5m0*0*0* m0m0m0m0m0m00m00m0m0m0*0*m0TEGChol MIMAT0004981 f0*0*0 hsa-miR-939 5′Pm005f005f05f05f05f0f005f05f05f05m0*0* m0m000m0m0000m0m00*m0*m0TEGChol MIMAT0004982 5m0*5m0*f0*0*0 hsa-miR-940 5′Pm0005f0f005f005f005f05f0f05m0*5m0*0 m0m000m0m0m00m0m00m0*m0*m0TEGChol MIMAT0004983 *0*5m0*5m0*0 hsa-miR-941 5′Pm005f00f0005f0f0000f05m0*0*0*5m0*f0 m0m0m0m0m0m00m0m0m0m00*m0*m0TEGChol MIMAT0004984 *0*0 hsa-miR-942 5′Pm05f005f0f05f0005f05f05f005f05m0*0*5 m0m0m000m0m0m00m00m0*0*m0TEGChol MIMAT0004985 m0*5m0*5m0*5m0*0 hsa-miR-943 5′Pm0000f05f005f0f05f05f05f0f00*5m0*0*5 m0m0000m00m00m0m0m0*m0*m0TEGChol MIMAT0004986 m0*f0*0*0 hsa-miR-944 5′Pm005f00f05f05f05f05f0000f00*0*0*0*5m m0m0m0m0m0m0000m0m00*m0*m0TEGChol MIMAT0004987 0*0*0 hsa-miR-95 5′Pm00005f0000f05f000f05m0*5m0*5m0*0 m0m0m0m00m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0000094 *f0*5m0*0 hsa-miR-96 5′Pm0005f0f0005f0f05f0005f00*5m0*0*0*5 m0m0m0m00m00m0m0m00m0*m0*m0TEGChol MIMAT0000095 m0*5m0*0 hsa-miR-96* 5′Pm005f00f005f005f00005f00*5m0*5m0*0 m0m0m0m0m0m0m00m0m0m00*m0*m0TEGChol MIMAT0004510 *f0*5m0*0 hsa-miR-98 5′Pm0000f005f05f05f05f000f00*0*0*0*5m0 m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0000096 *5m0*0 hsa-miR-99a 5′Pm005f00f005f00f05f005f05f05m0*0*5m0 m0m00m00m0m00m0m0m00*m0*m0TEGChol MIMAT0000097 *5m0*f0*0*0 hsa-miR-99a* 5′Pm005f05f05f05f000f05f005f05f05m0*5m0 m0m00m00m0m0m00m000*m0*m0TEGChol MIMAT0004511 *5m0*5m0*5m0*5m0*0 hsa-miR-99b 5′Pm0000f0005f0f05f005f0f00*5m0*0*0*f0* m0m00m00m00m0m0m0m0m0*m0*m0TEGChol MIMAT0000689 5m0*0 hsa-miR-99b* 5′Pm00005f05f05f05f0f0000f05m0*0*5m0*5 m0m0m0m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0004678 m0*f0*0*0

Having thus described several aspects of at least one embodiment of this invention, it is to be appreciated various alterations, modifications, and improvements will readily occur to those skilled in the art. Such alterations, modifications, and improvements are intended to be part of this disclosure, and are intended to be within the spirit and scope of the invention.

Accordingly, the foregoing description and drawings are by way of example only.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

All references, including patent documents, disclosed herein are incorporated by reference in their entirety. This application incorporates by reference the entire contents, including all the drawings and all parts of the specification. 

1. An isolated nucleic acid molecule comprising a guide strand of 18-23 nucleotides in length that has complementarity to a miRNA sequence, and a passenger strand of 8-16 nucleotides in length, wherein the guide strand and the passenger strand form the nucleic acid molecule such that the nucleic acid has a double stranded region and a single stranded region, wherein the single stranded region is the 3′ end of the guide strand and comprises at least two phosphorothioate modifications, and wherein at least 50% of the pyrimidines in the nucleic acid molecule are modified.
 2. The nucleic acid molecule of claim 1, wherein the nucleotide in position one of the guide strand has a 2′-O-methyl modification.
 3. The nucleic acid molecule of claim 2, wherein the nucleotide in position one of the guide strand is a 5P-2′O-methyl U.
 4. The nucleic acid molecule of claim 1, wherein at least 60% at least 80%, at least 90%, or 100% of the pyrimidines in the nucleic acid molecule are modified. 5-7. (canceled)
 8. The nucleic acid molecule of claim 1, wherein modified pyrimidines are 2′fluoro or 2′O methyl modified.
 9. The nucleic acid molecule of claim 1, wherein at least one U or C includes a hydrophobic modification.
 10. (canceled)
 11. The nucleic acid molecule of claim 9, wherein the hydrophobic modification is a methyl or ethyl hydrophobic base modification.
 12. The nucleic acid molecule of claim 1, wherein the guide strand contains 6-8 phosphorothioate modifications.
 13. The nucleic acid molecule of claim 1, wherein the 3′ terminal 10 nucleotides of the guide strand include at least eight phosphorothioate modifications.
 14. The nucleic acid molecule of claim 1 wherein the guide strand includes 4-14 phosphate modifications.
 15. The nucleic acid molecule of claim 1, wherein the single stranded region of the guide strand is 6 nucleotides long.
 16. (canceled)
 17. The nucleic acid molecule of claim 1, wherein the double stranded region is 16 nucleotides long.
 18. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule has one end that is blunt or includes a one nucleotide overhang.
 19. The nucleic acid molecule of claim 1, wherein the passenger strand is linked at the 3′ end to a lipophilic group.
 20. The nucleic acid molecule of claim 19, wherein the lipophilic group is a sterol.
 21. (canceled)
 22. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule is an miRNA mimic and wherein the miRNA sequence to which the guide strand is complementary is a miRNA recognition element.
 23. The nucleic acid molecule of claim 22, wherein the miRNA mimic is a mimic of an miRNA selected from the group consisting of miR21, miR 139, miR 7, miR29, miR 122, miR 302-367 cluster, miR 221, miR-96, miR 126, miR 225 and miR
 206. 24-32. (canceled)
 33. A method of modulating miRNA-mediated gene expression in a subject comprising: administering to a subject an effective amount for modulating miRNA-mediated gene expression of the isolated nucleic acid molecule of claim
 1. 34. The method of claim 33, wherein the administration is systemic, intravenous, intraperitoneal, intradermal, topical, or intraocular.
 35. The method of claim 33, wherein the subject is a human. 